<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href="http://www.blogger.com/styles/atom.css" type="text/css"?><feed xmlns='http://www.w3.org/2005/Atom' xmlns:openSearch='http://a9.com/-/spec/opensearchrss/1.0/' xmlns:georss='http://www.georss.org/georss' xmlns:gd='http://schemas.google.com/g/2005' xmlns:thr='http://purl.org/syndication/thread/1.0'><id>tag:blogger.com,1999:blog-4164540472824980814</id><updated>2012-01-26T23:28:57.931-08:00</updated><title type='text'>Ultimate Guide for the MBBS Student.</title><subtitle type='html'>Searchable Index to the Popular Textbooks in Medicine, Surgery, Obstetrics, Gynaecology, Paediatrics.</subtitle><link rel='http://schemas.google.com/g/2005#feed' type='application/atom+xml' href='http://mesmedicalcollege.blogspot.com/feeds/posts/default'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4164540472824980814/posts/default?max-results=100'/><link rel='alternate' type='text/html' href='http://mesmedicalcollege.blogspot.com/'/><link rel='hub' href='http://pubsubhubbub.appspot.com/'/><author><name>Hafeesh Fazulu</name><uri>http://www.blogger.com/profile/17139976392365489719</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='22' height='32' src='http://2.bp.blogspot.com/_NnNOcS4DuOU/SxakX6Ie8VI/AAAAAAAAHpw/VmFBc5kW3pk/S220/me+face.jpg'/></author><generator version='7.00' uri='http://www.blogger.com'>Blogger</generator><openSearch:totalResults>13</openSearch:totalResults><openSearch:startIndex>1</openSearch:startIndex><openSearch:itemsPerPage>100</openSearch:itemsPerPage><entry><id>tag:blogger.com,1999:blog-4164540472824980814.post-3188455601850433532</id><published>2010-03-18T00:55:00.001-07:00</published><updated>2010-03-18T00:55:57.219-07:00</updated><title type='text'>FINAL MBBS QUESTIONS</title><content type='html'>&lt;span xmlns=''&gt;&lt;p&gt;Â GURUÂ THE FINAL MBBS MANUAL&lt;br /&gt;Â HAFEESH FAZULU&lt;br /&gt;Â Â Â Â &lt;span style='font-family:Arial'&gt;â€ƒ&lt;/span&gt;Â CONTENTSÂ MEDICINEÂ 6Â PAPER 1Â 6Â General MedicineÂ 6Â Clinical Biochemistry and MetabolismÂ 7Â Kidney and Urinary Tract DiseaseÂ 7Â Cardiovascular DiseaseÂ 8Â Endocrine DiseaseÂ 10Â Diabetes MellitusÂ 10Â Alimentary Tract and Pancreatic DiseaseÂ 11Â Liver and Biliary Tract DiseaseÂ 11Â Blood DisordersÂ 12Â Musculoskeletal DisordersÂ 13Â Neurological DisordersÂ 13Â UnallocatedÂ 16Â PAPER 2Â 18Â PoisoningÂ 18Â Medical PsychiatryÂ 18Â OncologyÂ 18Â Infectious DiseasesÂ 18Â HIVÂ 19Â Sexually Transmitted DiseasesÂ 20Â Respiratory DiseaseÂ 20Â Skin DiseaseÂ 21Â UnallocatedÂ 21Â PRACTICALSÂ 21Â COMMON CLINICAL PROCEDURESÂ 21Â Measurement of PulseÂ 21Â Measurement of Blood PressureÂ 21Â Measurement of TemperatureÂ 21Â Looking for PallorÂ 22Â Looking  for CyanosisÂ 22Â Looking for ClubbingÂ 22Â Looking for JaundiceÂ 22Â PainÂ 22Â Long CasesÂ 22Â Mitral StenosisÂ 22Â Mitral IncompetenceÂ 22Â Aortic StenosisÂ 22Â Aortic IncompetenceÂ 22Â Bacterial EndocarditisÂ 22Â Pleural EffusionÂ 22Â PneumothoraxÂ 22Â HydropneumothoraxÂ 22Â ConsolidationÂ 22Â COPD/AsthmaÂ 22Â Viral HepatitisÂ 22Â Liver CirrhosisÂ 22Â Pyloric StenosisÂ 22Â HemiplegiaÂ 22Â ParaplegiaÂ 22Â ParkinsonismÂ 22Â Peripheral NeuropathyÂ 22Â SHORT CASESÂ 22Â Lung CollapseÂ 22Â Superior Mediastinal SyndromeÂ 22Â AscitesÂ 22Â Abdominal LumpÂ 23Â HepatosplenomegalyÂ 23Â Cerebellar DisorderÂ 23Â Bulbar PalsyÂ 23Â SURGERYÂ 24Â PAPER 1Â 24Â UnallocatedÂ 24Â PeritoneumÂ 24Â Abdominal TuberculosisÂ 24Â The LiverÂ 24Â GallbladderÂ 25Â The SpleenÂ 26Â The PancreasÂ 26Â Retroperitoneal SpaceÂ 27Â Mass AbdomenÂ 27Â Abdominal Wall and UmbilicusÂ 27Â HerniaÂ 27Â OesophagusÂ 28Â StomachÂ 28Â The Small IntestineÂ 30Â Large IntestineÂ 30Â Intestinal ObstructionÂ 31Â The Vermiform AppendixÂ 31Â The Rectum and Anal CanalÂ 31Â ORTHOPEDICSÂ 32Â Anatomy of Bone and Fracture HealingÂ 33Â Treatment of FracturesÂ 33Â Splints and TractionsÂ 33Â Recent Advances in Fracture TreatmentÂ 33Â Approach to FractureÂ 33Â Complications of FracturesÂ 33Â Dislocations and SubluxationsÂ 34Â Fractures in ChildrenÂ 34Â Peripheral Nerve InjuriesÂ 34Â Treatment of Orthopedic DisordersÂ 35Â Shoulder InjuriesÂ 35Â Elbow InjuriesÂ 35Â Forearm and Wrist InjuriesÂ 36Â Hand InjuriesÂ 36Â Pelvic FracturesÂ 36Â Injuries around HipÂ 37Â Fracture shaft of FemurÂ 37Â Injuries around KneeÂ 37Â Injuries to Leg, Ankle and FootÂ 37Â Spinal InjuriesÂ 38Â Infections of Bones and JointsÂ 38Â Tuberculosis of Bones and JointsÂ 39Â Infections of the HandÂ 39Â CTEVÂ 39Â Congenital Dislocation of HipÂ 39Â PoliomyelitisÂ 40Â Bone TumoursÂ 40Â Prolapsed IV DiscÂ 40Â ScoliosisÂ 40Â BackpainÂ 40Â ArthritisÂ 40Â Degenerative DisordersÂ 41Â Affections of Soft tissuesÂ 41Â Metabolic Bone DiseasesÂ 41Â Miscellaneous affections of BoneÂ 41Â Miscellaneous Regional DiseasesÂ 42Â Amputations and ProstheticsÂ 42Â Sports MedicineÂ 42Â PAPER 2Â 44Â General SurgeryÂ 44Â Infectious DiseasesÂ 44Â SwellingsÂ 45Â Electrolyte and NutritionÂ 45Â ShockÂ 45Â Haemorrhage and Blood TransfusionÂ 45Â BurnsÂ 45Â TraumaÂ 46Â Hand and FootÂ 46Â Arterial DiseasesÂ 46Â Hamartoma and Vasculoar LesionsÂ 47Â Venous DiseasesÂ 47Â LymphaticsÂ 47Â Peripheral NervesÂ 47Â NeoplasmÂ 48Â Skin TumoursÂ 48Â SarcomasÂ 48Â AmputationsÂ 48Â ReconstructionÂ 48Â TransplantationÂ 48Â Faciomaxillary DiseasesÂ 48Â Oral CavityÂ 48Â Salivary GlandsÂ 49Â NeckÂ 49Â ThyroidÂ 50Â Parathyroid and AdrenalsÂ 51Â BreastÂ 51Â UrologyÂ 52Â KidneyÂ 52Â Urinary BladderÂ 53Â ProstrateÂ 54Â UrethraÂ 54Â PenisÂ 55Â ScrotumÂ 55Â TestisÂ 55Â NeurosurgeryÂ 55Â ThoraxÂ 56Â AnaesthesiaÂ 56Â Adjuvant TherapyÂ 56Â Advanced Imaging MethodsÂ 56Â Operative SurgeryÂ 56Â PRACTICALSÂ 58Â INSTRUMENTS TO CARRYÂ 58Â BASIC SURGERYÂ 58Â COMMON CLINICAL PROCEDURESÂ 58Â Long CasesÂ 58Â BreastÂ 58Â ThyroidÂ 62Â Varicose VeinsÂ 68Â Peripheral Vascular DiseaseÂ 70Â Abdominal LumpÂ 72Â SHORT CASESÂ 73Â HerniaÂ 73Â SwellingÂ 74Â Swelling â€“ LipomaÂ 74Â Swelling â€“ Sebaceous CystÂ 74Â Swelling - Thyroglossal CystÂ 74Â Swelling  - Dermoid CystÂ 74Â Swelling - HemangiomaÂ 74Â Swelling - GanglionÂ 74Â Swelling - BursitisÂ 74Â Diabetic UlcerÂ 74Â SinusÂ 74Â Marjolin's UlcerÂ 74Â BCCÂ 75Â Cervical LymphadenopathyÂ 75Â Parotid TumourÂ 75Â Carcinoma CheekÂ 75Â GynaecomastiaÂ 75Â Umbilical HerniaÂ 75Â Femoral HerniaÂ 75Â HydroceleÂ 75Â VaricoceleÂ 75Â Cellulitis LegÂ 75Â FuniculitisÂ 75Â OBSTETRICS &amp;amp; GYNAECOLOGYÂ 76Â PAPER 1 â€“ OBSTETRICSÂ 76Â Anatomy of Female Reproductive OrgansÂ 76Â Fundamentals of ReproductionÂ 76Â Placenta and MembranesÂ 76Â The FetusÂ 76Â Physiological Changes in PregnancyÂ 76Â Endocrinology in relation to ReproductionÂ 76Â Diagnosis of PregnancyÂ 77Â Fetus in UteroÂ 77Â Fetal Skull and Maternal PelvisÂ 77Â Antenatal CareÂ 78Â Antenatal Assessment of Fetal Well BeingÂ 78Â Normal LabourÂ 78Â Normal PuerperiumÂ 79Â Vomiting in PregnancyÂ 79Â Haemorrhage in early PregnancyÂ 79Â Multiple PregnancyÂ 80Â Hypertensive Disorders in PregnancyÂ 81Â Antepartum HaemorrhageÂ 81Â Medical &amp;amp; Surgical Illness complicating PregnancyÂ 81Â Gynaecological Disorders in PregnancyÂ 82Â Preterm Labour &amp;amp; IUDÂ 82Â Special CasesÂ 82Â Contracted PelvisÂ 83Â Abnormal Uterine actionÂ 83Â Malposition, Malpresentation and Cord ProlapseÂ 83Â Prolonged Labour, Obstructed Labour and DystociaÂ 83Â Complications of Third Stage of LabourÂ 84Â Injuries to Birth CanalÂ 84Â Abnormalities of PuerperiumÂ 84Â NeonatologyÂ 84Â PharmacotherapeuticsÂ 85Â Induction of LabourÂ 85Â ContraceptionÂ 85Â Operative ObstetricsÂ 86Â Special TopicsÂ 86Â Imaging in ObstetricsÂ 86Â UnallocatedÂ 86Â PRACTICALSÂ 87Â Long CasesÂ 87Â Pregnancy Induced HypertensionÂ 87Â PAPER 2 â€“ GYNAECOLOGYÂ 88Â Not AllocatedÂ 88Â Anatomy of the Female Pelvic OrgansÂ 88Â Congenital Malformations of the Female Genital OrgansÂ 88Â Puberty and MenopauseÂ 88Â Neuroendocrinology in relation to ReproductionÂ 88Â MenstruationÂ 89Â Examination of a Gynaecological PatientÂ 89Â Pelvic InfectionÂ 89Â Sexually transmitted DiseasesÂ 89Â Infections of the Individual Pelvic OrgansÂ 89Â Dysmenorrhoea and other disorders of Menstrual CyclesÂ 90Â Abnormal Menstrual BleedingÂ 90Â Displacement of the UterusÂ 91Â InfertilityÂ 91Â Benign Lesions of the Vulva and VaginaÂ 92Â Benign lesions of the CervixÂ 92Â Benign lesions of the UterusÂ 92Â Benign lesions of OvaryÂ 93Â Endometriosis and AdenomyosisÂ 93Â Premalignant LesionsÂ 94Â Genital MalignancyÂ 94Â Urinary Problems in GynaecologyÂ 94Â Genital FistulaeÂ 95Â Genital Tract InjuriesÂ 95Â IntersexÂ 95Â AmenorrhoeaÂ 95Â ContraceptionÂ 95Â Radiotherapy Chemotherapy Immunotherapy Genetherapy in GynaecologyÂ 96Â Hormones in Gynaecological PracticeÂ 96Â Special TopicsÂ 96Â Operative GynaecologyÂ 97Â Endoscopic Surgery in GynaecologyÂ 97Â Practical GynaecologyÂ 97Â PEDIATRICSÂ 98Â Normal GrowthÂ 98Â Disorders of GrowthÂ 98Â Normal DevelopmentÂ 98Â Developmental DisordersÂ 99Â Adolescent Health and DevelopmentÂ 100Â Fluid and Electrolyte DisturbancesÂ 100Â NutritionÂ 100Â Micronutrients in Health and DiseaseÂ 100Â Newborn InfantsÂ 101Â Immunity and ImmunisationÂ 102Â Infections and InfestationsÂ 102Â Diseases of Gastrointestinal System and LiverÂ 103Â Hematological DisordersÂ 104Â Diseases of Ear, Nose and ThroatÂ 105Â Disorders of Respiratory SystemÂ 105Â Disorders of Cardiovascular SystemÂ 106Â Disorders of Kidney and Urinary TractÂ 106Â Endocrine and Metabolic DisordersÂ 107Â Central Nervous SystemÂ 107Â Neuromuscular DisordersÂ 108Â Childhood MalignanciesÂ 108Â Rheumatological DisordersÂ 108Â Genetic DisordersÂ 108Â Inborn Errors of MetabolismÂ 108Â Eye DisordersÂ 108Â Skin DisordersÂ 108Â Poisonings, Injuries and AccidentsÂ 108Â Pediatric Critical CareÂ 108Â Common Medical ProceduresÂ 108Â Rational Drug TherapyÂ 108Â Integrated Management of Neonatal and Childhood IllnessesÂ 108Â Rights of ChildrenÂ 109Â Unallocated QuestionsÂ 109Â  Â Â &lt;span style='font-family:Arial'&gt;â€ƒ&lt;/span&gt;Â  Â MEDICINEÂ Â Paper 1Â Â Â Â GENERAL MEDICINEÂ Â Â 1.Â Drug AddictionÂ 32Â APR-2004Â 2.Â Human Genome ProjectÂ 38Â APR-2004Â 3.Â Klinefelter's SyndromeÂ 46Â OCT-2002Â 4.Â Burkitt's LymphomaÂ 47Â DEC-2006Â 5.Â FISHÂ 51Â AUG-2002Â 6.Â Fragile X SyndromeÂ 52Â AUG-2002Â 7.Â Prenatal DiagnosisÂ 57Â SEP-2003Â 8.Â Genetic CounsellingÂ 57Â SEP-2003Â AUG-2001Â 9.Â Gene TherapyÂ 61Â APR-2004Â AUG-2001Â DEC-2006Â 10.Â Natural ImmunityÂ 65Â OCT-2002Â 11.Â Antigen PresentationÂ Â DEC-2004Â 12.Â TNF a AntagonistÂ Â JUN-2005Â 13.Â Mast CellsÂ 68Â JUN-2005Â 14.Â Natural Killer CellsÂ 68Â APR-2004Â 15.Â CD4 CountÂ 70Â AUG-2001Â 16.Â Cell mediated ImmunityÂ 69Â OCT-2002Â 17.Â Diagnosis of AmyloidosisÂ 79Â MAR-2003Â 18.Â Draw &amp;amp; Label : Schematic diagram of Major Histocompatibility Complex (HLA)Â 80Â DEC-2006Â 19.Â Sjogren SyndromeÂ 80Â OCT-2002Â 20.Â Rheumatoid factorÂ 81Â APR-2004Â JUN-2006Â 21.Â Antinuclear Antibodies (ANA)Â 81Â APR-2004Â MAR-2003Â 22.Â Anti neutrophil cytoplasmic antibodiesÂ 83Â SEP-2003Â 23.Â Type I Anaphylactic ReactionÂ 86Â MAR-2003Â 24.Â Anaphylactic ShockÂ 87Â MAY-1999Â 25.Â AdrenalineÂ 87Â JUN-2005Â 26.Â Immune Complex mediated reactionÂ Â OCT-2002Â DEC-2006Â 27.Â Decayed hypersensitivityÂ Â FEB-2001Â 28.Â ImmunotherapyÂ 88Â JUN-2005Â APR-2004Â 29.Â Health hazards of SmokingÂ 97Â APR-2004Â SEP-2000Â 30.Â Smoking CessationÂ 97Â SEP-2003Â 31.Â Malignant HyperpyrexiaÂ 102Â DEC-2004Â 32.Â Frost BioteÂ 102Â JUN-2005Â 33.Â Heat StrokeÂ 103Â JUN-2005Â DEC-2004Â DEC-2006Â 34.Â Management of DrowningÂ 105Â OCT-2002Â 35.Â ObesityÂ 111Â AUG-2001Â 36.Â HypervitaminosisÂ Â DEC-2006Â 37.Â PellagraÂ 124Â JAN-2002Â 38.Â Treatment of PellagraÂ 124Â OCT-2002Â 39.Â Thiamine deficiencyÂ 124Â MAR-2003Â 40.Â ScurvyÂ 125Â MAR-2003Â 41.Â Weil Felix ReactionÂ 143Â OCT-2002Â 42.Â Broad Spectrum AntibioticÂ Â DEC-2004Â 43.Â Broad Spectrum PenicillinÂ Â DEC-2004Â 44.Â BetalactamaseÂ 146Â JUN-2006Â 45.Â PenicillinaseÂ 148Â DEC-2004Â 46.Â Polymerase chain reactionÂ 142Â JUN-2006Â 47.Â Ziehl Neelson TechniqueÂ 142Â MAR-2003Â 48.Â Western Blot TestÂ 142Â SEP-2003Â 49.Â Generations of CephalosporinsÂ 149Â DEC-2004Â 50.Â AminoglycosidesÂ 150Â JAN-2002Â 51.Â Quinolone AntibacterialsÂ 151Â DEC-2004Â 52.Â InterferonÂ 157Â OCT-2002Â DEC-2006Â 53.Â Positive Pressure VentillationÂ Â JUN-2005Â 54.Â Postural HypotensionÂ 167Â DEC-2004Â 55.Â Management of HypotensionÂ 167Â DEC-2006Â 56.Â ARDSÂ 188Â AUG-2002Â DEC-2006Â 57.Â Nosocomial InfectionsÂ 190Â AUG-2001Â 58.Â VasodilatorsÂ 192Â FEB-2001Â 59.Â Oxygen therapyÂ 193Â AUG-2001Â 60.Â Mechanical VentillationÂ 193Â FEB-2002Â 61.Â Total Parentral NutritionÂ 197Â OCT-2002Â 62.Â Barbiturate PoisoningÂ Â DEC-2006Â 63.Â Organ TransplantationÂ 200Â APR-2000Â 64.Â Salicylate PoisoningÂ 209Â FEB-2001Â 65.Â HeroinÂ 215Â JUN-2006Â 66.Â Management of CO PoisoningÂ 216Â AUG-2002Â 67.Â Organophosphorous poisoningÂ Â AUG-2001Â 68.Â Treatment of Organophosphrous PoisoningÂ 218Â AUG-2001Â 69.Â AtropineÂ Â JUN-2006Â 70.Â Complications of Organophosphorous poisoningÂ Â DEC-2006Â 71.Â PhobiasÂ 239Â JUN-2006Â 72.Â HysteriaÂ 250Â JUN-2006Â 73.Â Cardiac TamponadeÂ 261Â AUG-2002Â 74.Â Motion SicknessÂ 279Â MAR-2003Â 75.Â EosinophilÂ 296Â DEC-2004Â 76.Â RetrovirusÂ 299Â 1039Â FEB-2001Â Â CLINICAL BIOCHEMISTRY AND METABOLISMÂ Â Â 1Â SIADHÂ 430Â 793Â AUG-2001Â FEB-2001Â 2Â Psychogenic PolydipsiaÂ 430Â 472Â DEC-2006Â 3Â HypokalemiaÂ 432Â OCT-2002Â 4Â GIK regimeÂ Glucose-Insulin-Potassium iv infusion.Â given in diabetic patients.Â Â Â 5Â ECG changes in HyperkalemiaÂ 433Â JUL-2007Â 6Â Anxiety DisorderÂ 439Â DEC-2004Â OCT-2002Â 7Â Metabolic AcidosisÂ 437Â APR-2004Â 8Â HyperlipidemiaÂ 446Â AUG-2002Â 9Â Classification of HyperlipidaemiaÂ 447Â Â 10Â HypercholesterolaemiaÂ 447Â SEP-2000Â 11Â Remnant HyperlipideamiaÂ 448Â Â 12Â Why Phaeochromocytoma is called 10% tumourÂ 450Â JUL-2008Â Â KIDNEY AND URINARY TRACT DISEASEÂ Â Â 1Â DysuriaÂ Â JUL-2007Â 2Â Draw &amp;amp; Label :  NephronÂ Â JUN-2005Â 3Â Draw &amp;amp; Label :  GlomerulusÂ -Â AUG-2002Â 4Â Draw &amp;amp; Label :  Casts in UrineÂ 457Â AUG-2002Â 5Â Casts in UrineÂ 457Â DEC-2004Â 6Â Retroperitoneal fibrosisÂ 466Â 509Â JUL-2008Â 7Â Urinary tract infections in a femaleÂ 467Â FEB-2001Â 8Â Treatment of Acute CystitisÂ 467Â OCT-2002Â 9Â Acute Urethral SyndromeÂ 467Â Â 10Â Asymptomatic BacteruriaÂ 470Â MAR-2003Â 11Â Acute PyelonephritisÂ 470Â OCT-2002Â 12Â Erectile ImpotenceÂ 476Â JUN-2005Â 13Â HaematuriaÂ 477Â FEB-2002Â 14Â Evaluation for HaematuriaÂ 477Â OCT-2002Â 15Â Diet therapy in Nephrotic SyndromeÂ 478Â DEC-2006Â 16Â Complications of nephrotic syndrome.Â Â FEB-2001Â 17Â Differential diagnosis of protenuriaÂ 479Â FEB-2001Â 18Â Acute Tubular Necrosis (ATN)Â 482Â OCT-2002Â JUL-2008Â 19Â Prerenal causes of ARFÂ 483Â JUL-2007Â 20Â A 18 years old female is admitted with hlo swelling oflimbs puffiness of face and decreased urine output with normal blood pressure.Â 1 What is the provisional diagnosis?Â 2 What is the immunological injury ?Â 3 What are the other types of immunological injuries to glomerulus?Â 4 Outline the investigations.Â 5 Outline the management.Â 485Â DEC-2006Â 21Â Renal OsteodystrophyÂ 489Â JAN-2002Â 22Â HemodialysisÂ Â FEB-2001Â 23Â Peritoneal DialysisÂ 491Â APR-2004Â 24Â Urinary findings in Acute GlomerulonephritisÂ 491Â OCT-2002Â AUG-2001Â FEB-2001Â 25Â IgA NephropathyÂ 500Â FEB-2002Â 26Â Henoch-Schonlein PurpuraÂ 500Â 1141Â OCT-2002Â 27Â Lupus NephritisÂ 501Â 515Â JUL-2008Â 28Â Goodpasteur's SyndromeÂ 503Â AUG-2002Â 29Â Features of Acute NephritisÂ 504Â JUL-2007Â 30Â Alports SyndromeÂ 504Â AUG-2002Â 31Â Polycystic Disease of KidneysÂ 506Â DEC-2006Â 32Â Non Diabetic MilituriaÂ [G. meli, honey, + ouron, urine]Â 508Â DEC-2004Â 33Â Rectal ExaminationÂ 510Â DEC-2004Â 34Â NephrocalcinosisÂ 510Â MAR-2003Â 35Â Medical therapy of enlarged ProstrateÂ 511Â JUN-2005Â JUN-2006Â 36Â Addisonian CrisisÂ Â AUG-2001Â Â CARDIOVASCULAR DISEASEÂ Â Â 1Â Non modifiable risk factors for ischaemic heart disease (IHD)Â Â JUL-2008Â 2Â Draw &amp;amp; Label : Auscultogram in Mitral RegurgitationÂ Â JUL-2008Â 3Â Coronary AngiographyÂ 523Â JUN-2005Â 4Â Coronary Artery DiseaseÂ 526Â SEP-2000Â 5Â Draw &amp;amp; Label :  JVPÂ -Â AUG-2002Â JUL-2007Â 6Â Draw &amp;amp; Label : Conduction system of the HeartÂ 527Â JUN-2005Â APR-2004Â 7Â 2D EchoÂ 530Â DEC-2006Â 8Â MRIÂ 532Â APR-2004Â 9Â NYHA ClassificationÂ 534Â Â 10Â Paroxysmal Nocturnal Dyspnoea.Â 539Â JUN-2006Â 11Â OrthopnoeaÂ 540Â MAR-2003Â 12Â ESSAY â€“ HEART FAILUREÂ Â Â 13Â DD of Peripheral EdemaÂ 545Â Â 14Â Cardiac CachexiaÂ 545Â Â 15Â Complications of Heart FailureÂ 546Â Â 16Â ACE InhibitorsÂ adverse reactions 30Â aortic regurgitation 628Â atherosclerosis prevention 581Â chronic renal failure 488Â diabetic cardiovascular diseaseÂ and nephropathy 838Â diabetic nephropathy 514Â drug-induced cough 658Â effect on renal function 496, 5 17Â effect of renal insufficiency 26, 27Â heart failure 546, 549Â dosages 550Â site of action 549Â hypertension 613, 614, 615Â microalbuminuria in type IÂ diabetes 842Â mitral regurgitation 622Â myocardial infarction 600Â 549Â DEC-2004Â 17Â Cardiac TransplantationÂ 550Â Â 18Â Hypertensive Heart DiseaseÂ 551Â 608Â Â 19Â SyncopeÂ 551Â AUG-2001Â 20Â Carotid Sinus SyndromeÂ 553Â Â 21Â Management of cardiac arrest.Â 554Â FEB-2001Â SEP-2000Â 22Â Second SoundÂ 558Â JUL-2008Â 23Â DD of Mid-Diastolic murmer at apexÂ 559Â AUG-2001Â 24Â Paroxymal TachycardiaÂ 561Â APR-2004Â 25Â Atrial FibrillationÂ 562Â APR-2004Â AUG-2002Â 26Â Treatment of atrial fibrillationÂ Â SEP-2000Â 27Â Draw &amp;amp; Label :  ECG of WPW SyndromeÂ 565Â APR-2004Â 28Â Draw &amp;amp; Label :  ECG of First Degree Heart BlockÂ 570Â JUN-2005Â 29Â Complete Heart BlockÂ 570Â JUN-2005Â 30Â DefibrillationÂ 575Â APR-2004Â 31Â DigoxinÂ 575Â JUL-2007Â 32Â Cardiac PacemakersÂ 576Â JUN-2005Â JUN-2006Â 33Â Pathogenesis of Atheroma formationÂ 579Â Â 34Â Treadmill testÂ Bruce ProtocolÂ 582Â 528Â Â 35Â Low Dose Aspirin TherapyÂ 75-150mgÂ 583Â Â 36Â Manaagement of Angina PectorisÂ 583Â MAY-1999Â 37Â NYHA ClassificationÂ 534Â Â 38Â Unstable AnginaÂ 589Â 537Â 581Â JUL-2008Â 39Â Syndrome XÂ 589Â Â 40Â Acute Coronary SyndromeÂ 589Â Â 41Â Treatment of Unstable AnginaÂ 590Â FEB-2002Â 42Â Silent MIÂ 591Â Â 43Â Signs of MIÂ 591Â Â 44Â Draw &amp;amp; Label : ECG changes in Acute Myocardial InfarctionÂ 592Â DEC-2006Â 45Â Investigations in Myocardial infarction.Â 592Â SEP-2000Â 46Â TroponinÂ 593Â 538Â 525Â JUL-2008Â 47Â Draw &amp;amp; Label : Graph showing Enzyme changes after MIÂ 594Â Â 48Â Role of Analgesia in MIÂ 595Â Â 49Â Thrombolytic therapyÂ Steptokinase 1.5mU in 100ml saline over 1hrÂ Alteplase 15mg over 90min followed byâ€¦Â Tenecteplaseâ€¦Â Reteplase (rPA)Â 595Â 728Â 1207Â JUL-2008Â 50Â Mechanical Complications of MIÂ 597Â Â 51Â Ventricular RemodellingÂ 598Â Â 52Â Dresslers SyndromeÂ â€¦The post-myocardial infarction syndrome (Dressler's syndrome) is characterised by persistent fever, pericarditis and pleurisy, and is probably due to autoimmunity. The symptoms tend to occur a few weeks or even months after the infarct and often subside after a few days; prolonged or severe symptoms may require treatment with high-dose aspirin, an NSAID or even corticosteroidsâ€¦. (Davidson p. 598)Â 598Â AUG-2002Â 53Â Renal HypertensionÂ -Â AUG-2001Â 54Â Raynaud's phenomenonÂ 604Â DEC-2006Â SEP-2000Â 55Â A 3oyr old man admitted with headache, giddiness, vomitinf of 2 days duration. His BP was 180/110 of Hg.Â What is the provisional Diagnosis?Â What are the common causes of secondary Hypertension?Â Outline the investigation?Â Outline the management?Â Â JUL-2008Â 56Â Antihypertensive DrugsÂ 608Â AUG-2002Â 57Â Drugs used in hypertensive emergenciesÂ 613Â JUL-2008Â 58Â Malignant HypertensionÂ 614Â 498Â MAR-2003Â FEB-2001Â 59Â Management of Hypertensive crisisÂ Â JUL-2007Â 60Â Endocrine causes of HypertensionÂ Â JUL-2008Â 61Â RHEUMATIC FEVERÂ Â Â 62Â Achoff's NodulesÂ 616Â FEB-2002Â 63Â Jones CriteriaÂ 617Â Â 64Â Syndenham's ChoreaÂ 617Â Â 65Â Lab Diagnosis of Rheumatic feverÂ 616Â DEC-2006Â 66Â Radiological features of Mitral StenosisÂ 619Â AUG-2002Â MAY-1999Â 67Â Peripheral signs of Aortic RegurgitationÂ 626Â DEC-2006Â 68Â Pulmonary StenosisÂ 629Â JUL-2007Â 69Â Bacterial EndocarditisÂ Â SEP-2000Â 70Â Discuss the aetiology, clinical features, investigations, treatment of infective endocarditisÂ Â APR-2000Â 71Â Subacute EndocarditisÂ 630Â Â 72Â Osler's NodesÂ 630Â Â 73Â Modified Duke's CriteriaÂ 631Â Â 74Â Treatment of SABEÂ 632Â OCT-2002Â 75Â Valve ReplacementÂ 633Â APR-2004Â 76Â Eissenmenger's SyndromeÂ 636Â 550 629Â 634Â 639Â Â 77Â Chest X-ray findings in Lt to Rt shunt like ASD/VSD.Â Â DEC-2006Â 78Â Chest Xray findings in Coarctation of AortaÂ 637Â JUL-2007Â 79Â VSDÂ 638Â 634Â Â 80Â Radiological features of TOFÂ 639Â OCT-2002Â 81Â Viral MyocarditisÂ 641Â 306Â JUL-2007Â 82Â TB PericarditisÂ 645Â MAR-2003Â 83Â Constrictive PericarditisÂ 646Â JUL-2008Â 84Â Kussmaul's SignÂ 646Â AUG-2002Â 85Â CyanosisÂ -Â AUG-2002Â 86Â Differential Cyanosis.Â Â JUN-2006Â 87Â Left Ventricular HypertrophyÂ -Â FEB-2002Â 88Â CardiomegalyÂ Â FEB-2002Â 89Â Beta BlockersÂ -Â JAN-2002Â 90Â Collapsing PulseÂ -Â AUG-2001Â JUL-2007Â 91Â Corrigan's PulseÂ Â MAY-1999Â 92Â Acute Left Ventricular FailureÂ Â AUG-2001Â 93Â Discuss the aetiology, clinical features investigations and treatment of acute left ventricularÂ failure.Â Â FEB-2001Â 94Â ACE inhibitors in medicineÂ Â SEP-2000Â Â ENDOCRINE DISEASEÂ Â Â 1Â Thyroid Function TestsÂ 745Â OCT-2002Â 2Â Management of Thyroid StormÂ 749Â JUL-2007Â 3Â Features of HypothyroidismÂ 750Â MAR-2003Â 4Â Causes of HyperthyroidismÂ 755Â JUL-2007Â 5Â NeomercazoleÂ (Carbimazole)Â 755Â OCT-2002Â 6Â Radioiodine TherapyÂ 761Â APR-2004Â 7Â Thyroid StoneÂ -Â AUG-2001Â 8Â HypogonadismÂ 766Â AUG-2001Â 9Â HypercalcaemiaÂ 772Â AUG-2001Â 10Â Addison's DiseaseÂ 782Â APR-2004Â AUG-2002Â 11Â Carcinoid SyndromeÂ 791Â AUG-2002Â 12Â DwarfismÂ 793Â FEB-2001Â 13Â AcromegalyÂ 801Â OCT-2002Â 14Â SomatostatinÂ 810Â 853Â 859Â DEC-2006Â 15Â Insulin Resistance SyndromeÂ 813Â Â 16Â Diabetic KetoacidosisÂ 822Â JUL-2007Â 17Â Oral antidiabeticsÂ 831Â FEB-2001Â 18Â Newer SulphonnylureasÂ 832Â JUN-2006Â 19Â Dawn PhenomenonÂ 835Â AUG-2002Â Â DIABETES MELLITUSÂ Â Â 1Â Diagnostic Criteria for DiabetesÂ Â OCT-2002Â 2Â Non Ketotic Hyperosmolar Diabetic ComaÂ 823Â APR-2004Â AUG-2001Â 3Â Human InsulinÂ 834Â DEC-2004Â 4Â Insulin AnaloguesÂ Â JUN-2005Â DEC-2004Â JUN-2006Â 5Â Insulin Pens and Insulin PumpsÂ 834Â JUN-2005Â JUN-2006Â 6Â Dieary management in a Diabetic PatientÂ Â FEB-2002Â DEC-2006Â 7Â Oral hypoglycaemic agentsÂ Â SEP-2000Â 8Â Diabetic NephropathyÂ 841Â FEB-2002Â MAY-1999Â 9Â MicroalbuminuriaÂ 842Â APR-2000Â 10Â Specific test for Glucose in UrineÂ -Â JUN-2005Â 11Â Somogyi EffectÂ in diabetes, a rebound phenomenon of reactive hyperglycemia in response to a preceding period of relative hypoglycemia that has increased secretion of hyperglycemic agents (epinephrine, norepinephrine, glucagon, cortisol, and growth hormone); described in diabetic patients given too much insulin who developed unrecognized nocturnal hypoglycemia that made them hyperglycemic (suggesting insufficient insulin) when tested the next morning.Â -Â OCT-2002Â 12Â Hypoglycemic ComaÂ -Â JAN-2002Â 13Â Myxoedemic ComaÂ Â MAY-1999Â Â ALIMENTARY TRACT AND PANCREATIC DISEASEÂ Â Â 1Â Â Â Â 2Â Barium EnemaÂ 848Â FEB-1998Â 3Â ERCPÂ 860Â DEC-2004Â 4Â Barium SwallowÂ 860Â OCT-2002Â 5Â DysphagiaÂ 864Â OCT-2002Â 6Â DD of HaematemesisÂ Â MAY-1999Â 7Â Causes of upper GI BleedingÂ 866Â DEC-2006Â 8Â Differentiate Haemoptysis and HaematemesisÂ Â SEP-2000Â 9Â Describe the pathogenesis and management of acute haematemesis in a chronic alcoholic male aged 55.Â Â SEP-2000Â 10Â Occult blood in stoolsÂ 869Â DEC-2004Â 11Â Medical causes of Acute AbdomenÂ 874Â JUL-2008Â 12Â Oral thrushÂ 877Â OCT-2002Â 13Â Treatment of GERDÂ 877Â AUG-2002Â 14Â H PyloriÂ 885Â AUG-2002Â SEP-2000Â 15Â Antacids for Peptic UlcerÂ 887Â MAR-2003Â 16Â Treatment of H Pylori InfectionÂ 888Â APR-2004Â 17Â Dumping SyndromeÂ 888Â Â 18Â Proton Pump InhibitorsÂ Refer George Mathew pg 501Â 889Â AUG-2001Â 19Â Types of Abdominal TuberculosisÂ 902Â OCT-2002Â 20Â Carcinoid TumourÂ 903Â DEC-2006Â 21Â Complications of Acute PancreatitisÂ 905Â MAR-2003Â 22Â Inflammatory Bowel DiseaseÂ 910Â OCT-2002Â 23Â Chimeric Monoclonal AntibodyÂ 917Â DEC-2004Â 24Â AscitesÂ 947Â JUL-2008Â 25Â Investigations for diagnosis of AscitesÂ 948Â MAY-1999Â 26Â Stomach WashÂ Â Â 27Â Pancreatic AbscessÂ Â JUL-2007Â Â LIVER AND BILIARY TRACT DISEASEÂ Â Â 1Â Ehrlich's TestÂ Â JUN-2006Â 2Â Urine in JaundiceÂ 940Â MAY-1999Â 3Â Draw &amp;amp; Label :  Hepatic LobuleÂ -Â FEB-2002Â 4Â Liver BiopsyÂ 942Â APR-2004Â 5Â Alkaline PhosphataseÂ 943Â AUG-2001Â 6Â TIPPSÂ 949Â Â 7Â Factors precipitating Hepatic EncephalopathyÂ 950Â MAR-2003Â 8Â Cryptogenic CirrhosisÂ Â Â 9Â Complications of Liver CirrhosisÂ 956Â AUG-2001Â 10Â Portal HypertensionÂ 957Â JUL-2008Â 11Â Management of portal hypertensionÂ Â SEP-2000Â 12Â Portosystemic ShuntsÂ Portocaval ShuntsÂ 960Â JUN-2005Â 13Â Caput MedusaeÂ Â JUL-2008Â 14Â Hepatitis BÂ Â SEP-2000Â 15Â HbsAgÂ Â JAN-2002Â 16Â Outline the transmission, clinical features and complications of Hepatitis B infection. Mention aÂ note on Hepatitis B prophylaxis?Â Â SEP-2000Â 17Â Causes of Viral HepatitisÂ 962Â MAR-2003Â 18Â Complications of Acute Viral HepatitisÂ 963Â MAY-1999Â 19Â Prevention of viral hepatitis.Â Â FEB-2001Â 20Â Control of Hepatitis A infection in CommunityÂ Â DEC-2006Â 21Â Hepatitis B ProphylaxisÂ Â JUN-2006Â 22Â Hepatitis B Vaccines.Â Â JUN-2006Â 23Â Chronic Persistant Hepatitis (CPH)Â Â JUL-2007Â 24Â Post Hepatitis SyndromeÂ Â Â 25Â Anicteric HepatitisÂ Â Â 26Â Wilsons DiseaseÂ 975Â AUG-2002Â 27Â Cardiac CirrhosisÂ 983Â Â 28Â Draw &amp;amp; Label : Hydatid CystÂ Â JUN-2006Â 29Â Hepatic AmoebiasisÂ 987Â AUG-2001Â 30Â Lab diagnosis and treatment of Amoebic liver abscessÂ Â SEP-2000Â 31Â Liver TransplantationÂ 989Â APR-2004Â 32Â Indian Childhood CirrhosisÂ Â Â 33Â Types of GallstonesÂ Â JUL-2007Â 34Â Risk factors for Cholesterol GallstonesÂ Â JUL-2007Â Â BLOOD DISORDERSÂ Â Â 1Â Platelet TransfusionÂ Â JUL-2007Â 2Â APTTÂ 1011Â FEB-2002Â 3Â Blood GroupsÂ Â AUG-2001Â 4Â Hazards of Blood TransfusionÂ Â MAY-1999Â 5Â Mismatch Blood TransfusionÂ 1023Â JUN-2005Â 6Â Exchange TransfusionÂ Â APR-2004Â 7Â Draw &amp;amp; Label :  PS of Fe deficiency AnemiaÂ -Â MAR-2003Â 8Â Causes of normocytic normochromic anaemiaÂ 1012Â DEC-2006Â 9Â PolycythemiaÂ 1014Â FEB-2002Â 10Â Treatment of Polycythemia VeraÂ 1014Â AUG-2001Â 11Â HypersplenismÂ 1015Â AUG-2002Â 12Â Thrombocytopenia Â 1017Â AUG-2002Â 13Â Prevention of Deep Venous thrombosisÂ 1018Â MAR-2003Â JUL-2007Â 14Â Causes of PancytopeniaÂ 1018Â JUL-2008Â 15Â Pernicious Anaemia  Â 1028Â MAR-2003Â 16Â Anaemia of Chronic Renal FailureÂ 1030Â FEB-2002Â 17Â SplenectomyÂ 1031Â JUN-2006Â 18Â Coombs TestÂ 1033Â JUN-2005Â 19Â Sickle Cell Disease Â 1035Â AUG-2001Â JUL-2007Â 20Â MethhemoglobinemiaÂ 1035Â AUG-2002Â 21Â Paroxysmal Nocturnal HemoglobinuriaÂ Â MAR-2003Â 22Â Hemoglobin AICÂ Â MAR-2003Â 23Â ThalassemiaÂ 1038Â MAY-1999Â JUL-2008Â 24Â DesferrioxamineÂ 1038Â MAR-2003Â 25Â Treatment of acute leukemia.Â 1040Â FEB-2001Â 26Â Bone marrow transplantationÂ 1043Â JAN-2002Â 27Â Draw &amp;amp; Label : PS in CMLÂ 1045Â JUN-2006Â 28Â Treatment of Chronic Myeloid LeukemiaÂ Â DEC-2006Â APR-2000Â 29Â Myelodysplastic SyndromesÂ 1047Â MAR-2003Â FEB-2001Â 30Â Hodgkin's LymphomaÂ 1048Â MAY-1999Â 31Â Draw &amp;amp; Label : RS CellÂ 1048Â Â 32Â Staging of Hodgkin's LymphomaÂ Ann Arbor ClassificationÂ 1048Â Â 33Â Pel-Ebstein FeverÂ the remittent fever common in Hodgkin diseaseÂ -Â Â 34Â CHOP RegimenÂ 1051Â Â 35Â International Prognostic Index (IPI)Â (Harrison p. 692)Â The International Prognostic Index (IPI) is a clinical tool developed by oncologists to aid in predicting the prognosis of patients with aggressive non-Hodgkin's lymphoma. Prior to 1993, when the IPI was developed, the primary consideration in assessing prognosis was the Ann Arbor stage alone, but this was increasingly found to be an inadequate means of predicting survival outcomes, and so other factors were studied. Â Low risk (0-1 points) - 5-year survival of 73%Â Low-intermediate risk (2 points) - 5-year survival of 51%Â High-intermediate risk (3 points) - 5-year survival of 43%Â High risk (4-5 points) - 5-year survival of 26%Â http://en.wikipedia.org/wiki/International_Prognostic_IndexÂ 1051Â Â 36Â ParaproteinemiasÂ 1051Â DEC-2006Â 37Â ESSAY â€“ MULTIPLE MYELOMAÂ Â Â 38Â Diagnosis of Multiple MyelomaÂ 1052Â FEB-2002Â 39Â Treatment of Multiple MyelomaÂ 1052Â Â 40Â Aplastic AnemiaÂ Causes of Aplastic AnemiaÂ 1054Â DEC-2006Â APR-2000Â 41Â Management of ITPÂ 1055Â AUG-2001Â 42Â HaemophiliaÂ 1057Â OCT-2002Â 43Â Management of HaemophiliaÂ Â AUG-2002Â 44Â DICÂ 1060Â AUG-2002Â Â MUSCULOSKELETAL DISORDERSÂ Â Â 1Â Rheumatoid FactorÂ 1074Â 81Â JUN-2006Â 2Â Serum Alkaline PhosphataseÂ 1076Â DEC-2006Â 3Â ElectromyographyÂ 1076Â 1154Â DEC-2004Â APR-2004Â JUN-2006Â 4Â PolymyositisÂ 1078Â 1083Â 82Â Â 5Â Selective COX 2 InhibitorsÂ 1091Â JUN-2005Â 6Â Juvenile Rheumatoid ArthritisÂ Â SEP-2003Â 7Â Stills DiseaseÂ Â OCT-2002Â 8Â Intraarticular Injection TherapyÂ 1095Â Â 9Â Hand deformities in Rheumatoid ArthritisÂ 1103Â JUN-2005Â 10Â Ocular lesions of Rheumatoid ArthritisÂ Â APR-2004Â DEC-2004Â 11Â Biological response modifiers in Rheumatoid Arthritis TherapyÂ Â SEP-2003Â 12Â Management of rheumatoid arthritisÂ Â FEB-2001Â SEP-2000Â 13Â Felty's SyndromeÂ 1105Â AUG-2001Â 14Â DMARDÂ 1105Â APR-2004Â 15Â Ankylosing SpondylitisÂ 1106Â DEC-2006Â 16Â Seronegative SpondyloarthropathyÂ 1106Â OCT-2002Â 17Â SulfasalazineÂ 1108Â JUL-2008Â 18Â Reiter's SyndromeÂ 1108Â 1034Â 917Â 1309Â APR-2004Â 19Â Psoriatic ArthritisÂ 1109Â DEC-2004Â JUN-2006Â 20Â GoutÂ Â MAY-1999Â 21Â Acute Gouty AttackÂ 1112Â JUN-2005Â 22Â Gouty TophiÂ 1113Â DEC-2004Â 23Â ColchicineÂ 1112Â OCT-2002Â 24Â Diagnosis of OsteoporosisÂ Â JUN-2006Â 25Â Radiological features in OsteoporosisÂ 1121Â DEC-2006Â 26Â Osteomalacia.Â 1126Â SEP-2000Â 27Â Steroids in MedicineÂ 1126Â 973Â APR-2000Â 28Â CREST SyndromeÂ 1135Â AUG-2002Â 29Â Charcots JointÂ 1144Â DEC-2004Â JUN-2006Â 30Â Assistive Device in Chronic ArthritisÂ -Â JUN-2005Â JUN-2006Â Â NEUROLOGICAL DISORDERSÂ Â Â 1Â Abdominal reflexÂ Â JUN-2006Â 2Â Dissociated Sensory lossÂ Â JUN-2006Â 3Â False localising signs in CNS DiseaseÂ Â JUL-2008Â 4Â Draw &amp;amp; Label : Course of the Cortico Spinal Tract.Â Â JUN-2006Â JUL-2008Â DEC-2006Â 5Â Draw &amp;amp; Label :  Course of Facial NerveÂ -Â FEB-2002Â 6Â Draw &amp;amp; Label :  Circle of WillisÂ -Â MAR-2003Â 7Â Berry AneurysmÂ Â JUN-2006Â 8Â Draw &amp;amp; Label :  Reflex arc of Knee JerkÂ Â JUN-2005Â 9Â Pendular Knee JerkÂ 1147Â DEC-2004Â 10Â SildenafilÂ 1150Â JUN-2005Â DEC-2004Â JUN-2006Â 11Â Draw &amp;amp; Label : EEG in Primary Generalised EpilepsyÂ 1154Â 1167Â Â 12Â Lumbar PunctureÂ 1159Â MAR-2003Â FEB-2002Â 13Â Nerve BiopsyÂ 1159Â JUN-2006Â 14Â MigraineÂ 1162Â DEC-2006Â 15Â Treatment of MigraineÂ Â APR-2000Â 16Â Cluster HeadacheÂ 1163Â FEB-2002Â 17Â Simple Partial SeizuresÂ 1167Â DEC-2006Â 18Â PetitmalÂ 1168Â Â 19Â Temporal Lobe EpilepsyÂ 1169Â APR-2004Â 20Â Jacksonian EpilepsyÂ 1169Â Â 21Â Todd's ParalysisÂ paralysis of temporary duration (normally not more than a few days) that occurs in the limb or limbs involved in jacksonian epilepsy after the seizure. Syn: Todd postepileptic paralysis.Â (Stedman)Â 1169Â FEB-2002Â 22Â Sturge-Weber SyndromeÂ [MIM*185300]. in its complete form, a triad of unilateral occurrence of 1) congenital capillary malformation (flame nevus) in the distribution of the trigeminal nerve; 2) leptomeningeal vascular malformations with intracranial calcification and neurologic signs; and 3) vascular malformation of the choroid, often with secondary glaucoma. Inheritance is unclear with most cases sporadic. See Also: encephalotrigeminal vascular syndrome. Syn: cephalotrigeminal angiomatosis, encephalotrigeminal angiomatosis, Sturge-Weber disease, Sturge-Kalischer-Weber syndrome.Â (Stedman)Â 1170Â OCT-2002Â 23Â Classify EpilepsyÂ Discuss the clinical picture of Generalised Tonic Clonic seizure.Â Describe the investigations of EpilepsyÂ Describe the management of Status EpilepticusÂ 1170Â AUG-2001Â 24Â Surgery for EpilepsyÂ -Â DEC-2004Â 25Â SUDEPÂ Sudden unexplained death in epilepsyÂ 1173Â Â 26Â Status EpilepticusÂ 1173Â OCT-2002Â DEC-2006Â 27Â PseudoseizuresÂ 1176Â Â 28Â Transient AmnesiaÂ 1176Â Â 29Â NarcolepsyÂ 1177Â SEP-2003Â 30Â Draw &amp;amp; Label :  Pyramidal TractÂ 1178Â OCT-2002Â 31Â Draw &amp;amp; Label : Extrapyramidal SystemÂ Â JUL-2007Â 32Â Draw &amp;amp; Label :  Visual PathwayÂ Â DEC-2004Â 33Â Draw &amp;amp; Label :  Visual Field DefectÂ Â OCT-2002Â 34Â Cerebellar AtaxiaÂ 1181Â FEB-2002Â 35Â TremorsÂ 1181Â FEB-2001Â 36Â HemiballismusÂ 1182Â AUG-2001Â 37Â ClonusÂ 1183Â DEC-2004Â 38Â DementiaÂ 1188Â MAY-1999Â 39Â Wernic's AphasiaÂ 1191Â APR-2004Â 40Â Sensory AphasiaÂ Â MAR-2003Â 41Â Lateral Medullary SyndromeÂ 1192Â DEC-2004Â 42Â Pseudobulbar PalsyÂ 1192Â MAR-2003Â 43Â Draw &amp;amp; Label : Pathway of Pupillary ReflexÂ 1197Â DEC-2004Â 44Â Pupillary ReflexÂ 1197Â DEC-2004Â 45Â Draw &amp;amp; Label :  Optic NeuritisÂ 1198Â OCT-2002Â 46Â Fundus examination in MedicineÂ 1198Â APR-2000Â 47Â Neurogenic BladderÂ 1200Â JUN-2005Â 48Â STROKEÂ A 24yr old female is admitted with chest pain, palpitation, breathlessnessfollowed by weakness of left half of body.Â What is the provisional diagnosis?Â List four common causes of stroke in young? Pg 1204Â What are the clinical triads of mitral stenosis?Â Outline the management ?Â Â JUL-2007Â 49Â Transient Ischaemic attacks (TIA)Â 1200Â OCT-2002Â AUG-2002Â DEC-2006Â 50Â Reversible Ischemic Neurological Deficit (RIND)Â ischemic neurologicla deficit lasting 24-96 hoursÂ Â Â 51Â Amaurosis FugaxÂ transient monoocular blindnessÂ 1200Â 1194Â Â 52Â DD of StrokeÂ 1201Â Â 53Â Reversible Ischemic Neurological DeficitÂ Â Â 54Â Evolving StrokeÂ 1200Â Â 55Â Complete StrokeÂ 1201Â Â 56Â Mini StrokeÂ Â Â 57Â Stroke SyndromesÂ TACSÂ PACSÂ POCSÂ LACSÂ From 3rd European Stroke ConferenceÂ 1201Â Â 58Â Wallenberg SyndromeÂ Â Â 59Â Lacunar InfarctÂ 1202Â 1206Â FEB-2002Â DEC-2006Â 60Â Ischaemic PenumbraÂ Penumbra  - The region of partial illumination or radiation caused by light or x-rays not originating from a point source; also called geometric unsharpness.Â Origin [Mod. L., fr. L. paene, almost, + umbra, shadow]Â (Stedman)Â 1202Â Â 61Â Discuss the aetiology, clinical features investigations and management of intra cerebral haemorrhage.Â 1203Â FEB-2001Â 62Â Subarachnoid HemorrhageÂ 1210Â 1161Â 1203Â DEC-2006Â 63Â Subdural HematomaÂ 1211Â JUL-2008Â 64Â MethylprednisoloneÂ [see also 196 918 990 1088 1137]Â 1216Â JUN-2006Â 65Â Alzheimer's DiseaseÂ 1217Â JUN-2005Â AUG-2002Â 66Â Management of ParkinsonismÂ Â JUL-2007Â 67Â L DopaÂ 1220Â JUN-2005Â JUN-2006Â 68Â Stereotaxic Surgery for ParkinsonismÂ 1221Â JUN-2005Â APR-2004Â 69Â CSF in MeningitisÂ Â JUL-2008Â 70Â Discuss the aetiology, clinical features, investigations and treatment of acute pyogenic meningitis in childrenÂ Â AUG-2001Â 71Â Treatment of Pyogenic MeningitisÂ 1227Â AUG-2001Â 72Â Management of TB MeningitisÂ 1228Â OCT-2002Â 73Â Viral EncephalitisÂ 1229Â FEB-2002Â 74Â Management of Dog BiteÂ 1229Â APR-2004Â 75Â Rabies vaccinationÂ Â SEP-2000Â 76Â Non Nerve Tissue Vaccine against RabiesÂ Â JUN-2005Â 77Â Pulse Polio ImmunisationÂ 1230Â JUN-2005Â 78Â Polio VaccinesÂ 1230Â SEP-2003Â 79Â A 40 year old manual labourer is admitted with Trismus;Â List 2 differential diagnosis.Â List 2 important points each in favour of each of these 2 diagnosis.Â List 4 drugs useful in treating one of these conditions.Â List 2 complications of one of these conditions.Â How this condition can be prevented?Â Â JUN-2006Â 80Â Treatment of TetanusÂ 1232Â OCT-2002Â 81Â Jacob-Creutzfeldt DiseaseÂ 1234Â APR-2004Â 82Â Management of Raised ICTÂ 1235Â AUG-2002Â 83Â MRI of BrainÂ 1236Â 1205Â DEC-2006Â 84Â Paraneoplastic syndromesÂ 1238Â APR-2000Â 85Â OpsoclonusÂ 1239Â Â 86Â IV Disc ProlapseÂ 1241Â JUN-2005Â 87Â Medical complications of cervical spondylosisÂ 1241Â SEP-2000Â 88Â Subacute combined degeneration of CordÂ 1245Â AUG-2002Â 89Â Entrapment of NeuropathyÂ 1246Â 1104Â JUL-2007Â 90Â Metabolic causes of Peripheral NeuropathyÂ 1246Â JUL-2008Â 91Â A 40 year old male is admitted with headache, vomitjng, tinnitus and ataxia of right side.Clinical examination showed Nerve Deafness. LMN Facial Palsy and Cerebeilar Signs on theRight side only. Ophthalmoscopy showed bilateral early papilloedema:Â 1 What is the most likely diagnosis?Â 2 Mention two points to be specifically looked for during general examination ofthis patient.Â 3 List four Investigations which willl help in conlirming the diagnosis here.Â 4 List four points to differential between LMN and UMN Facial Palsy.Â 5 List four causes for Bilateral LMN Facial Palsy.Â Â JUN-2006Â 92Â Bell's PalsyÂ 1249Â JUL-2007Â 93Â Claw Hand DeformityÂ 1251Â DEC-2004Â 94Â Management of MyastheniaÂ 1253Â JUL-2008Â Â UNALLOCATEDÂ Â Â 1Â Biological warfareÂ Â JUL-2007Â 2Â Side effects of steroid therapyÂ Â JUN-2005Â FEB-2002Â 3Â Aura of EpilepsyÂ 1168Â JUN-2005Â 4Â RadioimmunoassayÂ Â JUN-2005Â 5Â Â Â Â 6Â Cyclooxygenase IsoenzymesÂ Â DEC-2004Â 7Â TNF-a AgonistsÂ Â DEC-2004Â 8Â Intravenous Drug AbuseÂ Â DEC-2004Â SEP-2003Â 9Â X linked Inheritence Â Â APR-2004Â 10Â X linked Recessive DisorderÂ Â MAR-2003Â 11Â Formic acid PoisoningÂ Â APR-2004Â 12Â Antigen presenting CellÂ Â SEP-2003Â 13Â SuperantigensÂ Â SEP-2003Â 14Â QBCÂ Â MAR-2003Â 15Â HyperkalemiaÂ Â DEC-2006Â 16Â Treatment of HyperkalemiaÂ Â MAR-2003Â OCT-2002Â 17Â Malignant Otitis ExternaÂ Â OCT-2002Â 18Â Glycosylated HbÂ Â SEP-2000Â  Â Â Paper 2Â Â Â Â Recombinant DNA TechnologyÂ Â APR-2000Â Â POISONINGÂ Â Â 1Â Theophylline intoxicationÂ 212Â OCT-2002Â 2Â A 14 year old boy is brought with history of snakebite 2 hours ago.Â If there is ptosis and dysarthria what is the most likely explanation?Â Briefly describe the first-aid measures which should have been given at the place of bite itself?Â Which are the "Parameters" to be included in observing the patient's progress' with a "Progress monitoring chart".Â Enumerate the complications this patient could develop.Â List the steps in treatment.Â Â APR-2004Â 3Â Non poisonous snake biteÂ 221Â SEP-2003Â 4Â Treatment of Snake BiteÂ 221Â MAR-2003Â OCT-2002Â APR-2000Â 5Â Universal AntidoteÂ -Â MAR-2003Â 6Â Traube's SpaceÂ Â MAR-2003Â 7Â OctreotideÂ Â MAR-2003Â Â MEDICAL PSYCHIATRYÂ Â Â 1Â Define Hallucinations and IllusionsÂ 232Â MAR-2003Â 2Â HallucinationsÂ 232Â APR-2004Â OCT-2002Â 3Â DelusionÂ Â OCT-2002Â 4Â Conversion DisordersÂ 236Â AUG-2002Â 5Â Electroconvulsive Therapy (ECT)Â 237Â DEC-2004Â SEP-2003Â MAR-2003Â 6Â Treatment of DepressionÂ 241Â AUG-2001Â 7Â AntidepressantsÂ 241Â APR-2004Â 8Â SchizophreniaÂ 242Â JAN-2002Â FEB-2001Â 9Â Complications of AlcoholismÂ 245Â APR-2004Â 10Â Alcohol withdrawalÂ Â SEP-2003Â 11Â Anorexia NervosaÂ 248Â AUG-2002Â 12Â HysteriaÂ 250Â APR-2004Â JUN-2006Â 13Â Hysterical uncounsciousnessÂ Â SEP-2003Â 14Â Paranoid StateÂ Â SEP-2003Â 15Â Lucid Interval Â -Â MAR-2003Â Â ONCOLOGYÂ Â Â 1Â Tumour markersÂ 258Â SEP-2000Â 2Â Antimalignant DrugsÂ Â DEC-2006Â 3Â CyclophosphomideÂ 266Â OCT-2002Â Â INFECTIOUS DISEASESÂ Â Â 1Â Diagnosis of Typhus feverÂ Â JUN-2006Â 2Â Liver BiopsyÂ 287Â DEC-2004Â OCT-2002Â 3Â Correction of DehydrationÂ 294Â OCT-2002Â 4Â Chronic DiarrhoeaÂ 295Â AUG-2001Â 5Â Larva MigransÂ 298Â DEC-2004Â FEB-2001Â 6Â Complications of MumpsÂ 302Â DEC-2006Â 7Â Shingles/Herpes ZosterÂ 305Â OCT-2002Â JAN-2002Â 8Â Dengue Hemorrhagic FeverÂ 309Â SEP-2003Â 9Â Japanese EncephalitisÂ 312Â APR-2004Â 10Â Transmission of JEÂ 312Â JUN-2005Â JUN-2006Â 11Â Prevention of JEÂ Â DEC-2004Â 12Â TSSÂ 314Â SEP-2003Â 13Â Relapsing FeverÂ 320Â APR-2004Â 14Â Leptospirosis/Weils DiseaseÂ 321Â AUG-2001Â MAY-1999Â 15Â Diagnosis of LeptospirosisÂ Â DEC-2006Â 16Â A 20 year old man gives a history of fever of 1 week and is disoriented. Â Discuss the differential diagnosis and relevant investigations.Â Mention the drugs used in typhoid fever with correct dosages.Â Â SEP-2000Â 17Â PlagueÂ 322Â SEP-2000Â 18Â Carrier State in TyphoidÂ 324Â JUN-2005Â 19Â Complications of TyphoidÂ 324Â JUN-2005Â 20Â Describe the etiology, pathogenesis, clinical features and managemne tof enteric fever.Â Â JAN-2002Â 21Â Chemoprophylaxis of TyphoidÂ Â AUG-2002Â 22Â Typhoid VaccinesÂ 325Â DEC-2004Â APR-2004Â 23Â Management of Typhoid feverÂ Â DEC-2006Â 24Â Widal TestÂ Â JUN-2006Â 25Â Control of spread of Cholera in the communityÂ Â JUN-2006Â 26Â Difference between Bacterial and Amoebic DysentryÂ 330Â APR-2004Â 27Â Management of DysentryÂ 331Â AUG-2002Â 28Â BotulismÂ 333Â JUN-2005Â 29Â Lepra BacillusÂ Â SEP-2003Â 30Â Lepra ReactionÂ 335Â JUN-2005Â OCT-2002Â AUG-2002Â 31Â Reactions in LeprosyÂ 335Â APR-2004Â JUN-2006Â 32Â Lab diagnosis of LeprosyÂ Â DEC-2004Â 33Â Biological WarfareÂ 342Â APR-2004Â 34Â Draw &amp;amp; Label : Gametocytes of all four species of PlasmodiaÂ 344Â APR-2004Â 35Â Draw &amp;amp; Label : Ring forms of all four species of PlasmodiaÂ 344Â SEP-2003Â 36Â Gametocytes of MalariaÂ Â JUN-2006Â 37Â Cerebral MalariaÂ 345Â SEP-2000Â 38Â ChloroquineÂ 347Â DEC-2004Â 39Â ArtemeterÂ 347Â MAR-2003Â 40Â Treatment of MalariaÂ Â OCT-2002Â 41Â Drug resistance in MalariaÂ Â SEP-2003Â 42Â Chemoprophylaxis of MalariaÂ Â JUN-2005Â DEC-2004Â JUN-2006Â 43Â Cerebral MalariaÂ Â APR-2004Â 44Â Treatment of Cerebral MalariaÂ Â MAR-2003Â 45Â Draw &amp;amp; Label :  Entamoeba HistolyticaÂ 359Â DEC-2004Â 46Â Draw &amp;amp; Label : Schematic diagram of Amoebic Ulcer in IntestineÂ Â DEC-2006Â 47Â Extraintestinal AmoebiasisÂ Â AUG-2002Â 48Â Treatment of Extraintestinal AmoebiasisÂ Â MAR-2003Â 49Â Hepatic AmoebiasisÂ 987Â JAN-2002Â 50Â Draw &amp;amp; Label :  Life Cycle of AnkylostomiasisÂ Â MAR-2003Â 51Â Draw &amp;amp; Label : Hook Worm Ova as seen in stools.Â Â JUN-2006Â 52Â Draw &amp;amp; Label :  Ova of Trichuris TrichuraÂ 360Â OCT-2002Â 53Â Draw &amp;amp; Label :  Ova of Round worm &amp;amp; Hook wormÂ 360Â APR-2004Â 54Â Broad Spectrum AntihelminthicsÂ 360Â JUN-2005Â 55Â StrongyloidosisÂ 361Â AUG-2001Â 56Â Draw &amp;amp; Label :  Ascariasis OvaÂ 362Â OCT-2002Â 57Â Describe the aetiology, clinical features, complications, investigations and management ofÂ Bancroftian filariasis.Â 363Â FEB-2001Â 58Â IvermectinÂ 363Â MAR-2003Â 59Â Guinea WormÂ 366Â MAY-1999Â 60Â Draw &amp;amp; Label :  A Segment of Pork TapewormÂ 370Â DEC-2004Â 61Â NeurocysticercosisÂ 371Â DEC-2004Â 62Â Hydatid DiseaseÂ 371Â SEP-2000Â 63Â Draw &amp;amp; Label :  Hydatid CystÂ 371Â SEP-2003Â 64Â Hydatid CystÂ 371Â DEC-2004Â 65Â Oral CandidiasisÂ 373Â AUG-2001Â DEC-2006Â Â HIVÂ Â Â 1Â HIV InfectionÂ Â SEP-2000Â 2Â Cutaneous manifestations of HIVÂ Â MAR-2003Â 3Â Oral manifestations of HIV infection.Â Â FEB-2001Â 4Â Diagnosis for HIV InfectionÂ Â SEP-2003Â AUG-2001Â JUN-2006Â 5Â Prevention of HIV InfectionÂ Â JUN-2005Â 6Â Opportunistic infectionsÂ 383Â APR-2000Â 7Â Oesophageal CandidiasisÂ 386Â MAR-2003Â 8Â Pneumocystis cariniiÂ 389Â AUG-2001Â 9Â PCNSNLÂ 392Â Â 10Â Kaposi SarcomaÂ 396Â AUG-2002Â JAN-2002Â Â SEXUALLY TRANSMITTED DISEASESÂ Â Â 1Â Primary SyphilisÂ Â DEC-2006Â 2Â Specific Tests for SyphilisÂ 411Â APR-2004Â JUN-2005Â 3Â Jarisch Herxheimer reactionÂ 413Â MAR-2003Â 4Â Congenital syphilisÂ Â JUN-2006Â Â RESPIRATORY DISEASEÂ Â Â 1Â Pulmonary EdemaÂ Â DEC-2006Â 2Â Complications of Lobar PneumoniaÂ Â JUN-2006Â 3Â Management of Acute Pulmonary OedemaÂ Â JUN-2006Â 4Â Draw &amp;amp; Label :  Pulmonary SegmentsÂ 650Â MAR-2003Â 5Â Management of Acute BreathlessnessÂ 658Â AUG-2002Â 6Â Differentiation between Hemoptysis and HaematemesisÂ 662Â SEP-2003Â 7Â Bronchial AdenomasÂ 663Â FEB-2002Â 8Â Investigations for Pleural EffusionÂ 664Â Â 9Â Causes of Pleural EffusionÂ 665Â Â 10Â Pleural tapÂ 665Â AUG-2002Â 11Â Pleural aspiration diagnostic valueÂ 665Â SEP-2000Â 12Â Sleep Apnoea SyndromeÂ 666Â SEP-2003Â AUG-2002Â 13Â Leukotriene AntagonistÂ 674Â JUN-2005Â JUN-2006Â 14Â Management of AsthmaÂ 675Â AUG-2001Â 15Â AminophyllineÂ 678Â DEC-2004Â JUN-2006Â 16Â BCG VaccinationÂ Â MAR-2003Â 17Â Pulmonary function tests in obstructive airway disease.Â 680Â FEB-2001Â 18Â Discuss the aetiology, clinical features and management of bronchiectasis. Enumerate its complicationsÂ Â APR-2000Â 19Â Cystic FibrisisÂ 685Â FEB-2002Â 20Â Community Acquired PneumoniaÂ 689Â FEB-2002Â 21Â Describe the etiology, clinical features, complications, investigations and treatment of lobar pneumonia?Â 690Â 691Â JAN-2002Â 22Â Pathogenesis of ConsolidationÂ 698Â DEC-2006Â 23Â Treatment of Lung AbscessÂ 694Â MAR-2003Â 24Â ESSAY : A 25 year old mal-nourished adult presented with evening rise of temperature, chestpain, breathlessness and cough of two weeks duration.Â What is the provisional diagnosis?Â Enumerate the investigations.Â What are the complications?Â Outline the management.Â Â DEC-2006Â 25Â What is primary complex? Â Enumerate the symptoms of primary complex?Â what are the complications of childhood tuberculosis?Â discuss the investigations and treatment of primary complex?Â 695Â FEB-2001Â 26Â Miliary TuberculosisÂ Â JAN-1999Â 27Â Tuberculin TestingÂ 700Â JUN-2005Â 28Â Mantoux TestÂ 700Â MAR-2003Â AUG-2001Â 29Â Drug Resistance in TBÂ 702Â APR-2004Â JUN-2006Â 30Â MDRTBÂ 702Â AUG-2001Â 31Â Prevention of Drug Resistance in TBÂ Â JUN-2005Â 32Â AtelectasisÂ 707Â MAR-2003Â 33Â Hypersensitivity PneumonitisÂ 719Â Â 34Â Farmer's LungÂ 719Â Â 35Â Byssinosis / Monday FeverÂ 720Â Â 36Â SCWPÂ 721Â Â 37Â Progressive Massive Fibrosis (PMF)Â 721Â Â 38Â Caplan SyndromeÂ 721Â 723Â Â 39Â SilicotuberculosisÂ 721Â Â 40Â Asbestos BodiesÂ 722Â Â 41Â Pulmonary eosinophiliaÂ 723Â FEB-2001Â 42Â Pulmonary ThromboembolismÂ 724Â OCT-2002Â 43Â EmpyemaÂ Pus in a body cavity; when used without qualification, refers specifically to pyothorax.Â 732Â DEC-2006Â 44Â PyothoraxÂ Empyema in a pleural cavity.Â 732Â DEC-2006Â 45Â PyopneumothoraxÂ Â Â 46Â Intercostal tube drainageÂ Â Â 47Â Spontaneous PneumothoraxÂ Â Â 48Â Tension pneumothorax.Â 734Â SEP-2000Â 49Â Closed PneumothoraxÂ 734Â Â 50Â MesotheliomaÂ 734Â Â 51Â Causes of elevation of HemidiaphragmÂ 736Â FEB-2002Â 52Â Pigeon Chest deformityÂ 737Â Â Â SKIN DISEASEÂ Â Â 1Â Treatment of UrticariaÂ 1270Â MAR-2003Â 2Â Nail in Systemic DisordersÂ 1281Â AUG-2002Â 3Â ClubbingÂ 1283Â 850Â MAR-2003Â 4Â PsoriasisÂ 1287Â MAY-1999Â 5Â ScabiesÂ Â AUG-2001Â JUN-2006Â 6Â Norwegian ScabiesÂ 1298Â APR-2004Â 7Â Treatment of ScabiesÂ Â SEP-2003Â MAR-2003Â 8Â Exfoliative DermatitisÂ 1307Â OCT-2002Â 9Â Steven Johnson SyndromeÂ 1308Â AUG-2002Â 10Â XanthomaÂ 1308Â DEC-2004Â Â UNALLOCATEDÂ Â Â 1Â Serum Protein ElectrophoresisÂ 420Â JUN-2005Â 2Â TelemedicineÂ Telemedicine is a rapidly developing application of clinical medicine where medical information is transferred through the phone or the Internet and sometimes other networks for the purpose of consulting, and sometimes remote medical procedures or examinations.Â Telemedicine may be as simple as two health professionals discussing a case over the telephone, or as complex as using satellite technology and videoconferencing equipment to conduct a real-time consultation between medical specialists in two different countries. Telemedicine generally refers to the use of communications and information technologies for the delivery of clinical care.Â en.wikipedia.org/wiki/TelemedicineÂ -Â JUN-2005Â JUN-2006Â 3Â Prefrontal LeucotomyÂ Â DEC-2004Â 4Â Ehrlich's TestÂ Â DEC-2004Â 5Â Paraneoplastic EndocrinopathiesÂ Â APR-2004Â 6Â H2 Receptor Blocking AgentsÂ Â APR-2004Â 7Â Bed SoreÂ Â APR-2004Â 8Â Features of Chron's DiseaseÂ Â FEB-2002Â 9Â Hysterical Conversion ReactionÂ Â AUG-2001Â PracticalsÂ COMMON CLINICAL PROCEDURESÂ VIVA QUESTIONS IN GENERAL EXAMINATIONÂ Measurement of PulseÂ 1. Â Measurement of Blood PressureÂ Measurement of TemperatureÂ 2. Sites to measure temperature?Â 3. Which site will you prefer ?Â 4. What is the difference in the oral and axillary temperatures?Â oral is 1Â°F higher than axillaÂ 5. Types of Fever?Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; THREE typesÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; continuedÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; remittentÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; intermittent Â Looking for PallorÂ Looking  for CyanosisÂ 6. What is Cyanosis?Â bluish or purplish discoloration of skin OR mucous membrane due to the presence of excessive amount of reduced Hemoglobin in the UNDERLYING blood vesselsÂ 7. Amount of REDUCED Hb to present to show cyanosis?Â 5g/dl (or say 5 g%)Â NOTE: avoid mistakes like 5mg% etcÂ 8. Types ?Â centralÂ peripheralÂ Looking for ClubbingÂ 9. Grades of ClubbingÂ Looking for JaundiceÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Examine in day lightÂ 10. Sites to look for Jaundice?Â ScleraÂ Nail BedÂ Ear LobuleÂ Nose tipÂ Tongue undersurfaceÂ 11. How to differentiate Jaundice from Hypercarotenemia?Â by its absence in sclera, but presence in face, palms and solesÂ seen in vegetarians (excess carrot intake)Â 12. Cause of jaundice?Â presence of lipid soluble yellow pigments in the plasmaÂ PainÂ 13. Â LONG CASESÂ 14. Â CVSÂ Mitral StenosisÂ Mitral IncompetenceÂ Aortic StenosisÂ Aortic IncompetenceÂ Bacterial EndocarditisÂ RESPIRATORY SYSTEMÂ Pleural EffusionÂ PneumothoraxÂ HydropneumothoraxÂ ConsolidationÂ COPD/AsthmaÂ GITÂ Viral HepatitisÂ Liver CirrhosisÂ 15. xÂ 140/1990 mmHg or more with proteinuria after the 20th weekÂ 16. How to differentiate jaundice from carotenemia?Â xÂ Pyloric StenosisÂ CNSÂ HemiplegiaÂ ParaplegiaÂ ParkinsonismÂ Peripheral NeuropathyÂ SHORT CASESÂ RESPIRATORY SYSTEMÂ Lung CollapseÂ Superior Mediastinal SyndromeÂ GITÂ AscitesÂ Abdominal LumpÂ HepatosplenomegalyÂ CNSÂ Cerebellar DisorderÂ Bulbar PalsyÂ Â Â  Â SURGERYÂ 1Â Paper 1Â Â Â 2Â UNALLOCATEDÂ Â Â 3Â Draw &amp;amp; Label : Branches of Abdominal AortaÂ Â DEC-2004Â 4Â Anastamosis in the Gastrointestinal TractÂ Â SEP-2003Â 5Â Intestinal AnastamosisÂ Â FEB-2008Â 6Â Surgical care of Abdominal DistensionÂ Â FEB-2008Â 7Â Indications of OSD ExplorationÂ Â JUL-2008Â 8Â Internal BleedingÂ Â FEB-2008Â 9Â PERITONEUMÂ Â Â 10Â A ten year old child is brought to casualty with the history of acute abdominal pain of one day duration. There is history of vomiting and blood stained motion. On examination the child is having abdominal distension. The child cries immediately on touching the abdomen.Â What are the conditions to be considered in diagnosis?Â Discuss the pathology of any one condition?Â How will you investigate?Â Detail the different types of treatment of the most common condition?Â In what way the treatment differes from the adult?Â Â APR-2004Â 11Â Resuscitative measures to be done in a patient who has perforative peritonitis of 12 hours durationÂ Â MAR-2003Â 12Â Spontaneous peritonitisÂ 504Â Â 13Â Pneumococcal PeritonitisÂ Â Â 14Â Types of Tubercular PeritonitisÂ Â Â 15Â Stages of Peritonitis Â Â Â 16Â Complications of PeritonitisÂ Â Â 17Â Pelvic AbscessÂ 506Â Â 18Â Subphrenic SpacesÂ Â Â 19Â Subphrenic AbscessÂ Â Â 20Â Sub-diaphragmatic AbscessÂ 507Â MAY-1999Â 21Â Common causes of Subphrenic abscessÂ Clinical features and investigations of Subphrenic abscessÂ Management of subphrenic abscessÂ Complicaitons of subphrenic abscessÂ 508Â AUG-2001Â 22Â Draw &amp;amp; Label : Peritoneal SpacesÂ 508Â APR-2004 Â JUL-2007Â 23Â Classify CystsÂ 510Â MAR-2003Â 24Â Types of Mesenteric CystsÂ 510Â APR-2004Â 25Â Carcinoma PeritoneiÂ 511Â Â 26Â Investigations in a case of PeritonitisÂ Â MAY-1999Â 27Â Clinical Significance of Douglas PouchÂ Â APR-2004Â 28Â Transpyloric planeÂ Â FEB-2002Â Â ABDOMINAL TUBERCULOSISÂ Â Â 29Â Management of Caecal TuberculosisÂ Â AUG-1998Â 30Â Tuberculous lesions of intestinesÂ Â SEP-1997Â 31Â Tuberculous PeritonitisÂ 518Â AUG-2001Â 32Â Treatment of Tuberculous PeritonitisÂ Â SEP-2000Â 33Â Types of Tuberculous PeritonitisÂ 518Â JUL-2008Â 34Â THE LIVERÂ 525Â Â 35Â Sites of Portosystemic anastamosisÂ Â Â 36Â Primary Biliary CirrhosisÂ Â Â 37Â Draw &amp;amp; Label : Segments of LiverÂ 526Â Â 38Â Liver BiopsyÂ 527Â Â 39Â Your are  seeing a surgeon doing a needle liver biopsy for a case of hepatomegaly in male of 65 years old who is jaundiced.Â 1 What precautions should have been taken before the procedure to prevent undue bleedingand risk of infection?Â 2 Which area ofthe abdomen is chosen for the needle biopsy and why?Â 3 What are the types of liver biopsy needles you know?Â 4 To enhance the chance of targeting the truly representative sample, what other investigationÂ may be combined with this.Â 5 What is hepato renal syndrome?Â Â MAR-2003Â 40Â Amoebic Liver AbscessÂ 528Â AUG-2001Â 41Â Comlications of Amoebic Liver AbscessÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Rupture into LungsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Rupture into peritoneumÂ 529Â Â 42Â Management of Liver AbscessÂ 528Â 656Â JUL-2007Â 43Â Pyogenic Liver abscessÂ 537Â Â 44Â Malignancies of LiverÂ 538Â AUG-2002Â 45Â Types of HepatomaÂ 539Â Â 46Â Histological types of Liver MalignancyÂ 540Â MAR-2003Â 47Â Portocaval AnastomosisÂ 546Â DEC-2004Â 48Â Sites of Portosystemic anastomosisÂ 546Â MAR-2003Â 49Â TIPSSÂ 552Â Â 50Â Budd Chiari SyndromeÂ 557Â NOV-2002Â 51Â Discuss the causes of Splenic enlargement?Â Discuss the management of Portal Hypertension?Â Discuss the management of Splenic Injury?Â Â JAN-1999Â 52Â Hepatic EncephalopathyÂ 558Â DEC-2006Â 53Â Portal HypertensionÂ Â MAY-2002Â 54Â A 45 year old male is brought to the casuality with history of severe vomitting of blood of six hours duration. He is in shock with a blood pressure of 60 systolic. There is history of alcoholism.Â What are the possible conditions to be considered in the diagnosis?Â Discuss the pathology of any one condition?Â How will you investigate the patient?Â Detail the different types of treatment of the most common condition?Â How will you resuscitate the patient in the casuality?Â Â DEC-2004Â 55Â A 30 year old man is brought to the casuality with history of 7 bout of vomitting of blood. He has history of alcoholism. On Examination the patient is in shock. He has abdominal distension. Aspiration yields clear fluid.Â What are the possible conditions to be considered in the diagnosis?Â What is the emergency management of any one condition?Â How will you investigate the patient?Â Detail the different type of treatment for the most common condition?Â Â SEP-2003Â 56Â Draw &amp;amp; Label : Types of Portal ObstructionÂ Â JUN-2005Â Â GALLBLADDERÂ Â Â 57Â Oral Cholecystogram (OCG)Â 6 tabs of iopanoic acidÂ 562Â MAY-1999Â 58Â Parts of extra hepatic biliary ductÂ 562Â AUG-2002Â 59Â Draw &amp;amp; Label : Duodenum with Pancreatic Biliary DuctsÂ supraduodenal partÂ retroduodenal partÂ intraduodenal partÂ 562Â FEB-2002Â 60Â Calot's TriangleÂ 562Â Â 61Â ERCPÂ 563Â APR-2004Â JUL-2008Â FEB-1998Â 62Â PTCÂ Â Â 63Â T TubeÂ 565Â JUN-2005Â 64Â Choledochal CystÂ 567Â Â 65Â Types of Biliary AtresiaÂ 569Â Â 66Â Caroli's DiseaseÂ 569Â Â 67Â Gall StoneÂ 571Â AUG-2001Â JUN-2006Â AUG-2001Â 68Â Types of Gall StonesÂ 571Â APR-2000Â 69Â Types of Biliary StonesÂ 571Â MAR-2003Â 70Â Cholesterol StonesÂ 571Â Â 71Â Pigment StonesÂ 572Â Â 72Â Moynihan's humpÂ [see Bailey 1112]Â 572Â Â 73Â Treatment of Gall StonesÂ 571Â APR-2000Â 74Â Management of Calculous obstruction of common bile ductÂ Â FEB-2001Â 75Â Seagull SignÂ 572Â Â 76Â Saints triadÂ Gallstones Â Diverticulosis of ColonÂ Hiatus HerniaÂ 572Â 726Â 820Â MAY-2002Â 77Â Limey BileÂ 573Â Â 78Â Complications of Gall StonesÂ 574Â APR-2000Â 79Â Mirizzis's SyndromeÂ 575Â Â 80Â CholecystitisÂ 576Â APR-2004Â 81Â Management of Acute CholecystitisÂ 577Â MAY-1999Â 82Â Mucocele of Gall BladderÂ 580Â JAN-1999Â 83Â Murphy's SignÂ 581Â Â 84Â Charcot's TriadÂ intermittent painÂ intermittent feverÂ intermittent jaundiceÂ 583Â FEB-2002Â JUL-2008Â 85Â Implications of Charcot's triad in SurgeryÂ 583Â SEP-2003Â 86Â Acalculous CholecystitisÂ 586Â 578Â Â 87Â Courvoisier's LawÂ "In a pt with jaundice if there is palpable GB, it is not due to stones"Â 586Â 632Â AUG-2002Â MAR-2003Â 88Â A 60 year old male presents with progressive jaundice of 3 months duration. There was no fever or abdominal pain. He has severe itching all over the body and passes clay coloured stools.Â What is the most probable diagnosis?Â How will you investigate this patient?Â Name the surgical procedure for periampullary carcinoma?Â What are the palliative procedures in inoperable Ca head of Pancreas?Â What is the treatment for CSD stones?Â Â JUL-2008Â 89Â Obstructive JaundiceÂ 587Â SEP-2003Â MAY-1999Â 90Â Surgical causes of Obstructive JaundiceÂ 587Â FEB-2001Â 91Â Klatskin's tumourÂ 587Â 592Â Â 92Â Investigations for Obstructive JaundiceÂ 588Â FEB-2001Â MAY-1999Â 93Â Investigation of Surgical JaundiceÂ 588Â JUL-2007Â JUN-2006Â 94Â Biliary StrictureÂ 589Â OCT-2002 MAY-2002Â 95Â Management of CBD StoneÂ 589Â APR-2000Â 96Â Pringle's ManoevreÂ 590Â APR-2004Â 97Â Primary Sclerosing CholangitisÂ 590Â Â 98Â CholangiocarcinomaÂ 592Â Â 99Â Gallstone IlleusÂ 593Â Â 100Â White BileÂ 594Â SEP-1997Â 101Â CholecystectomyÂ 595Â OCT-2002Â 102Â Laparoscopic CholecystectomyÂ Â Â 103Â THE SPLEENÂ Â Â 104Â SplenenculiÂ 600Â Â 105Â Splenic RuptureÂ 600Â JUN-2005Â JUN-2006Â FEB-2001Â 106Â Traumatic rupture of spleenÂ 600Â FEB-2002Â MAR-2003Â 107Â SplenosisÂ 601Â Â 108Â Kehr's SignÂ 601Â FEB-2002Â 109Â Ballance's SignÂ 601Â Â 110Â Diagnostic Peritoneal Lavage (DPL)Â 602Â 124Â Â 111Â Indications for SplenectomyÂ 608Â Â 112Â Complications of SplenectomyÂ 608Â 603Â 126Â OCT-2002 MAY-2002Â 113Â OPSIÂ 609Â Â 114Â HypersplenismÂ 610Â JUL-2008Â DEC-2006Â 115Â THE PANCREASÂ Â Â 116Â Draw &amp;amp; Label : Anatomy of PancreasÂ 612Â Â 117Â MRCPÂ 613Â Â 118Â PANCREATITISÂ Causes of Acute PancreatitisÂ Investigations in Acute PancreatitisÂ Management of Acute PancreatitisÂ Â AUG-1998Â 119Â Inflammation of PancreasÂ 613Â SEP-2003Â 120Â Clinical features of Acute PancreatitisÂ 614Â DEC-2004Â 121Â Cullen's SignÂ 615Â JUN-2006Â 122Â Grey turner's SignÂ 615Â Â 123Â Treatment of a patient having positve Cullen's SignÂ 615Â SEP-2003Â 124Â OctreotideÂ 618Â 641Â Â 125Â Sentinel LoopÂ Â Â 126Â Complications of Acute PancreatitisÂ 618Â JUL-2008Â 127Â Pseudocyst of PancreasÂ 620Â OCT-2002Â MAY-2002Â AUG-2001Â 128Â Pathology of Pseudopancreatic CystÂ 620Â 618Â 659Â JUN-2005Â 129Â Ranson's CriteriaÂ 620Â APR-2004Â JUN-2006Â 130Â Juraz OperationÂ 622Â APR-2004Â JUN-2006Â JUN-2005Â 131Â Puestow's OperationÂ 627Â Â 132Â PANCREATIC CARCINOMAÂ Â Â 133Â Investigation in a case of Pancreatic MalignancyÂ 633Â SEP-1997Â 134Â Treatment of Ca Head of PancreasÂ 634Â FEB-2008 JUN-2005Â 135Â Treatment of carcinoma ampulla Vater.Â 635Â FEB-2001Â 136Â Whipples OperationÂ 635Â 627Â 629Â FEB-2002Â 137Â Whipple's triadÂ HypoglycemiaÂ Blood Sugar &amp;lt;45 mg%Â Relieved by Glucese infusionÂ 638Â OCT-2002Â 138Â Zollinger Ellison SyndromeÂ 640Â Â 139Â Annular PancreasÂ 641Â MAR-2003Â 140Â Pancreatis DivisumÂ 642Â Â 141Â RETROPERITONEAL SPACEÂ Â Â 142Â Seatbelt SyndromeÂ (Bailey p. 1003)Â -Â Â 143Â MASS ABDOMENÂ 653Â Â 144Â DD of Epigastric massÂ 658Â JUL-2007Â FEB-2008Â 145Â DD of Epigastric LumpÂ 658Â 711Â DEC-2004Â 146Â Management of IntussusceptionÂ 663Â 863Â AUG-2001Â 147Â A 53 yr old female attends the surgical OP with history of anorexia, nausea and vomiting. On examination there is a lump in the abdomen.Â What are the possible conditions to be considered in diagnosis?Â Discuss the pathology of any one condition?Â How will you investigate the patient?Â Detail the different types of treatment of the most common condition?Â What are the complications if the patient is untreated?Â Â Â 148Â Discuss the clinical features, investigations and management of a patient with Carcinoma Caecum?Â 663Â JAN-2002Â 149Â DD of Lump in Right Illiac FossaÂ 663Â JUN-2006Â 150Â Appendicular massÂ Â APR-2000Â FEB-2001Â FEB-1998Â 151Â ABDOMINAL WALL AND UMBILICUSÂ 666Â Â 152Â Surgical Causes of Abdominal DistensionÂ Â JUN-2005Â 153Â Desmoid TumourÂ 672Â 71Â FEB-2008Â 154Â HERNIAÂ 677Â Â 155Â Classify Inguinoscrotal SwellingsÂ -Â SEP-2003Â 156Â Anatomical types of Inguinal HerniaÂ 679Â JUL-2008Â 157Â Surface marking of inguinal ligamentÂ 680Â FEB-2002Â 158Â Draw &amp;amp; Label : Complete Inguinal HerniaÂ 683Â MAR-2003Â 159Â Internal Ring Occlusion TestÂ 683Â FEB-2002Â 160Â HerniorhaphyÂ 687Â MAR-2003Â 161Â Bassini's Hernia RepairÂ 687Â Â 162Â Conservative Treatment for HerniaÂ 691Â Â 163Â TaxisÂ 691Â Â 164Â Complications of Inguinal HerniaÂ Â FEB-2008Â 165Â Laparoscopic Hernia RepairÂ 694Â FEB-2008Â 166Â Incarcerated HerniaÂ 697Â Â 167Â Strangulated HerniaÂ 697Â JAN-1999Â 168Â Management of Strangulated Inguinal HerniaÂ 697Â APR-2000Â 169Â Maydle's HerniaÂ 698Â DEC-2004Â 170Â Sliding HerniaÂ 701Â FEB-2002Â MAR-2003Â MAY-1999Â 171Â Procedure for surgery of Pantaloon HerniaÂ 702Â Â SEP-2003Â 172Â Femoral HerniaÂ 702Â APR-2000Â AUG-1998Â 173Â Incisional HerniaÂ 706Â AUG-2001Â APR-2000Â SEP-1997Â 174Â Umbilical HerniaÂ 709Â JAN-1999Â 175Â Paraumbilical HerniaÂ 710Â JAN-2002Â 176Â Mayo's OperationÂ 711Â MAR-2003Â 177Â Spigelian HerniaÂ 712Â Â 178Â OESOPHAGUSÂ Â Â 179Â Hamman's SignÂ Â Â 180Â Bleeding Oesophagial varicesÂ Â AUG-2001Â 181Â Dysphagia LusoriaÂ 720Â Â 182Â Barium SwallowÂ 721Â 383Â MAY-1999Â 183Â GORDÂ 722Â Â 184Â Belsey mark IV ProcedureÂ 724Â 004Â APR-2004Â 185Â GastroplastyÂ 724Â Â 186Â Hiatus herniaÂ 726Â 1079Â OCT-2002Â 187Â Rolling HerniaÂ 726Â Â 188Â Reflux OesophagitisÂ 727Â OCT-2002Â 189Â Barret's OesophagusÂ 728Â JUL-2008Â 190Â Heller's OperationÂ 730Â JUN-2005Â 191Â Achalasia CardiaÂ 730Â JUL-2008Â FEB-2001Â AUG-1998Â JAN-2002Â 192Â Plummer Vinson SyndromeÂ 731Â Â 193Â Boerhave's SyndromeÂ 733Â Â 194Â Schatzkis RingÂ 733Â Â 195Â Tracheo oesophageal fistulaÂ 734Â Â 196Â Mallory Weis SyndromeÂ 734Â Â 197Â Zenker's DiverticulumÂ 735Â Â 198Â Management of Carcinoma OesophagusÂ Â Â 199Â STOMACHÂ Â Â 200Â Function of Gastric MucusÂ â€¦Gastric mucus is an important physioÂ­logical barrier to protect the gastric mucosa from mechanical damage, and also the effects of acid and pepsin. Its considerÂ­able buffering capacity is enhanced by the presence of bicarÂ­bonate ions within the mucous. Many factors can lead to the break down of this gastric mucous barrier. These includeâ€¦Â (Bailey)Â -Â MAR-2003Â 201Â Phases of secretion of Gastric juiceÂ ... Classically, three phases of gastric secretion are described. The cephalic phase is mediated by vagal activity secondary to sensory arousal as first demonstrated by Pavlov. The gastric phase is a response to food within the stomach that is mediÂ­ated principally, but not exclusively, by gastrin. In the intestiÂ­nal phase, the presence of chyme in the duodenum and small bowel inhibits gastric emptying and, as mentioned above, the acidification of the duodenum leads to the production of secretin that also inhibits gastric acid secretion, along with numerous other peptides originating from the gutâ€¦.Â (Bailey p. 1047)Â -Â MAR-2003Â 202Â Investigation of a patient with Bleeding Oesophageal VaricesÂ Â SEP-2000Â 203Â StomachÂ 745Â JUL-2007Â 204Â Draw &amp;amp; Label : Parts of StomachÂ 745Â MAR-2003Â 205Â Draw &amp;amp; Label : Blood Supply of StomachÂ 745Â OCT-2002Â AUG-2002Â 206Â Draw &amp;amp; Label : Lymphatic drainage of StomachÂ 747Â Â 207Â (a) Enumerate the causes of upper gastro-intestinal bleeding.Â (b) Discuss the management of oesophageal variceal bleeding.Â (c) Discuss the management of duodenal ulcer haemorrhage.Â Â FEB-2001Â 208Â H PyloriÂ 751Â Â 209Â Visible gastric peristalsisÂ 752Â AUG-2002Â 210Â Types of GastritisÂ 753Â Â 211Â Treatment of Chronic Duodenal UlcerÂ 759Â JUL-2007Â JUN-2006Â 212Â Management of Duodenal Ulcer PerforationÂ 762Â MAY-1999Â FEB-1998Â 213Â Enteric PerforationÂ Management of Enteric PerforationÂ 762Â JAN-1999Â MAY-1999Â FEB-2001Â 214Â Surgical Procedure for Peptic UlcerÂ 762Â AUG-2002Â 215Â Common causes of Intestinal PerforationÂ -Â SEP-2000Â JAN-1999Â 216Â Gastric TetanyÂ 762Â Â 217Â Paradoxic aciduriaÂ 762Â Â 218Â Management of Bleeding Duodenal UlcerÂ 766Â SEP-2000Â JAN-1999Â 219Â PneumoperitoneumÂ 766Â FEB-2002Â 220Â Causes of HaematemesisÂ 769Â JUN-2005 Â JUL-2007Â SEP-2000Â 221Â Stomal UlcerÂ ulcer in the anastomotic site of GJ/GDÂ 772Â Â 222Â Dumping SyndromeÂ 772Â Â 223Â TrichobezoarsÂ Trichobezoar (hair balls)  are unusual and are virtually exclusively found in female psychiatric patients, often young. It is caused by the pathological ingestion of hair which remains undigested in the stomach. The hair ball can lead to ulceration and gastrointestinal bleeding, perforation or obstructionâ€¦.Â (Bailey)Â 773Â Â 224Â PhytobezoarsÂ Phytobezoars are made of the vegetable matter and found principally in patients who have gastric stasis.Â (Bailey)Â 774Â Â 225Â Wilkie's SyndromeÂ Ileus - Mechanical, dynamic, or adynamic obstruction of the bowel; may be accompanied by severe colicky pain, abdominal distention, vomiting, absence of passage of stool, and often fever and dehydration.Â Origin [G. eileos, intestinal colic, from eilb, to roll up tight]Â (Stedman)Â 774Â 748Â Â 226Â Volvulus of StomachÂ 775Â Â 227Â Gastric PolypsÂ 776Â Â 228Â CARCINOMA STOMACHÂ Â Â 229Â Precursor lesions of Carcinoma StomachÂ 778Â Â 230Â Types of Gastric CarcinomaÂ 779Â Â 231Â Krukenburg's tumourÂ 782Â 235Â JUL-2008Â 232Â Sister Mary Joseph nodulesÂ 782Â Â 233Â Linitis PlasticaÂ 783Â AUG-2002Â 234Â Marnagement of Carcinoma StomachÂ 787Â JUL-2007Â DEC-2004Â 235Â Treatment of Carcinoma StomachÂ 787Â JUN-2006Â 236Â D2 dissection in Carcinoma StomachÂ 787Â SEP-2003Â 237Â MALTOMAÂ 790Â Â 238Â GISTÂ 791Â 812Â Â 239Â PyloroplastyÂ 792Â APR-2004Â 240Â GastrostomyÂ 793Â 83Â DEC-2004 Â SEP-2003Â 241Â Draw &amp;amp; Label : Billroth AnastomosisÂ 794Â Â 242Â Billroth II GastrectomyÂ 794Â 787Â Â 243Â GastrojujunostomyÂ 794Â APR-2004Â 244Â Poly GastrectomyÂ 794Â OCT-2002Â 245Â Blind Loop SyndromeÂ â€¦ It has been shown in dogs that, if a blind loop of the small intestine is made,defects of absorption will appear. If this occurs in the upper intestine the defect is chiefly of fat absorption; if in the lower intestine there is vitamin B12 deficiency. This has been found to occur in humans and is referred to as the blind loop syndrome.Â Essentially, the stasis produces an abnormal bacterial flora, which prevents proper breakdown of the food (especially fat) and mops up the vitamins that are present. Sometimes the only manifestation is anaemia, resulting from vitamin B12 deficiency, but if steatorrhoea appears, other serious malabsorption features follow. In general, high loops produce steatorrhoea, whereas low loops tend to produce anaemia.Â (Bailey)Â stagnation of intestinal contents with bacterial overgrowth producing substances that interfere with absorption of fat, vitamins, and other nutrients, usually occurs in a portion of small intestine that has been excluded from the flow of chyme.Â (Stedman)Â Â Â 246Â Complications of GastrectomyÂ 794Â Â 247Â Types of VagotomyÂ 795Â Â 248Â Draw &amp;amp; Label : Highly Selective VagotomyÂ 795Â 746Â AUG-2002Â 249Â Complications of VagotomyÂ Â Â 250Â IHPSÂ Infantile hypertrophic pyloric stenosisÂ (Bailey)Â ?Â Â 251Â Debulking surgeryÂ Ulcer craterÂ Augmented histamine testÂ Â Â 252Â THE SMALL INTESTINEÂ Â Â 253Â A 32yr old female was admitted with severe central abdominal pain, vomiting and constipation. There was nothing significant in the past history except the appendix operation when she was young. Abdomen was distended. Xray abdomen showed distension of the ileum with fluid levels.Â What is the most likely diagnosis?Â What is the immediate treatment?Â What is the procedure of choice?Â What are the complications following specific treatment?Â How will you prevenet the recurrence?Â Â MAY-2002Â 254Â Meckel's DiverticulumÂ 799Â AUG-2002Â FEB-2001Â MAY-1999Â 255Â Meckel's DiverticulectomyÂ 799Â OCT-2002Â MAY-2002Â 256Â Crohn's DiseaseÂ 800Â JAN-1999Â 257Â Typhoid perforation of ileumÂ 803Â AUG-2001Â 258Â Treatment of Typhoid Ulcer PerforationÂ 803Â SEP-2000Â 259Â Acute Mesenteric IschaemiaÂ 806Â Â 260Â Carcinoid SyndromeÂ 813Â Â 261Â LARGE INTESTINEÂ Â Â 262Â Draw &amp;amp; Label : Blood Supply of Colon and RectumÂ Â SEP-2003Â 263Â Hisrchsprung's DiseaseÂ 818Â JUL-2008Â OCT-2002Â MAY-2002Â 264Â DiverticulosisÂ 821Â Â 265Â Ramsted's OperationÂ 824Â Â 266Â Complications of Ulcerative ColitisÂ 828Â MAY-2002Â 267Â Ulcerative ColitisÂ 827Â Â 268Â Classification of Carcinomoa ColonÂ Â Â 269Â Predisposing factors of CA ColonÂ 830Â AUG-2002Â 270Â Carcinoma left side of colonÂ Â AUG-1998Â 271Â Polyps of Colon and RectumÂ 830Â OCT-2002Â 272Â Peutz Jeghers SyndromeÂ 831Â Â 273Â Types of ColostomyÂ 843Â APR-2004 Â AUG-2002Â 274Â Complications of ColostomyÂ Â Â 275Â Duodenal AtresiaÂ 858Â Â 276Â Hartmann's ProcedureÂ 858Â 868Â 897Â Â 277Â Bishop Koop ProcedureÂ 862Â Â 278Â IntussusceptionÂ 863Â 663Â Â 279Â Radiological Features of Volvulus of Sigmoid ColonÂ 866Â JUN-2005Â 280Â Ogilvie's SyndromeÂ 868Â 842Â Â 281Â Management of Volvulus of Sigmoid Colon Â Â AUG-1998Â 282Â VolvulusÂ Â JUN-2006Â AUG-1998Â 283Â Left HemicolectomyÂ Â MAY-2002Â 284Â Rectal PolypÂ 830Â AUG-2001Â MAY-1999Â 285Â Adenomatous PolypÂ 832Â SEP-2000Â 286Â Familial PolyposisÂ 834Â JUL-2008Â 287Â INTESTINAL OBSTRUCTIONÂ Â Â 288Â A 40 year old male with a/c Bowel Obstruction since 20 hrs.Â What is the purpose of passing Ryles Tube?Â Distance between incisor teeth and GO jn in an adult male?Â How do you find out radiographically the tip of Ryles tube?Â What is third space?Â Â FEB-2002Â 289Â A 70 year old man is brought to the casuality with h/o abdominal distension and constipation of 5 days duration. Hb â€“ 6 GM -/dLÂ Differential DiagnosisÂ InvestigationsÂ Pathology of your Diagnosis?Â Discuss the physiology of Abdominal Distension?Â Â JUN-2005Â 290Â Cardinal features of intestinal ObstructionÂ 851Â FEB-2002Â 291Â Common causes of Acute Small Intestinal ObstructionÂ 851Â AUG-2001Â AUG-1998Â 292Â Causes of Intestinal ObstructionÂ 851Â DEC-2004Â 293Â Different types of Intestinal ObstructionÂ 851Â SEP-2003Â 294Â Management of Roundworm bolus obstrucitonÂ 852Â AUG-2001Â 295Â Closed loop Obstruction of large intestineÂ 854Â 838Â 841Â FEB-2002Â 296Â Radiological findings in intestinal ObstructionÂ 855Â SEP-2003Â 297Â Types of Jejunal AtresiaÂ 858Â Â 298Â Meconium ileusÂ 862Â Â 299Â Diagnosis of Acute intussusceptionÂ 863Â 663Â DEC-2004Â 300Â Signe de DanceÂ 865Â DEC-2004Â 301Â Paralytic IlleusÂ 868Â DEC-2004Â 302Â Paul Mikulikz ProcedureÂ 868Â Â 303Â Intestinal BandsÂ 869Â Â 304Â Internal HerniationsÂ 872Â JUL-2007Â 305Â Draw &amp;amp; Label : Internal HerniationsÂ 872Â JUN-2006Â 306Â THE VERMIFORM APPENDIXÂ Â Â 307Â A 27yr old male colleg estudent attends the surgical casuality with history of acute abdominal pain radiating to the back. He has history of alcoholism. On examination he is in severe shock.Â What are the possible conditions to be considered in diagnosis?Â Discuss the pathology of any one condition?Â How will you investigate the patient?Â Deatil the different types of treatment of the most common condition?Â What are the complications if the patient is untreated?Â Â JUL-2007Â 308Â Management of Appendicular PerforationÂ Â SEP-2000Â 309Â Appendicular abscessÂ 875Â 883Â FEB-2002Â AUG-1998Â JAN-1999Â 310Â Clinical features of Acute AppendicitisÂ 876Â JUN-2006Â 311Â DD of Acute AbdomenÂ Â 877Â DEC-2004Â 312Â Interval AppendicectomyÂ 882Â AUG-2002Â 313Â Paracentesis abdominisÂ Â Â 314Â Pseudomyxoma peritoneiÂ 884Â Â 315Â THE RECTUM AND ANAL CANALÂ Â Â 316Â Solitary Rectal UlcerÂ Â SEP-2000Â 317Â Lymphatic Drainage of Rectum and Anal CanalÂ Â SEP-2000Â 318Â Anal StenosisÂ Â MAY-1999Â 319Â ProctoscopyÂ 890Â 1125Â APR-2004Â 320Â Obstruction due to Rectosigmoid malignancyÂ Â AUG-2001Â 321Â Draw &amp;amp; Label : Distribution of Colorectal cancer by siteÂ 891Â JUL-2008Â 322Â A 60 year old man with past history of rectal bleeding was admitted with abdominal pain, vomitting , and constipation. Is said he lost weight and anorexic. O/E his temperature was 99c, pulse 90/min. BP was 150/90. Abdomen was distended with no hepatosplenomegaly. PR was emptyÂ What is the most likely diagnosis?Â What are the investigations?Â What is the operation required for this patient?Â Mention the precancerous conditions of the colon and rectum?Â Â OCT-2002Â 323Â Duke's StagingÂ 892Â MAY-2002Â 324Â Anterior ResectionÂ 896Â JUL-2007Â 325Â Pilonidal sinusÂ 903Â AUG-2002Â AUG-1998Â JAN-2002Â SEP-1997Â FEB-2008Â 326Â Complications and management of HemorrhoidesÂ 905Â SEP-1997Â 327Â Lord's DilatationÂ 909Â Â 328Â Fissure in AnoÂ 911Â DEC-2004Â MAY-1999Â FEB-2001Â SEP-1997Â 329Â Acute Anal FissureÂ Â FEB-2001Â 330Â Sentinel PileÂ 913Â FEB-2002Â 331Â Prolapsed thrombosed Pile MassÂ Â SEP-1997Â 332Â Perianal AbscessÂ Ischiorectal AbscessÂ 914Â AUG-2002Â JAN-1999Â MAY-1999Â 333Â Management of Ischiorectal AbscessÂ 914Â APR-2000Â 334Â Fistula in AnoÂ 915Â JUL-2008Â SEP-2000Â MAY-2002Â FEB-1998Â 335Â Management of Anal Canal TumourÂ 920Â APR-2000Â 336Â Laparaoscopic SurgeryÂ 1139Â SEP-2003Â 337Â A 45 year old male attends the casualty with complaints of bleeding pel' rectum. He is in a moribund state and is lying listless.Â (a) What are the possible causes of bleeding per rectum?Â (b) What is your diagnosis in this patient who is lying listless? Explain the pathology.Â (c) How will you investigate the patient to reach your diagnosis?Â (d) What is the emergency management?Â (e) Detail the different types of treatment for your diagnosis.Â Â JUN-2006Â 338Â You are witnessign a surgeon doing per rectal examination on a women who complains of mucous discharge per anum.Â What is the patients position during examination?Â What is Goodsaal's rule?Â What are the common positions of primary piles?Â Define Partial prolpse of rectum?Â Â AUG-2002Â 339Â Investigation of Bleeding per RectumÂ Â JUL-2007Â FEB-2008Â JUN-2005Â 340Â Causes of Bleeding PRÂ Â JUN-2006Â 341Â Carcinoma Anal CanalÂ Â SEP-1997Â Â ORTHOPEDICSÂ Â Â 342Â Finkelstein's SignÂ Â Â 343Â Austin Moores ProsthesisÂ Â Â 344Â Draw &amp;amp; Label : Ossification centres at elbow with age of appearance in X RayÂ Â JUL-2007Â 345Â Bryant's triangleÂ Â JAN-2002Â 346Â Butcher's thighÂ Â JUL-2007Â 347Â Satellar tapÂ Â JUL-2007Â 348Â Swan neck deformityÂ Â OCT-2002Â 349Â Garden's ClassificationÂ Â OCT-2002Â 350Â Erb's PalsyÂ Â AUG-2002Â 351Â Tuberculous GranulomaÂ Â AUG-2002Â 352Â Draw &amp;amp; Label : Tuberculous GranulomaÂ Â FEB-2002Â 353Â A 16yr old girl is admitted to the ward with severe pain above the knee of 3 month duration. O/E bony swelling all around lower end of femur.Â What are the possible conditionsÂ Name the muscles at the levelÂ InvestigationsÂ Treatment of any one conditionÂ How will you ambulate  the patient after amputationÂ Â JUN-2005Â 354Â Classification of FracturesÂ Traumatic and PathologicalÂ Displaced and UndisplacedÂ Open and ClosedÂ Transverse, Oblique, Spiral, Comminuted and SegmentalÂ 1Â Â 355Â Open fracturesÂ 1Â JAN-2002Â FEB-2008Â 356Â A 35yr old man was brought to the orthopedic casuality with open fracture of the Rt Tibia following a road traffic accident.Â How are open fractures graded?Â What can be the associated injuries to the Right Leg?Â What are the steps in the management of open fractures?Â How th open fractures of tibia normally stabilised?Â Enumerate the immediate and late complications associated with open fractures?Â Â OCT-2002Â 357Â Pott's fracture of AnkleÂ bimalleolarÂ 2Â JUN-2005Â 358Â Draw &amp;amp; Label : Potts Fracture 3 degreesÂ Â Â 359Â Hangman's FractureÂ subluxation of c2 over c3Â fracture through pedicle and lamina of c2 vertebraÂ 3Â Â 360Â Pathological Fracture.Â Surgical conditions producing pathological fractures of Bones.Â 3Â JUN-2005Â APR-2000Â JUN-2006Â OCT-2002Â 361Â SprainÂ 4Â Â 362Â ANATOMY OF BONE AND FRACTURE HEALINGÂ Â Â 363Â Draw &amp;amp; Label : Blood Supply of a Long BoneÂ 8Â Â 364Â Stages of Fracture HealingÂ 8Â Â 365Â Callus formationÂ 9Â AUG-2002Â 366Â Factors affecting fracture HealingÂ 10Â Â 367Â TREATMENT OF FRACTURESÂ Â Â 368Â Methods of Fracture ReductionÂ closed reductionÂ continuous tractionÂ open reductionÂ 12Â Â 369Â Indications for Open ReductionÂ 12Â Â 370Â Plaster of ParisÂ 13Â FEB-2002Â 371Â Internal FixationÂ 15Â Â 372Â External FixatorÂ 16Â JUN-2005Â 373Â Classification of Open FracturesÂ 17Â Â 374Â SPLINTS AND TRACTIONSÂ Â Â 375Â Draw &amp;amp; Label : Thomas SplintÂ 120 degreesÂ 20Â AUG-2002Â 376Â Thomas SplintÂ 20Â OCT-2002Â FEB-2002Â 377Â Tractions in OrthopedicsÂ fixed and sliding tractionÂ skin &amp;amp; skeletal tractionÂ 21Â JAN-1999Â 378Â Skeletal TractionÂ 21Â JUL-2007Â 379Â RECENT ADVANCES IN FRACTURE TREATMENTÂ Â Â 380Â Static CompressionÂ 23Â Â 381Â Dynamic Coxmpression Plate (DCP)Â 23Â Â 382Â LCDCPÂ 25Â Â 383Â Functional BracingÂ 25Â Â 384Â Interlocking nailÂ 25Â JUL-2007Â MAY-2002Â 385Â Illizarows techniqueÂ 26Â Â 386Â APPROACH TO FRACTUREÂ Â Â 387Â Old FractureÂ Â Â 388Â COMPLICATIONS OF FRACTURESÂ Â Â 389Â Late Complications of FractureÂ MalÂ NonÂ DelayedÂ CrossÂ 34Â MAR-2003Â 390Â Crush SyndromeÂ 35Â Â 391Â Compartment SyndromeÂ 37Â JAN-2002Â MAY-2002Â 392Â Non UnionÂ Define Non UnionÂ process of fracture healing comes to a stand before completionÂ Classify Non UnionÂ Atrophic &amp;amp; HypertrophicÂ Common causes of Non unionÂ Treatment of Non unionÂ Bone graftingÂ Excision of FragmentsÂ No treatmentÂ Ilizarow's TechniqueÂ 38Â JAN-2002Â JUL-2008Â DEC-2004Â MAY-1999Â SEP-1997Â APR-2004Â 393Â Non Union of TibiaÂ Â FEB-2001Â 394Â Delayed UnionÂ 38Â Â 395Â MalUnionÂ 39Â Â 396Â Sudek's OsteodystrophyÂ 41Â JUN-2005Â FEB-1998Â 397Â Myositis OssificansÂ ossification of hematoma around a jointÂ 42Â AUG-1998Â OCT-2002Â FEB-2002Â 398Â DISLOCATIONS AND SUBLUXATIONSÂ Â Â 399Â Define DislocationÂ all apposition between the articular surfaces are lostÂ 43Â Â 400Â Define SubluxationÂ retain some contact between themÂ 43Â Â 401Â Traumatic DislocationÂ 43Â Â 402Â Recurrent DislocationÂ 44Â Â 403Â Fracture DislocationÂ Â Â 404Â FRACTURES IN CHILDRENÂ Â Â 405Â Common fractures in childrenÂ 46Â Â 406Â Epiphyseal InjuriesÂ 46Â Â 407Â Salter and Harris ClassificationÂ 47Â Â 408Â Green Stick FractureÂ 47Â MAR-2003Â MAY-2002Â 409Â PERIPHERAL NERVE INJURIESÂ Â Â 410Â Draw &amp;amp; Label : Structure of a NerveÂ 49Â Â 411Â Crutch PalsyÂ 50Â Â 412Â Seddons Classification Â Classify Nerve InjuriessÂ (NAN)Â Neurapraxia â€“ disruption of conductionÂ Axonotmesis â€“ axons are damagedÂ Neurotmesis â€“ nerve structure damaged, wallerian degeneration occurs.Â 50Â Â 413Â Wrist DropÂ seen in radial nerve palsyÂ 51Â AUG-2002Â 414Â Foot DropÂ common peroneal nerve palsyÂ 51Â JUL-2008Â FEB-2001Â APR-2004Â AUG-2002Â 415Â Ulnar Claw handÂ ulnar nerve palsyÂ more marked in low ulnar nerve palsyÂ Reson for clawing in ulnar claw hand deformityÂ 51Â JUL-2008Â FEB-2008Â JUN-2006Â MAR-2003Â 416Â Ulnar ParadoxÂ Â Â 417Â Pointing IndexÂ 52Â Â 418Â Froments SignÂ 56Â Â 419Â Tinel's SignÂ 57Â MAR-2003Â 420Â ElectromyographyÂ graphical recording of the electrical activity of a muscleÂ 57Â JUL-2007Â 421Â Nerve RepairÂ Nerve sutureÂ Nerve graftingÂ 59Â Â 422Â Nerve SutureÂ Epineural sutureÂ Epi-Perineural sutureÂ Perineural sutureÂ Group Fascicular sutureÂ 59Â Â 423Â Nerve GraftingÂ when the gap is &amp;gt; 10cmÂ Â Â 424Â NeurolysisÂ 60Â Â 425Â TREATMENT OF ORTHOPEDIC DISORDERSÂ Â Â 426Â Drugs in OrthopedicsÂ 67Â Â 427Â OsteotomyÂ 67Â Â 428Â ArthrodesisÂ fusion of bones forming a jointÂ Types â€“ intra articular, extra articular, combinedÂ 68Â Â 429Â ArthroplastyÂ construction of a new movable jointÂ Types â€“ Excision, Hemiarthroplasty, Total replacementÂ Â Â 430Â Types of Bone GraftingÂ AutograftÂ Allograft â€“ other humanÂ Xenograft â€“ other speciesÂ Artificial BoneÂ 69Â DEC-2004Â Â 431Â Techniques of Bone GraftingÂ Solid slab. Eg fibulaÂ Cancellous bone chips. Eg illiac crestÂ 70Â DEC-2004Â 432Â Tendon TransfersÂ 71Â Â 433Â SHOULDER INJURIESÂ Â Â 434Â FRACTURE CLAVICLEÂ Â Â 435Â Discuss the clinical features of fracture of clavicle. How will you manage a fracture clavicle patient aged 25 years? Enumerate the complications?Â 73Â AUG-2001Â 436Â Fracture ClavicleÂ 73Â APR-2000Â JUL-2008Â 437Â SHOULDER DISLOCATIONÂ Â Â 438Â Describe the clinical features of anterior dislocation of the shoulder?Â How will you manage a case of acute anterior dislocation of the shoulder?Â Enumerate three possible complications of dislocation of the shoulder?Â Â FEB-2001Â 439Â Anterior Dislocation of ShoulderÂ 74Â MAR-2003Â 440Â Clinical features of anterior dislocation of shoulderÂ 74Â Â 441Â Luxatio erectaÂ rare positionÂ head comes to lie in the sub-glenoid positionÂ 74Â Â 442Â Hill Sach's LesionÂ 74Â Â 443Â Kocher's Manoevre in Shoulder dislocationÂ 75Â Â 444Â Fracture shaft of HumerusÂ 76Â Â 445Â ELBOW INJURIESÂ Â Â 446Â Carrying angleÂ male â€“ 11Â female â€“ 14Â 79Â Â 447Â Draw &amp;amp; Label : Epiphyseal centres around elbowÂ 80Â Â 448Â SUPRACONDYLAR FRACTUREÂ Â Â 449Â Discuss the clinical diagnosis, radiologicla features and management of supracondylar fracure of humerus in a six year old child. Enumerte four comlications of this conditionÂ 80Â APR-2000Â SEP-1997Â 450Â A 7yr old child presents with supracondylar fracture of the right humerus with severe pain in the right forearm and absent radial pulse.Â What is your disgnosis?Â What are the signs of Volkmann's ischaemia?Â What is the treatment for Acute Compartment Syndrome?Â What is  the late consequence of untreated compartment syndrome?Â What is Volkmann's sign?Â 80Â MAR-2003Â 451Â Describe the mechanism, clinical features and management of supracondylar fracture of Elbow. Enumerate the complications?Â Â AUG-1998Â 452Â Supracondylar FractureÂ 80Â DEC-2004Â 453Â Types of Supracondylar fracture of humerus in ChildrenÂ Extension type â€“ 80%Â Flexion type â€“ 20%Â 80Â FEB-2008Â 454Â Management of supracondylar fracture of humerusÂ Closed reduction + percut K wireÂ Open reduction + K wireÂ Continuous tractionÂ 81Â JUN-2005Â 455Â Complications of Supracondylar fracture of the HumerusÂ Injury to Brachial ArteryÂ Injury to NervesÂ Volkmanns ischaemiaÂ MalunionÂ Myositis ossificansÂ VICÂ 82Â JUN-2006Â 456Â Cubitus varus / Gun stock deformityÂ 85Â JAN-2002Â FEB-2008Â FEB-2002Â 457Â Volkman's Ischaemic ContractureÂ 85Â JUN-2006Â MAY-2002Â 458Â Volkmann's SignÂ Â Â 459Â Cubitus ValgusÂ 86Â Â 460Â Discuss the etiology, clinical features management of dislocation of elbow joint. Enumerate the complications?Â Â JAN-1999Â 461Â Pulled elbowÂ when a child is lifted up by the wrist, the head of radius slips out.Â treated by â€“ fully supinating the forearm and pressure over radial head.Â 88Â Â 462Â Fracture head of radiusÂ 89Â Â 463Â FOREARM AND WRIST INJURIESÂ Â Â 464Â Monteggia fractureÂ Ulna fracture (upper third) + radial head dislocationÂ hyperpronation injuryÂ Two types â€“ flexion and extensionÂ 92Â Â 465Â Galeazzi fracture Â Radius fracture (lower third) + dislocation of radio-ulnar jointÂ 93Â JAN-2002Â 466Â COLLE'S FRACTUREÂ Â Â 467Â A 70yr old lady was brought to the Orthopedic casuality with history of fall on the outstretched left hand. The clinical and radiological examination revealed Colle's fracture on Lt side.Â Why Colle's fracture is common in elderly women?Â What are the other injuries she could have sustained due to this?Â How Colle's fracture differ from Smith's Fracture?Â What are the steps in reducing Colle's Fracture?Â What are the complications of Colle's Fracture?Â Â MAY-2002Â 468Â A 60yr old lady is brought to the casuality after a fall on outstretched hand. Clinical examination reveals Colle's fracture of Right Radius.Â What are the complications you expect in this patient?Â Name two late complications?Â What Is the deformity the patient presents with?Â What is the treatment for a closed undisplaced Colle's fracture?Â How will you immobilise the wrist?  Â Â FEB-2002Â 469Â Enumerate the fractures following fall on an outstretched hand. Describe the fractures and management of Colle's fracture?Â 92Â MAY-1999Â 470Â Draw &amp;amp; Label : Displacement in Colle's FractureÂ 94Â JUL-2008Â 471Â Clinical features of Colles FractureÂ 94Â FEB-2008Â 472Â Dinner fork deformityÂ 94Â Â 473Â Management of Colle's fracture in a 60 yr old ladyÂ 95Â JUN-2006Â 474Â Complication of Colle's fractureÂ 95Â FEB-2008Â JUN-2006Â 475Â Displacements and Complications of Colle's FractureÂ 95Â APR-2004Â 476Â Smith's FractureÂ Reverse of Colles FractureÂ distal fracgment displaces ventrally and tilts ventrallyÂ 96Â FEB-2002Â 477Â Barton's FractureÂ 96Â Â 478Â Two complications of Fracture ScaphoidÂ 97Â FEB-2002Â 479Â HAND INJURIESÂ Â Â 480Â Bennett's FractureÂ extra-articular fracture atÂ base of 1st metacarpalÂ 99Â MAY-2002Â 481Â Rolando's FractureÂ intra-articular fracture atÂ base of 1st metacarpalÂ Â Â 482Â Mallet fingerÂ mallet â€“ a hammerÂ distal inter-phalangeal jointÂ sudden passive flexionÂ avulsion of the tendinous attachmentÂ 100Â JUL-2007Â AUG-2002Â 483Â PELVIC FRACTURESÂ Â Â 484Â Fracture of the PelvisÂ 104Â APR-2004Â JUN-2005Â 485Â Types of Pelvic FracturesÂ 105Â Â 486Â Open Book Pelvic FractureÂ 106Â Â 487Â Complications of Pelvic FracturesÂ Rupture Urethra &amp;amp; BladderÂ Injury to Rectum, Vagina, major vessels, nervesÂ Rupture of DiaphragmÂ 108Â Â 488Â INJURIES AROUND HIPÂ Â Â 489Â Draw &amp;amp; Label : Blood supply of proximal femoral neck and head in adultÂ Retinacular vesselsÂ Foveal vesselsÂ Medullary vesselsÂ 110Â MAR-2003Â OCT-2002Â 490Â Posterior dislocation of HipÂ 111Â Â 491Â FRACTURE NECK OF FEMURÂ Â Â 492Â Describe the etiology, clinical features and management of fracture neck of femur in an elderly female aged 65 yearsÂ 112Â FEB-1998Â 493Â Impacted FractureÂ the patient arrives walkingÂ 114Â Â 494Â Unsolved FractureÂ 115Â Â 495Â Management of transcervical type of neck of femur fracture in a 60 yr old ladyÂ McMurray's OsteotomyÂ HemiarthroplastyÂ Meyer's ProcedureÂ 115Â FEB-2008Â 496Â Mc Murrays OsteotomyÂ 116Â 68Â Â 497Â Complication of Fracture Neck of FemurÂ Non-unionÂ Avascular NecrosisÂ OsteoarthritisÂ 117Â JUN-2005Â FEB-2001Â MAR-2003Â 498Â Mc Murray's TestÂ -Â MAY-2002Â 499Â Intertrochanteric FractureÂ 118Â Â 500Â FRACTURE SHAFT OF FEMURÂ Â Â 501Â Hip SpicaÂ 120Â Â 502Â Interlocking NailingÂ 121Â Â 503Â Kuntscher's Nail (K Nail)Â 121Â Â 504Â Gallows TractionÂ 122Â Â 505Â INJURIES AROUND KNEEÂ Â Â 506Â Draw &amp;amp; Label : Extensor LagÂ 124Â Â 507Â Fracture PatellaÂ 125Â AUG-2002Â 508Â Stellate FractureÂ comminuted fracture of the whole of patellaÂ 126Â Â 509Â Tension band wiringÂ 126Â Â 510Â O'Donoghue triadÂ Injury to :Â Anterior Cruciate ligamentÂ Medial Collateral LigamentÂ Medial MeniscusÂ 128Â Â 511Â Drawer Test Â 128Â Â 512Â Meniscal injuriesÂ Medial meniscal injuryÂ 129Â JAN-2002Â JUL-2007Â 513Â Draw &amp;amp; Label : Types of Meniscal InjuryÂ Bucket Handle (commonest)Â RadialÂ Anterior hornÂ Posterior hornÂ ComplexÂ 129Â Â 514Â ArthroscopyÂ 283Â 130Â JUN-2005Â 515Â Recurrrent dislocation patellaÂ 131Â JAN-2002Â 516Â INJURIES TO LEG, ANKLE AND FOOTÂ Â Â 517Â Phemister GraftingÂ Phemister - Dallas B., American surgeon, 1882â€“1951Â 134Â Â 518Â Fracture CalcaneumÂ 140Â Â 519Â Aviator's FractureÂ Â Â 520Â March FractureÂ fatigue fracture of metatarsal bonesÂ heals spontaneouslyÂ 142Â 003Â MAY-2002Â 521Â Jone's FractureÂ # at base of 5th metatarsalÂ 142Â Â 522Â SPINAL INJURIESÂ Â Â 523Â Classify Spinal injuries according to mechanismÂ 144Â JUN-2005Â 524Â Chance FractureÂ due to the seat beltÂ 146Â Â 525Â Jefferson's FractureÂ 149Â Â 526Â INFECTIONS OF BONES AND JOINTSÂ Â Â 527Â Draw &amp;amp; Label : Types of MetaphysesÂ intra articular &amp;amp; extra articularÂ 157Â Â 528Â OSTEOMYELITISÂ Â Â 529Â Causes of Acute OsteomyelitisÂ StaphylococcusÂ StreptococcusÂ PneumococcusÂ 157Â FEB-2002Â 530Â Pathogenesis of Acute OsteomyelitisÂ 157Â FEB-2008Â 531Â Clinical features of Acute OsteomyelitisÂ 158Â JUN-2006Â 532Â Complications of Acute Osteomyelitis femurÂ Septicemia &amp;amp; pyaemiaÂ Chronic OsteomyelitisÂ Pathological FractureÂ Pyogenic ArthritisÂ Growth plate disturbancesÂ Â JUN-2006Â 533Â A 17yr old boy is brought to the casuality with severe pain in the right thigh of 4 days duration. He is febrile and there is tenderness and thickening of the femur. Xray confirms the diagnosis.Â What Is the diagnosis? Â What are the differential diagnosis you suspect in this patient?Â Discuss the pathology of the condition?Â What are the xray changes that occur as the disease progresses?Â How will you treat the acute condition?Â How will you treat the possible comlications of the condition?Â Â APR-2004Â 534Â Discuss the etiology, pathology, clinical features and management of acute Haematogenous Osteomyelitis. Â Enumerate the complications?Â Â JAN-1999Â 535Â A 35 year old male with chronic osteomyelitis for femur with draining sinus.Â What are the causes of his draining sinus in the femur.Â Enumerate the investigations ?Â Which is the commonest organism which causes osteomyelitis ?Â What surgery you perform ?Â Enumerate the complications of this infection ?Â Â JUL-2008Â 536Â A 7 year old boy is brought to the orthopaedic casualty with severe pain in the left leg and high fever.Â (a) What is the differential diagnosis?Â (b) Discuss the pathology of bone inflammation?Â (c) What are the poss ible radiological features in this patient?Â (d) How will you manage the condition?Â (e) What are the complications of your diagnosis?Â Â JUN-2006Â 537Â Chronic OsteomyelitisÂ 160Â MAR-2003Â 538Â Sequestra / Diaphyseal SequestrumÂ sequestrum, (pural is sequestra)Â A piece of necrotic tissue, usually bone, that has become separated from the surrounding healthy tissue.Â OriginÂ [Mod. L. use of Mediev. L. sequestrum, something laid aside, fr. L. sequestro, to lay aside, separate]Â (Stedman)Â 160Â AUG-1998Â SEP-1997Â MAR-2003Â 539Â Radiological features of chronic OsteomyelitisÂ 161Â FEB-2008Â 540Â InvolucrumÂ involucrum, pl. involucraÂ 1. An enveloping membrane, e.g., a sheath or sac.Â 2. The sheath of new bone that forms around a sequestrum.Â  Syn: involucre. [L. a wrapper, fr. in-volvo, to roll up]Â OriginÂ [L. a wrapper, fr. in-volvo, to roll up]Â (Stedman)Â 161Â Â 541Â Garre's OsteomyelitisÂ 163Â Â 542Â Brodie's AbscessÂ Management of Brodie's AbscessÂ 163Â JAN-2002Â JUN-2005Â AUG-2002Â 543Â Management of Acute Septic ArthritisÂ 165Â SEP-1997Â 544Â Tom Smith's ArthritisÂ septic arthritis of hip in infancyÂ 165Â Â 545Â TUBERCULOSIS OF BONES AND JOINTSÂ Â Â 546Â Types of Vertebral TuberculosisÂ 173Â Â 547Â TB SPINEÂ Â Â 548Â Management of Tuberculosis of dorsolumbar spineÂ 172Â JUN-2005Â 549Â Draw &amp;amp; Label : Trendelenburg GaitÂ Trendelenburg GaitÂ ?Â DEC-2004Â MAY-1999Â 550Â Pott's SpineÂ 172Â DEC-2004Â 551Â Classification of Spine FracturesÂ Â Â 552Â GibbusÂ Extreme kyphosis, hump, or hunch; a deformity of spine in which there is a sharply angulated segment, the apex of the angle being posterior.Â Origin [L. a hump]Â (Stedman)Â 174Â Â 553Â KyphusÂ 174Â Â 554Â Pott's ParaplegiaÂ 178Â JUL-2007Â 555Â TB HIPÂ Â Â 556Â Draw &amp;amp; Label : Changes in Tuberculosis of HipÂ 181Â JUN-2006Â 557Â Wandering AcetabulumÂ 181Â Â 558Â Pathogenesis of Tuberculossi of Hip JointÂ 182Â JUN-2006Â 559Â TB KNEEÂ Â Â 560Â Describe the etiology, clinical features and management of Tuberculosis of knee joint?Â 185Â AUG-1998Â 561Â Name triple deformity in TB KneeÂ Â JUL-2008Â 562Â Caries siccaÂ 187Â JUL-2007Â 563Â Spina VentousaÂ 188Â Â 564Â INFECTIONS OF THE HANDÂ Â Â 565Â Acute ParonychiaÂ 188Â Â 566Â Apical AbscessÂ 190Â Â 567Â FelonÂ 190Â Â 568Â Middle Volar Space InfectionÂ 190Â Â 569Â Management of Thenar Space InfectionÂ 191Â SEP-2000Â 570Â Acute Suppurative TenosynovitisÂ 192Â Â 571Â Kanavel's SignÂ 192Â Â 572Â CTEVÂ Â Â 573Â [L. talus, ankle, + pes, foot]Â [L. equinus, fr. equus, horse]Â [Varus . L. bent inward,]Â Â Â 574Â CTEVÂ Â Â 575Â Club FootÂ Management of Club FootÂ 193Â JUL-2008Â FEB-2002Â 576Â Congenital Club FootÂ Â MAY-2002Â 577Â A newborn baby is brought with inward deviation of both feet.Â What are the deformities in club footÂ What are the causes of club footÂ Name the spinal anomalies which are associated with club footÂ When will you start treatmentÂ What are the radiological features of clubfootÂ Â JUL-2007Â 578Â Discuss the aetiological factors in Congenital Club Foot? Â What are the clinical features of the same? How do you conservatively manage a newborn child with club foot?Â 193Â AUG-2001Â 579Â Describe the etiology, pathology, clinical features and management of congenital talipes equino varusÂ Â FEB-1998Â 580Â Deformities of CTEV and the mention three types of treatmentÂ Â APR-2004Â 581Â CONGENITAL DISLOCATION OF HIPÂ Â Â 582Â Treatment of Congenital Dislocation of HipÂ 200Â JUN-2005Â 583Â Barlow's TestÂ 201Â AUG-2002Â 584Â Ortolanis TestÂ 201Â Â 585Â Galeazzis signÂ 202Â Â 586Â PsedarthosisÂ 205Â Â 587Â POLIOMYELITISÂ Â Â 588Â Triple displacement of KneeÂ 207Â OCT-2002Â 589Â Spina bifidaÂ 210Â Â 590Â BONE TUMOURSÂ Â Â 591Â Classification of tumours of BoneÂ 214Â JUN-2005Â 592Â Premalignant Bone LesionsÂ Â Â 593Â Serum Alkaline PhosphataseÂ Â Â 594Â OsteomaÂ Â Â 595Â Metastatic Bone TumoursÂ Â Â 596Â Osteoid OsteomaÂ 214Â FEB-1998Â APR-2004Â 597Â AdamantinomaÂ 215Â Â 598Â OsteoclastomaÂ 216Â Â 599Â Draw &amp;amp; Label : Radiological appearance in Giant Cell TumourÂ 216Â FEB-2008Â 600Â Soap Bubble AppearanceÂ 216Â FEB-2002Â 601Â Describe the etiology, pathology  clinical features and management of osteogenic sarcoma of lower end of femur?Â Â MAY-1999Â 602Â OsteosarcomaÂ 218Â Â 603Â Radiological differences between Osteosarcoma and OsteoclastomaÂ Â JUN-2006Â 604Â Draw &amp;amp; Label : Microscopic appearance of OsteosarcomaÂ Â MAY-2002Â 605Â Draw &amp;amp; Label : Radiological features of OsteosarcomaÂ Â JUN-2005Â APR-2004Â 606Â A 14yr old male presents with pain and swelling over the lower end of right femur of 3 months duration. A clinical diagnosis of Osteosarcoma was made.Â What are the xray features of this condition?Â How will you confirm the diagnosis?Â What is the treatment of choice?Â What are the modalities of treatment other than surgery?Â What are the common sites of this tumour?Â Â AUG-2002Â 607Â Discuss the clinical and radiological features of Ewing's Sarcoma.Â  How would you manage an eight year old child with ES of the tibia?Â 221Â APR-2000Â 608Â Ewing's SarcomaÂ 221Â JAN-2002Â JAN-1999Â 609Â Bence Jone's ProteinsÂ 223Â OCT-2002Â 610Â ChondrosarcomaÂ 224Â JUN-2005Â APR-2004Â 611Â OsteochondromaÂ Complications of OsteochondromaÂ 225Â FEB-2008Â SEP-1997Â 612Â EnchondromasÂ 226Â Â 613Â Solitary Bone Cyst Â 226Â AUG-2002Â 614Â Fibrous DysplasiaÂ 227Â Â 615Â PROLAPSED IV DISCÂ Â Â 616Â IV Disc ProplapseÂ 228Â OCT-2002Â 617Â Pathology of Disc ProlapseÂ 229Â Â 618Â SCOLIOSISÂ Â Â 619Â Cobb's AngleÂ 234Â Â 620Â KyphosisÂ 236Â JAN-2002Â 621Â Differentiate Gibbus and knuckle deformitiesÂ Â 236Â Â 622Â Seronegative ArthritisÂ Â MAY-2002Â 623Â Scottish Dog SignÂ Â Â 624Â SpondylolysisÂ 237Â Â 625Â SpondylolisthesisÂ 237Â 204Â 35Â Â 626Â BACKPAINÂ Â Â 627Â SciaticaÂ 243Â Â 628Â ARTHRITISÂ Â Â 629Â RHEUMATOID ARTHRITISÂ Â Â 630Â What are the clinical features of Rheumatoid Arthritis?Â How will you manage conservatively a case of Rheumatoid arthritis?Â 244Â FEB-2001Â 631Â Diagnostic Criteria for RAÂ 244Â Â 632Â Deformities in Rheumatoid ArthritisÂ 245Â Â 633Â Ankylosing SpondylitisÂ Ankylo - [G. ankylos, bent, crooked; ankylbsis, stiffening of the joints, fr. ankos, a bend, a hollow]Â Spondylo - [G. spondylos, vertebra]Â (Stedman)Â 248Â Â 634Â DEGENERATIVE DISORDERSÂ Â Â 635Â OSTEOARTHRITISÂ Â Â 636Â Describe clinical features and management of chronic Osteoarthritis of Knee JointÂ 252Â SEP-1997Â 637Â Clinical features of OsteoarthritisÂ 252Â Â 638Â AFFECTIONS OF SOFT TISSUESÂ Â Â 639Â Causes, pathogenesis and Treatment of BunionÂ A localized swelling at either the medial or dorsal aspect of the first metatarsophalangeal joint, caused by an inflammatory bursa; a medial bunion is usually associated with hallux valgus.Â Origin [O.F. buigne, bump on the head]Â (Stedman)Â 256Â APR-2004Â 640Â TenosynovitisÂ Acute TenosynovitisÂ 256Â 190Â FEB-2001Â APR-2000Â 641Â Dupuytren's ContractureÂ 256Â MAR-2003Â 642Â Tennis ElbowÂ inflammation at origin of extensor tendonsÂ 257Â AUG-2001Â MAY-1999Â MAR-2003Â 643Â Golfer's ElbowÂ inflammation at origin of flexor tendonsÂ 257Â MAY-2002Â 644Â Dequervain's DiseaseÂ pain and swelling over radial styloid processÂ Dequervain's TenosynovitisÂ 257Â JAN-2002Â JUL-2008Â APR-2004Â MAY-2002Â 645Â Trigger fingerÂ 257Â JUL-2007Â FEB-2001Â 646Â GanglionÂ mucoid degeneration of tendon sheath or joint capsuleÂ 258Â Â 647Â Carpal Tunnel SyndromeÂ 258Â DEC-2004Â OCT-2002Â 648Â Phalen's TestÂ maneuver in which the wrist is maintained in volar flexion; paresthesia occurring in the distribution of the median nerve within 60 sec may be indicative of carpal tunnel syndromeÂ (Stedman)Â Â Â 649Â Frozen ShoulderÂ 258Â JUL-2008Â 650Â Painful arc SyndromeÂ mid range of gleno humeral abductionÂ 259Â Â 651Â Meralgia ParestheticaÂ 259Â Â 652Â Causes of Heel PainÂ 259Â Â 653Â METABOLIC BONE DISEASESÂ Â Â 654Â OsteoporosisÂ 261Â Â 655Â OsteomalaciaÂ 261Â OCT-2002Â 656Â RicketsÂ Clinical features of RicketsÂ 263Â FEB-2008Â JUN-2006Â JAN-1999Â 657Â Renal RicketsÂ Â MAY-2002Â 658Â Radiological features of RicketsÂ Â APR-2004Â 659Â MISCELLANEOUS AFFECTIONS OF BONEÂ Â Â 660Â AchondroplasiaÂ failure of normal ossificaiton of long bonesÂ 268Â Â 661Â A 7 year old presented 10 orthopaedic outpatient  with h/o limping and pain in the left Hip.Â (a) What is the differential diagposis ?Â (b) Discus the pathology of Perthe's disease.Â (c) What are the radiological features?Â (d) How will you treat the patient?Â (e) What are the complications?Â 269Â FEB-2008Â 662Â A 14yr old boy is brought to the orthopedic OP with a history of limping for three months. He has shortening of the right lower limbÂ What are the possible causesÂ How will you differentiate between the most common conditionsÂ How will you treat one of themÂ What are the common dislocations in the bodyÂ 269Â DEC-2004Â 663Â Multiple ExostosisÂ 269Â MAR-2003Â 664Â ExostosisÂ Two Types of ExostosisÂ Â APR-2004Â 665Â Paget's Disease Â Osteochondritis DessicansÂ 269Â JUN-2005Â APR-2004Â FEB-2002Â 666Â Perthe's DiseaseÂ osteochondritis of epiphysis of femoral headÂ 269Â DEC-2004Â 667Â Perthe's DiseaseÂ (Coxa Plana, Pseudocoxanglia)Â Â Â 668Â Kienbocks DiseaseÂ 269Â Â 669Â Osgood Shlatters DiseaseÂ OsteochondritisÂ 269Â Â 670Â Avascular necrosis of HipÂ 270Â Â 671Â Sulcus SignÂ Ledge SignÂ Â Â 672Â MISCELLANEOUS REGIONAL DISEASESÂ Â Â 673Â Congenital TorticollisÂ 272Â FEB-2008Â 674Â Adolescent coxa varaÂ 274Â JUL-2007Â 675Â Slipped Capital Femoral EpiphysisÂ 274Â OCT-2002Â 676Â Baker's CystÂ 276Â OCT-2002Â AUG-2002Â 677Â Loose Bodies in KneeÂ 276Â Â 678Â Flat FootÂ 276Â AUG-2001Â 679Â AMPUTATIONS AND PROSTHETICSÂ Â Â 680Â Below Knee amputationÂ Complications of Below Knee amputationÂ 278Â DEC-2004Â JUL-2008Â MAY-2002Â 681Â Genu VarumÂ Â AUG-2001Â APR-2000Â 682Â Genu ValgumÂ Â AUG-2002Â 683Â SPORTS MEDICINEÂ Â Â 684Â ArthroscopyÂ 283Â 130Â JUN-2005Â  Â Â Paper 2Â Â Â 685Â Conn's SyndromeÂ Â MAY-2002Â 686Â Classify LymphodermaÂ Â FEB-2008Â 687Â Thomos TestÂ Â FEB-1998Â 688Â CDHÂ Â AUG-1998Â 689Â Muscle RelaxantsÂ Â AUG-1998Â 690Â Tinnel SignÂ Â JAN-1999Â 691Â Fluids and ElectrolytesÂ Â JUN-2005Â 692Â Usual derangements of Water, Sodium and PostassiumÂ Â JUN-2005Â 693Â Classify swellings of neural originÂ Â DEC-2004Â 694Â Bone ScanÂ Â DEC-2004Â 6957Â TNM ClassificationÂ Â DEC-2004Â APR-2004Â 696Â Ann Arbor StagingÂ Â APR-2004Â 697Â Pinhole meatusÂ Â MAR-2003Â 698Â Methods of spread of a malignant tumourÂ Â MAR-2003Â 699Â 3 Dimensional ExcisionÂ Â MAR-2003Â 700Â Abdominal AnginaÂ Â MAR-2003Â 701Â BUJ ObstructionÂ Â NOV-2002Â 702Â Local GigantismÂ Â AUG-2002Â 703Â Functions of Lymph NodeÂ Â SEP-1997Â 704Â PCKDÂ Â FEB-2002Â 705Â Tuberculous EmpyemaÂ Â MAY-2002Â 706Â Therapeutic EmbolisationÂ Â Â 707Â TriageÂ Â Â 708Â Focussed Abdominal Sonogram for Trauma (FAST)Â Â Â 709Â Missile InjuryÂ Â Â 710Â Hidradenitis SuppurativaÂ Â Â 711Â Necrotising FascitisÂ Â Â 712Â GENERAL SURGERYÂ Â Â 713Â Wound HealingÂ 4Â JUN-2005Â 714Â Healing by Secondary IntentionÂ Â MAR-2003Â 715Â Factors influencing Wound HealingÂ Â FEB-2008Â 716Â Wound DehiscenceÂ Â NOV-2002Â 717Â Delayed primary closure of WoundsÂ Â AUG-2002Â 718Â KeloidÂ 8Â AUG-2002Â JAN-1999Â MAY-2002Â 719Â Hypertrophic ScarsÂ Â Â 720Â Marjolin's UlcerÂ 11Â MAY-2002Â 721Â Types of Edges in an UlcerÂ 12Â FEB-2002Â 722Â Management of UlcersÂ 17Â APR-2004Â 723Â Trophic UlcerÂ 18Â 175Â AUG-1998Â 724Â INFECTIOUS DISEASESÂ Â Â 725Â Cold AbscessÂ 37Â 391Â 393Â APR-2004Â FEB-1998Â MAR-2003Â 726Â Tuberculous SinusÂ Â SEP-2000Â 727Â Drainage of Abscess by Hiltons methodÂ 36Â Â 728Â Hidradenitis SuppurativaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; blockage of apocrine glandsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; commonly in axilla and groinÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; seen in womenÂ 38Â Â 729Â Diabetic CarbuncleÂ 39Â AUG-1998Â 730Â Management of CarbuncleÂ 39Â FEB-2001Â 731Â Tetany Â 42Â JUL-2008Â 732Â Post operative TetanyÂ 42Â AUG-2002Â 733Â Management of severe form of TetanusÂ 43Â APR-2000Â MAY-2002Â 734Â Treatment of TetanusÂ 44Â AUG-2001Â FEB-2001Â 735Â Gas GangreneÂ Gangrene of Lower LimbÂ 45Â AUG-2002Â AUG-2001Â 736Â Treatment of Gas GangreneÂ 45Â JUN-2005Â FEB-2001Â AUG-1998Â 737Â DD for Gas GangreneÂ 45Â JUN-2005Â 738Â ActinomycosisÂ 49Â NOV-2002Â JAN-2002Â 739Â Madura FootÂ 50Â AUG-2002Â SEP-1997Â MAY-2002Â AUG-2002Â 740Â SWELLINGSÂ Â Â 741Â LipomaÂ 61Â AUG-2001Â APR-2000Â FEB-2001Â 742Â Different types of Cystic SwellingÂ 63Â SEP-2003Â 743Â Epidermal CystÂ 66Â SEP-2003Â 744Â WENÂ 66Â JUN-2005Â 745Â Dermoid CystÂ Â AUG-1998Â 746Â Sequestration DermoidÂ Â FEB-2002Â 747Â Sebaceous CystÂ Â MAY-1999Â 748Â Glomus Tumour Â 70Â Â 749Â NeuromaÂ 75Â Â 750Â MENÂ 77Â Â 751Â ELECTROLYTE AND NUTRITIONÂ Â Â 752Â HypokalemiaÂ Post Operative HypokalemiaÂ 82Â NOV-2002Â MAY-2002Â 753Â Parentral NutritionÂ 88Â APR-2004Â NOV-2002Â 754Â Complications of TPNÂ 89Â Â 755Â Gastrostomy feedingÂ 88Â 793Â Â 756Â SHOCKÂ Â Â 757Â SHOCKÂ What is Shock? Describe the clinical features and management of a patient with hemorrhagic shock?Â Â JAN-2002Â 758Â Management of Septic ShockÂ 91Â 93Â MAY-1999Â 759Â SIRSÂ 92Â 97Â Â 760Â MODSÂ 92Â 42Â Â 761Â Expand and Define : SIRS TPN MRSA ATLSÂ SIRS â€“ Sytemic inflammatory response syndromeÂ TPN â€“ Total Parentral NutritionÂ 97Â 88Â JUL-2008Â 762Â Central Venous PressureÂ 96Â NOV-2002Â 763Â HAEMORRHAGE AND BLOOD TRANSFUSIONÂ Â Â 764Â Secondary HemorrhageÂ 100Â AUG-2002Â 765Â Blood FractionsÂ 103Â Â 766Â Blood SubstitutesÂ Â Â 767Â Complications of Blood TransfusionÂ 103Â AUG-1998Â 768Â Blood Component TherapyÂ Â JUL-2008Â 769Â AutotransfusionÂ 104Â NOV-2002Â 770Â BURNSÂ Â Â 771Â A 42 year old lady weighing 40 kg is brought to the casuality with history of attempted suicide by self immolation.Â How do you asses the severity of burns?Â What is the managemnet if 60% body surface is burnt?Â What investigations will you do in this case?Â What are the late complications?Â What are the medicolegal implications? How will you get a dying declaration?Â Â SEP-2003Â 772Â A 55 year old woman with 35% of the body surface burn of the chest and abdomen.Â How burns are classified?Â Under what circumstances should burns be stem grafted?Â What are the priorities in the initial treatment of a burns patient?Â How should the burns wound be treated?Â Â NOV-2002Â 773Â Discuss the clinical features and management of a patient with 50% butns?Â Â JAN-2002Â 774Â Types of BurnsÂ Â Â 775Â Wallace's Rule of NineÂ Â Â 776Â Pathology of BurnsÂ Â APR-2004Â 777Â Complications of Deep BurnsÂ 109Â DEC-2004Â 778Â Management of BurnsÂ Â AUG-1998Â 779Â Electric BurnsÂ Â Â 780Â Le Forte ClassificationÂ Â Â 781Â TRAUMAÂ Â Â 782Â Blast LungÂ Â Â 783Â Revised Trauma ScoreÂ Â Â 784Â Role of Crystalloids and Colloids in SurgeryÂ Â APR-2004Â 785Â HAND AND FOOTÂ Â Â 786Â ParonychiaÂ Causes and Treatment of ParonychiaÂ 132Â APR-2004Â JAN-2002Â MAY-2002Â 787Â Terminal Pulp Space InfectionÂ 133Â SEP-2000Â FEB-2001Â 788Â Collar Stud AbscessÂ 133Â 392Â MAY-1999Â JAN-2002Â JUL-2008Â 789Â Deep Palmar Space infectionÂ 134Â SEP-1997Â 790Â Compound Palmar GanglionÂ 135Â MAY-1999Â 791Â Management of Acute TenosynovitisÂ 135Â AUG-2001Â SEP-1997Â 792Â Kenawel's SignÂ 135Â NOV-2002Â 793Â Ingrowing toe nailÂ 142Â APR-2000Â 794Â ARTERIAL DISEASESÂ Â Â 795Â Scalene TriangleÂ 144Â NOV-2002Â 796Â Thoracic Outlet syndromeÂ 144Â Â 797Â Intermittent ClaudicationÂ 145Â Â 798Â A 32 year old male patient attends the surgery OP with complaints of pain in the right calf on walking for two months. He had been a chronic smoker for ten years. On examination he has reduction in peripheral pulses in the affected lower limb.Â What is the differential diagnosis?Â What is Boyd's grading and the principle behind it?Â What investigations will you do in this case?Â What are the amputtions usually performed in the lower limb?Â What procedures can be done to improve lower limb circulation? Explain one operation?Â 145Â APR-2004Â 799Â A 60 yr old lady with myocardial infarction on the 7th day suddenly developed severe pain, pareaesthesia and pallor of the right lower limb.Â What is the cause?Â What is the treatment?Â What are the associated complications if the treatment is delayed?Â What is Forgarty's Catheter?Â Are lytic enzymes helpful?Â Regime of Anticoagulant therapy?Â Â MAY-2002Â 800Â Rest painÂ 146Â MAR-2003Â 801Â Critical Limb IschaemiaÂ Pre-GangreneÂ 146Â JUL-2008Â 802Â Classification of GangreneÂ 147Â JAN-1999Â FEB-2008Â 803Â Dry GangreneÂ 147Â APR-2000Â 804Â Line of DemarcationÂ 147Â FEB-2008Â 805Â Harvey's SignÂ 148Â MAR-2003Â 806Â Lerich's SyndromeÂ 148Â 164Â MAR-2003Â JUL-2008Â 807Â DSA (Digital substration Angiography)Â 150Â Â 808Â TAOÂ Pathology of Thromboangitis obliteransÂ 152Â DEC-2004Â SEP-2003Â MAY-2002Â 809Â Raynaud's PhenomenonÂ 155Â SEP-2003Â AUG-2002Â MAY-2002Â 810Â Horner's SyndromeÂ 160Â 325Â 395Â 1075Â NOV-2002Â 811Â Draw &amp;amp; Label : Lumbar SympathectomyÂ 160Â DEC-2004Â 812Â Fat EmbolismÂ 165Â APR-2000Â JUL-2008Â 813Â AneurysmÂ 166Â JUN-2005Â 814Â Types of AneurysmÂ fusiformÂ saccularÂ dissectingÂ 166Â APR-2004Â 815Â Aortic AneurysmÂ 168Â Â 816Â Popliteal AneurysmÂ 170Â NOV-2002Â 817Â Dissecting AneurysmÂ 171Â Â 818Â Diabetic FootÂ 174Â FEB-2001Â 819Â Wagner's Classification of Diabetic FootÂ -Â Â 820Â Management of Diabetic FootÂ Â MAY-1999Â 821Â Diabetic Gangrene of FootÂ Â FEB-2002Â 822Â HAMARTOMA AND VASCULOAR LESIONSÂ Â Â 823Â HaemangiomaÂ Classify HaemangiomesÂ 179Â SEP-2003Â AUG-1998Â JAN-1999Â FEB-2008Â 824Â Cirsoid AneurysmÂ pulsating bag of wormsÂ 182Â Â 825Â AV FistulaÂ 183Â NOV-2002Â 826Â Branham's SignÂ 185Â Â 827Â VENOUS DISEASESÂ Â Â 828Â Draw &amp;amp; Label : Venous drainage of lower limbÂ 187Â Â 829Â DEEP VEIN THROMBOSISÂ Â Â 830Â Deep vein ThrombosisÂ 187Â MAR-2003Â AUG-2002Â JAN-1999Â AUG-2001Â FEB-2002Â MAY-2002Â 831Â Risk factors for Deep Vein Thrombosis Â Â JUL-2008Â 832Â Prophylaxis for Deep Vein ThrombosisÂ Â MAY-2002Â 833Â Treatment of Deep Vein ThrombosisÂ 188Â JUN-2005Â 834Â Virchows TriadÂ 188Â Â 835Â Causes of Acute Swollen LimbÂ -Â Â 836Â VARICOSE VEINSÂ Â Â 837Â Newer Modalities in the treatment of Varicose VeinsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Endovenous Laser TherapyÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Radiofrequency ablationÂ Â Â 838Â White Cell trapping HypothesisÂ 192Â Â 839Â CEAP ClassificationÂ 193Â Â 840Â Saphena VarixÂ 194Â 703Â SEP-2003Â 841Â Modified Perthe's TestÂ 195Â APR-2004Â 842Â PlethysmographyÂ 197Â Â 843Â Cokketa Dodd's OperationÂ 201Â NOV-2002Â 844Â Hook PhlebotomyÂ -Â Â 845Â Brown's Vasomotor IndexÂ ?Â FEB-2008Â 846Â Varicose VeinsÂ Â MAY-1999Â 847Â Complications of Varicose veinsÂ 204Â APR-2000Â 848Â Test for Varicose VeinsÂ Â FEB-2008Â 849Â Management of Varicose VeinsÂ Â MAY-1999Â 850Â Trendelenberg OperationÂ Â Â 851Â Venous UlcerÂ Â AUG-1998Â 852Â Management of Venous UlcerÂ 204Â SEP-2003Â 853Â Complications of Varicose UlcerÂ Â FEB-2008Â 854Â Bisgaard's RegimenÂ 204Â FEB-2002Â 855Â Migrating ThrombophlebitisÂ 206Â OCT-2002Â MAY-2002Â 856Â LYMPHATICSÂ Â Â 857Â LymphangitisÂ Â SEP-2000Â 858Â LymphoedemaÂ Aetiological Classification of LymphoedemaÂ 209Â SEP-2000Â JUL-2008Â 859Â Primary LymphoedemaÂ 209Â NOV-2002Â 860Â Milroy's DiseaseÂ 210Â Â 861Â LYMPHOMASÂ Â Â 862Â Treatment of Hodgkin's LymphomaÂ 219Â DEC-2004Â 863Â MOPP Regimes for Hodgkin's DiseaseÂ Â JUL-2008Â 864Â Classification of clinical staging of the Hodgkin's LymphomaÂ Â SEP-1997Â FEB-2008Â FEB-2002Â 865Â Investigations of LymphomaÂ Â SEP-1997Â 866Â Management of stage III of Hodgkins LymphomaÂ Â SEP-1997Â 867Â PERIPHERAL NERVESÂ Â Â 868Â Tinel's SignÂ prognostic indicator of nerve regenerationÂ 225Â MAR-2003Â 869Â Carpal Tunnel SyndromeÂ compression of median nerveÂ 227Â APR-2004Â 870Â NEOPLASMÂ Â Â 871Â Soft tissue sarcomaÂ 232Â Â 872Â Types of BiopsyÂ 237Â Â 873Â FNACÂ 240Â 478Â DEC-2004Â MAR-2003Â 874Â SKIN TUMOURSÂ Â Â 875Â Draw &amp;amp; Label : Layers of Skin Â 243Â FEB-2002Â 876Â Inflammations of SkinÂ 243Â SEP-2003Â 877Â Premalignant lesions of skinÂ 248Â FEB-2008Â APR-2004Â 878Â Squamous cell carcinomaÂ 248Â Â 879Â Precancerous lesion in SCCÂ Â Â 880Â Basal Cell CarcinomaÂ 252Â AUG-2002Â 881Â Rodent UlcerÂ 252Â MAY-1999Â JAN-2002Â 882Â MOHSÂ 254Â Â 883Â NaevusÂ 255Â DEC-2004Â 884Â Junctional NaeviÂ 255Â NOV-2002Â 885Â MALIGNANT MELANOMAÂ Â Â 886Â Malignant MelanomaÂ Types of Malignant MelanomaÂ 256Â AUG-1998Â FEB-2008Â FEB-2002Â 887Â Breslow's StagingÂ 257Â Â 888Â Clarks GradingÂ 257Â Â 889Â Management of Malignant MelanomaÂ 260Â APR-2004Â 890Â SARCOMASÂ Â Â 891Â Treatment of FibrosarcomaÂ 267Â SEP-2003Â 892Â AMPUTATIONSÂ Â Â 893Â Types of AmputationÂ Â Â 894Â Syme's AmputationÂ Â Â 895Â RECONSTRUCTIONÂ Â Â 896Â Skin GraftingÂ Types of Skin GraftsÂ 282Â AUG-1998Â FEB-2002Â 897Â Myocutaneous FlapÂ 286Â AUG-2001Â 898Â TRANSPLANTATIONÂ Â Â 899Â Graft rejectionÂ 293Â Â 900Â Types of Allograft RejectionÂ 293Â JUL-2008Â 901Â Cimino FistulaÂ therapeutic fistula created for dialysisÂ 295Â 185Â Â 902Â FACIOMAXILLARY DISEASESÂ Â Â 903Â Cleft LipÂ Â Â 904Â Cleft Palate RepairÂ 304Â Â 905Â Draw &amp;amp; Label : Types of Maxillary fracturesÂ 305Â SEP-2003Â 906Â Fracture of MandibleÂ 311Â FEB-2001Â AUG-1998Â 907Â EpulisÂ 315Â APR-2004Â 908Â OdontomesÂ 316Â Â 909Â AdamantinomaÂ 317Â FEB-2001Â 910Â Dentigerous CystÂ 318Â JAN-2002Â 911Â Alveolar AbscessÂ 319Â JAN-1999Â 912Â ORAL CAVITYÂ Â Â 913Â RannulaÂ 321Â SEP-2003Â MAY-1999Â 914Â Premalignant lesions of Oral CavityÂ Â Â 915Â LeukoplakiaÂ Â Â 916Â ErythroplakiaÂ 324Â JUL-2008Â 917Â Submucous fibrosisÂ 324Â Â 918Â Draw &amp;amp; Label : Lymphatic Drainage of TongueÂ 341Â MAY-2002Â 919Â Lymphatic Drainage of TongueÂ 341Â SEP-1997Â 920Â Carcinoma TongueÂ 342Â Â 921Â Describe the aetiology, clinical features and treatment of a case of Ca tongue?Â Â JAN-2002Â 922Â A male aged 45 comes with a painless indurated ulcer on the lateral border of the tongue of 4 months duration.Â What is the investigation to be done to clinch the diagnosis?Â What histopathological type is most common, if it is a malignant condition?Â If the patient complains of pain in the left ear what is your inference?Â What are the etiological factors for a malignant ulcer of the tongue?Â What are the various modalities of treatment for the condition?Â What is the ideal treatment for a lesion which is less than 2cm in sixe without palpable nodes?Â If the lesion has extended to involve the neighbouring mandible, what clinical and radiological features wound be appreciable?Â What terminal events may bring death from an uncontrolled primary tumour?Â 342Â MAR-2003Â 923Â Hypoglossal Nerve PalsyÂ Â FEB-2002Â 924Â DD of Ulcers in CheekÂ Â DEC-2004Â 925Â SALIVARY GLANDSÂ Â Â 926Â Surface anatomy of Parotid DuctÂ 356Â MAR-2003Â 927Â Draw &amp;amp; Label : Surgical Anatomy of Parotid glandÂ Â NOV-2002Â 928Â XerostomiaÂ 358Â Â 929Â SialographyÂ 359Â FEB-2001Â 930Â Parotid AbscessÂ 362Â FEB-2001Â JAN-1999Â 931Â Management of Parotid AbscessÂ Â SEP-2000Â 932Â SialectasisÂ 362Â SEP-2003Â 933Â SailolithiasisÂ Â Â 934Â SailosisÂ Â Â 935Â Salivary CalculiÂ Â FEB-2001Â MAY-1999Â FEB-2002Â 936Â Salivary fistulaÂ 363Â APR-2000Â 937Â Sjogrens SyndromeÂ 364Â Â 938Â Mikulikz SyndromeÂ 365Â Â 939Â Classification of Salivary Gland Tumours Â Â Â 940Â Pleomorphic AdenomaÂ Â Â 941Â Mixed Parotid tumourÂ Â MAY-1999Â MAY-2002Â 942Â Malignant Parotid tumoursÂ Classify Parotid Gland NeoplasmsÂ Â SEP-1997Â FEB-2008Â 943Â Warthins TumourÂ 368Â AUG-2002Â APR-2004Â 944Â Adenoid Cystic CarcinomaÂ 369Â Â 945Â Freys SyndromeÂ 373Â FEB-2008Â 946Â NECKÂ Â Â 947Â Ludwig's AnginaÂ ?Â Â 948Â Bezold's AbscessÂ Â Â 949Â You are witnessing a surgeon doing an excision biopsy of a nodular mass n the posterior triangle of neck of male aged 20yrs under local anaesthesia.Â What are the boundaries of posterior trinagle?Â What drug is used for local anaesthesia?Â What are the types of Biopsies?Â What are the advantages of adding adrenaline with local anaesthetic agent?Â Where is Adrenaline + LA contraindicated?Â What are the histological types of Hodgkins Disesae?Â What are the chemotherapeutic agents used in Hodgkins Disease?Â What is staging Laparotomy?Â Â FEB-2002Â 950Â Lymphatic Drainage of NeckÂ Â JAN-1999Â 951Â Levels of Lymph Nodes in NeckÂ 394Â Â 952Â Cervical RibsÂ 379Â AUG-2001Â NOV-2002Â SEP-2000Â JAN-2002Â JAN-1999Â 953Â Vascular complications of Cervical RibÂ Â AUG-2002Â 954Â Adsons TestÂ 380Â 148Â FEB-2008Â 955Â Branchial CystÂ 381Â APR-2000Â AUG-2001Â FEB-2002Â 956Â Branchial FistulaÂ Â SEP-2000Â JAN-1999Â MAY-2002Â 957Â Pharyngeal PouchÂ Â Â 958Â LaryngoceleÂ Â Â 959Â Cystic HygromaÂ 384Â AUG-2001 APR-2000Â JUN-2005Â DEC-2004Â 960Â Carotid Body TumourÂ ChemodectomaÂ 388Â AUG-2001`Â 961Â Waldeyer's RingÂ 377Â MAR-2003Â 962Â DD of a swelling in the middle of the neckÂ 377Â DEC-2004Â 963Â Tuberculous LymphadenitisÂ 391Â Â 964Â Cold AbscessÂ 393Â AUG-1998Â 965Â Treatment of TB Cold Abscess of NeckÂ 393Â AUG-2001Â APR-2000Â 966Â Types of Neck DissectionÂ 398Â Â 967Â Management of Tuberculous Cervical Lymphadenitis Â Â JAN-1999Â 968Â THYROIDÂ Â Â 969Â Adenoma ThyroidÂ Â AUG-1998Â 970Â A patient underwent sub total thyroidectomy for Grave's Disease and is in the post operative ward and six hours after surgery develops acute respiratory distress with swelling of operated site.Â What is the cause of this respiratory distress?Â What should be done immediately to relieve the respiratory distress?Â What is thyroid storm?Â How do you manage a case of thyrotoxic crisis?Â What part of thyroid is left behind in subtotal thyroidectomy and why?Â Â AUG-2002Â 971Â Development of ThyroidÂ Â Â 972Â Draw &amp;amp; Label : Blood Supply of ThyroidÂ 404Â JUN-2005Â FEB-2002Â 973Â Thyroglossal CystÂ 405Â JAN-1999Â FEB-2008Â MAY-2002Â 974Â Thyroglossal FistulaÂ Â JUL-2008Â 975Â Lingual ThyroidÂ 405Â SEP-2000Â JUL-2008Â 976Â Lateral Aberrant ThyroidÂ Misnomer; cervical lymphadenopathy due to papillary carcinoma of thyroid.Â 407Â MAR-2003Â 977Â Investigations of Thyroid SwellingÂ 407Â DEC-2004Â 978Â Thyroid Function TestsÂ 407Â NOV-2002Â 979Â Natural history of GoitreÂ Â Â 980Â Colloid GoitreÂ 410Â MAR-2003Â 981Â FNAC in thyroid MalignanciesÂ Â MAR-2003Â 982Â Causes of clinically solitary noduleÂ Â JUL-2008Â 983Â Retrosternal GoitreÂ 415Â AUG-2002Â 984Â Grave's DiseaseÂ 417Â APR-2000Â AUG-1998Â 985Â A 30yr old female patient with history of thyroid swelling of six months duration. She had symptoms and signs of thyrotoxicosis. Examination of neck revealed uniform enlargemnet of thyroid gland.Â What is the likely diagnosis?Â How should the patient be investigated?Â How would you treat this patient?Â Â FEB-2008Â 986Â Treatment of ThyrotoxicosisÂ 417Â DEC-2004Â 987Â Preop preparation of a toxic thyroidÂ Â Â 988Â Clinical features of thyrotoxicosisÂ 417Â JUN-2005Â 989Â Signs and symptoms of HyperthyroidismÂ 418Â SEP-2003Â 990Â Eye Signs in ThyrotoxicosisÂ 418Â Â 991Â Malignant ExophthalmosÂ 419Â Â 992Â Thyroid AcropachyÂ 421Â Â 993Â Carcinoma of ThyroidÂ Â FEB-2001Â 994Â Rule of 12Â (Bailey p. 779)Â Â Â 995Â Classify malignancy of ThyroidÂ 425Â DEC-2004Â 996Â Pathological types of Carcinoma ThyroidÂ 425Â SEP-2003Â 997Â Papillary Carcinoma ThyroidÂ Â Â 998Â Microcarcinoma ThyroidÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; tiny foci of papillary carcinomaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; no clinical symtoms/signsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; foci less than1 cmÂ (Bailey p. 794)Â Â Â 999Â Hurthle Cell CarcinomaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; a variant of follicular ca thyroidÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; poor prognosisÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; syn: Askanazy CellsÂ (Bailey p. 794)Â Â Â 1000Â Medullary Carcinoma ThyroidÂ Â FEB-2002Â 1001Â Treatment of Carcinoma ThyroidÂ 430Â JUN-2005Â 1002Â Hashimoto's ThyroiditisÂ 434Â FEB-2008Â FEB-2002Â 1003Â De-Quervain's ThyroiditisÂ 434Â Â 1004Â Complications of ThyroidectomyÂ 438Â 1134Â Â 1005Â Thyroid CrisisÂ 439Â 1134Â Â 1006Â Signs and symptoms of HypothyroidismÂ 440Â APR-2004Â 1007Â MyxoedemaÂ Â Â 1008Â Recurrent Laryngeal Nerve ParalysisÂ 441Â AUG-2002Â 1009Â PARATHYROID AND ADRENALSÂ Â Â 1010Â Development of ParathyroidsÂ Â NOV-2002Â 1011Â Parathyroid AdenomaÂ Â MAY-2002Â 1012Â Acute ParotitisÂ Â AUG-2002Â 1013Â Secondary HyperparathyroidismÂ Â APR-2004Â 1014Â Types of Hyperparatyroidism and their differentiationÂ Â JUL-2008Â 1015Â HyperadrenalismÂ Â SEP-2003Â 1016Â Clinical features of Addisons DiseaseÂ Â MAR-2003Â 1017Â Von Hippel Lindau DiseaseÂ 451Â Â 1018Â BREASTÂ Â Â 1019Â Draw &amp;amp; Label : Cross sectional Anatomy of BreastÂ Â JUL-2008Â 1020Â Draw &amp;amp; Label : Lymphatic Drainage of BreastÂ 455Â JUN-2005Â SEP-2003Â 1021Â Lymphatic Drainage of BreastÂ 455Â SEP-2000Â 1022Â MammographyÂ 455Â MAR-2003Â 1023Â Mondor's DiseaseÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; cord like feel beneath skinÂ 455Â Â 1024Â ANDIÂ 456Â JUN-2005Â AUG-2002Â JUL-2008Â 1025Â FibroadenomaÂ 456Â APR-2000Â MAY-1999Â FEB-2002Â 1026Â Giant FibroadenomaÂ Â Â 1027Â FibroadenosisÂ 458Â AUG-2001Â SEP-1997Â 1028Â Hard fibroadenomaÂ 458Â JUN-2005Â 1029Â Breast MouseÂ another name for fibroadenomaÂ called so bcoz fibroadenoma is not fixed to the breast tissue and is mobile.[Refer Clnical DAS]Â Â MAR-2003Â 1030Â Phylloides Tumour Â Cystosarcoma PhyllodesÂ 459Â AUG-2002Â FEB-2008Â 1031Â GalactoceleÂ 460Â JAN-1999Â 1032Â Breast AbscessÂ 461Â APR-2000Â FEB-2001Â SEP-1997Â 1033Â Management of Breast AbscessÂ 462Â SEP-2000Â 1034Â AntibiomaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; occurs when breast abscess is treated only with antibiotics and not by drainageÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; sterile pus surrounded by thick fibrous tissue coverÂ 463Â 1991Â 1035Â Duct ectasiaÂ 464Â Â 1036Â Tietze's DiseaseÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; costochondritis of second costal cartilageÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; mimics mastalgiaÂ 465Â Â 1037Â Duct Papilloma of BreastÂ 466Â 1985Â 1038Â GynaecomastiaÂ 466Â Â 1039Â Carcinoma Male BreastÂ 466Â Â 1040Â Pathological Types of Carcinoma BreastÂ 469Â APR-2004Â 1041Â Pagets Disease of NippleÂ 470Â 1987Â 1989Â 1042Â Paget's Disease of BreastÂ 470Â MAY-1999Â 1043Â Cancer en cuirasseÂ 474Â Â 1044Â BSEÂ 476Â Â 1045Â Manchester Staging for Carcinoma BreastÂ 476Â 1994Â 1990Â 1046Â TNM Classification for Carcinoma of BreastÂ 476Â 1986Â 1993Â 1047Â Sentinel Node Biopsy (SLNB)Â 479Â APR-2004Â 1048Â Triple AssesmentÂ 480Â Â 1049Â Treatment of Carcinoma BreastÂ 480Â SEP-2003Â 1050Â Surgical procedures for early carcinoma of female breastÂ Â 1992Â 1051Â QUARTÂ Â Â 1052Â Types of MastectomyÂ 484Â Â 1053Â Complications of MastectomyÂ Â Â 1054Â Advanced carcinoma BreastÂ Â 1990Â 1055Â TRAMÂ 495Â Â 1056Â Retracted NippleÂ 497Â Â 1057Â Classification of discharge from nippleÂ 497Â JUN-2005Â 1058Â BBD ClassificationÂ ?Â Â 1059Â Investigations in a case of abnormal nipple dischargeÂ Â 1986Â 1060Â UROLOGYÂ Â Â 1061Â KIDNEYÂ Â Â 1062Â Boari's OperationÂ ?Â Â 1063Â KUB X RayÂ 930Â AUG-1998Â 1064Â IVCÂ Â Â 1065Â Intravenous PyelogramÂ 932Â JAN-1999Â 1066Â Reflux NephropathyÂ 932Â 982Â Â 1067Â MCUÂ 932Â Â 1068Â Swan Ganz CatheterÂ a balloon-tipped flexible catheter commonly used in the treatment of critically ill patients; introduced via a major peripheral vein, usually jugular or subclavian, and floated under pressure waveform guidance, with or without fluoroscopy, sequentially through the right atrium, right ventricle, and pulmonary artery, ultimately to wedge, when the balloon is inflated, in a small arterial branch where the tip measures pressure-transmitted retrograde from the left side of the heart, which is assumed to represent left ventricular end-diastolic pressure; side holes allow measurement of central venous pressure; with the balloon deflated, catheter measures pulmonary artery systolic, diastolic, and mean pressures; also allows infusion via catheter; some catheters are fitted with pacing electrodes. Syn: pulmonary artery catheter.Â (Stedman)Â Â NOV-2002Â 1069Â Cabot's NephrostomyÂ 938Â 962Â Â 1070Â Percutaneous NephrostomyÂ 938Â Â 1071Â Causes of HematuriaÂ 939Â FEB-2008Â 1072Â Benzidine TestÂ a test for blood; the suspected fluid is treated with glacial acetic acid and ether, and the latter is then decanted and treated with hydrogen peroxide and a solution of benzidine in acetic acid; the presence of blood is indicated by a bluish color turning to purple. Syn: Adler test.Â (Stedman)Â Â Â 1073Â Horseshoe KidneyÂ 940Â FEB-2008Â 1074Â Crossed DystopiaÂ â€¦Unilateral fusion (syn. crossed dystopia) is rare but the urogram appearance is striking. Both kidneys are in one loin and are usually fused. The ureter of the lower kidney crosses the midline to enter the bladder on the contralateral side. Both renal pelves can lie one above each other medial to the renal parenchyma (unilateral long kidney) or the pelvis of the crossed kidney faces laterally [unilateral S-shaped kidneyâ€¦Â (Bailey)Â Â Â 1075Â Polycystic Kideney DiseaseÂ autosomal dominantÂ 941Â Â 1076Â Postcaval Ureter/Retrocaval UreterÂ The right ureter passes behind the inferior vena cava instead of lying to the right of it. If this causes obstructive symptoms, the ureter can be divided and rejoined in front of the cava using a long oblique anastomosis without tension. Unusually, the retrocaval portion of the ureter is fibrotic and must be excisedÂ (Bailey)Â 943Â Â 1077Â UreterocoelÂ 943Â Â 1078Â Classification of Renal InjuryÂ 944Â Â 1079Â Draw &amp;amp; Label : Types of Renal TraumaÂ 945Â FEB-2008Â 1080Â Renal TuberculosisÂ 946Â Â 1081Â Draw &amp;amp; Label : Types of Renal TuberculosisÂ 946Â APR-2004Â 1082Â Describe the clinical features and management of Hydronephrosis?Â 948Â FEB-1998Â 1083Â HydronephrosisÂ 948Â Â 1084Â Causes of HydronephrosisÂ 948Â DEC-2004Â 1085Â Draw &amp;amp; Label : Intrarenal PelvisÂ 951Â MAR-2003Â 1086Â Renal CarbuncleÂ renal parenchymal necrosis by Staph aureusÂ 954Â Â 1087Â Sources of Perinephric AbscessÂ 954Â Â 1088Â Periurethral AbscessÂ Periurethral abscesses can be either penile, bulbar or chronic.Â A penile periurethral abscess usually arises as an acute gonococcal infection of one of the glands of LittrÃ©. The tender induration felt on the underside of the penis points and discharges externally, often leaving a fistula.Â Treatment. An anterior urethrotomy will encourage the abscess to burst into the urethra. When the abscess lies behind a stricture, it should be opened externally.Â A bulbar periurethral abscess is a spreading cellulitis due to infection with streptococci and anaerobic organisms. It may or may not be associated with a urethral stricture, and extravasation of urine is not unusual.Â Clinical features. There is perineal pain with pyrexia, rigors and a rapid pulse rate. Tenderness and swelling rapidly spread from the perineum to the penis and the anterior abdominal wall.Â Treatment. Appropriate antibiotics are essential. Collections of pus should be drained and the urethra should be defuntioned by inserting a suprapubic urinary catheter.Â A chronic periurethral abscess sometimes results from a long-standing urethral stricture. The multiple loculi of pus should be drained and the stricture treated appropriately. Urethral fistula may occur either spontaneously or as a result of incision of the abscess.Â (Bailey)Â -Â Â 1089Â Ureteric StonesÂ Renal StonesÂ Types of urinary stonesÂ 956Â JUN-2005Â APR-2000Â AUG-1998Â 1090Â Obstructive NephropathyÂ â€¦More than 70 per cent of the kidney function must be lost before renal failure becomes evident: there is a large functional reserve. It follows that renal damage must be extensive before changes occur in blood constituents whose level is controlled by renal excretion. Such damage is of three main types: reduction of renal plasma flow, destruction of glomeruli or impairment of tubular function. In severe hypertension or renal artery stenosis, the plasma flow is impaired. In glomerulonephritis or acute cortical necrosis, there is a loss of glomeruli, while in pyelonephritis tubular function is most severely affected. In obstructive nephropathy, back-pressure on the renal parenchyma causes all three types of damageâ€¦.Â (Bailey)Â Â Â 1091Â ESWLÂ 957Â Â 1092Â Wilm's TumourÂ 962Â Â 1093Â Treatment of stag horn calculusÂ NephropyelolithotomyÂ PCNL is becoming popular nowÂ 963Â JUN-2005Â 1094Â Renal CarcinomaÂ 964Â MAY-2002Â 1095Â Grawitz TumourÂ 964Â Â 1096Â Discuss the clinical fatures and management of HypernephromaÂ 964Â MAY-1999Â 1097Â Canon ball SecondariesÂ 965Â Â 1098Â Stauffer's SyndromeÂ 966Â Â 1099Â URINARY BLADDERÂ Â Â 1100Â Vesical CalculiÂ 970Â MAY-1999Â 1101Â Ectopia VesicaeÂ 970Â Â 1102Â Hunner's UlcerÂ 974Â Â 1103Â Thimble BladderÂ a contracted bladder, unable to relax and distendÂ 975Â Â 1104Â Endemic HematuriaÂ 975Â Â 1105Â Discuss the clinical features and management of Bladder TumoursÂ 976Â AUG-1998Â 1106Â Painless HematuriaÂ â€¦Painless haematuria is by far the most common symptom and should be regarded as indicative of a bladder carcinoma until proven otherwiseâ€¦Â (Bailey)Â Â Â 1107Â Rupture BladderÂ 979Â Â 1108Â Bladder DiverticulaeÂ 982Â Â 1109Â Urinary FistulaÂ Â Â 1110Â Urethral SyndromeÂ Â Â 1111Â Urinary DiversionÂ 983Â Â 1112Â PSAÂ ?Â Â 1113Â PROSTRATEÂ Â Â 1114Â Draw &amp;amp; Label : Anatomy of ProstrateÂ Â MAY-2002Â 1115Â Draw &amp;amp; Label : Various zones in the prostrate gland (Mc Neal)Â Â AUG-2002Â 1116Â Discuss the clinical features and management of BPHÂ Â APR-2000Â 1117Â BPHÂ Â FEB-1998Â FEB-2002Â MAY-2002Â 1118Â Prostratism sans prostrateÂ -Â MAR-2003Â 1119Â ProstatismÂ Â AUG-2002Â 1120Â Discuss Carcinoma Prostrate in the following headings :Â Clinical featuresÂ Investigations of the diseaeÂ Treatment of the diseaseÂ Â SEP-1997Â AUG-2001Â 1121Â Retropubic ProstatectomyÂ 989Â NOV-2002Â 1122Â TURPÂ 989Â AUG-2002Â 1123Â Carcinoma ProstrateÂ ?Â SEP-1997Â 1124Â Investigations of Obstructive UropathyÂ 990Â JUN-2005Â 1125Â Ureteric ColicÂ This is an acute pain felt in the loin and radiating to the ipsilateral iliac fossa and genitalia. The patient often rolls around in agony as waves of excruciating sharp pain are imposed upon a continuing background of discomfort. ConÂ­trast this with the patient suffering from penitoneal pain who lies still to avoid exacerbating the pain by movement.Â Ureteric colic is caused by the passage of a foreign body, usually a stone. The site of the pain can be a guide to the progress of the stone: the more the pain radiates into the groin, the more distal the stone. Local tenderness is much less than would be expected from the severity of the pain.Â (Bailey)Â Â Â 1126Â Secondary Urinary Bladder StoneÂ Â JUL-2008Â 1127Â A 40 year old man had a fall from a building site. He has not passed urine for 12 hours. Catheterisation produced severe bleeding.Â What are the possible causes of retention of urine in this patient?Â What is the emergency treatment?Â What all investigations will you do for this patient?Â How will you manage the condition and its complications?Â Â Â 1128Â A 65yr old male attends the surgery casuality with c/o inability to pass urine 2 days. O/E Bladder distended upto umbilicus.Â Causes of retensionof urine in this patient?Â Investigations ?Â Emergency management given in the casuality?Â Complications possible if treatment not instituted in this patient?Â Operations to cure the original cause for the complaint?Â 990Â JUN-2005Â 1129Â URETHRAÂ Â Â 1130Â Draw &amp;amp; Label : Rupture of male membranous urethraÂ 995Â DEC-2004Â 1131Â Clinical features of rupture of UrethraÂ 996Â JUN-2005Â 1132Â Rupture of Bulbar UrethraÂ 996Â Â 1133Â Management of Rupture UrethraÂ 996Â SEP-2003Â 1134Â Stricture UrtethraÂ Management of Stricture UrtethraÂ 997Â SEP-2003Â JAN-1999Â FEB-2001Â MAY-2002Â 1135Â Treatment of Stricture UrethraÂ 997Â JUN-2005Â 1136Â HypospadiasisÂ 999Â AUG-2002Â JUL-2008Â 1137Â EpispadiasisÂ 999Â Â 1138Â Posterior Urethral ValveÂ 1000Â 982Â Â 1139Â Extravasation of UrineÂ 1001Â SEP-1997Â 1140Â Urine ExtravasationÂ Supr v/s deepÂ 1001Â Â 1141Â Reiter's SyndromeÂ 1001Â Â 1142Â Retension of UrineÂ Management of RetensionÂ 1002Â APR-2004Â JAN-1999Â 1143Â PENISÂ Â Â 1144Â ParaphimosisÂ 1004Â JUL-2008Â 1145Â Management of PhimosisÂ 1004Â JAN-1999Â 1146Â CircumcisionÂ 1006Â 1131Â Â 1147Â BalanoposthitisÂ 1007Â Â 1148Â PriapismÂ 1007Â Â 1149Â Peyronie's DiseaseÂ 1007Â Â 1150Â ChordeeÂ 1007Â 997Â Â 1151Â Draw &amp;amp; Label : Lymphatic drainage of PenisÂ Â JUL-2008Â 1152Â Premalignant conditions of Carcinoma PenisÂ Â JUL-2008Â FEB-2002Â 1153Â Carcinoma Penis Â Treatment of Carcinoma PenisÂ 1011Â DEC-2004 APR-2004Â APR-2000Â SEP-1997Â 1154Â SCROTUMÂ Â Â 1155Â Layers of ScrotumÂ 1015Â FEB-2002Â 1156Â Classify Scrotal SwellingÂ -Â DEC-2004Â 1157Â Fournier's GangreneÂ 1015Â Â 1158Â Draw &amp;amp; Label : Types of HydroceleÂ 1016Â FEB-2008Â APR-2004Â 1159Â HydroceleÂ 1016Â DEC-2004Â 1160Â Clinical features of Secondary HydroceleÂ 1018Â FEB-2002Â 1161Â Filarial HydroceleÂ Ram's Horn PenisÂ 1018Â Â 1162Â ChyloceleÂ 1018Â Â 1163Â DD of a Scrotal SwellingÂ 1019Â Â 1164Â Jabouley's OperationÂ 1020Â Â 1165Â Lord's PlicationÂ 1020Â Â 1166Â SpermatoceleÂ 1022Â Â 1167Â Epididymal cystÂ Management of Epididymal cystÂ 1022Â APR-2004Â NOV-2002Â APR-2000Â JAN-1999Â 1168Â VaricoceleÂ 1023Â FEB-1998Â SEP-1997Â FEB-2008Â FEB-2002Â 1169Â TESTISÂ Â Â 1170Â Complications of undescended testesÂ 1028Â Â 1171Â OrchiopexyÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Surgical treatment of an undescended testicle by freeing it and implanting it into the scrotum. Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Syn: cryptorchidopexy, orchidorraphy, orchiorrhaphy.Â 1029Â Â 1172Â Indications for Orchidectomy Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; torsion of testesÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; undescended testes even after 8yrÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Prostrate CarcinomaÂ Â Â 1173Â Ectopic TestesÂ 1029Â NOV-2002Â 1174Â Retractile TestesÂ 1030Â MAR-2003Â 1175Â Testes TorsionÂ 1030Â MAR-2003Â 1176Â Classify Testicular TumoursÂ 1031Â APR-2004Â 1177Â Discuss the clinical features and management of seminoma testis?Â Â FEB-2001Â 1178Â SeminomaÂ 1032Â AUG-2002Â 1179Â A 38yr old man presented with a painless swelling in his right testes. Ultrasound scan of the right testes showed ill-defined hypo echoic mass in the upper pole. Left testes is normal.Â What is the diagnosis?Â How is the condition classified?Â Name the tumour markers related to this condition?Â Which of the histological types is the most sensitive?Â What is the long term prognosis?Â Â JUL-2008Â 1180Â Teratoma TestesÂ 1032Â Â 1181Â Tuberculous EpididymoorchitisÂ 1035Â Â 1182Â Different types of Urinary DiversionÂ 845Â SEP-2003Â 1183Â Ileal Urinary DiversionÂ 845Â Â 1184Â Lateral SphicterotomyÂ Â MAR-2003Â 1185Â NEUROSURGERYÂ Â Â 1186Â Lucid IntervalÂ Â FEB-2008Â SEP-2003Â MAR-2003Â 1187Â Coupe injuryÂ Â Â 1188Â Counter Coupe injuryÂ Â Â 1189Â Cerebral ConcussionÂ 1038Â DEC-2004Â 1190Â Subdural HemorrhageÂ Â AUG-2002Â 1191Â Extradural HematomaÂ Â Â 1192Â Anterior cranial fossa fractureÂ Â Â 1193Â Glasgow's Coma ScaleÂ 1039Â MAY-2002Â 1194Â Treatment of Subdural HemorrhageÂ 1043Â APR-2004Â 1195Â Chronic Subdural AbscessÂ 1047Â APR-2000Â 1196Â THORAXÂ Â Â 1197Â Treatment of Blunt Trauma to ChestÂ 1060Â DEC-2004Â 1198Â Classify Chest injuriesÂ 1060Â DEC-2004Â 1199Â Stove in ChestÂ Â Â 1200Â Flail ChestÂ 1063Â NOV-2002Â 1201`Â PneumothoraxÂ 1064Â MAR-2003Â FEB-2002Â MAY-2002Â 1202Â Tension PneumothoraxÂ 1064Â Â 1203Â Empyema NecessitansÂ 1066Â 1067Â Â 1204Â Intercostal Tube DrainageÂ 1069Â SEP-2003Â 1205Â Diagnosis of Pulmonary EmbolusÂ 1070Â NOV-2002Â 1206Â Pulmonary EmbolismÂ 1070Â Â 1207Â Pancoast tumourÂ 1074Â Â 1208Â Pericardial TamponadeÂ 1077Â AUG-2002Â 1209Â Sites of herniation in diaphragmÂ 1077Â Â 1210Â Immunosuppresive therapyÂ 1096Â NOV-2002Â 1211Â Whiplash injuryÂ Â AUG-2002Â 1212Â ANAESTHESIAÂ Â Â 1213Â Regional AnaesthesiaÂ 1103Â SEP-2003Â 1214Â Local AnaesthesiaÂ 1104Â MAY-1999Â 1215Â Bier's BlockÂ 1104Â Â 1216Â Epidural AnaesthesiaÂ Â FEB-1998Â MAY-2002Â 1217Â Spinal AnaesthesiaÂ Â JAN-1999Â FEB-2001Â FEB-2008Â 1218Â Difference between Spinal and Epidural AnaesthesiaÂ Â JUL-2008Â 1219Â ADJUVANT THERAPYÂ Â Â 1220Â Â Â Â 1221Â ADVANCED IMAGING METHODSÂ Â Â 1222Â Ultrasound ScanÂ 1107Â DEC-2004Â 1223Â Endoluminal UltrasoundÂ Â Â 1224Â Disphragmatic HerniaÂ 1077Â JUL-2007Â 1225Â CT ScanÂ 1109Â JUN-2005Â 1226Â Tubes used in the Gastrointestinal TractÂ 1124Â SEP-2003Â 1227Â DiathermyÂ 1129Â DEC-2004Â 1228Â Types of DiathermyÂ 1129Â Â 1229Â Short wave DiathermyÂ Â MAY-2002Â 1230Â VasectomyÂ 1131Â JAN-1999Â 1231Â HypoparathyroidismÂ 113444Â Â 1232Â HypocalcaemiaÂ 1134Â MAR-2003Â 1233Â MRIÂ Â JUN-2005Â APR-2004Â AUG-1998Â 1234Â Contraindications of MRIÂ Â Â 1235Â USSÂ Â JUN-2005Â 1236Â Day surgery unitÂ 1146Â Â 1237Â OPERATIVE SURGERYÂ Â Â 1238Â Ideal TheatreÂ Â Â 1239Â Principle of AutoclaveÂ 1114Â FEB-2002Â 1240Â Sterilisation of InstrumentsÂ 1114Â JUN-2005Â SEP-2003Â 1241Â Suture materials used in SurgeryÂ 1127Â SEP-2003Â 1242Â Why braided and multifilament sutures are less ideal than monofilament sutures?Â Â FEB-2002Â 1243Â Post Operative DrainagesÂ Â SEP-2003Â 1244Â TracheostomyÂ 1135Â JAN-2002Â 1245Â CryosurgeryÂ 1136Â Â &lt;span style='font-family:Arial'&gt;â€ƒ&lt;/span&gt;Â PracticalsÂ INSTRUMENTS TO CARRYÂ 1. TapeÂ 2. TorchÂ 3. Seven TorniquetÂ 4. IlluminoscopeÂ 5. Thread â€“ to measure depth of ulcerÂ 6. Cotton â€“ to measure area of ulcerÂ 7. Knee HammerÂ 8. StethoscopeÂ 9. Hall TicketÂ 10. Identity CardÂ 11. Writing BoardÂ 12. Pen, Scale etcÂ BASIC SURGERYÂ 1. What is a Symptom?Â 2. What is a Sign?Â can be elicited and demonstratedÂ 3. When do you say "Chronic"? Chronicity?Â 4. What is a Sinus?Â (Das p. 55)Â 5. What is a Fistula?Â abnormal blind tract lined by epithelium, connecting internal to external OR two str in the bodyÂ (Das p. 55)Â 6. What is an Ulcer?Â 7. What is a Boil?Â 8. what is a Furuncle?Â 9. What is a Carbuncle?Â 10. Wound Healing?Â 11. Difference in the wounds healed by Primary intention and secondary intention?Â 12. Skin Grafting?Â 13. Suture Materials?Â 14. Complications of Absorbable Sutures?Â 15. Enema? Types?Â Retension enema Â Evacualtion enemaÂ 16. Types of Drainage? Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; OpenÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; ClosedÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Closed SuctionÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Sump SuctionÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; UnderwaterÂ (SRB p. 1123)Â 17. Disadvantages of Open Drain?Â soilingÂ cannot measureÂ infectionÂ 18. Types of Anaesthesia?Â COMMON CLINICAL PROCEDURESÂ Refer  Medicine Practicals on page 19Â LONG CASESÂ THE FIVE IMPORTANT LONG CASES IN SURGERY ARE :Â 1.Â BreastÂ 2.Â ThyroidÂ 3.Â Abdominal LumpÂ 4.Â PVDÂ 5.Â Varicose VeinsÂ Â The following questions will help you in self assessment after reading Clinical DASÂ BreastÂ Based on Class by Dr.Vishwanathan. MSÂ Based on Class by Dr.Abid Ali. MSÂ Prepared by : Hafeesh, GouriÂ (Das pp. 308-324)Â (SRB pp. 453-497)Â (Bailey pp. 837-847)Â (Synapse p. 61)Â (IBS p. 185)Â (Robbins pp. 710-716)Â 1. Three Common diagnosis in Breast Cases?Â Carcinoma *** (common Breast Case for exam)Â FibroadenomaÂ FibroadenosisÂ EXAMINATION OF PATIENTÂ CASE SHEETÂ PRESENTATIONÂ HISTORYÂ 2. Significance of Menstrual history?Â Early menarche and late menopause ï‚® increased estrogenic activity  ï‚® breast cancerÂ Menstruation and Breast Surgery?Â Breast surgery is best during LUTEAL phase of menstuationÂ INSPECTIONÂ 3. Positions for Breast examination?Â SittingÂ Semi-recumbentÂ RecumbentÂ Bending forwardÂ 4. Various positions while sitting?Â hands by sideÂ arms raised ï‚® nipple retraction or deviationÂ hands on hips ï‚® lump is more evident (contraction of PM)Â bending forwards ï‚® any fixity to chest, both breasts should fall forward equally, fibrosis behind nippleÂ 5. @ Extent of Breast?Â 2 to 6th rib in midclavicular lineÂ sternum to mid-axillary lineÂ axillary tail of spenceÂ (SRB p. 453)Â 6. Best Position to detect nipple retraction?Â 7. Cause of Nipple retraction in carcinoma?Â infiltration of  lactiferous ducts with subsequent fibrosisÂ (Das p. 322)Â 8. Types of Nipple Retraction?Â slit like â€“ duct ectasia &amp;amp; periductal mastitisÂ circumferential â€“ carcinomaÂ (SRB p. 497)Â 9. Demonstrate eversion of a retracted nipple?Â 10. Types of Nipple Discharge?Â Fresh Blood â€“ Carcinoma &amp;amp; Duct PapillomaÂ Black â€“ Duct Papilloma with Obstructed DuctÂ Watery/Greenish â€“ FibroadenosisÂ Milky/White â€“ Lactation, Galactocoele, Galactorrhoea, Mammary Duct EctasiaÂ Purulent â€“ Acute Mastitis, Chroinic breast abscess with duct ectasiaÂ 11. What is Pagets Disease of Nipple?Â 12. Best Position to see a lump?Â 13. Demonstrate Peau'd orange appearance?Â squeezing a segment of skin over the breastÂ Das Color Plate IXÂ 14. Significance of Peau'd orange appearance?Â 15. Mechanism of Peau'd orange appearance?Â blockage of subcuticular lymphatics by cancer cellsÂ 16. Why is the edema in Peau'd Orange pitting?Â fixation of hair follicles and sebaceous glands to the subcutaneous tissueÂ (Das p. 322)Â 17. How to differentiate ulceration due to carcinoma and phyllodes tumour?Â pass a probe under skin marginÂ carcinoma ï‚® not possibleÂ phyllodes tumour ï‚® possibleÂ 18. How to estimate the level of nipples?Â measure vertical distance from clavicle and horizontal distance from midlineÂ Das Color Plate IXÂ 19. Accessory Nipple ?Â 20. Quadrants of the Breast? How is breast divided?Â FIVE quadrantsÂ CentralÂ Upper outerÂ Upper innerÂ Lower OuterÂ Lower InnerÂ 21. Milk Line ?Â 22. ïƒ„ Development of BreastsÂ 23. Describe a normal areola?Â 24. What is 'Cancer en cuirasse'?Â coat of armourÂ 25. Brawny Oedema?Â 26. Why the arms become oedematous after Mastectomy?Â lymphatic obstructionÂ PALPATIONÂ 27. Demonstrate the palpation of breast?Â position of patient? hands by sideÂ palpate normal breast firstÂ palpate with palmar surface of FINGERSÂ palpate between pulp of fingers and thumb when a swelling is feltÂ palpate quadrant wiseÂ palpate for axillary tailÂ palpate just behind the nippleÂ 28. Demonstrate fluctuation in the swelling?Â stand behind the patientÂ (Das p. 313)Â 29. Causes of a Cystic Swelling in the Breast?Â FibroadenosisÂ Chronic abscessÂ HaematomaÂ GalactoceleÂ Hydatid CystÂ Lymph Cyst Â Phyllodes tumour Â Colloid Carcinoma â€¦Â (Das p. 321)Â 30. Condition in which a cystic swelling shows negative fluctuation test?Â tense cystic swellingÂ 31. Conditions to diagnose a cyst as non-malignant?Â not blood stained on aspirationÂ no residual lumpÂ no refillingÂ no malignant cells in cytologyÂ (Das p. 321)Â 32. Demonstrate Transillumination test?Â 33. Demonstrate fixity to skin?Â move lump side to side/up and downÂ move skin over lumpÂ pinch the skinÂ 34. Differentiate Tethering and Fixity?Â Tethering ï‚® infiltration of COOPERS ligaments &amp;amp; shorteningÂ Fixity ï‚® infiltration of skinÂ 35. Demonstrate Tethering?Â move lump side to side and look for dimpling of skinÂ Significance? infiltrating carcinomaÂ 36. Explain the terms?Â DimplingÂ TetheringÂ Puckering- skin is pulled towards lesion and shows foldsÂ 37. Demonstrate fixity to breast tissue?Â use both handsÂ 38. Demonstrate fixity to Pectoralis Major?Â press hip as hard as possibleÂ check for mobility of the lumpÂ Das Color Plate XÂ 39. Demonstrate fixity to serratus anterior?Â ask patient to push against examiner's shoulder(without flexing elbow) with the hand of affected sideÂ check for mobility of the lumpÂ 40. Implication of Serratus anterior fixity?Â it implies chest wall fixity ie T4aÂ (Pectoralis fixity does not alter the T staging)Â 41. Demonstrate fixity to chest wall?Â same as serratus anterior fixityÂ 42. Demonstrate fixity to Latissimus Dorsi?Â extending the shoulder against resistanceÂ (SRB p. 472)Â 43. Demonstrate Axillary LN Palpation?Â Das Color Plate XIÂ 44. Name the axillary LN groups?Â 45. Levels of Axillary Lymph NodesÂ I â€“ anterior, posterior, lateralÂ II â€“ centralÂ III - apicalÂ 46. Demonstrate Supraclavicular LN Palpation?Â 47. @ Lymphatic Drainage of Breast?Â (SRB p. 455)Â (IBS p. 185)Â DIAGNOSISÂ 48. Findings in Early Carcinoma?Â no axillary LNÂ 49. Findings in Locally Advanced Carcinoma?Â ulceration over breastÂ 50. Findings in Metastatic Carcinoma?Â INVESTIGATIONSÂ 51. Mammography? Indication?Â 52. Features of malignancy in Mammography?Â SpiculationÂ MicrocalcificationÂ TentaculationÂ 53. Role of Mammogram?Â screening purposeÂ  to evaluate contralateral breastÂ to detect recurrence following breast conserving surgeryÂ 54. Xeroradiography?Â (Das p. 318)Â 55. USG?Â to differentiate solid from cystic swellings greater than 2.5cmÂ 56. FNAC?Â  23G needleÂ 57. Specificity of FNAC?Â almost 100%Â 58. Grading of FNACÂ C0 - Â C1 - Â C2 - benignÂ C3Â C4Â C5 - malignantÂ 59. Frozen Section?Â not useful in breast cases, but useful in thyroid casesÂ 60. Trucut Biopsy?Â 11G needleÂ 61. Advantage of Trucut BiopsyÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; to differentiate DCIS and invasive caÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; receptor statusÂ 62. Pathological Grading of the Tumour?Â Based on :Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; nuclear pleomorphismÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; tubule formationÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; mitotic rateÂ Graded as :Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Grade 1 - well differentiated Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Grade 2 - moderately differentiatedÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Grade 3 - poorly differentiatedÂ 63. Incisional Biopsy?Â lump is more than 4cmÂ a portion of the lump is removed and sent for biopsyÂ 64. Excisional Biopsy?Â lump is less than 4cmÂ whole lump is removed with 1 cm margin and sent for biopsyÂ 65. Sentinel Node Biopsy?Â Sentinel Node is the first node encountered by the tumour cellsÂ (Makhanlal p. 196)Â 66. Other Malignancies in which sentinel node biopsy is practiced?Â Carcinoma PenisÂ Malignant MelanomaÂ 67. MRM? Types?Â Patey'sÂ ScalonÂ AuchinclossÂ TREATMENTÂ 68. Treatment for ?Â Early Ca â€“ Breast Conserving Surgery WITH ADJUVANT THERAPYÂ Locally advanced Ca â€“ give neoadjuvant chemo (induction)ï‚® tumour size reduced ï‚® simple mastectomy + chemo + radio.Â Metastatic Ca- Â 69. Criteria for Breast Conserving Surgery?Â lump &amp;lt;4cmÂ no axillary LNÂ adequate sized breast ï‚® for RADIATION (6wks)Â 70. Name the incisions for Breast Surgery?Â 71. Types of Breast Surgeries?Â 72. The Most Important Prognostic Marker in Ca Breast?Â Axillary LNÂ 73. Axillary Sampling?Â 74. Why Curvillinear incision in Breast Conserving Surgery?Â 75. QUART?Â 76. What are the Adjuvant Therapies?Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Radiotherapy Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Chemotherapy ï‚® CMF, CAF (6 cycles)Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Hormone Therapy ï‚® Tamoxifen (20mg/day for 5yrs)Â (SRB p. 490)Â 77. Dose of Radiations after Breast Conservative Surgery?Â 78. What do you mean by Tumour Clearance?Â CARCINOMAÂ (SRB p. 467)Â 79. What is your diagnosis?Â Carcinoma of Breast in Stage ?Â 80. Why do you say this is Carcinoma?Â from HISTORYÂ middle aged womanÂ painless lumpÂ h/o loss of wtÂ INSPECTIONÂ Paeu d'Orange appearanceÂ Ulceration and fungationÂ Nipple drawn upwardsÂ Nipple retractionÂ Dimpling of skinÂ Edema of armÂ PALPATIONÂ stony hard mass in upper and outer quadrantÂ uneven surfaceÂ irregular marginÂ fixed to skin, breast tissue, pectoralis &amp;amp; serratus, OR thoracic wallÂ Nipple discharge Â Palpable LN'sÂ 81. Commonest Breast Carcinoma?Â Cirrhous type (60%)Â cartilaginous consistencyÂ 82. In which quadrant Carcinoma is common?Â upper outerÂ Why? breast tissue is more hereÂ 83. Classify Breast Carcinoma?Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; non-invasive (ductal* &amp;amp; lobular) ie DCIS &amp;amp; LCISÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; invasive (ductal &amp;amp; lobular)Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; DUCTAL Ca is common.Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; LOBULAR Ca is only an incidental finding and does not produce any swellingÂ 84. How to manage DCIS?Â Breast Conservative SurgeryÂ 85. How to differentiate Carcinoma from traumatic Fat necrosis?Â history of injuryÂ discolouration of skinÂ no enlargement of LNÂ (Das p. 320)Â 86. How to differentiate Carcinoma from Antibioma?Â h/o pain and antibiotic treatmentÂ lump is soft at centreÂ (Das p. 320)Â 87. Risk Factors?Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; OestrogensÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Genetic â€“ BRCA1 and BRCA2 genesÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; OCP useÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Ionising RadiationsÂ (SRB p. 468)Â 88. Estrogen and Breast Cancer?Â 89. Medical Adrenelectomy?Â Adrenal gland is the main source of endogenous estrogen in POST MENOPAUSAL women.Â AMINOGLATETHEMIDE (mititane) was used.Â 90. Types?Â Scirrhous, Medullary, Colloid, â€¦Â 91. Staging of Breast Carcinoma?Â 92. Anterior Chemotherapy ? Â 93. Breast Self Examination?Â 94. Demonstrate the mobility of the mass ?Â 95. Trosier's Sign?Â 96. Why edema in upper limb post-operatively?Â 97. Complication of limb edema? Lymphangioasarcoma?Â occurs 5yrs after edema of ULÂ 98. Cardinal Symptoms of Breast Carcinoma?Â Pain, Lump, DischargeÂ 99. Puberty Mastitis?Â 100. Lactational Mastitis?Â (SRB p. 461)Â 101. Dangers of taking biopsy in Breast Carcinomas?Â Severe bleedingÂ 102. Commonest Site of Metastasis?Â Bone( Cancellous) â€“ 50-65% ï‚® skullÂ 103. Other Sites?Â LungÂ PleuraÂ Soft tissueÂ LiverÂ BrainÂ AdrenalsÂ 104. Order of Metastasis?Â Lumbar Vertebra &amp;gt; Femur &amp;gt; thoracic vertebra &amp;gt; RibsÂ 105. How to determine Bone Metastasis?Â Bone ScanÂ 106. What is Colloid mucinous Carcinoma?Â 107. What do you mean by Neo-adjuvant therapy?Â 108. Toilet Mastectomy?Â 109. Advice on discharge?Â 110. How to Followup?Â 1-2yr â€“ every 2 monthsÂ 3-5yr â€“ every 6 monthsÂ &amp;gt;5yr - yearlyÂ 111. Male Breast Malignancy?Â FIBROADENOMAÂ (SRB p. 457)Â 112. Why do you say this is Fibroadenoma?Â PALPATIONÂ firm massÂ well deinfed marginÂ NOT fixed to skin, breast tissue, pectoralis &amp;amp; serratus, OR thoracic wallÂ highly mobileÂ Axillary nodes NOT ENLARGEDÂ (Das p. 322)Â 113. How to differentiate Fibroadenoma and early carcinoma of Breast?Â 114. What is ANDI?Â variety of benign breast disordersÂ 115. Commonest manifestations of ANDI?Â cyclical pain + lumpÂ 116. Types of FibroadenomaÂ Pericanalicular â€“ hard â€“ youngÂ Intracanalicular â€“ soft â€“ middle agedÂ (Das p. 322)Â more dangerousÂ metastasis are more commonÂ ThyroidÂ Based on Class by Dr.Mujeeb Rahman. MSÂ (Das pp. 284-297)Â (SRB pp. 403-443)Â (Bailey pp. 772-806)Â EXAMINATION OF PATIENTÂ CASE SHEETÂ PRESENTATIONÂ Chandrika, 46yr old female residing at Kondotty is a House wifeÂ PCÂ Swelling in the neck for 6 months ; Â Hoarseness of voice for 2 monthsÂ HPCÂ Swelling in the neck was initially seen as a small swelling of a marble size which gradually increased in size to attain the present large size. There is no history of a sudden increase in the size of the swelling. There is no associated pain. She has no difficulty in breathing, swallowing, and no change in voice.Â She also gives a history of hoarseness since 2 months,Â No other pressure symptoms like dysnoea, dysphagia, Â She has increased sweating and intolerance to heat. Tremor of the hands is also present. No other toxic symptoms like loss of weight, muscle weakness etc.Â She has diplopia. No other eye symptoms like difficulty in closing the eyesÂ No history of diarhoeaÂ No symptoms of hypothyroidismÂ On Inspection an irregular shaped swelling is noticed in the front and sides of the neck. The right half of the swelling measures around 6x4 cm and the left half measures around 5x3 cm. The swelling in the midline measures 3x4 cm. On either sides the swelling extends above one finger breadth from the level of thyroid cartilage and below upto the clavicle. Laterally the swelling passes under the SCM muscle. The midline swelling extends below upto suprasternal notch and above two finger breadth from the suprasternal notch. Surface is nodular (avoid saying bosselated). A transverse scar of about 10 cm is seen over the swelling. No redness, sinuses to rule out a thyroglosssal fistula ,or dilated veins over the swelling. No visible pulsations in the swelling. Margins are rounded. Skin over the swelling normal. The Swelling moves with deglution but does not move with protrusion of tongue. No evidence of any retrosternal extension.Â On Palpation, there is no local rise of temperature and no tenderness. The swelling was palpated from the back with the patient sitting, hands by the side and neck slightly extended. Inspectory findings are confirmed. Swelling is firm soft, hard, variable in consistency. It is mobile in vertical and but restricted mobility in horizontal direction. Skin is pinchable. It is possible to get below the thyroid gland(tracheal rings are felt). Trachea is central(deviated in solitary nodule thyroid). Carotid pulsations are palpable. No palpable thrill in the upper pole. No enlarged cervical LNs. Circumference of the neck at the maximium extent of the swelling is        --- cm. Toxic manifestations like lid retraction, exophthalmos, are present. Eye signs like Von-Graffe, Joffroy's, Moebius, Darlympe's Stellwag's are positive. Tremor is present in outstretched hands and tongue. Kocher's test is negative.Â On Percussion over the manubrium sterni, it is resonantÂ On Auscultation, no bruit (systolic) primary toxic goitre heard over the upper pole of the thyroid.Â The Diagnosis is a toxic, multinodular goiter without any pressure symptomsÂ 117. Word meaning of thyroid?Â shield likeÂ Greek wordÂ 118. Word meaning of goiter?Â Latin. guttur ï‚® throatÂ HISTORYÂ 119. Some Important points to ask in history?Â Sleep?Â Voice change?Â Any difficulty in swallowing?Â Stridor?Â loss of wt?Â heat intolerance?Â excessive sweating?Â tremor?Â goitrogenic drug intake?Â 120. Significance of Hoarseness?Â denotes infiltration of Recurrent Laryngeal NerveÂ 121. ïƒ„Muscles supplied by Recurrent Laryngeal NerveÂ 122. Symptoms of HYPOthyroidism?Â weight gainÂ intolerance to coldÂ 123. Drugs causing Hypothyroidism?Â Anti-thyroid DrugsÂ Lithium, AmiodaroneÂ 124. Symptoms of Hyperthyroidism?Â weight loss INSPITE of GOOD APPETITE (should be a recorded weight to be significant)Â intolerance to heat, preference to coldÂ 125. WAYNE'S Index?Â (SRB p. 419)Â 126. What is the importance of Age in this case?Â 127. What is the importance of Sex in this case?Â eight time commoner in femalesÂ 128. What is the importance of Place in this case?Â hilly areasÂ 129. Name the goitre's seen in families?Â Iodine deficiency goiterÂ Medullary* carcinoma thyroidÂ 130. Cause of a rapid increase in the thyroid swellingÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Hemorrhage into noduleÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; anaplastic carcinomaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; ThyroiditisÂ 131. Cause of pain in thyroid case?Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; ThyroiditisÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Anaplastic CarcinomaÂ 132. Causes of Respiratory distress in a thyroid case?Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Carcinoma thyroidÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Retrosternal goiterÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Long standing MNGÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; CCF due to thyrotoxicosisÂ 133. Significance of Menstrual History in a Thyroid Case?Â 134. Bedside test for Thyrotoxicosis?Â Sleeping pulse rateÂ done at around 4am before the patient wakes upÂ fast &amp;amp; irregular pulse ï‚® AFÂ 135. How to asses the degree of thyrotoxicosis based on pulse rate? CRILE's GRADINGÂ mild - &amp;lt;90Â moderate â€“ 90-110Â severe - &amp;gt;110Â (SRB p. 421)Â INSPECTIONÂ 136. Extent of Thyroid Gland?Â lies against c5 c6 c7 and T1Â vertically â€“ middle of thyroid cartilage to 4th or 5th tracheal ringsÂ horizontally â€“ Â Isthmus â€“ 2-4 tracheal ringsÂ 137. Normal size of Thyroid?Â Each lobe ï‚® 5x3x1.5cmÂ 138. Position for Inspection of Thyroid?Â patient sitting, neck slightly extendedÂ hand by the sideÂ 139. Pizillo's Method?Â only for short necked and obeseÂ occiput pressed against the clasped handsÂ 140. Why thyroid moves with deglutition?Â 141. Why thyroid does not move with protrusion of tongue?Â 142. Development of Thyroid?Â 143. Levator Glandular Thyroidae?  Â part of thyroglossal duct from hyoid bone to thyroid isthmus persists to form this fibrous cordÂ 144. Sites of Ectopic Thyroid?Â 145. Anoalies in Thyroid Development?Â 146. Explain the anatomy of Cervical fascia?Â 147. What is Berry's Ligament?Â 148. Why Larynx moves up with deglutition?Â 149. Mechanism of deglutition?Â 150. ïƒ„Enumerate Midline swellings of neck?Â 151. Enumerate Lateral swellings of neck?Â 152. Conditions in which a thyroid swelling does not move up with deglutition?Â a large thyroid swellingÂ Reidel's thyroiditisÂ 153. Other swellings that move with deglutition?Â Thyroglossal cystÂ Subhyoid bursaÂ prelaryngeal/pretracheal LN'sÂ Extrinsic carcinoma of larynxÂ 154. How to differentiate thyroid from thyroglossal cyst?Â thyroglossal cyst moves up with protrusion of tongueÂ 155. Demonstrate the movement of the swelling with protrusion of tongue?Â Ask the patient to keep mouth open.Â Then ask him to protrude the tongue in and out.Â 156. Why thyroglossal cyst moves up with protrusion?Â thyroglossal duct extends from foramen caecum of tongue to the isthmus of the thyroid glandÂ 157. What else moves with protrusion of tongue?Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; subhyoid bursitisÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; sublingual dermoisÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Thyroglossal fistulaÂ Anything attached to Hyoid Bone moves with protrusion of tingue.Â 158. ïƒ„Thyroglossal CystÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; tubulodermoidÂ Management â€“ sistrunk procedureÂ 159. Different Sites for a Thyroiglossal Cyst ?Â 160. ïƒ„Branchial Cyst?Â 161. Inspectory findings in retrosternal goiter?Â dilated veinsÂ 162. Demonstrate Pemberton's Sign?Â both hands above the ears for 2-3  minÂ congestion of face, respiratory distressÂ denotes retrosternal extensionÂ compression of veins ï‚® SUPERIOR THORACIC OUTLET SyndromeÂ 163. Define Retrosternal Goitre?Â more than 50% lies below thoracic inletÂ 164. Types of Retrosternal Goitre?Â primary &amp;amp; secondaryÂ 165. Suspision of Retrosternal Goitre?Â lower border not seenÂ 166. Complications of Retrosternal GoitreÂ 167. What is "Plunging" Goitre?Â present only during coughingÂ 168. What is the plane of the swelling in this case?Â 169. How will you determine the plane of swelling?Â Extend the neck â€“ Â Press chin against pressure â€“ Â 170. Fascia in the neck?Â 171. Strap Muscles?Â SternothyroidÂ SternohyoidÂ ThyrohyoidÂ 172. Most superficial Strap Muscle?Â 173. FNAC and Srap Muscles?Â adhesion of strap muscles to thyroid during surgeryÂ 174. Nerve Supply of the Strap Muscles?Â Ansa Cervicalis c1 c2 c3 (lower part)Â So, during surgery divide the muscle at the upper part to avoid injury to these nervesÂ PALPATIONÂ 175. Demonstrate Thyroid Palpation?Â never forget to flex neck forwardsÂ stand behind the patientÂ thumb on the occiput and four fingers in frontÂ flex neck to right/left to palpate the righ/left lobeÂ 176. Demonstrate feeling for local rise of temperature?Â Never forget to compare with the body temperature.Â 177. Which method will you choose to palpate in this patient and why?Â 178. Methods to palpate thyroid?Â Standard Method from back ï‚® for anterior surface of thyroidÂ Lahey's ï‚® for posteromedial surface of thyroidÂ Crile's ï‚® for small nodulesÂ 179. Demonstrate Lahey's Method of palpation?Â 180. Indication for Lahey's Method?Â to palpate the posteromedial surfaceÂ to palpate each lobe separatelyÂ 181. Demonstrate Crile's Method of palpation?Â using thumbÂ 182. Indication of Criles method?Â to palpate for small nodulesÂ 183. Various consistencies you expect?Â firm â€“ MNG, cystic noduleÂ hard â€“ carcinoma &amp;amp; reidel's thyroiditisÂ soft â€“ colloid, adenomaÂ 184. How to contract both SCM's simultaneously?Â ask patient to press chin against pressureÂ 185. Demonstrate the mobility of the swelling?Â 186. Demonstrate how to get below the thyroid?Â keep finger below the lower border and ask to swallowÂ palpate for the tracheal rings above the suprasternal notchÂ 187. Demonstrate position of trachea?Â 188. Trails Sign?Â 189. Demonstrate Kocher's Test? Explain ?Â Note â€“ push from the sideÂ 190. Who was Kocher?Â First Noble Prize winner in Surgery, 1909Â Done max no of thyroidectomies.Â Kocher's Collar IncisionÂ Kocher's ForcepsÂ Kocher's VeinÂ KocherisationÂ (SRB p. 440)Â 191. What is tracheomalacia?Â 192. Scabbard Trachea?Â seen in large and long standing MNG, infiltrating malignancyÂ x-ray appearance of narrowed tracheaÂ Meaning of Scabbard ? Â 193. Demonstrate Cervical LN Palpation?Â 194. Name the cervical Lymph Node groups?Â I â€“ submandibular &amp;amp; submentalÂ II â€“ upper jugularÂ III â€“ mid jugularÂ IV â€“ lower jugularÂ V â€“ posterior triangle + supraclavicularÂ VI â€“ pre-tracheal and pre-laryngealÂ VII â€“ mediastinalÂ 195. Lymphatic Drainage of Thyoid?Â Delphian NodesÂ (SRB p. 404)Â 196. Lateral aberrant Thyroid?Â 197. Demonstrate Carotid Palpation?Â 198. Where to look for Carotid Pulsations?Â antr border of sternocleidomastoid at the level of upper border of thyroid cartilageÂ NOT with thumbÂ 199. What is Berry's Sign?Â 200. What do you mean by positive Berry's Sign?Â when the carotid pulsations are OBLITERATED (avoid  saying ABSENT) Berry's sign is positiveÂ 201. Significance of Berry's Sign?Â 202. ïƒ„Branches of External Carotid Artery?Â CODE â€“ Sister Luci's Powdered Face Often Attracts Silly MedicosÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Superior ThyroidÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; LingualÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Posterior AuricularÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; FacialÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; OccipitalÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Ascending PharyngealÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Superficial temporalÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; MaxillaryÂ (IBS p. 805)Â 203. Sites of Percussion in Thyroid Case?Â Manubrium SterniÂ Medial end of ClavicleÂ 204. Where do you auscultate? Why?Â upper poleÂ coz superior thyroid artery is more superficial there (inferior thyroid artery in the lower pole enters the gland from deeper plane)Â it is the main arteryÂ Note â€“ use the bell of stethÂ 205. Why vascularity is increased in Thyrotoxicosis?Â increased thyroxine secretion ï‚® increased vascularity to take up the hormoneÂ 206. @ Blood Supply of Thyroid?Â 207. Inferior Thyroid Artery is a branch of ?Â 208. ïƒ„ Branches of SubClavian Artery ?Â 209. What are the toxic symptoms?Â loss of wt inspite of good apetiteÂ increased sweatingÂ intolerance to heatÂ palpitationÂ GENERAL EXAMINATIONÂ Â 210. Significance of Clubbing in Thyroid Case?Â Thyroid AcropachyÂ INVESTIGATIONSÂ 211. What are the investigations?Â FNACÂ USGÂ Thyroid ScanÂ LaryngoscopyÂ (Makhanlal p. 210)Â 212. Normal T3 T4 TSH Levels?Â T4 â€“ 4.5 to 12 Âµg/dLÂ T3 ï‚® 0.45 to 2 ng/dLÂ TSH ï‚® 0.3 to 4 U/LÂ 213. Which is the best TFT value to assess Hyperthyroidism?Â FREE T3Â 214. ïƒ„Steps of Thyroxine synthesis?Â 215. Peripheral conversion of T4Â 216. Classification of Anti-thyroid Drugs?Â synthesis inhibitorsÂ release inhibitors â€¦Â 217. Replacement Dose of Thyroxine?Â 0.1mg of L-thyroxineÂ 218. Maintanence Dose of Thyroxine?Â 219. Supplemental Dose of Thyroxine?Â 220. Suppressive Dose of Thyroxine?Â 0.3mg ODÂ to suppress TSH level Â given in papillary carcinomaÂ 221. Lugol's Iodine?Â 222. Anti-thyroid drug in pregnancy?Â PropylthiouracilÂ 223. MOA of Propylthiouracil?Â blockade of peroxidase enzymeÂ 224. Why to test for Serum Creatinine?Â Increased muscle catabolism ï‚® raised creatinine levelsÂ 225. Why to test for WBC Count ?Â anti-thyroid drugs causes agranulocytosisÂ 226. Complication encountered in surgery due to repeated FNAC?Â adhesion of muscles to thyroidÂ which muscles ?Â 227. Investigation to detect a retrosternal extension of thyroid that is not clinically appreciable?Â CECTÂ Avoid CECT if any plan for radioiodine therapyÂ 228. Isotopes of Iodine?Â I123 - diagnosticÂ I131 â€“ therapyÂ I127 â€“ organicÂ 229. Dose of radioidine for Radioiodine Scan?Â 5 micro curieÂ SURGERYÂ 230. Classify Thyroid Swellings?Â 231. DD of a Solitary nodule thyroid?Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Thyroid AdenomaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Papillary CAÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; palpable nodule of a MNGÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; thyroid cystÂ 232. Radioiodine Therapy? Indications?Â age &amp;gt; 45yrÂ 233. Radioisotope used? Dose?Â IÂ¬Â¬131Â 5-10 millicurieÂ 234. Precuation before giving Radioiodine therapy?Â stop thyroxine supplementation before 6wksÂ 235. What are the pre-op preparations?Â On the Evening before surgeryÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; CarbimazoleÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Propranolol ï‚® 20-40mg bdsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Lugol's Iodine 15drops for 10 days prior to surgeryÂ 236. Making the patient euthyroid before surgery?Â Carcimazole(NEOMERCAZOLE) 10mg 6-8hrly for 6-8wksÂ Last dose of carbimazole has to be given on the evening before the day of surgeryÂ 237. Position for Surgery?Â neck extended, but head should be a little higher than body. Why ? to prevent venous congestionÂ 238. Drugs and dosages to attain Euthyroid state before surgery?Â 239. ïƒ„ Anti-Thyroid Drugs &amp;amp; MOA ?Â 240. What are the pre-op investigations?Â 241. Why Laryngoscopy?Â asymptomatic unilateral vocal cord palsyÂ 242. Tensor of Vocal Cord?Â Cricothyroid.Â Supplied by ï‚® External Laryngeal NerveÂ 243. Nerve Supply of Larynx?Â Recurrent Laryngeal Nerve ï‚® supplies all intrinsic muscles of LarynxÂ Superior Laryngeal Nerve ï‚® internal and externalÂ External supplies CRICOTHYROIDÂ 244. Which is more dangerous? Unilateral / Bilateral vocal cord Palsy? Why ?Â 245. Simmond's Law?Â 246. Symptosms of Injury to Ext Laryngeal Nerve?Â feeling of food going into tracheaÂ 247. Recurrent Laryngeal Nerve? Difference in the course of Right and Left? Which is longer?Â Right is longer as it loops around the aortaÂ 248. Types of Thyroidectomy?Â ENUCLEATION - Â LOBECTOMY - Â HEMI â€“ benign one lobeÂ SUBTOTAL* â€“ toxic thyroid â€“ 1/8th of thyroid retained at lower poleÂ PARTIAL â€“ non-toxic multinodularÂ NEAR-TOTAL* â€“ papillary carcinoma â€“ tissue at TE grove retainedÂ TOTAL â€“ follicular/medullary/papillary carcinomaÂ 249. Berry Picking?Â (SRB p. 427)Â 250. Completion Thyroidectomy ?Â hemithyroidectomy ï‚® frozen section ï‚® if report positive ï‚® Completion thyroidectomyÂ (SRB p. 430)Â 251. Name the Incision?Â Kocher's Collar IncisionÂ 252. Precaution while ligating Inferior Thyroid Artery?Â ligate away from the gland to avoid injury to RLNÂ 253. Dangerous Thyroid Vein during surgery?Â Middle Thyroid VeinÂ severe bleeding ï‚® air embolismÂ Middle thyroid drains into ? internal JugularÂ 254. Normal Weight of ThyroidÂ 20-22gmÂ 255. FNAC report was nodular goiter, but BIOPSY report is Follicular CA? What will you do?Â 256. How can you investigate for  Thyroid CA, during Surgery?Â send for frozen section biopsyÂ result within 20 minÂ 257. Important Commplication during surgery?Â 258. ïƒ„ TracheostomyÂ 259. How to identify the parathyroid during surgery?Â Superior ParathyroidÂ seen between true and false capsuleÂ at the jn of upper 1/3rd of thyroid in the post surfaceÂ yellow gland seenÂ 260. Most important and common complication immediately after thyroid surgery?Â 261. How will you manage it?Â 262. Complication likely to occur if the trachea is accidently incised during Thyroidectomy? Management?Â Surgical EmphysemaÂ 263. Earlierst manifestations of Hypoparathyroidism after thyroid surgery?Â 264. Chvostek Weiss Sign?Â gentle tap on the facial nerve as it emerges in front of external auditory meatusÂ 265. Trousseau Sign?Â 266. Management of Hypoparathyroidism after Thyroidectomy?Â 10ml of 10% Calcium gluconate IV 8th hrlyÂ Oral Calcium 500mg 8th hrlyÂ Supplemt Vit D. Why? it favours Ca absorbtionÂ (SRB p. 439)Â 267. Thyroid Storm?Â 268. Type of Drain used after Thyroidectomy?Â continuous, closed Â 269. When to remove the drain?Â within 10 daysÂ 270. When to remove the sutures?Â within 5-7 daysÂ 271. ïƒ„Anatomy of Larynx?Â 272. Nerve Supply of Larynx?Â 273. Radical Neck Dissection?Â (SRB p. 398)Â 274. What are the structures removed in Classical?Â 275. What are the structures preserved in Modified ?Â nerve ï‚® spinal accessoryÂ muscle ï‚® sternocleidomastoidÂ vein ï‚® internal jugularÂ 276. Eltroxin?Â TOXIC GOITREÂ 277. Differentiating features between Primary and Secondary Thyrotoxicosis?Â Primary ï‚® symptoms appear first, eye signsÂ Secondary ï‚® swelling appear first, cardiac featuresÂ (SRB p. 420)Â 278. Name the toxic eye signs?Â Lid Retractionï‚® over activity of LPSÂ Exophthalmosï‚®retroorbital infiltrationÂ Ophthalmoplegiaï‚®infiltration of muscles(LR&amp;amp;IO)Â Chemosisï‚®blockage of venous drainageÂ 279. First sign to appear ?Â Stellwag's signÂ 280. Earliest sign of Ophthalmoplegia?Â Moebius SignÂ 281. Order of appearance of signs?Â StellwagÂ Von GraffeÂ JoffroyÂ MoebiusÂ (SRB p. 418)Â 282. Difference between Lid lag and Lid retraction?Â Lid Retraction is due to spasm of LPS ï‚® which is due to sympathetic overactivityÂ *LPS is partly innervated by sympathetic fibresÂ 283. What are the other signsÂ TremorÂ Moist handsÂ Thyroid BriutÂ 284. Demonstrate the toxic eye signs?Â 285. Demonstrate Lid Lag? Von-Graffe's Sign?Â Note - move the examiner's finger very slowlyÂ Do 5-6 timesÂ 286. Demonstrate Joffroy's Sign?Â fix the patients head by keeping examiners left hand over head.Â Patients head should be tilted downwards a littleÂ 287. Clinical estimation of Exophthalmos? What is Naffziger's Method?Â superior orbital margin is the landmarkÂ 288. Measurement of Exophthalmos?Â using exophthalmometerÂ 289. Demonstrate Naffziger's Test?Â 290. Difference between Exophthalmos and Proptosis?Â Exophthalmos ï‚® a bulge due to retro-orbital infiltrationÂ Proptosis ï‚® a bulge due to intraorbital massÂ 291. How to differentiate Exophthalmos and Proptosis?Â Exophthalmosï‚® eversion of upper eyelid is not possible.Â Proptosis ï‚® eversion if possibleÂ 292. Gifford's Sign?Â 293. What are the features of Progressive Exophthalmos?Â 294. Malignant Exophthalmos?Â loss of visionÂ (SRB p. 419)Â 295. What causes Retrobulbar Infiltration?Â 296. How will you manage the exophthalmos?Â Sleeping in propped up positionÂ Lateral TarsorhaphyÂ 297. Complications likely to occur if exophthalmos is not managed?Â 298. Orbital Muscles affected in Thyroid Ophthalmoplegia?Â LR  &amp;amp; IOÂ so, patient cannot look upwards &amp;amp; outwardsÂ 299. Why should it cause Chemosis?Â retrobulbar infiltration ï‚® blockage of the venous drainageÂ (Das p. 291)Â 300. Werner's Classification?Â (SRB p. 420)Â 301. Grading of Exophthalmos?Â mild ï‚® widening of palpebral fissureÂ moderateï‚® bulging of eyesÂ severeï‚® congestion, chemosis, ophthalmoplegiaÂ progressiveï‚® continues as severe grade,  inspite of treatmentÂ (SRB p. 420)Â 302. Causes of Horner's Syndrome in a thyroid case?Â infiltration of sympathetic trunkÂ 303. ïƒ„Features of Horner's SyndromeÂ Enophthalmos â€“ sinking eyeballÂ Pseudoptosis â€“ drooping lidÂ Miosis â€“ narrow pupilÂ Anhidrosis â€“ no facial sweatingÂ 304. ïƒ„ @ Cervical Sympathetic Ganglia?Â 305. Importance of Pulse in thyroid case?Â tachycardia in thyrotoxicosisÂ sleeping pulse rateÂ 306. Demonstrate Tremor in this case?Â Outstretched hands with slight fanning  of fingersÂ Another method is to keep a paper over the outstretched fingersÂ 307. Demonstrate Tremor at another site?Â open the mouth fully and put the tongue out for 15-30 secondsÂ tongue should not touch the teethÂ 308. Thyroid Acropachy ?Â clubbing of fingers and toes in primary thyrotoxicosisÂ (SRB p. 421)Â 309. DD of a thyroid swelling?Â 310. What do you mean by the term goiter?Â any enlargement of the thyroid glandÂ CARCINOMAÂ 311. Why do you say this is Carcinoma Thyroid?Â 312. Risk factors for Malignancy ThyroidÂ h/o radiationÂ long standing MNGÂ (Bailey)Â 313. Dunhill's ClassificationÂ Differentiated (Papillary &amp;amp; Follicular)Â UndifferentiatedÂ MedullaryÂ Malignant LymphomasÂ (SRB p. 425)Â 314. Carcinoma which causes LN Metastasis?Â PapillaryÂ 315. Commonest site for Secondaries?Â skullÂ 316. Papiillary and Follicular Carcinoma?Â Papillary â€“ spread by lymphatics â€“ 60%Â Follicular â€“ spread by blood â€“ 17%Â Papillary is more common than follicularÂ 317. Investigations in Thyroid Carcinoma?Â FNACÂ USGÂ TFTÂ Radioiodine StudyÂ S.Thyroglobulinï‚® for follicularÂ 318. TFT findings in Papillary Carcinoma?Â TSH raised ï‚® hormone dependent tumourÂ 319. Thyroid Paradox?Â seen in Papillary CarcinomaÂ Cellular tumours ï‚® softÂ Cystic tumours ï‚® hardÂ 320. FNAC for papillary and follicular?Â Papillary ï‚® very useful (always done)Â Follicular ï‚® not useful; cannot differentiate follicular adenoma and follicular carcinomaÂ 321. Surgery for ?Â Papillary ï‚® Total or SubtotalÂ Follicular ï‚® TotalÂ 322. Any role of Thyroglobulin estimation?Â to followup in follicular carcinomaÂ 323. Prognosis of Thyroid Carcinoms?Â AGESÂ PARATHYROIDÂ 324. Blood Supply of Parathyroid?Â superior ï‚® Â Inferior ï‚® inferior thyroid arteryÂ THYROIDITISÂ Hashimoto's Â De-Quervains'sÂ Reidel'sÂ MYXOEDEMAÂ 325. Demonstrate Tendon Reflexes?Â THYROGLOSSAL CYSTÂ 326. Surgery ?Â Sistrunk OperationÂ 327. Thyroglossal fistula?Â TG cyst bursts to produce fistulaÂ 328. Â Â Varicose VeinsÂ (Das pp. 73-80)Â (SRB pp. 187-208)Â (Bailey)Â EXAMINATION OF PATIENTÂ CASE SHEETÂ PRESENTATIONÂ Ahamed, 42yr old male, residing at Kottakkal is a ShopkeeperÂ Â PCÂ Irregular swelling in the Rt lower limb for 6 monthsÂ Dull aching pain in the calf region for 6 monthsÂ Dark pigmentation for 4 monthsÂ Ulcer in the ankle for 4 monthsÂ Â HPCÂ The swelling was insidious in onset, is present along the inner aspect of the right leg. The swelling was initially noticed in the lower part and it gradually ascended upwards. Swelling gets aggravated on prolonged standing and walking and is relieved by taking rest.Â He also has dull aching pain in the Right calf region. Pain is experienced more towards the evening. No h/o night cramps.Â He also has dark pigmentation around his anklesÂ An ulcer was seen in the inner aspect of the Lf ankle since 4 months. He has dull aching pain over the ulcer. There is serous discharge from the ulcer. Ulcer was increasing in size since it was first seen. Now he is using crepe bandages.Â No history suggestive of DVTÂ Â 329. Define Varicose veinÂ dilated tortuous elongated veinsÂ 330. Other Sites of Varicosities ?Â OesophagusÂ RectumÂ Spermatic CordÂ 331. Ambulatory Venous Hypertension? Value?Â 200 o r moreÂ Normal Venous Pressure â€“ 20mmHg (at ankle)Â (Bailey p. 927)Â HISTORYÂ 332. What causes pain in Varicose Veins? Compare with Claudication Pain in PVD?Â stretching of veinÂ 333. Claudication Distance?Â PALPATIONÂ 334. Demonstrate Trendelenberg test One?Â Torniquet is tied BELOW Saphenous openingÂ 335. What does it indicate?Â incompetence of SF jn.Â 336. Demonstrate Trendeleberg test two?Â 337. What does it indicate?Â 338. How to identify the saphenous opening?Â 3.5cm below and lateral to pubic tubercleÂ 339. How to locate the pubic tubercle?Â ADDUCT thigh against resistanceÂ palpate along the adductor longusÂ 340. Demonstrate Torniquet Test?Â 341. Demonstrate Multiple Torniquet Test?Â 342. Another name for Multiple Torniquet test?Â Oschner's Mahorner's TestÂ 343. Name the perforators in lower limb?Â [HDBCM]Â Hunterian - thighÂ Dodd â€“ mid thighÂ Above Knee perforatorÂ Boyd â€“ gastronemius perforator (Below Knee perforator)Â Cockett â€“ lower leg perforators (I, II, III) â€“ 5,10,15cm above the medial malleolusÂ May or Kuster â€“ ankle perforatorsÂ Other inconstant perforatorsÂ 344. Which is the largest Perforator?Â SF JnÂ 345. Demonstrate Modified Perthe's Test?Â 346. What is the modification in Perthe's Test?Â 347. What does it indicate?Â 348. Demonstrate Pratt's Test?Â 349. Demonstrate Morrissey's Test?Â 350. How do you mark the perforators clinically?Â Fegan's MethodÂ 351. Demonstrate Fegan's Method?Â palpate for CRESENTRIC gap in the deep fascia along the GSVÂ 352. Surface Marking of GSV?Â DIAGNOSISÂ 353. What is your diagnosis?Â 354. What is the grade of this case?Â 355. Causes of Varicose VeinsÂ Primary Â SecondaryÂ (Das p. 77)Â 356. What are the DD's ?Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; LymphoedemaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; AV MalformationÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Orthostatic OedemaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Renal and Cardiac diseasesÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Hepatic causesÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; VasculitisÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Metebolic Diseses like GoutÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Chronic Infections like TB, SyphilisÂ 357. CEAP Classification?Â (SRB p. 193)Â INVESTIGATIONSÂ 358. What investigations you do?Â Doppler USGÂ Duplex imagingÂ VenographyÂ PlethysmographyÂ USG AbdomenÂ (SRB p. 197)Â 359. Any Role for Venography?Â 360. Other Routine investigations?Â Blood â€“ Hb. TLC, DLC, ESRÂ Sugar, Urea, CreatinineÂ Chest X RayÂ ECGÂ 361. Complications of Varicose veins?Â Superficial thrombophlebitisÂ DVTÂ HaemorrhageÂ Skin pigmentationÂ LipodermatosclerosisÂ Venous UlcerÂ PeriosteitisÂ SURGERY - TRENDELENBERGÂ 362. What is the conservative treatment for Varicose Veins? Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; ExerciseÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Crepe BandagesÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Ulna BootsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Diosmin therapyÂ 363. What surgery will you do in this case?Â Trendelenburg + stripping + perforator ligationÂ 364. Surgeries for Varicose?Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; TrendelenbergÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Stripping of veinÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; SEPSÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Subfacial ligation of Cocket and DoddÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Linton'sÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Hook PhlebectomyÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; VNUSÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Trivex MethodÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; EVLAÂ 365. @ Anatomy of venous system in the LL?Â 366. Tributaries of LSV?Â 367. Tributaries of SSV?Â 368. Pre-op PreparationÂ mark the main trunk and perforators with gentian violetÂ 369. What do you mean by flush ligation?Â as close as possible to the femoral vein, to prevent any stump from the femoral veinÂ 370. Why is it ligated very close to the femoral vein?Â the stump of the femoral vein will produce SAPHENA VARIXÂ 371. Name the tributaries that you ligate?Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Superficial CircumflexÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Superficial External PudentalÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Superficial EpigastricÂ 372. What is Saphena Varix?Â dilated terminal end of the great saphenous vein where a thrill maybe palpableÂ 373. Post-op ?Â compression bandage for 2 daysÂ elastic stockinette for 7 daysÂ 374. Complications?Â BleedingÂ injury to nervesÂ echymosisÂ recurrence (most common)Â 375. Other options ?Â injection sclerotherapyÂ compression bandagesÂ 376. Stripping of the GS vein? Upto what level will you strip?Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Myers StripperÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; strips only upto knee, to prevent inury to saphenous  nerve ï‚® numbness (saphenous neuralgia)Â 377. ïƒ„ Cutaneous nerves of Lower Limb?Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt;  Saphenous NerveÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Sural nerveÂ 378. How will you manage small varicosities?Â 379. Newer modalities of treatment?Â ïƒ„Endovenous Laser (EVLA)Â ïƒ„Radiofrequency Ablation (RFA)Â (Bailey p. 931)Â SCLEROTHERAPYÂ 380. Mechanism?Â causes aseptic inflammationÂ 381. Indication?Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; minor varicositiesÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; residual varicosities after a surgeryÂ 382. Contraindication?Â 383. Sclerosants used?Â 2% PolidocanoneÂ STDS (sodium tetra decyl sulphate)Â Phenol in Olive/Almond OilÂ 384. Why mixed with air? Foam ?Â air displaces the blood and provides more  surface area for the sclerosant to actÂ 385. Procedure?Â USG guided, ideallyÂ 386. Complications?Â PigmentationÂ UlcerationÂ Superficial ThrombophlebitisÂ DVT (rarely)Â 387. Microsclerotherapy?Â venous stars and reticular veinsÂ cosmetic treatmentÂ VARICOSE ULCERSÂ 388. Characteristics?Â 389. How it develops?Â 390. Management?Â ulcer heals after the VV surgeryÂ compression bandageÂ DEEP VEIN THROMBOSISÂ 391. How did you rule out DVT in this case?Â h/o fever, pain and swelling in legÂ Modified Perthe's TestÂ 392. Homan's Sign?Â found only in ACUTE cases of DVTÂ 393. Moses Sign?Â found only in ACUTE cases of DVTÂ 394. Neuhof's Sign?Â 395. Inverted Champagne Bottle Sign?Â (SRB p. 194)Â 396. Virchows Triad?Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; StasisÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; HypercoagulabilityÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Vein wall injuryÂ 397. DD for DVT?Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Ruptured Bakers CystÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Ruptured Plantaris tendonÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Calf muscle hematomaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Cellulitis legÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Superf ThrombophlebitisÂ 398. Thrombolytic therapy for DVT?Â 399. Prevention of DVT?Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; leg elevationÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; crepe bandagesÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; LMVH â€“ 5000 U (subcut 2hr before surgery)Â Peripheral Vascular DiseaseÂ (Das p. 59 to 72)Â (SRB p. 144 to 178)Â (Bailey p. 900 to 918)Â TAO is the common diagnosis in PVDÂ 400. What is PVD ?Â HISTORYÂ 401. Intermittent ClaudicationÂ cramp like pain in the muscle during walking due to inadequate blood suppluÂ 402. Cause of Claudication painÂ accumulation of substance P, inadequate blood flowÂ 403. How to asses the claudication distance?Â Treadmill testÂ 404. If patient has only Claudication as the probem, How will you treat?Â Encourage patient to walk ï‚® collaterals develop and improvementÂ DRUGS â€“ Pentoxyphylline, Cilistazole (not very helpful)Â 405. Neurological Claudication?Â pain due to some neurological cause, usually NERVE COMPRESSIONÂ 406. How to differentiate from neurogenic claudication?Â pain persists on rest ï‚® compression of nervesÂ but relieves on assuming some postureÂ All peripheral pulses will be palpableÂ 407. Why Paresthesia occurring in a PVD Case?Â shunting of blood from skin to muscleÂ What is paresthesia? excess sensitivity to touchÂ 408. Boyd's Grading?Â 409. Fontaine's grading of chronic limb ischemiaÂ I â€“ asymptomaticÂ II â€“ intermittent claudicationÂ III â€“ rest painÂ IV â€“ ulceration/gangreneÂ (SRB p. 146)Â 410. Meaning of 'Claudio"Â I limpÂ 411. Cause of rest pain?Â ischemia of the nervesÂ present throughout day and nightÂ 412. Since this patient is diabetic, what precautions will you take before surgery?Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Avoid Anti-diabetics in the morning before surgery, coz  as a reflux response to trauma(surgery) ï‚® hyperglycemic hormones(insulin) will be releasedï‚® patient may go into hypoglycemiaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Investigate â€“ FBS, PPBSÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; So, Switch over to InsulinÂ 413. Important Negative histories to ask and Why?Â h/o Syncope â€“vertebrobasilar insufficiencyÂ INSPECTIONÂ 414. Demonstrate the estimation of Buerger's Angle?Â at the level of sternumÂ less than 30 â€“ severe ischemiaÂ 415. Can you estimate the pressure in the foot vessels clinically?Â the height in cm between the sternal angle and the level of heel at elevation indicates the pressure in mm of Hg in the foot vessels.Â 416. Demonstrate the assessment of time for Capillary FILLING?Â &amp;gt;30 seconds ï‚® ischemiaÂ 417. What are the signs of Ischemia?Â loss of hairÂ loss of subcut tissueÂ shiny skinÂ brittle nailsÂ some color change, compared to opposite limbÂ 418. First symptom of ischemia?Â claudication painÂ PALPATIONÂ 419. Demonstrate Capillary REfilling?Â 420. Demonstrate the Dorsalis Pedis pulse palpation?Â lateral to tendon of EXTENSOR HALLUCIS LONGUSÂ at the proximal first intermetatarsal space from a point midway between the two malleoliÂ 421. Demonstrate the assessment of wasting of muscles?Â 422. Demonstrate Reactive Hyperemia Test?Â DIAGNOSISÂ 423. Why do you say PVD in this case?Â from history (claudication pain etc)Â SmokerÂ middle aged male Â so this maybe ï‚® TAOÂ 424. What is the structural change in the vessel?Â T.intima is damagedÂ T.media causes vasospasm (autonomous nervous system)Â INVESTIGATIONSÂ 425. Name the investigations for this case?Â Arterial DopplerÂ DuplexÂ Â ArteriographyÂ 426. When will you do Arteriography?Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; only when planning arterial surgeryÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; to know the exact site and extendÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; to get an idea regarding collateral circulationÂ 427. Types of Arteriography?Â Retrograde ï‚® preferredÂ Lumbar (direct)Â 428. Complications of Arteriography?Â it can worsen the conditionÂ dissectionÂ 429. ïƒ„Doppler? Duplex? Principle?Â 430. Difference between Doppler and Duplex scan?Â 431. Advantage of Duplex?Â vessel can be visualisedÂ 432. Doppler Shift Principle ?Â 433. Angiography?Â 434. ABPI?Â 435. Brown's Vasomotor Index?Â Normal - &amp;lt;3Â (Das p. 67)Â TREATMENTÂ 436. What are the treatment options?Â ConservativeÂ Surgery (direct &amp;amp; indirect)Â 437. Role of exercises?Â exercise opens up the collateralsÂ 438. Drugs?Â PentoxiphyllineÂ Psilosamine ?Â VitaminsÂ 439. What is the MOA of Pentoxiphylline?Â alters the shape of RBC'sÂ prevents platelet aggregationÂ 440. Surgery?Â Lumbar SympathectomyÂ 441. LUMBAR SYMPATHECTOMY? Â removal of L1 to L4Â 442. How does it help?Â increases CUTANEOUS blood supply ï‚® healing of skin flaps and ulcerÂ level of amputation can be lowered after sympathectomyÂ SYMPATHECTOMY DOES NOT IMPROVE CLAUDICATIONÂ 443. Steps of Lumbar Sympathectomy?Â (SRB p. 160)Â 444. How to differentiate genitofemoral nerve and the sympathetic trunk during surgery?Â GFN lies on the anterior aspect of the psoas muscle while sympathetic trunk lies medialÂ 445. How to differentiate lymphatics and Sympathetic trunk?Â presence of distinct ganglia and the rami communicantesÂ 446. How to asses the success of the surgery?Â limbs become warmÂ rest pain disappearsÂ 447. Bilateral Sympathectomy? Precaution?Â Preserve L1 on one side, otherwise failure of ejaculationÂ DRY EJACULATIONÂ 448. Will you remove theStellate ganglion? Why?Â No.Â Horner's Syndrome will be produced.Â If necessary, the lower portion is removed.Â 449. ïƒ„ Anatomy of Stellate Ganglion?Â 450. ïƒ„ Anatomy of Sympathetic Ganglia ?Â 451. ïƒ„ Structure of Spinal Cord ?Â 452. Chemical Sympathectomy?Â 5ml phenol in water (1:16)Â 453. Precuation during chemical sympathectomy?Â never inject into aorta or IVCÂ 454. Omentopexy?Â principle â€“ neovascularisationÂ 455. Endarterectomy?Â 456. Artificial Dacron?Â 457. Autograft?Â saphenous vein usedÂ GANGRENEÂ 458. Define gangreneÂ 459. Dry and Wet Gangrene?Â 460. When do you get Wet gangrene?Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; sudden occlusion of vesselÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; both arterial and venous occlusionÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; supra-added infectionÂ 461. How to differentiate Gas Gangrene?Â crepitationsÂ h/o of deep penetrating wound from road traffic accident etcÂ 462. Types of Separation?Â aseptic and septicÂ 463. FIVE Signs of GangreneÂ ColorÂ TemperatureÂ SensationÂ PulsationÂ FunctionÂ (Das p. 68)Â 464. What is pregangrene?Â (Das p. 68)Â 465. Causes of Gangrene?Â 466. Line of demarcation ? ImportanceÂ line between viable and dying tissue, marked by a band of hyperemiaÂ helps in deciding the level of amputationÂ 467. Features of Arterial EmbolismÂ 5 P's â€“ Pain, Paralysis, Pallor, Pulseless, ParesthesiaÂ (Bailey p. 910)Â (Das p. 71)Â 468. ïƒ„Bed SoreÂ gangrene caused by local pressureÂ (Bailey p. 913)Â AMPUTATIONÂ 469. dead, deadly and dead loss?Â 470. Why high amputation in Dibetic?Â 471. Why low amputation in TAO?Â 472. Types of Amputation?Â 473. Symes AmputationÂ 474. Wagner's Classification ?Â 0 â€“ Â 1 â€“ superficial ulcerationÂ 2 â€“ involving deepÂ 3 â€“ muscle involvementÂ 4 â€“ Bone involvementÂ 5â€“ Frank GangreneÂ RAYNAUDS DISEASEÂ SENILE GANGRENEÂ DIABETIC GANGRENEÂ 475. Why Diabetics prone for gangrene?Â microangiopathyÂ peripheral neuritisÂ vasculitisÂ ERGOT POISONINGÂ LERISCH SYNDROMEÂ SUBCLAVIAN STEAL SYNDROMEÂ 476. ïƒ„Cervical Rib?Â 477. ïƒ„Surgeris for Cervical Rib?Â 478. Adsons Test?Â 479. Scalenus Anticus Syndrome?Â 480. ïƒ„Features of Horner's SyndromeÂ EnophthalmosÂ PseudoptosisÂ MiosisÂ AnhidrosisÂ (Das p. 289)Â Abdominal Lump Â (Das pp. 337-384)Â (Das pp. 413-414)Â (SRB pp. 653-665)Â CASE SHEETÂ Diagramatically depict the location of lump in the case sheetÂ HISTORYÂ 481. Pain ?Â 482. Radiating Pain? Characteristics?Â 483. Referred Pain? Mechanism?Â 484. Vomiting?Â (Das p. 12)Â INSPECTIONÂ Inspect from right, left, foot end, and eyes at the level of abdomenÂ 485. Planes of Abdomen? Name the dividing Lines?Â 486. Qadrants of Abdomen?Â 4 quadrantsÂ (SRB p. 655)Â 487. Regions of Abdomen?Â 9 regionsÂ 488. Troisier's Sign?Â PALPATIONÂ 489. Difference between Guarding and Rigidity?Â 490. How to demonstrate and extra-abdominal swelling?Â Head raising testÂ 491. Rising Test?Â 492. Carnett's Test?Â 493. Transmitted Pulsation?Â any swelling in front of aortaÂ 494. Expansile Pulsation?Â aneurysm of aortaÂ 495. How to differentiate the above?Â two fingers over swelling ï‚® fingers will be divertedÂ knee-elbow positionÂ 496. Points in favour of a swelling from Liver?Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; swelling continuous with the enlarged liverÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; dullness in the swelling is continuous with the liver dullnessÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; not possible to insinuate fingers between costal margin and swelling.Â 497. Why Liver Absces common on right side?Â 498. Which side abscess is dangerous?Â Left, coz it will rupture into the pericardial cavity.Â INTESTINAL OBSTRUCTIONÂ 499. Demosnstrate VGP?Â give as much fluid as you can to the patientÂ 500. How can you identify the source of GI obstruction from Visible Peristalsis?Â Stomach â€“ left to rightÂ SI â€“ step ladder (below upwards) Â LI â€“ Right to LeftÂ 501. What is the X-Ray feature in intestinal Obstruction?Â multiple air fluid levels (more than 2)Â 502. Importance of Catheterisation in Intestinal Obstruction?Â Around 3L of fluid in the gut ï‚® HypovolemiaÂ Catheterisation helps in measuring the urinary output, which reflects the ECF fluid statusÂ GASTRIC CARCINOMAÂ 503. Types of gastrectomy?Â SHORT CASESÂ HerniaÂ HISTORYÂ 504. What do you mean by Groin?Â 505. Reduces on lying down? What do you understand?Â that it is a herniaÂ 506. Why do you say it is a hernia?Â 507. Does not extend to scrotum? meaning?Â Two possibilities â€“ incomplete inguinal hernia OR femoral herniaÂ 508. Cause of draggin pain?Â peritoneum gets pulled into the hernia sacÂ 509. Why B&amp;amp;B habits  important here?Â predisposing factorsÂ 510. ïƒ„BPHÂ 511. Earliest sign of BPH?Â increased frequency at NIGHT â†’ disturbed sleepÂ 512. Young patient with micturition difficulty? Probable diagnosis?Â Stricture Urethra â€“ due to gonococcal infectionÂ 513. How to differentiate BPH and Stricture Urethra clinically?Â BPH â€“ strains more â†’ pass less urineÂ Stricture Urethra â€“ strains more ï‚® pass more urineÂ 514. Importance of Vomiting history?Â suggestive of intestinal obstructionÂ TREATMENTÂ 515. In Bilateral Hernia, will you do surgery on both sides together?Â No, the large hernia is done firstÂ After 4-6 wks the next one is done.Â 516. -----------------------------Â 517. Difference between a compressible and reducible swelling?Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Compressible â€“ reduaces partially; eg Hemangioma Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Reducible â€“ disappears completely, but reappears on counter pressure; eg HerniaÂ (Das p. 25)Â 518. Importance of the following in Hernia Case ?Â Abdominal Examination â€“ to check the muscle tone, helps in chosing HernioplastyÂ Rectal examination â€“ to detect BPH, chronic strainingÂ Chest examination â€“ to detect COPD, chronic coughÂ 519. How does MESH help?Â mesh induces fibrous reaction around itÂ made of polypropyleneÂ 520. Complications of Heria Surgery?Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; HemorrhageÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Pain &amp;amp; unable to pass urineÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Spinal ShockÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Spinal Headache â€“ CSF leakage ï‚® fall in CSF pressureï‚® headacheÂ 521. Predisposing factors for Hernia Recurrence?Â 522. What is Spigelian Hernia?Â 523. Occult Inguinal HerniaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; seen in sportsmen etcÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; no swelling presentÂ 524. Hernia Surgery in Children?Â In children both the supf and deep rings are at same levelÂ SwellingÂ 525. Difference between transmitted and expansile pulsationÂ 526. Difference between Compresible and Reducible SwellingÂ Swelling â€“ LipomaÂ (Das pp. 17-44)Â POSITIVE FINDINGSÂ lobulated surfaceÂ slip sign â€“ positiveÂ soft consistencyÂ freely mobileÂ compressible but not reducibleÂ 527. What is Lipoma?Â benign tumour from mature fat cellsÂ PALPATIONÂ 528. Demonstrate Slip Sign?Â 529. Demonstrate Fluctuation in this swelling?Â 530. Demonstrate plane of the swelling?Â 531. How will you make the following muscles taut?Â Lattisimus DorsiÂ TrapeziusÂ PactoralisÂ Quadriceps femoris â€¦Â (Das p. 27)Â DIAGNOSISÂ 532. Difference between a benign and malignant swelling?Â (Das p. 34)Â 533. Findings in a Malignant transformation?Â (Das p. 34)Â 534. Which lipomas undergo malignant chages usually?Â retroperitoneal lipomasÂ lipomas in thigh, shoulder.Â 535. Common Sites for a Lipoma?Â 536. What is Universal tumour?Â 537. Types of Lipoma?Â 538. Commonest type ?Â subcutaneous lipomaÂ 539. Pseudolipoma?Â 540. Lipomatosis?Â 541. Fibrolipoma?Â with excess fibrous tissueÂ 542. Naevolipoma?Â with dilated blood vesselsÂ 543. Neurolipoma?Â 544. Dercum's Disease/adiposis dolorosa?Â 545. DD for Lipoma?Â NeurofibromaÂ FibromaÂ Sebaceous CystÂ RhabdomyomaÂ 546. Complications of Lipoma?Â myxomatous degenerationÂ saponificationÂ calcificationÂ infectionÂ ulcerationÂ liposarcomaÂ 547. Treatment?Â excision under GA/LAÂ 548. Precautions during Lipoma Excision?Â try not to injure the capsuleÂ Swelling â€“ Sebaceous CystÂ Swelling - Thyroglossal CystÂ Swelling  - Dermoid CystÂ 549. Sites of demoid cysts? Embryology?Â sites of fusion of embryonic processesÂ eg : post auricular, outer canthus of eyeÂ Swelling - HemangiomaÂ Swelling - GanglionÂ Swelling - BursitisÂ Diabetic UlcerÂ (Das pp. 45-54)Â INSPECTIONÂ 550. Zones in an UlcerÂ (Das p. 47)Â 551. Margin?Â JUNCTION between normal epithelium and ulcerÂ 552. Edge?Â AREA between margin and floorÂ 553. Types of Edges with examples?Â 554. Sloping edge is seen in ?Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; healing ulcerÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; venous ulcerÂ 555. Base?Â on which the ulcer restsÂ better felt than seenÂ 556. Floor?Â exposed surface within the ulcerÂ SinusÂ Marjolin's UlcerÂ BCCÂ Cervical LymphadenopathyÂ (Das pp. 80-89)Â Parotid TumourÂ (Das p. 268)Â Carcinoma CheekÂ (Das pp. 260-268)Â 557. Neck Dissection?Â Carcinoma LipÂ 558. Etiology of this condition?Â Sunlight exposureÂ 559. How will you manage?Â 560. Complication of Radiotherapy in this case?Â Mandibular NecrosisÂ 561. Staging of the Secondaries?Â 562. Name the various flap surgeries for Ca Lip?Â GynaecomastiaÂ Umbilical HerniaÂ Femoral HerniaÂ HydroceleÂ 563. Types of HydroceleÂ 564. Difference between Congenital and Adult Hydrocele?Â 565. Demonstrate fluctuation in Hydrocele?Â do in two planesÂ 566. Demonstrate Transillumination in Hydrocele?Â 567. Why torch is kept at side?Â testes will obstruct if kept at backÂ 568. How to differentiate Primary and Secondary Hydrocele?Â 569. Conditions you get a negative transillumination in Hydrocele?Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; HaematoceleÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; PyoceleÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; ChyloceleÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; THICK SACÂ 570. Principle of Lords Plication?Â secreting surface is reduced.Â 571. Principle of Jaboulays Operation?Â Secreting surface is exteriorized, so scrotal wall will absorb the fluid secretedÂ 572. Layers of Scrotum?Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; SkinÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; DartosÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; External Spermatic fasciaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Creamasteric fasciaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Internal Spermatic fasciaÂ VaricoceleÂ Cellulitis LegÂ 573. Differentiate Cellulitis and Elephantiasis?Â 574. Why Fasciotomy done in Cellulitis?Â FuniculitisÂ Â Â  Â OBSTETRICS &amp;amp; GYNAECOLOGY Â Â Paper 1 â€“ ObstetricsÂ Â Â 1Â Gravindex TestÂ Â FEB-1998Â 2Â Corpus Luteum of PregnancyÂ Â JUL-2008Â Â ANATOMY OF FEMALE REPRODUCTIVE ORGANSÂ Â Â 3Â Perineal bodyÂ 10Â JUL-2007Â JUN-2006Â Â FUNDAMENTALS OF REPRODUCTIONÂ Â Â 4Â Capacitation of SpermsÂ 18Â Â 5Â Functions of Zona PellucidaÂ 21Â 637Â Â 6Â ImplantationÂ 23Â Â 7Â DeciduaÂ 24Â Â 8Â Decidual CastÂ 24Â JUN-2006Â 9Â Chorionic VilliÂ Â Â 10Â Draw &amp;amp; Label : Structure of Chorionic VillusÂ 25Â JUL-2008Â JUN-2006Â 11Â Draw &amp;amp; Label : Diagram showing chorionic frondosum, decidua basalia, decidua parietalis and decidua capsularis.Â 27Â MAY-2002Â Â PLACENTA AND MEMBRANESÂ Â Â 12Â Draw &amp;amp; Label : Placenta and membranesÂ 30Â MAY-2002Â 13Â Development of PlacentaÂ Â Â 14Â Functions of PlacentaÂ 35Â Â 15Â Draw &amp;amp; Label : Chorionic VillusÂ 35Â APR-2004Â 16Â Amniotic FluidÂ 37Â Â 17Â Umbilical CordÂ 39Â Â 18Â Draw &amp;amp; Label : Cross section of Umbilical CordÂ 39Â APR-2004Â Â THE FETUSÂ Â Â 19Â Foetal CirculationÂ Â JUN-2006Â 20Â Draw &amp;amp; Label : Fetal CirculationÂ 44Â JUL-2007Â 21Â Draw &amp;amp; Label : Transition from foetal to adult type of circulationÂ 45Â DEC-2006Â Â PHYSIOLOGICAL CHANGES IN PREGNANCYÂ Â Â 22Â Braxton Hicks ContractionÂ irregular, infrequent, spasmodic and painlessÂ without any effect on dilatation of cervixÂ 47Â AUG-2002Â DEC-2006Â 23Â Goodell's SignÂ softening of the cervixÂ 48Â Â 24Â Breast changes in pregnancy.Â 49Â FEB-1998Â 25Â Pregnancy MaskÂ 50Â Â 26Â Linea NigraÂ 50Â Â 27Â Striae gravidarumÂ 50Â Â 28Â Weight changes during PregnancyÂ 1 kg = 2.2 lb (pounds)Â Total wt gain = 11kg / 24lbÂ 1 + 5 + 5 = 11Â 50Â DEC-2004Â JUL-2008Â 29Â Cardiovascular changes in PregnancyÂ 52Â AUG-2002Â APR-2000Â DEC-2006Â APR-2001Â 30Â Changes in the urinary tract during pregnancyÂ 55Â DEC-2004Â 31Â Physiological anemia of PregnancyÂ Â MAY-2002Â 32Â ENDOCRINOLOGY IN RELATION TO REPRODUCTIONÂ Â Â 33Â HCGÂ 58Â FEB-2002Â FEB-2008Â 34Â Significance of beta HCG estimationÂ 61Â APR-2004Â 35Â DIAGNOSIS OF PREGNANCYÂ Â Â 36Â Diagnosis of pregnancy at first ANCÂ Â APR-2000Â APR-2001Â 37Â Fetilisation AgeÂ 280-14 = 266 daysÂ Â Â 38Â Placental SignÂ scanty cylical bleeding in first trimesterÂ until approximation of decidual spaceÂ Â Â 39Â Signs of PregnancyÂ Vagina â€“ bluish â€“ Chadwick's SignÂ Vagina â€“ pulsation â€“ Osiander's SignÂ Cervix â€“ soft â€“ Goodell's SignÂ Uterus â€“ fingers appose â€“ Hegar's SignÂ Uterus â€“ contractions â€“ Palmer's SignÂ Breast â€“ colostrum by 12 wksÂ 64Â MAY-2002Â 40Â Hegars signÂ 65Â FEB-2008Â 41Â Immunological tests for pregnancyÂ 66Â Â 42Â Uses of Pregnancy TestsÂ ectopic pregnancyÂ in-vitro fertilizationÂ hydatidiform moleÂ choriocarcinomaÂ Â Â 43Â QuickeningÂ perception of active fetal movements by 18wkÂ 68Â JUL-2007Â 44Â Draw &amp;amp; Label : The level of fundus uteri at the different weeks of pregnancyÂ 16, 24, 28, 32, 40, 36Â 69Â DEC-2006Â 45Â External BallotementÂ 69Â Â 46Â Internal BallotementÂ 70Â Â 47Â Uterine SouffleÂ 70Â Â 48Â Funic SouffleÂ 70Â Â 49Â DD of PregnancyÂ PseudocyesisÂ Cystic Ovarian tumourÂ FibroidÂ Encysted PeritonitisÂ Distended BladderÂ 72Â Â 50Â Absolute signs of PregnancyÂ Palpation of fetal parts â€“ 20wkÂ Ausculation of fetal heartÂ USG evidence of embryo â€“ 6wkÂ X-Ray evidence of skeleton â€“ 16wkÂ 72Â Â 51Â Draw &amp;amp; Label :  Nulliparous CervixÂ 72Â Â 52Â Methods to calculate EDDÂ 73Â JUL-2007Â 53Â Naegele's FormulaÂ 73Â Â 54Â Estimation of Gestational AgeÂ Â Â 55Â Estimation of Fetal WeightÂ 74Â Â 56Â FETUS IN UTEROÂ Â Â 57Â LieÂ relationship of the long axis of the fetus to the long axis of the centralized uterusÂ 75Â Â 58Â PresentationÂ part of fetus which occupies the lower pole of uterusÂ 76Â Â 59Â Presenting PartÂ part of the presentation which overlies the internal osÂ 76Â Â 60Â AttitudeÂ relation of the different parts of the fetus to one anotherÂ 76Â Â 61Â DenominatorÂ arbitrary bony fixed point on the presenting part which comes in relation with the various quadrants of the maternal pelvisÂ 76Â Â 62Â Leopold's ManoevreÂ 79Â Â 63Â Pawlik's GripÂ 79Â Â 64Â EngagementÂ 81Â Â 65Â FETAL SKULL AND MATERNAL PELVISÂ Â Â 66Â Draw &amp;amp; Label : Diameters of Fetal SkullÂ 85Â JUL-2008Â SEP-2003 MAY-2002Â 67Â MouldingÂ 86Â Â 68Â Caput SuccedaneumÂ 87Â FEB-2002Â FEB-1998Â 69Â Diameters of Gynecoid Pelvic  inletÂ Â Â 70Â Draw &amp;amp; Label : Biparietal DiameterÂ Â AUG-2002Â 71Â Biparietal diameterÂ Â FEB-2008Â JUN-2006Â 72Â Draw &amp;amp; Label : Diagonal ConjugateÂ 88Â APR-2004Â AUG-2002Â 73Â Diagonal ConjugateÂ 88Â FEB-2002Â Â ANTENATAL CAREÂ Â Â 74Â Objectives of Antenatal CareÂ 95Â AUG-2002Â 75Â Antenatal CareÂ 95Â DEC-2004Â 76Â Booking ScanÂ anomaly scan, 2nd trimester scanÂ Â Â 77Â Role of folic acid in pregnancyÂ 101Â 104Â 209Â 255Â 263Â 343Â 409Â 467Â DEC-2006Â 78Â Preconceptional Folic acid administrationÂ Â SEP-2003Â 79Â Tetanus Toxoid administration during PregnancyÂ 102Â APR-2004Â 80Â ANTENATAL ASSESSMENT OF FETAL WELL BEINGÂ Â Â 81Â Triple TestÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; biochemical test to detect Down's SyndromeÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; done at 15-18wkÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; MS-AFP, hCG, and UE3(oestriol)Â 107Â Â 82Â Prenatal Genetic DiagnosisÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; CVSÂ AmniocentesisÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; COrdocentesisÂ 107Â Â 83Â Chorionic Villus Sampling (CVS)Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; prenatal diagnosis of genetic disordersÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; between 10-12 wksÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; few villi collected from chorion frondosum under USG guidanceÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; cather introduced transcervicallyÂ 108Â Â 84Â CordocentesisÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; tapping blood from umbilical veinÂ 108Â Â 85Â Biophysical Profile (BPP)Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; DFMCÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; CTGÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; NSTÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; BPPÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; DopplerÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; CSTÂ 109Â 464Â Â 86Â Foetal Movement CountÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Cardiff FormulaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; DFMC (Daily Fetal Movt Count)Â 109Â FEB-2002Â SEP-2003Â 87Â Cardiff CountÂ 109Â Â 88Â GravidogramÂ Â Â 89Â CardiotocogramÂ 110Â Â 90Â Non Stress TestÂ 110Â Â 91Â Mannning ScoreÂ 110Â Â 92Â Draw &amp;amp; Label : NST Normal PatternÂ Â DEC-2004Â 93Â Draw &amp;amp; Label : A reactive nonstress testÂ Â FEB-2008Â 94Â NSTÂ 110Â JUN-2005Â Â NORMAL LABOURÂ Â Â 95Â A 22 year old Primigravida with occipito posterior presentation at term:Â How do you suspect occipito poterior position during clinical examination?Â Mention possible mechanisms of labour.Â Complications associated with occipito posterior deliveries.Â Â FEB-2008Â 96Â Normal LabourÂ "series of events that take place in the genital organs in an effort to expel the products of conception out of the womb through vagina into the outer world"Â Â Â 97Â Causes of onset of labourÂ 114Â Â 98Â False Labour Pain/Spurious LabourÂ 116Â Â 99Â Features of True Labour PainÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; painful contractions at regular intervalsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; increasing in intensity and durationÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; effacement and dilatation of cervixÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; show + bag of watersÂ Â Â 100Â Prelabour changesÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; 2-3 wks before true labourÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Lightning â€“ welcome signÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Cervix ripensÂ 117Â FEB-2001Â 101Â ShowÂ "expulsion of cervical mucus plug mixed with blood"Â Â Â 102Â Stages of LabourÂ FIRSTÂ Â 12hrÂ 6hrÂ SECONDÂ 2hrÂ 30minÂ THIRDÂ Â 15minÂ 15minÂ FOURTHÂ 1hrÂ 1hrÂ 117Â FEB-2008Â 103Â Lower Uterine SegmentÂ 120Â Â 104Â Draw &amp;amp; Label : Stages of dilatation of cervix in primi and multigravidaÂ 121Â DEC-2004Â 105Â Methods of Placental SeparationÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Central Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; MarginalÂ 123Â Â 106Â Mechanism of LabourÂ 125Â Â 107Â EngagementÂ defineÂ 125Â DEC-2004Â AUG-2002Â 108Â AsynclitismÂ "deflection of head in relation to pelvis"Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; AnteriorÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; PosteriorÂ 125Â Â 109Â CrowningÂ "maximium diameter of the head stretches the vulval outlet WITHOUT ANY RECESSION of the head even after contraction is over"Â 127Â 137Â Â 110Â Third Stage of LabourÂ 133Â JUN-2005Â MAY-2002Â 111Â Complications of Third Stage of labourÂ Â Â 112Â Write the physiology of third stage oflabour. How do you manage third stage oflabour?Â Â FEB-1998Â 113Â Draw &amp;amp; Label :  Stations of Head in relation to ischial spineÂ 134Â Â 114Â Convulsions in LabourÂ 136Â SEP-2000Â 115Â Care of the newborn from birth till discharge from hospitalÂ 139Â 448Â APR-2001Â 116Â Management of Third Stage of LabourÂ 140Â DEC-2004Â 117Â Brandt Andrew's MethodÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; controlled cord tractionÂ 141Â Â 118Â Fourth stage of LabourÂ 142Â AUG-2001Â 119Â Late DeccelerationÂ Â APR-2004Â MAR-2003Â Â NORMAL PUERPERIUMÂ Â Â 120Â PuerperiumÂ defineÂ 145Â Â 121Â LochiaÂ "vaginal discharge during first fortnight"Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; L rubraÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; L serosaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; L albaÂ 147Â Â 122Â Physiology of LactationÂ 149Â JUN-2006Â 123Â Contraindications for labourÂ Â FEB-2001Â 124Â Suppression of LactationÂ 150Â FEB-2002Â APR-2000Â APR-2001Â 125Â Rooming inÂ 151Â Â 126Â Draw &amp;amp; Label :  Puerperial ChartÂ Â Â 127Â Postnatal careÂ 153Â Â 128Â VOMITING IN PREGNANCYÂ Â Â 129Â Hyperemesis GravidarumÂ "incapacitates her in day to day activities"Â 155Â MAY-2002Â SEP-2000Â DEC-2006Â 130Â Complications of Hyperemesis GravidarumÂ Â Â Â HAEMORRHAGE IN EARLY PREGNANCYÂ Â Â 131Â AbortionÂ defineÂ Â Â 132Â Different types of abortionsÂ 159Â JUL-2007Â 133Â Causes of First Trimerster AbortionÂ Â Â 134Â Causes of Second Trimester AbortionÂ Â Â 135Â Cervical AbortionÂ "abortus accommodated in the cervical canal due to failure of dilatation of external os"Â 161Â Â 136Â Threatened AbortionÂ 161Â Â 137Â Inevitable AbortionÂ 163Â APR-2000Â APR-2001Â 138Â Missed AbortionÂ 164Â DEC-2006Â DEC-2004 MAR-2003Â DEC-2005Â 139Â Septic AbortionÂ "any abortion associated with clinical evidence of infection"Â 165Â JUL-2008Â 140Â Recurrent AbortionÂ "three or more consecutive spont abortion before 20 wks"Â 168Â Â 141Â Habitual AbortionÂ 168Â DEC-2004Â 142Â Mullerian Fusion DefectsÂ 169Â Â 143Â Bicornuate UterusÂ 169Â Â 144Â Cervical incompetenceÂ 169Â MAY-2002Â 145Â Explain MTP Law in India?Â Briefout MTP Methods available to terminate 20wks pregnancy?Â Â FEB-2001Â 146Â Methods of First trimester MTPÂ Â FEB-1998Â 147Â Methods of Second Trimester MTPÂ Â Â 148Â Cervical EncirclageÂ 171Â JUL-2008Â 149Â MTP Act of IndiaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; upto 20wksÂ 173Â AUG-2002Â JAN-2002Â 150Â Medical AbortionÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Mifepristone 600mg oral (DAY 1)Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Misoprostol 400Âµg oral (DAY 3)Â 175Â Â 151Â Second trimester MTPÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; 13-20wksÂ 176Â SEP-2000Â 152Â ECTOPIC PREGNANCYÂ Â Â 153Â Draw &amp;amp; Label : Different sites of Ectopic gestationÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; tubalÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; ovarianÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; abdominalÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; cervicalÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; cornualÂ Â FEB-2008Â 154Â Tubal abortionÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; common mode of termination if implantation occurs in ampulla/infundibulumÂ 181Â FEB-2008Â 155Â Cervical PregnancyÂ 193Â Â 156Â Causes of Ectopic PregnancyÂ Â Â 157Â Sequelae of Tubal PregnancyÂ Â Â 158Â Criteria for ovarian pregnancyÂ Â Â 159Â Decidual CastÂ Â Â 160Â SAMÂ Â Â 161Â Treatment of Ruptured EctopicÂ Â Â 162Â Medical Management of Ectopic PregnancyÂ Â Â 163Â Conservative Management of Ectopic PregnancyÂ Â Â 164Â Diagnosis and management of unruptured Ectopic PregnancyÂ 185Â AUG-2001Â 165Â Medical management of ectopicÂ Â DEC-2004Â 166Â Conservative surgical procedures in case of tubal ectopicÂ Â JUL-2008Â 167Â One Reliable investigation for diagnosis of Ectopic PregnancyÂ 186Â MAR-2003Â 168Â Postmolar BleedingÂ -Â SEP-2000Â 169Â Follow up of molar pregnancy.Â Â FEB-1998Â JUL-2008Â DEC-2004Â Â MULTIPLE PREGNANCYÂ Â Â 170Â Discordant twinsÂ ?Â JUL-2007Â 171Â Aetiology of Multiple PregnancyÂ 205Â SEP-2003Â 172Â Vanishing TwinÂ 205Â Â 173Â Complications of Multiple PregnancyÂ 207Â MAY-2002Â 174Â Twin to Twin TransfusionÂ 209Â Â 175Â Delivery of 2nd of the twinsÂ 210Â AUG-2002Â 176Â PolyhydramniosÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; exceeds 2000mlÂ 213Â JUL-2007Â 177Â Acute HydramniosÂ 217Â JUN-2006Â 178Â Chronic PolyhydramniosÂ Â Â 179Â OligohydramniosÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; less than 200mlÂ 218Â JUL-2007Â 180Â Succenturiate LobeÂ 219Â DEC-2006Â 181Â Placenta SpuriaÂ Â Â 182Â Vasa PraeviaÂ 220Â 260Â DEC-2006Â SEP-2003Â 183Â Placenta AcretaÂ 420Â Â Â HYPERTENSIVE DISORDERS IN PREGNANCYÂ Â Â 184Â Impending signs of EclampsiaÂ 221Â Â 185Â HELLP SyndromeÂ 224Â SEP-2003Â 186Â Antihypertensive therapy in pregnancyÂ 506Â DEC-2006Â 187Â Roll over TestÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; measure BP Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; side &amp;amp; back positionÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; increase of 20mmHg in DIASTOLICÂ 229Â FEB-2002Â SEP-2003Â 188Â A 28 year old primigravida at 30 weeks of gestation was brought to hospital with H/O convulsionsÂ Mention differential diagnosis.Â Relevant investigations.Â Complications that are expected.Â Briefly management of a care of Eclampsia at term.Â Â JUL-2007Â Â ANTEPARTUM HAEMORRHAGEÂ Â Â 189Â "Bleeding from or into genital tract after 28 weeks"Â Â Â 190Â What are APH's ?Â Clinical features, diagnosis and management of one of the commonest type of APH's in different period of gestation?Â Â APR-2001Â 191Â Classification of Placenta PraeviaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; low lying Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; marginalÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; partial centralÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; centralÂ Â Â 192Â DANGEROUS  - type II posteriorÂ Â Â 193Â Placenta Praevia â€“ Bleeding at 32 weeksÂ 243Â AUG-2002Â 194Â Grading of Abruptio PlacentaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Retroplacental HematomaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; RevealedÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; ConcealedÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; MixedÂ Â Â 195Â Couvelaire UterusÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Uteroplacental apoplexyÂ 256Â AUG-2001Â JUL-2007Â 196Â Indications for caesarean section in Abuptio placentaÂ 259Â FEB-2008Â Â MEDICAL &amp;amp; SURGICAL ILLNESS COMPLICATING PREGNANCYÂ Â Â 197Â ANAEMIA IN PREGNANCYÂ Â Â 198Â What are the complications of anaemia in pregnancy?Â How would you investigate a case of anaemia in pregnancy?Â Discuss the management of anaemia in pregnancy.Â Â FEB-1998Â 199Â Causes of Anemia in PregnancyÂ 262Â DEC-2004Â FEB-2002Â FEB-2008Â 200Â Treatment of Iron deficiency Anemia in pregnancyÂ Â APR-2004Â 201Â Copmlications of AnemiaÂ 266Â Â 202Â Parentral Iron TherapyÂ 269Â Â 203Â Iron metabolism in PregnancyÂ Â APR-2000Â 204Â Estimation of Iron requirementÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; 0.3 x W(in pounds) (100-Hb%)mg of elemental ironÂ 269Â Â 205Â HEART DISEASE IN PREGNANCYÂ Â Â 206Â Functional grading of Heart Disease in PregnancyÂ 278Â Â 207Â Dry ManagementÂ v/s wetÂ Â Â 208Â GDMÂ Â Â 209Â GCTÂ 284Â DEC-2004Â DEC-2006Â JUN-2006Â 210Â Glucose Challenge TestsÂ 284Â APR-2004Â AUG-2002Â 211Â O Sullivans Blood Glucose ValuesÂ Â Â 212Â Gestational DiabetesÂ Â FEB-1998Â 213Â Obstetric management of Gestational DiabetesÂ 284Â SEP-2003Â 214Â Baby born to Diabetic motherÂ 287Â MAY-2002Â SEP-2000Â 215Â PlacentosisÂ 289Â Â 216Â Viral Hepatitis in pregnancyÂ 291Â FEB-1998Â 217Â Pyelonephritis in pregnancyÂ 296Â APR-2004Â AUG-2002Â FEB-2002Â SEP-2003Â 218Â Complications of UTIÂ Â Â 219Â Asymptomatic BacteruriaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; above 105/ml in mid-stream clean catch specimen on 2 occasions, without symptoms of UTIÂ 297Â MAR-2003Â FEB-2008Â JUN-2006Â AUG-1998Â 220Â Management of HIV during pregnancyÂ 300Â JUL-2007Â 221Â AlbuminuriaÂ 303Â FEB-2002Â Â GYNAECOLOGICAL DISORDERS IN PREGNANCYÂ Â Â 222Â Trichomonas VaginalisÂ 306Â JUL-2008Â 223Â Fibroids complicating pregnancyÂ Â Â 224Â Red DegenerationÂ 309Â FEB-2002Â 225Â Ovarian tumour in PregnancyÂ 310Â SEP-2000Â 226Â HematocolposÂ -Â JUN-2005Â 227Â Asherman's SyndromeÂ absence of menses because of endometrial scarring or cervical stenosis resulting from injury or disease.Â -Â JUN-2005Â 228Â DysgerminomaÂ A malignant neoplasm of the ovary (counterpart of seminoma of the testis), composed of undifferentiated gonadal germinal cells and occurring more frequently in patients less than 20 years of age. The neoplasms are gray-yellow and firm, contain foci of necrosis and hemorrhage, and tend to be encapsulated; characteristically, they spread by way of lymphatic vessels, but widespread metastases also occur. Â  [dys- + L. germen, a bud or sprout, + G. -bma, tumor] Â (Stedman)Â -Â JUN-2005Â 229Â Fixed Retroverted UterusÂ 311Â FEB-2001Â Â PRETERM LABOUR &amp;amp; IUDÂ Â Â 230Â Preterm LabourÂ "labour starts before 37 completed wks, counting from first day of last menstrual period"Â 315Â FEB-2002Â 231Â Causes of Preterm labourÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; activation of HPA axisÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; UTIÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; multiple pregnancyÂ 315Â APR-2004Â 232Â PROMÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; PreLABOUR ROM orÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; PreMATURE ROMÂ Â Â 233Â Drugs used in PROMÂ Â Â 234Â PPROMÂ defineÂ Â Â 235Â A 25-year old primigravida with amenorrhoea of 42 weeks not in labour:Â Describe the methods by which you will confirm postdatism.Â Complications related to postdatism.Â Methods of induction.Â 317Â DEC-2006Â 236Â Intraamniotic Saline Â Â FEB-1998Â 237Â Post MaturityÂ 318Â JUN-2005Â 238Â Causes of Post term labourÂ Â Â 239Â Complications of Post term labourÂ 320Â Â 240Â Causes of Recurrent IUDÂ Â Â 241Â Term IUDÂ Â Â 242Â Spalding SignÂ 324Â Â Â SPECIAL CASESÂ Â Â 243Â Requisites for VBACÂ 329Â Â 244Â Indications for Recurrent CSÂ Â Â 245Â Rh IncompatibilityÂ 331Â Â 246Â IsoimmunisationÂ 333Â Â 247Â Prevention of Rh IsoimmunisationÂ Â Â 248Â Hydrops FetalisÂ 333Â Â 249Â Icterus Gravis NeonatorumÂ 333Â Â 250Â Kleihauer CountÂ 334Â 652Â Â 251Â Indirect Coombs TestÂ 335Â 338Â DEC-2006Â 252Â Liley ChartÂ 336Â Â 253Â Bad Obstetric HistoryÂ "present obstetric outcome is likely to be affected by the nature of previous obstetric disaster"Â 343Â Â Â CONTRACTED PELVISÂ Â Â 254Â GynaecoidÂ AnthropoidÂ AndroidÂ PlatypelloidÂ Â Â 255Â Draw &amp;amp; Label : Brim of Gynaecoid PelvisÂ 345Â APR-2004Â 256Â Anthropoid PelvisÂ 346Â JUL-2008Â 257Â Android PelvisÂ 346Â JUN-2005Â 258Â Flat PelvisÂ 348Â JUN-2006Â 259Â Internal PelvimetryÂ 349Â Â 260Â CPDÂ 352Â MAR-2003Â 261Â Munro Kerr Muller MethodÂ 353Â Â 262Â Trial LabourÂ "conduction of spont labour in a moderate degree of CPD, in an institution under supervision"Â 355Â Â 263Â Mention the causes of unengaged head at term in a primigravida. How do you manage Trial Labour?Â 355Â AUG-1998Â Â ABNORMAL UTERINE ACTIONÂ Â Â 264Â Incordinate Uterine ActionÂ 359Â JUL-2008Â 265Â Precipitate LabourÂ "combined duration of 1 &amp;amp; 2 stage is less than 2hrs"Â 361Â SEP-2003Â 266Â Bandl's Ring / Retraction RingÂ "a groove formed between US and LS"Â 362Â JUN-2005Â AUG-2002Â AUG-1998Â 267Â Constriction RingÂ 363Â Â Â MALPOSITION, MALPRESENTATION AND CORD PROLAPSEÂ Â Â 268Â A Primigravida at 40 weeks of gestation is admitted with labour pain. The head is mobile.Â What are the causes for mobile head in a primi at term?Â What investigations will you do?Â How will you diagnose occipito-posterior position?Â How will you manage deep transverse arrest?Â Â JUN-2006Â 269Â Persistant Occipito PosteriorÂ 369Â Â 270Â Mento PosteriorÂ Â Â 271Â Deep transverse arrestÂ "no progress in descent of head even after Â½ - 1 hr of full cervical dilatation"Â 372Â SEP-2000Â FEB-1998Â 272Â Footling PresentationÂ legs and thighs are partially extended, bring the legs to present at the brimÂ 375Â JUN-2005Â 273Â Burn-Marshall technique`Â delivery of the after coming headÂ 384Â Â 274Â Mauriceau-Smellie-Veit techniqueÂ 384Â Â 275Â Pinard's manoeuvreÂ 386Â Â 276Â Lovset's ManoeverÂ 387Â Â 277Â Neglected ShoulderÂ Â Â 278Â Face Poster PositionÂ 388Â AUG-2001Â 279Â Brow PresentationÂ 392Â DEC-2004Â 280Â Mechanism of Delivery in faceÂ Â Â 281Â Transverse lieÂ "long axis of the fetus lies perpendicular to maternal spine/centralized uterine axis"Â 393Â JUL-2008Â 282Â Discuss the aetiology, diagnosis and management of transverse lie.Â Â FEB-1998Â 283`Â Cord ProlapseÂ "cord lies inside vagina or outside vulva after membrane rupture"Â 398Â MAY-2002Â SEP-2000Â 284Â Cord PresentationÂ "cord is slipped down below the presenting part and is felt lying in the intact bag of membranes"Â 399Â Â 285Â Face to pubis deliveryÂ Â FEB-2001Â Â PROLONGED LABOUR, OBSTRUCTED LABOUR AND DYSTOCIAÂ Â Â 286Â Shoulder DystociaÂ 406Â Â 287Â HydrocephalusÂ 407Â JUN-2005Â DEC-2006Â 288Â AnencephalyÂ 408Â Â 289Â Neural Tube DefectsÂ 408Â Â 290Â CephalocentesisÂ 408Â Â Â COMPLICATIONS OF THIRD STAGE OF LABOURÂ Â Â 291Â A 3rd gravida just delivered having profuse post partum hemorrhage.Â Describe predisposing factors for post partum hemorrhage?Â Management of post partum Hemorrhage?Â Complications of massive PPH?Â Â JUL-2008Â 292Â Following a term delivery a multiparous woman developed profuse vaginal bleeding.Â How will you differentiate Atonic and Traumatic PPH?Â What are the drugs(with dosage) you will utilise if it is an atonic PPH?Â Name two surgical options for intractable atonic PPH?Â How will you prevent atonic PPH?Â Â SEP-2003Â 293Â Define Postpartum haemorrhage. (PPH)Â What are the different causes of PPH ?Â Outline the management (both prophylactic and therapeutic) of atonic PPH.Â Â SEP-2000Â 294Â POST PARTUM HEMORRHAGEÂ Â Â 295Â Atonic PPHÂ Â APR-2000Â APR-2001Â 296Â Treatment of Atonic PPHÂ 413Â APR-2004Â 297Â Traumatic PPHÂ Â Â 298Â Manual removal of placenta.Â 414Â FEB-1998Â 299Â Causes of retained PlacentaÂ 419Â Â 300Â Placenta accreteÂ "placenta directly anchored to myometrium"Â 420Â JUL-2007Â JUN-2006Â 301Â Acute inversion of UterusÂ 421Â MAR-2003Â FEB-1998Â Â INJURIES TO BIRTH CANALÂ Â Â 302Â Draw &amp;amp; Label :  Degrees of Perineal tearÂ 423Â Â 303Â Complete Prineal TearÂ 422Â APR-2004Â AUG-2002Â JUL-2008Â 304Â Cervical TearÂ 425Â MAR-2003Â 305Â Causes of Rupture UterusÂ Â Â 306Â What are the causes of Rupture Uterus?Â How will you diagnose Rupture Uterus?Â How do you manage a case of complete rupture?Â 427Â FEB-1998Â 307Â Scar DehiscenceÂ 429Â 328Â Â 308Â Evidence of impending RuptureÂ 430Â Â Â ABNORMALITIES OF PUERPERIUMÂ Â Â 309Â Define Puerperium. How do you manage Puerperal Sepsis?Â Â AUG-1998Â 310Â Puerperial FeverÂ "rise of oral temp 100.4Â°F or more on TWO separate occasions at 24hrs apart, within first 10 DAYS following delivery"Â 433Â MAY-2002Â SEP-2000Â JUL-2007Â 311Â Puerperial SepsisÂ "infection of the genital tract as a complication of delivery"Â 433Â Â 312Â Causes of subinvolution of uterusÂ 437Â Â 313Â Post Natal Retention of UrineÂ 438Â FEB-2002Â Â NEONATOLOGYÂ Â Â 314Â Management of newborn immediately after deliveryÂ 448Â AUG-2001Â 315Â Advantages of Breast FeedingÂ 451Â JUN-2005Â AUG-2001Â SEP-2003Â 316Â LBW babyÂ "birth wt &amp;lt; 2500 irrespective of gestational age"Â 457Â Â 317Â Pre-term BabyÂ "born before 37 completed wks of gestation"Â Â Â 318Â IUGRÂ "birth wt is below the 10th percentile of the average for the gestational age"Â 462Â JUN-2005Â 319Â Assymetric IUGRÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; 80%Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; extrinsic to fetusÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; total cell number is normalÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; head larger than abdomenÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Ponderal Index â€“ lowÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Eg â€“ reduced utero-placental blood flowÂ 463Â APR-2004Â 320Â Foetal distressÂ 469Â FEB-2008Â AUG-1998Â 321Â Apgar ScoreÂ 471Â MAR-2003Â FEB-2002Â DEC-2006Â 322Â RDSÂ 474Â APR-2001Â 323Â Hyaline Membrane DiseaseÂ 475Â Â 324Â Meconium aspiration syndrome.Â 477Â JUL-2007Â APR-2001Â 325Â Physiological JaundiceÂ 477Â APR-2001Â AUG-2001Â 326Â Causes of jaundice in newbornÂ 477Â AUG-2001Â 327Â Significance of Meconium stained liquirÂ 477Â APR-2004Â MAR-2003Â 328Â Neonatal ConvulsionsÂ 482Â FEB-2001Â APR-2001Â 329Â What are the various birth injuries in neonate?Â Explain the causes and treatment of Facial Palsy and Erb's PalsyÂ Â APR-2001Â 330Â Draw &amp;amp; Label : CephalhematomoaÂ 484Â JUN-2005Â 331Â Significance of CephalhematomaÂ 484Â MAR-2003Â 332Â Erb's PalsyÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; 5 &amp;amp; 6 Cranial Nerve Roots are involvedÂ 486Â SEP-2000Â FEB-1998Â 333Â Necrotising EnterocolitisÂ 491Â AUG-2001Â 334Â Down's SyndromeÂ 495Â APR-2004Â MAR-2003Â 335Â MongolismÂ 495Â APR-2001Â 336Â Hydrops FetalisÂ 497Â 333Â FEB-2001Â 337Â Lumbosacral MeningomyeloceleÂ -Â FEB-2001Â 338Â Nappy RashÂ -Â FEB-2001Â Â PHARMACOTHERAPEUTICSÂ Â Â 339Â 1 ml = 15 dropsÂ Â Â 340Â OxytocinÂ 498Â 115Â MAR-2003Â 341Â Oxytocin Challenge TestÂ 501Â Â 342Â Oxytocin Sensitivity TestÂ 501Â Â 343Â MethylergometrineÂ 502Â AUG-2001Â 344Â Prostaglandins in LabourÂ 503Â 115Â Â 345Â Tocolytic AgentÂ 507Â JUN-2005Â 346Â Placental BarrierÂ 511Â Â 347Â Gestational Clock Â 511Â Â 348Â Epidural Analgesia in ObstetricsÂ 516Â Â 349Â VaginismusÂ 518Â Â 350Â INDUCTION OF LABOURÂ Â Â 351Â Bishops ScoreÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; cervical scoring systemÂ [CODE â€“ DLCPS]Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; DilatationÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; LengthÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; ConsistencyÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; PositionÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; StationÂ Total Score 13Â Favourable Score 6-13Â 522Â AUG-2002Â FEB-1998Â 352Â Medical Induction of LabourÂ 522Â Â 353Â Surgical Induction of LabourÂ 523Â Â 354Â Controlled ARMÂ 523Â Â 355Â Artificial rupture of membranesÂ 523Â FEB-2008Â 356Â StrippingÂ "digital separation"Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; release of PG'sÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Ferguson reflexÂ Â Â 357Â Draw &amp;amp; Label : PartographÂ 528Â 131Â JUN-2005Â JUN-2006Â JUN-2006Â 358Â PartogramÂ 528Â 131Â FEB-2008Â 359Â Ethacridine lactateÂ Â Â Â CONTRACEPTIONÂ Â Â 360Â Eligible CoupleÂ "wives in the reproductive age groups of 15-45yrs who require FP"Â 531Â Â 361Â PEARL IndexÂ 531Â Â 362Â Failure of Female SterilisationÂ 550Â SEP-2000Â 363Â No Scapel VasectomyÂ 551Â Â 364Â Natural method of Family Planning.Â Â FEB-1998Â 365Â Mechanism of action of Copper-TÂ Â FEB-1998Â Â OPERATIVE OBSTETRICSÂ Â Â 366Â Indication of Dilation and CurettageÂ Â AUG-1998Â 367Â Vaccum ExtractionÂ 565Â DEC-2004Â DEC-2006Â JUL-2007Â 368Â Advantages of Vaccum over ForcepsÂ Â MAR-2003Â SEP-2000Â 369Â Menstrual RegulationÂ 565Â Â 370Â EpisiotomyÂ 567Â JUN-2005Â JUN-2006 DEC-2006Â DEC-2005Â 371Â RMLEÂ Â APR-2004Â MAR-2003Â 372Â Draw &amp;amp; Label : One blade of Outlet ForcepsÂ 572Â FEB-2002Â 373Â Indication for Forceps DeliveryÂ 573Â JUN-2005Â MAY-2002Â 374Â Complications of Forceps DeliveryÂ 578Â Â 375Â Outlet forceps operationÂ 577Â FEB-2001Â FEB-2008Â 376Â Ventouse ApplicationÂ 579Â AUG-2002Â 377Â External Cephalic version.Â 582Â FEB-2008Â JUN-2006Â 378Â Internal Podalic VersionÂ 583Â FEB-2002Â SEP-2003Â 379Â Indications for Caesarian SectionÂ 588Â DEC-2004Â FEB-1998Â 380Â Classical CSÂ 590Â JUN-2005Â JUL-2008Â JUN-2006Â 381Â Steps of LSCSÂ 592Â Â 382Â Management of Previous CSÂ Â DEC-2004Â 383Â Internal RotationÂ Â JUN-2006Â Â SPECIAL TOPICSÂ Â Â 384Â RCHÂ Â Â 385Â ICDSÂ Â Â 386Â MMRÂ 602Â FEB-2002Â 387Â Causes of Maternal MortalityÂ 602Â DEC-2004Â 388Â Perinatal MortalityÂ 602Â FEB-2002Â SEP-2003Â AUG-1998Â 389Â Perinatal MortalityÂ 605Â JUL-2008Â 390Â Still BirthÂ Â Â 391Â Septic ShockÂ 614Â Â 392Â Amniotic fluid EmbolismÂ 628Â Â 393Â Obstetric causes of DICÂ 628Â MAY-2002Â 394Â High Risk PregnancyÂ Â Â Â IMAGING IN OBSTETRICSÂ Â Â 395Â AmniocentesisÂ 642Â 336Â 217Â 111Â 107Â Â 396Â Uses of Ultrasound in ObstetricsÂ 645Â MAY-2002Â FEB-2001Â 397Â Singers TestÂ 652Â AUG-2001Â Â UNALLOCATEDÂ Â Â 398Â First Referral UnitsÂ Â SEP-2003Â 399Â Universal Precautions in Labour RoomÂ Â SEP-2003Â 400Â Face to Pubis DeliveryÂ Â JUN-2005Â 401Â Problems of short primiÂ Â DEC-2004Â 402Â Acute left ventricular failureÂ Â AUG-2002Â 403Â Teenage PregnancyÂ Â AUG-2002Â 404Â Causes of Large for Date PregnancyÂ Â MAY-2002Â 405Â VDRLÂ Â MAY-2002Â 406Â Posterior ColpocentesisÂ Â FEB-2001Â 407Â PseudocyesisÂ Â DEC-2006Â 408Â Magnesium sulphate in obstetrics.Â Â FEB-2008Â 409Â Chorioamnionitis.Â Â JUL-2007Â Â PracticalsÂ LONG CASESÂ Pregnancy Induced HypertensionÂ 575. Deine Pre-Eclampsia?Â 140/90 mmHg or more with proteinuria after the 20th weekÂ 576. What do you mean by MAP?Â testÂ 577. Â Â Â Â Â  Â Â Paper 2 â€“ GynaecologyÂ Â Â Â NOT ALLOCATEDÂ Â Â 1Â Mesntrual RegulationÂ Â DEC-2004Â 2Â Ethacridine LactateÂ Â DEC-2004Â 3Â MTP Act of IndiaÂ 173Â AUG-2002Â JAN-2002Â 4Â Methods of Second Trimester MTPÂ Â JAN-2002Â 5Â List the methods of Second Trimester MTP.Â Explain the procedure of any one of them?Â Â JAN-2002Â Â 6Â HysterotomyÂ Â DEC-2006Â 7Â MirenaÂ Â DEC-2006Â Â ANATOMY OF THE FEMALE PELVIC ORGANSÂ Â Â 8Â Bartholins GlandÂ 2Â DEC-2005Â 9Â Doderlein's BacillusÂ 7Â APR-2004Â JUL-2007Â 10Â Vaginal Epithelium Â Â Â 11Â Draw &amp;amp; Label : Fallopian TubeÂ 10Â APR-2004Â 12Â Draw &amp;amp; Label :  Parts of Fallopian tubeÂ 10Â DEC-2004Â 13Â Female UrethraÂ Â Â 14Â Pelvic UreterÂ Â 1994Â 1989Â 15Â Pelvic DiaphragmÂ Â Â 16Â Levator aniÂ 17Â 1995Â 1990Â 17Â Pelvic FloorÂ 17Â DEC-2004Â 18Â Draw &amp;amp; Label : Cross section of Pelvic LigamentsÂ Â JUL-2007Â 19Â Cardinal LigamentsÂ Â Â 20Â Draw &amp;amp; Label : Attachments of uterosacral ligamentÂ 22Â AUG-2002Â 21Â Draw &amp;amp; Label : Blood Supply to UterusÂ Â JUN-2006Â 22Â Branches of Internal IlliacÂ Â Â 23Â Draw &amp;amp; Label :  Lymphatic Drainage of UterusÂ 28Â JUN-2005Â 24Â Lymphatic Drainage of VulvaÂ Â FEB-1998Â 25Â Draw &amp;amp; Label : Parts of UterusÂ 7Â 41Â JUL-2007Â 26Â Lymphatic Drainage of CervixÂ 28Â AUG-2002Â 27Â Draw &amp;amp; Label : Female Genital TractÂ 32Â DEC-2005Â Â CONGENITAL MALFORMATIONS OF THE FEMALE GENITAL ORGANSÂ Â Â 28Â Imperforate HymenÂ 39Â AUG-2002Â 29Â HaematocolposÂ 39Â 413Â MAR-2003Â JUN-2006Â DEC-2006Â 30Â CryptomenorrhoeaÂ 40Â 413Â APR-2004Â 31Â Mullerian Duct AnomaliesÂ 41Â Â Â PUBERTY AND MENOPAUSEÂ Â Â 32Â Precocious PubertyÂ 48Â JUN-2005Â 33Â Precocious MenstruationÂ 48Â Â 34Â Puberty MenorrhagiaÂ 50Â JUN-2006Â 35Â ClimatericÂ 52Â Â 36Â Symptoms of MenopauseÂ 53Â Â 37Â HRTÂ 55Â APR-2004Â Â NEUROENDOCRINOLOGY IN RELATION TO REPRODUCTIONÂ Â Â 38Â Ovarian SteroidogenesisÂ 65Â Â 39Â Draw &amp;amp; Label : Hypothalamo-Pituitary Ovarian AxisÂ 70Â Â Â MENSTRUATIONÂ Â Â 40Â Graafian FollicleÂ 77Â Â 41Â Draw &amp;amp; Label :  Graffian FollicleÂ 77Â JUN-2005Â JUL-2007Â MAR-2003Â 42Â Follicular StudyÂ -Â AUG-2002Â 43Â LH SurgeÂ 78Â 85Â Â 44Â Corpus LuteumÂ 79Â DEC-2005Â 45Â EndometriumÂ 81Â Â 46Â Draw &amp;amp; Label : Endometrium in Secretory PhaseÂ 82Â FEB-2008Â DEC-2005Â 47Â Artificial Postponement of MenstruationÂ Combined pill 2tabs daily ORÂ Norethisterone 5mg twice dailyÂ Taken 3-6 days before the expected dateÂ Menstruation occurs 2-3 days after stopping the drugÂ 87Â Â Â EXAMINATION OF A GYNAECOLOGICAL PATIENTÂ Â Â 48Â Importance of Breast Examination in GynecologyÂ 91Â 513Â Â 49Â Pap Smear*Â 102Â JUN-2005Â DEC-2006Â 50Â Cornification IndexÂ 105Â Â 51Â Cervical Mucus studyÂ 106Â 224Â Â 52Â Post Coital TestÂ 106Â Â 53Â ColposcopyÂ 107Â DEC-2005Â 54Â Fern TestÂ 106Â 1989Â 55Â Ultrasound in GynaecologyÂ 108Â JUL-2007Â 56Â CuldocentesisÂ 111Â Â 57Â Diagnostic Laparoscopy in GynecologyÂ 112Â 1995Â Â 58Â Second look SurgeryÂ 112Â Â Â PELVIC INFECTIONÂ Â Â 59Â Discuss the clinical features diagnosis and management of a case of Pelvic inflammatory diseaseÂ 118Â AUG-1998Â 60Â Stages of PIDÂ 119Â Â 61Â Management of PIDÂ 122Â Â Â Tuberculous lesions in Fallopian TubeÂ 129Â Â 62Â HSG findings in TB Fallopian tubeÂ lead pipe tubesÂ tobacco pouch appearanceÂ 132Â Â Â SEXUALLY TRANSMITTED DISEASESÂ Â Â 63Â GonorrheaÂ 138Â Â 64Â LGVÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Chlamydia trachomatisÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; painless papule/pustule which breaks down ï‚® abscessÂ 142Â Â 65Â Granuloma InguinaleÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Donovan bodiesÂ 142Â Â 66Â Bacterial VaginosisÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; creamy vaginal discharge with fishy smellÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Clue CellsÂ 142Â DEC-2004Â 67Â Genital HerpesÂ 143Â MAR-2003Â 68Â Condyloma AccuminatumÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; HPV type 6 &amp;amp; 11Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; paint with 20% PODPHYLLIN resin in liquid paraffinÂ 146Â Â 69Â Molluscum ContagiosumÂ 147Â Â Â INFECTIONS OF THE INDIVIDUAL PELVIC ORGANSÂ Â Â 70Â Bartholin's CystÂ 152Â APR-2004Â FEB-1998Â 71Â MarsupialisationÂ 152Â MAR-2003Â 72Â Vaginitis Â Trichomonas Vaginalis (TV) Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; strawberry cervixÂ 153Â AUG-2002Â JUN-2006Â AUG-1998Â 73Â Draw &amp;amp; Label : Trichomonas VaginalisÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; undulating membraneÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; 4 flagellaeÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; axostyleÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; nucleusÂ 153Â 101Â APR-2004Â MAR-2003Â 74Â CandidiasisÂ 154Â 101Â Â 75Â Monilial VaginitisÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Candida AlbicansÂ 154Â DEC-2006Â JAN-2002Â 76Â Draw &amp;amp; Label :  MoniliaÂ 101Â Â 77Â Senile VaginitisÂ 155Â FEB-2008Â JAN-2002Â 78Â Toxic Shock SyndromeÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; use of vaginal tampon Â Â Â 79Â Chronic CervicitisÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; commonest lesion in gynec OPÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; infection of endocervixÂ 157Â Â 80Â PyometraÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; collection of pus in the uterine cavityÂ CAUSESÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; infection of lochiaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Ca uterus, cervixÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; senile endometritisÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; tb endometritisÂ 159Â APR-2004Â DEC-2006Â 81Â HydrosalpinxÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; collection of mucus secretion in the fallopian tubeÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; repeated endosalpingitisÂ 161Â JAN-2002Â 82Â Salpingitis Isthmica NodosaÂ 163Â 130Â JAN-2002Â 83Â Pelvic AbscessÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; encysted pus in the PODÂ 165Â Â Â DYSMENORRHOEA AND OTHER DISORDERS OF MENSTRUAL CYCLESÂ Â Â 84Â DysmenorrhoeaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; "painful menstruation of sufficient magnitude so as to incapacitate day to day activities"Â 168Â DEC-2004Â 85Â Spasmodic DysmenorrhoeaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; seen in adolescentsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; no identifiable pelvic pathologyÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Mefenamic acid 250-500mgÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Ibuprofen 400mgÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Surgery â€“ Cervical DilatationÂ 168Â Â 86Â Congestive DysmenorrhoeaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; seen in thirtiesÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; presence of pelvic pathologyÂ 171Â Â 87Â Ovulation PainÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Mittelschmerz's SyndromeÂ 172Â AUG-2002Â 88Â Premenstrual SyndromeÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; psychosomatic disorder of unknown etiology, prior to menstruationÂ 172Â FEB-2008Â Â ABNORMAL MENSTRUAL BLEEDINGÂ Â Â 89Â 55yr old obese, hypertensive and diabetic lady complaining of bleeding per vaginum.Â What is the most probable diagnosis?Â Discuss the clinical features of that condition?Â Discuss one reliable investigation for diagnosing the condition?Â What are the steps of abdominal hysterectomy?Â Â AUG-2002Â 90Â A 45 year old lady with Menorrhagia:Â 1 History you elicit to arrive at diagnosis.Â 2 Differential diagnosis.Â 3 Investigations.Â 4 How will you manage a case of fibroid uterus?Â Â JUL-2007Â 91Â MENORRHAGIAÂ POLYMENORRHOEAÂ METRORRHAGIAÂ OLIGOMENORRHOEAÂ HYPOMENORRHOEAÂ Â Â 92Â Causes of MenorrhagiaÂ 175Â Â 93Â MetrorrhagiaÂ irregular acylic bleedingÂ Causes of MetrorrhagiaÂ 176Â FEB-2008Â FEB-2001Â 94Â What are the common causes of Metrorrhagia? Explain clinical features, investigations and management of one of the common condition in a 40yr old multiparous woman coming with metrorrhagia?Â Â JAN-2002Â APR-2000Â 95Â DYSFUNCTIONAL UTERINE BLEEDINGÂ Â Â 96Â Endometrial findings in DUBÂ 177Â Â 97Â Classification of DUBÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; ovular &amp;amp; anovular bleedingÂ 177Â Â 98Â DOC in Ovulatory MenorrhagiaÂ Â Â 99Â Management of DUBÂ 177Â Â 100Â Cystic glandular HyperplasiaÂ Metropathia HemorrhagicaÂ 178Â AUG-2002Â 101Â Cystic glandular Hyperplasia in a woman aged 33yrsÂ 178Â FEB-2001Â 102Â Draw &amp;amp; Label : Endometrium in Cystic Glandular HyperplasiaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; swiss cheese appearanceÂ 179Â DEC-2006Â 103Â Endometrial AblationÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; LaserÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; TCREÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Roller BallÂ 183Â 564Â Â Â DISPLACEMENT OF THE UTERUSÂ Â Â 104Â A 52 year old postmenopausal lady with mass per vaginum. Discuss.Â 1 Relevant history you would ask.Â 2 Differential diagnosis.Â 3 Investigations.Â 4 Describe, briefly the steps of Fothergill's operationÂ Â FEB-2008Â 105Â Symptoms of RetroversionÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; "long axis of corpus and cervix are in same line"Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Chronic pelvic painÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; BakacheÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; DyspareuniaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; InfertilityÂ 188Â Â 106Â Pessary TestÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Hodge-Smith pessaryÂ 188Â Â 107Â Supports of UterusÂ Upper TierÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Round LigÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Broad LigÂ Middle TierÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Transverse Cerv LigÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Uterosacral LigÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Pubo-cerv LigÂ Inferior TierÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; musculofacial tone of vaginaÂ 190Â JUN-2005Â JUN-2006Â 108Â Nulliparous ProlapseÂ -Â FEB-1998Â 109Â Draw &amp;amp; Label : Various degrees of Prolapse of UterusÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; 1 - ext os inside vaignaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; 2 â€“ uterus body inside vaginaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; 3 â€“ uterus body outside the introitusÂ 194Â JUN-2006Â 110Â ProcidentiaÂ 194Â APR-2004Â 111Â Decubitis UlcerÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; diminished circulationÂ 274Â 194Â JUN-2006Â 112Â CystoceleÂ 195Â AUG-1998Â 113Â Draw &amp;amp; Label :  CystoceleÂ 195Â Â 114Â Diagnosis and Treatment of CystoceleÂ 192Â 195Â 198Â JAN-2002Â 115Â RectoceleÂ 196Â AUG-2002Â 116Â Draw &amp;amp; Label :  RectoceleÂ Â Â 117Â Ring PessaryÂ 198Â 585Â FEB-2008Â 118Â Fothergill's OperationÂ 203Â JUN-2006Â JAN-2002Â 119Â Steps of Vaginal HysterectomyÂ 205Â Â 120Â Le Fortes RepairÂ 207Â Â 121Â Sling Surgery for ProlapseÂ 208Â Â Â INFERTILITYÂ Â Â 122Â Causes of Male InfertilityÂ 212Â FEB-2001Â 123Â A 24yr old  woman married for 5yrs with infertility.Â How will you investigate the male partner?Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Routine Blood &amp;amp; UrineÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Semen AnalysisÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Serum Testosterone, FSH, LH, Prolactin, TSHÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Testicular BiopsyÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; TRUSÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; KaryotypeÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Immunological TestsÂ Describe one test to diagnose ovulation?Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; BBTÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Cervical Mucus StudyÂ Desribe briefly two treatment orotocols if she is found to have anovulation?Â How will you treat her if she is having bilateral tubal block?Â Â APR-2004Â 124Â Discuss the clinical features, investigations and treatment of female infertility?Â Â JAN-2002Â Â 125Â How do you investigate a couple for primary infertility?Â Â FEB-1998Â 126Â Semen AnalysisÂ 217Â MAR-2003Â 127Â Draw &amp;amp; Label : Structure of Spermatozoon Â -Â FEB-2008Â 128Â AzoospermiaÂ 218Â AUG-2002Â 129Â Effective Sperm CountÂ Â Â 130Â Tests for OvulationÂ 220Â Â 131Â Tests for Tubal patencyÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Rubin's TestÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; HSG*Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; LaparoscopyÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; SonoHSGÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; FalloposcopyÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; SalpingoscopyÂ 223Â Â 132Â Cervical Mucus in infertilityÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; SCMCTÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; mid-cycle cervical mucus + semenÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; penetration of spem on shaking movementsÂ 224Â 1994Â 1992Â 133Â Induction of OvulationÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; ClomipheneÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; hMGÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; FSHÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; hCGÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; GnRHÂ SURGERYÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Wedge Resection â€¦Â 229Â JAN-2002Â 134Â Artificial InseminationÂ 234Â Â 135Â IVFÂ 235Â Â 136Â GIFTÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Gamete Intra-Fallopian Tube TransferÂ 237Â Â 137Â ZIFTÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Zygote  Intra-Fallopian Tube TransferÂ 238Â Â 138Â ICSIÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Intra Cytoplasmic Sperm InjecitonÂ 238Â Â Â BENIGN LESIONS OF THE VULVA AND VAGINAÂ Â Â 139Â Types of Vulval DystrophiesÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Lichen SclerosisÂ 242Â Â 140Â Gartner's CystÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; retension cyst in remnants of wolfian ductÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; anterolateral wall of vaginaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; DD - CystoceleÂ 246Â 196Â 48Â Â 141Â VulvodyniaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; burning sensation over vulvaÂ 247Â Â Â BENIGN LESIONS OF THE CERVIXÂ Â Â 142Â Carcinoma insitu CervixÂ Â MAR-2003Â 143Â Cervical ErosionÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; "squam epith of ECTOcervix is replaced by colum epith, which is continuous with ENDOcervix"Â 248Â 1992Â 144Â Cervical EctopicÂ 248Â JUL-2007Â 145Â EctropionÂ 250Â 157Â Â 146Â Cervical TearÂ 250Â Â 147Â Nabothian follicleÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; multipleÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; blockage of cervical gland mouthsÂ 250Â 157Â Â Â BENIGN LESIONS OF THE UTERUSÂ Â Â 148Â A 35 year old nulliparous lady comes with HlO menorrhagia, dysmenorrhoea and-mass abdomenÂ (a) What are the differential diagnosis?Â (b) How will you evaluate the lady?Â (c) What is the most probable diagnosis?Â (d) How will you manage this condition?Â Â JUN-2006Â 149Â What are the clinical features of fibroid uterus? Â Discuss the investigations and treatment of fibroid uterus in a 30yr old nulliparous married lady?Â Â JAN-2002Â 150Â Draw &amp;amp; Label : Common sites of origin of Fibroid UterusÂ 253Â DEC-2004Â 151Â Draw &amp;amp; Label : Diagram of Uterus with various tyes of FibroidsÂ 253Â DEC-2006Â 152Â Changes in fibroidsÂ CODE - DANIVSÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; DegenerationÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; AtrophyÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; NecrosisÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; InfectionÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Vasular changesÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Sarcomatous  changesÂ 256Â Â 153Â Red DegenerationÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; carneous degenerationÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; necrobiosisÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; raw-beef appearanceÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; fishy odourÂ 256Â DEC-2004Â 154Â Complications of FibroidsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; DegenerationÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; HaemorrhageÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; NecrosisÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; InfectionÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; TorsionÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Sarcomatous  changesÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; PolycythemiaÂ 257Â Â 155Â Cervical FibroidsÂ 264Â Â 156Â Fibroid PolypÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; extrusion of submucous fibroid into uterine cavityÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; confused with uterine inversionÂ 267Â MAR-2003Â 157Â Cervical PolypÂ 267Â Â Â BENIGN LESIONS OF OVARYÂ Â Â Â Functional Cyst of OvaryÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; &amp;lt; 5cmÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; regresses spontaneouslyÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; UnilocularÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; clear fluidÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; lined by fn epithelium of the unitÂ 270Â FEB-1998Â Â Follicular Cyst of Ovary Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; commonest fn cystÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; multipleÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; hyper-estrinismÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; follow up for 3 monthsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; OCP ï‚® regressÂ 270Â FEB-2008Â Â Write the differential diagnosis of mass per Abdomen. How do you manage a case of Benign Ovarian Cyst?Â Â AUG-1998Â Â Lutein Cyst of OvaryÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; bilateralÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; excess hCG secretion (GTN)Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; lined by theca lutein cellsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; spont regressionÂ 271Â Â Â WHO Classification of Ovarian tumourÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; EpithelialÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Sex CordÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Germ CellÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Lipid CellÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; GonadoblastomaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; UnclassifiedÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Secondary MetsÂ 272Â Â Â LMP tumoursÂ -Â Â Â Brenner tumourÂ 272Â Â Â Mucinous Cystadenoma OvaryÂ 272Â Â Â Serous Cystadenoma OvaryÂ 273Â Â Â Dermoid CystÂ 274Â FEB-2008Â JUN-2006Â DEC-2005Â JAN-2002Â Â Teratoma OvaryÂ 274Â Â Â Struma OvariiÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; predominant thyroid tissue ï‚® hyperthyroidismÂ 275Â Â Â Complications of Ovarian TumoursÂ 279Â Â Â Decubitis UlcerÂ 274Â 194Â JUN-2006Â Â Meig's SyndromeÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Ascites + Hydrothorax (rt)Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; + Ovarian tumourÂ 277Â AUG-2002Â Â Pseudomeig's SyndromeÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Ascites + HydrothoraxÂ 277Â Â Â Pseudomyxoma PeritoneiÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; mucinous ascitesÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; assoc with mucinous cystadenoma ovary ï‚® spont perforationÂ 280Â FEB-2008Â Â Surgical Treatment of Ovarian TumourÂ 281Â JAN-2002Â Â Â Ovarian CystectomyÂ 281Â DEC-2006Â Â Bordeline ovarian tumoursÂ 282Â Â Â Parovarian TumoursÂ 282Â Â Â Staging LaparotomyÂ -Â Â Â Management of Twisted Ovarian CystÂ -Â 1987Â Â ENDOMETRIOSIS AND ADENOMYOSISÂ Â Â 158Â A 65 y:ear old lady is admitted with HlO bleeding per vaginum : .Â (a) How will you clinically arrive at a diagnosis ?Â (b) What are the differential diagnosis?Â (c) What are the investigations you will do ?Â (d) How will you manage early care of Ca endometrium?Â 285Â DEC-2005Â 159Â A 60yr old lady is admitted with progressive distension of the abdomen and loss of weight of short duration.Â What are the differential diagnosis?Â What clinical features help you to diagnose the condition?Â What are the investigations?Â How will you manage the case?Â 285Â MAR-2003Â 160Â ENDOMETRIOSISÂ Â Â 161Â "presence of fn endometrium in sites other than uterine mucosa"Â Â Â 162Â Theories of EndometriosisÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Retrograde menstruationÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Coelomic metaplasiaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Direct implantationÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Lymphatic theoryÂ 285Â Â 163Â Chocolate Cyst of OvaryÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; endometriotic implant on ovaryÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; rupture ï‚® thick, tarry materialÂ 288Â APR-2004Â JUL-2007Â FEB-2001Â 164Â Management of EndometriosisÂ 290Â Â 165Â DanazolÂ 291Â 483Â DEC-2004Â MAR-2003Â 166Â AdenomyosisÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; "ingrowth of endometrium into myometrium"Â 293Â 603Â DEC-2005Â Â PREMALIGNANT LESIONSÂ Â Â 167Â VINÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Vulval Intraepithelial NeoplasiaÂ 297Â Â 168Â CIN IIIÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; whole thickness except one or two superficial layersÂ 299Â APR-2004Â AUG-2002Â 169Â LLETZÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Large loop excision of the transformation zoneÂ 306Â Â Â GENITAL MALIGNANCYÂ Â Â 170Â Staging of Carcinoma CervixÂ 318Â Â 171Â Radiotherapy for Ca CervixÂ Â 1992Â 1993Â 172Â Endocervical CarcinomaÂ Â Â 173Â VIAÂ Â Â 174Â A 45yr old lady with c/o post coital bleeding.Â How will you evaluate her?Â What are the common causes of such complaints?Â What is the etiology of CA Cervix?Â How will you manage CA in situ Cervix?Â Â DEC-2004Â 175Â A 40 year old lady with postcoital bleeding. DiscussÂ (a) Differential diagnosis.Â (b) Investigations.Â  (c) Treatment options available in a case of carcinoma cervix stage II A.Â Â DEC-2006Â 176Â What are the causes of post menopausal bleeding?Â Discuss the clinical features of Ca Cx?Â How will you investigate and treat a case of Ca Cx Stage I ?Â Â JAN-2002Â 177Â Schiller's TestÂ 320Â JUL-2007Â 1991Â 178Â Discuss the pre-disposing factors and management of endometrial carcinoma.Â Â FEB-1998Â 179Â Staging of Endometrial CracinomaÂ 330Â 1989Â 180Â Draw &amp;amp; Label : Microscopic structure of Hydatidiform MoleÂ 335Â AUG-2002Â 181Â Invasive MoleÂ 336Â JUN-2005Â APR-2004Â 182Â ChoriocarcinomaÂ 336Â 591Â JUN-2006Â 183Â Follow up in a case of Vesicular MoleÂ -Â Â 184Â Check CurettageÂ -Â Â 185Â MAC RegimeÂ 339Â Â 186Â Suburethral NoduleÂ -Â Â 187Â Sarcoma BotryoidesÂ 342Â Â 188Â Krukenberg TumourÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; metastatic tumour from stomach, breast, LIntestine to ovaryÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; retrtograde lymphaticsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; signet ring appearanceÂ 345Â Â 189Â Management of Ca OvaryÂ Stage 1Â 350Â 1981Â 190Â CA 125Â 350Â 477Â FEB-2001Â Â DysgerminomaÂ 352Â Â 191Â Endodermal Sinus TumourÂ 354Â MAR-2003Â 192Â Granulosa cell tumourÂ 355Â Â Â URINARY PROBLEMS IN GYNAECOLOGYÂ Â Â 193Â Supports of BladderÂ 361Â Â 194Â Stress Urinary IncontinenceÂ 366Â JUL-2007Â 195Â UrodynamicsÂ 368Â Â 196Â Kelly's PlicationÂ 371Â JUL-2007Â 197Â Causes of Urinary retension in femalesÂ 377Â 1993Â 198Â Urethral SyndromeÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; chronic form of urethritisÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; dysuria, frequency &amp;amp; urgencyÂ 379Â Â 199Â Urethral CaruncleÂ 382Â Â Â GENITAL FISTULAEÂ Â Â 200Â Vaginal FistulaÂ 385Â Â 201Â Vesicovaginal FistulaÂ 386Â DEC-2006Â 202Â Three Swab TestÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; to differentiateÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; URETERO-vaginalÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; URETHRO-vaginalÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; VESICO-vaginalÂ 387Â Â 203Â Flap splitting OperationsÂ 393Â 1989Â Â GENITAL TRACT INJURIESÂ Â Â 204Â Classification of Perineal TearÂ 395Â Â 205Â Complete Perineal TearÂ 395Â DEC-2006Â 206Â Post coital tearÂ 399Â Â Â INTERSEXÂ Â Â 207Â Down's SyndromeÂ -Â FEB-2008Â 208Â HermaphroditismÂ 407Â Â 209Â PseudohermaphroditismÂ -Â Â 210Â Turner's SyndromeÂ 405Â APR-2004Â JUL-2007Â 211Â Androgen Insensitivity SyndromeÂ 406Â FEB-2008Â Â AMENORRHOEAÂ Â Â 212Â CryptomenorrhoeaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; menstrual blood fails to come out from the genital tractÂ CAUSESÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; imperforate hymenÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; vaginal septumÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; vaginal atresia (upper third) â€¦Â 413Â 40Â Â 213Â HaematocolposÂ 39Â 413Â MAR-2003Â JUN-2006Â DEC-2006Â 214Â Primary AmenorrhoeaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; "not menstruated by 16 yr"Â Â Â 215Â Rokitansky Mayer Kuster Flauser syndromeÂ 416Â DEC-2006Â 216Â Secondary AmenorrhoeaÂ 419Â 421Â DEC-2005Â 217Â Polycystic Ovarian Syndrome (PCOD)Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Stein Levinthal Syndrome Â 421Â DEC-2004Â JUL-2007Â 218Â Asherman's SyndromeÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; uterine synechiae formation after uterine curettageÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; honey-comb appearance on HSGÂ 421Â 432Â 602Â 130Â Â 219Â Premature MenopauseÂ 425Â 57Â Â 220Â Anorexia NervosaÂ 426Â MAR-2003Â 221Â Congenital Adrenal Hyperplasia (CAH)Â 427Â 404Â Â Â CONTRACEPTIONÂ Â Â 222Â FemilonÂ -Â Â 223Â Pearl IndexÂ -Â FEB-2008Â 224Â Nonoxynol 9Â Â DEC-2006Â FEB-2001Â 225Â BromocriptineÂ 432Â Â 226Â Today Vaginal SpongeÂ 437Â Â 227`Â Natural Methods of Family PlanningÂ 438Â DEC-2006Â 228Â Billings Cervical mucus methodÂ -Â JUL-2007Â 229Â Conventional ContraceptivesÂ 436Â JAN-2002Â FEB-2001Â 230Â CondomsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; polyurethane / latexÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; 14/HWYÂ 436Â JUN-2006Â 231Â Female CondomÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; polyurethaneÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; 15cmÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; 21/HWYÂ 438Â AUG-2002Â 232Â FemshieldÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; female condomÂ 438Â Â 233Â IUCDÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; 0.1 â€“ 2/HWYÂ 439Â 462Â JUN-2005Â 234Â Translocated IUCDÂ Â 1988Â 1992Â 235Â Copper TÂ Â FEB-2008Â 236Â Insertion technique of Copper TÂ 439Â APR-2004Â 237Â ProgestacertÂ 440Â Â 238Â Post IUCD thread not seenÂ 443Â FEB-2001Â 239Â Hormonal ContraceptionÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; 0.1/HWYÂ 445Â DEC-2004Â 240Â OCPÂ 445Â DEC-2005Â 241Â Contraindications for OC PillsÂ 446Â JUN-2005Â FEB-2001Â 242Â Non Contraceptive Benefits of OCPÂ 448Â JUL-2007Â 243Â Triphasic PillÂ 450Â AUG-2002Â JAN-2002Â 244Â Progestin Only PillÂ 450Â FEB-2008Â 245Â Male PillÂ Â FEB-2001Â 246Â DepoproveraÂ 451Â Â 247Â Injectable ContraceptivesÂ 451Â JUN-2006Â 248Â NorplantÂ 451Â MAR-2003Â AUG-2002Â 249Â Post natal Contraception MethodÂ Â FEB-2001Â 250Â Emergency ContraceptionÂ 452Â JUN-2005Â APR-2004Â 251Â InterceptivesÂ 453Â Â 252Â VasectomyÂ 453Â DEC-2004Â JAN-2002Â 253Â TubectomyÂ 455Â JUL-2007Â DEC-2005Â 254Â Modified Pomroy's method of SterilisationÂ 455Â MAR-2003Â 255Â Minilap SterilisationÂ 456Â Â 256Â Medical TubectomyÂ Â JAN-2002Â 257Â Laparoscopic SterilisationÂ 457Â DEC-2005Â 258Â Complications of Laparoscopic SterilisationÂ 457Â 1992Â 1989Â 1990Â 259Â Post Partum SterilisationÂ 460Â JAN-2002Â 260Â CentchromanÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; OrmeloxifineÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; CDRI, LucknowÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; 30mg twice a wkÂ SaheliÂ 461Â APR-2004Â JAN-2002Â 261Â Medical AbortionÂ -Â JUN-2005Â JUN-2006Â DEC-2005Â Â RADIOTHERAPY CHEMOTHERAPY IMMUNOTHERAPY GENETHERAPY IN GYNAECOLOGYÂ Â Â 262Â BrachytherapyÂ 465Â Â 263Â After loading techniqueÂ Â Â 264Â EMACO RegimeÂ Â Â 265Â MethotrexateÂ 471Â 474Â JAN-2002Â 266Â Tumour MarkersÂ 477Â Â Â HORMONES IN GYNAECOLOGICAL PRACTICEÂ Â Â 267Â Ovarian Hyperstimulation Syndrome (OHSS)Â 482Â Â 268Â HCGÂ 482Â 477Â 230Â JUN-2006Â DEC-2006Â 269Â DanazolÂ 483Â Â 270Â Uses of Estrogen PreparationsÂ 485Â Â 271Â Adverse effects of EstrogensÂ 485Â Â 272Â SERMÂ 486Â Â 273Â Clomiphene CitrateÂ 486Â JUN-2005Â JUN-2006Â 274Â TamoxifenÂ 487Â Â 275Â Uses of ProgesteroneÂ 487Â Â 276Â NorethisteroneÂ 488Â Â 277Â MifepristoneÂ 490Â APR-2004Â 278Â Ru 486Â 490Â MAR-2003Â 279Â AntiandrogensÂ 491Â Â Â SPECIAL TOPICSÂ Â Â 280Â LeucorrhoeaÂ 503Â JUL-2007Â 281Â Discuss the differential diagnosis of Discharge PV ?Â What is the diagnosis and treatment of such discharge with itching in a young woman of 23 years?Â Â FEB-2001Â 282Â Pruritis VulvaeÂ 505Â Â 283Â Pruritis AniÂ 505Â FEB-2008Â 284Â Pelvic Pain SyndromeÂ 507Â Â 285Â Post Menopausal BleedingÂ 511Â Â 286Â Uterine PerforationÂ 516Â Â 287Â Causes of Nipple DischargeÂ 518Â Â 288Â DyspareuniaÂ Â Â 289Â Virilising TumourÂ 521Â Â 290Â HirsutismÂ 521Â Â Â OPERATIVE GYNAECOLOGYÂ Â Â 291Â Dilatation and CurettageÂ 533Â Â 292Â Fractional CurettageÂ -Â 1995Â 1992Â 293Â Hysterosalpingogram (HSG)Â 536Â 599Â JUL-2007Â DEC-2005Â AUG-1998Â 294Â Biopsy CervixÂ 536Â JUN-2006Â 295Â Cone BiopsyÂ 537Â JUN-2005Â 296Â Types of Abdominal HysterectomyÂ 541Â Â 297Â Steps of Abdominal HysterectomyÂ Â Â 298Â MyomectomyÂ 551Â MAR-2003Â 299Â Bonney's TestÂ 551Â Â Â ENDOSCOPIC SURGERY IN GYNAECOLOGYÂ Â Â 300Â LAVHÂ 561Â FEB-2008Â 301Â HysteroscopyÂ 562Â 112Â DEC-2004Â DEC-2005 JUN-2005Â Â PRACTICAL GYNAECOLOGYÂ Â Â 302Â SpeculoscopyÂ 566Â Â  Â PEDIATRICS Â 1Â A 5yr old boy is admitted with fever, cough and edema. He had oen episode of edema earlier also and was on some medication.Â What is the probable diagnosis?Â What investigations will you order?Â What treatment will you give?Â What are the likely complications?Â Â JUN-2005Â 2Â A 5â€¢year old child is brought with bleeding gums. She also has irregular fever, tiredness and body pain for the last 3 months.Â What is the probable diagnosis?Â What physical examination findings will you look for?Â What investigations will you order?Â What are the differential diagnosis ?Â Â DEC-2004Â 3Â Anterior FontanelleÂ Â FEB-2001Â 4Â Juvenile DelinquencyÂ Â JUN-2006Â 5Â Kernig SignÂ Â FEB-2002Â 6Â Clinical features of KernicterusÂ Â FEB-2002Â 7Â Danger Sings in the New bornÂ Â FEB-2002Â 8Â NORMAL GROWTHÂ Â Â 9Â Define GrowthÂ net increase in size or mass of tissuesÂ 1Â Â 10Â Define DevelopmentÂ maturation of functionsÂ 1Â Â 11Â Factors affecting Growth and DevelopmentÂ Â MAY-2002Â JUL-2008Â 12Â Laws of GrowthÂ 3Â Â 13Â Perinatal PeriodÂ 22wks to 7 days after birthÂ 3Â Â 14Â ToddlersÂ 1-3 yrsÂ 3Â Â 15Â Primary DentitionÂ 4Â JUN-2006Â MAR-2003Â 16Â Lean Body MassÂ fat free components like muscle tissue, internal organs and skeletonÂ 4Â Â 17Â Head CircumferenceÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; occipital protuberance to supra-orbital ridgesÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; crossed tape methodÂ 5Â AUG-2002Â FEB-2002Â 18Â Midarm CircumferenceÂ midway between tip of acromion process of scapula to olecranon of ulnaÂ 5Â 64Â AUG-2001Â 19Â Z ScoreÂ Â Â 20Â DISORDERS OF GROWTHÂ Â Â 21Â SHORT STATUREÂ Â Â 22Â Define Short StatureÂ ht below 3rd centile or more than 2 SD below the median height for that age and sex according to the population standardÂ 17Â Â 23Â Causes of Short StatureÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; undernutritionÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; chronic systemic illnessÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; GH deficiencyÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Hypothyroidismâ€¦Â 18Â FEB-2008Â 24Â MPHÂ Mid-Parental HeightÂ 18Â Â 25Â SMRÂ Sexual maturity ratingÂ 18Â Â 26Â Management of Short StatureÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; counselingÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; dietary adviceÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt;&lt;br /&gt;				&lt;span style='font-family:MS Gothic'&gt;â„ž&lt;/span&gt; renal tubular acidosis/celiac diseaseÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; limb lengthening proceduresÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; levethyroxine in hypothyroidismÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; subcut GH in GHDeficiencyÂ Â Â 27Â Define Failure to Thrive (FTT)Â physical growth is significantly less than theit peers of same age and sexÂ infants and children upto 5 yrsÂ 21Â DEC-2005Â 28Â A 1 Â½ year old child is brought with failure to thrive, difficulty in breast feeding and recurrent respiratory infections.O/E there is a pansystolic murmer in the lower left sternal border.Â What is the probable diagnosis?Â How will you investigate the child?Â How will you treat this child?Â What are the complications of this condition?Â Â FEB-2008Â 29Â NORMAL DEVELOPMENTÂ Â Â 30Â Define DevelopmentÂ maturation of functionsÂ 1Â Â 31Â Developmental Milestones of a 4 month old babyÂ GROSS MOTORÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; neck holding â€“ 3 monthsÂ FINE MOTORÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; reaching out for abjects with both hands (bidectrous reach) â€“ 4 monthsÂ SOCIALÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; social smile â€“ 2 monthsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; recognizes mother â€“ 3 monthsÂ LANGUAGEÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; alerts to sound â€“ 1 monthÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; coos â€“ 3 monthsÂ Â JUN-2005Â 32Â Developmental Milestones of 7 month old infantÂ GROSS MOTORÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; neck holding â€“ 3 monthsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; sitting with support â€“ 6 monthsÂ FINE MOTORÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; reaching out for abjects with both hands (bidectrous reach) â€“ 4 monthsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; unidextrous reach â€“ 6 monthsÂ SOCIALÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; social smile â€“ 2 monthsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; recognizes mother â€“ 3 monthsÂ LANGUAGEÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; alerts to sound â€“ 1 monthÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; coos â€“ 3 monthsÂ 27Â 28Â Â 33Â Developmental Milestones of 10 month old babyÂ Â JUN-2006Â 34Â Developmental Milestones of 1 year oldÂ 27Â 28Â DEC-2004Â 35Â Developmental Milestones of 2 year oldÂ 27Â 28Â DEC-2005Â 36Â Developmental Milestones of 3 year oldÂ 27Â 28Â Â 37Â Pincer GraspÂ 28Â AUG-2002Â 38Â Four Causes of Global Developmental DelayÂ 31Â JUL-2007Â 39Â Developmental QuotientÂ 32Â Â 40Â DEVELOPMENTAL DISORDERSÂ Â Â 41Â EnuresusÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; urinary incontinence Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; after 4yr daytimeÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; after 6yr nighttimeÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; after 3 months of drynessÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; wetting twice a wk for 3 consecutive monthsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Normal Bladder Control â€“ 5yrÂ CLASSIFICATIONÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; PrimaryÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; SecondaryÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; NocturnalÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; DiurnalÂ 35Â DEC-2004Â 42Â Breath Holding SpellsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; anger ï‚® crying ï‚® apnoea &amp;amp; cyanosisÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; highly pampered childrenÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt;&lt;br /&gt;				&lt;span style='font-family:MS Gothic'&gt;â„ž&lt;/span&gt; - Iron Supplementation, 3mg/kg/dayÂ 37Â AUG-2002Â DEC-2005Â 43Â Attention Deficit Hyperactivity DisorderÂ 38Â JUN-2005Â 44Â DyslexiaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; poor word decoding abiltyÂ ETIOLOGYÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; genetic â€“ 50%Â MANAGEMENTÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; remediation approachÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; taught in small groupsÂ 39Â Â 45Â StutteringÂ Spasmodic repetition of some syllables with pausesÂ MANAGEMENTÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; reassure that it resolves on its own,if  2-5yrÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; speech therapistÂ 39Â Â 46Â AutismÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; commonest of PDD'sÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; impairment in verbal and non-verbal communicationÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; imaginative activityÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; social interactionsÂ ETIOLOGYÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; geneticÂ CLINICAL FEATURESÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; poor eye contactÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; delayed speechÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; stereotypical body movementsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; seizuresÂ DIAGNOSISÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; by 18 monthsÂ MANAGEMENTÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; intensive behavioral therapyÂ 40Â DEC-2005Â 47Â Munchausen SyndromeÂ 40Â Â 48Â ADOLESCENT HEALTH AND DEVELOPMENTÂ Â Â 49Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Adolescent â€“ 10 â€“ 19 yrÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Youth â€“ 15 â€“ 24 yrÂ Â Â 50Â AFHSÂ 46Â Â 51Â Complications of PrematurityÂ Â JUL-2007Â FEB-2001Â 52Â FLUID AND ELECTROLYTE DISTURBANCESÂ Â Â 53Â HyperkalemiaÂ CAUSESÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; renal failureâ€¦Â MANAGEMENTÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; moderate â€“ glucose-insulin infusionÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; severe â€“ calcium gluconate i.vÂ 53Â JUL-2007Â 54Â NUTRITIONÂ Â Â 55Â Essential Amino AcidsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; LILMPTTVÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Histidine and Arginine are essential during infancy.Â 57Â Â 56Â Reference ProteinsÂ 57Â Â 57Â Biological Value of ProteinsÂ 57Â DEC-2004Â 58Â Digestibility Quotient of ProteinsÂ 57Â JUN-2005Â 59Â Net Protein Utilisation (NPU)Â 57Â JUN-2006Â 60Â Chemical Score of ProteinÂ ?Â DEC-2005Â 61Â Complimentary action of ProteinÂ Â Â 62Â PUFAÂ Â Â 63Â PhrynodermaÂ ?Â Â 64Â Omega 3 Fatty AcidsÂ 59Â Â 65Â Dietary FibreÂ 60Â Â 66Â Balanced DietÂ 60Â DEC-2005Â 67Â IAP Grading of Nutritional status in &amp;lt;5yrÂ Â Â 68Â Difference between Stunting and WastingÂ 62Â Â 69Â Wellcome classification in PEMÂ Â Â 70Â WHO Classification of MalnutritionÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; wt, ht &amp;amp; edemaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; moderate -  -2 to -3Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; severe - &amp;lt; -3Â 63Â Â 71Â IAP Classification of MalnutritionÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; 50th percentile of Harvard standardsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; weight for ageÂ 63Â FEB-2008Â 72Â Grading of MarasmusÂ Â Â 73Â Constant features of KwashiorkarÂ 67Â MAR-2003Â MAY-2002Â FEB-2001Â 74Â SEVERE MALNUTRITIONÂ Â Â 75Â Complications of Severe MalnutritionÂ 68Â JUL-2007Â 76Â National Nutritional PolicyÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; ICDS ï‚® anganwadi ï‚® six servicesÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Mid-day Meals ProgÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; National Nutritional Anemia Control ProgÂ Â Â 77Â WeaningÂ Â AUG-2001Â 78Â Weaning food in PEMÂ Â Â 79Â MICRONUTRIENTS IN HEALTH AND DISEASEÂ Â Â 80Â AntioxidantsÂ 78Â DEC-2004Â AUG-2002Â 81Â Sources of Vitamin AÂ Shark &amp;amp; Cod Liver Oil, Carrots, Dark green leafy vegetables, squash, oranges, tomatoes.Â 79Â Â 82Â Functions of Vitamin AÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; VisionÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Maintainence of epithelial tissuesÂ 79Â Â 83Â WHO Classification of XerophthalmiaÂ 79Â JUN-2006Â 84Â Draw &amp;amp; Label : Bitot's SpotsÂ -Â MAR-2003Â 85Â Koplik's SpotsÂ -Â FEB-2002Â 86Â Hypervitaminosis AÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; &amp;gt; 50,000 IU/dayÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; fatigue, malaise, anorexia, vomiting, headache and diplopiaÂ 79Â Â 87Â CarotenemiaÂ 80Â Â 88Â Treatment of Vitamin A deficiencyÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; ORALÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; &amp;lt;6m â€“ 50,000 IUÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; 6-12m â€“ 1 lakhÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; &amp;gt;1yr â€“ 2 lakhÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; repeated next day and 4 wks laterÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; PARENTRALÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; &amp;lt;6m â€“ 3/4th doseÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; 6-12m â€“ Â½ doseÂ 80Â Â 89Â Vitamin A ProphylaxisÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; less than 3 yrs onlyÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; 9m â€“ 1 lakh (with measles)Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; 15m â€“ 2 lakh (with DPT booster)Â 80Â AUG-2002Â 90Â Metabolism of Vitamin DÂ 81Â Â 91Â Draw &amp;amp; Label : Active RicketsÂ 82Â AUG-2002Â 92Â Clinical features of RicketsÂ 82Â Â 93Â Rachitic Rosary Â 82Â Â 94Â Radiological changes in RicketsÂ 82Â Â 95Â Treatment of RicketsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; oral, single dose, 6 lakh IUÂ OR Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; 60,000 IU for 10 days ï‚® 400 IU / dayÂ 83Â Â 96Â Causes of RicketsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Familial RicketsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Nutritinal RicketsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Renal Tubular AcidosisÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Chronic Kidney DiseaseÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; ONcogenous RicketsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Metaphyseal DysplasiaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; FluorosisÂ 83Â DEC-2005Â 97Â Classification of RicketsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Familial RicketsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Nutritional RicketsÂ 83Â Â 98Â Vitamin D resistant RicketsÂ 83Â Â 99Â Role of Vitamin EÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; co-factor in â€¦ glutamic acid ï‚® glutamateÂ 85Â DEC-2004Â 100Â Hemorrhagic disease of New BornÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; GI bleeding in the 1st weekÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; seen in breast fed infantsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt;&lt;br /&gt;				&lt;span style='font-family:MS Gothic'&gt;â„ž&lt;/span&gt; - 0.5 â€“ 1.0 mg im at birth ï‚® 1 mg every weekÂ 86Â Â 101Â BeriberiÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; def of Vitamin B1Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; cardiomegaly, cyanosis, dysnoea, aphoniaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; three forms â€“ dry, wet, acuteÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; breast fed infants of thiamine deficient mothersÂ 87Â Â 102Â Riboflavin Deficiency/AriboflavinosisÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; photophobia, glossitis, angular stomatitis, seborrhoec dermatitis, corneal vascularisation, cataractsÂ 87Â Â 103Â PellagraÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; 3 d'sÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Dermatitis, Diarhoea, DementiaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt;&lt;br /&gt;				&lt;span style='font-family:MS Gothic'&gt;â„ž&lt;/span&gt; - Oral 'Nicotinamide'Â 88Â Â 104Â Infantile Scurvy/Barlow's DiseaseÂ 91Â Â 105Â Scorbutic RosaryÂ 91Â Â 106Â Role of ZincÂ 92Â DEC-2005Â 107Â Role of SeleniumÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; constituent of glutathione peroxidaseÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; scavenges free radicalsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; prevents cell damage by free radicalsÂ 93Â JUN-2006Â 108Â Keshan DiseaseÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; cardiomyopathy in young childrenÂ Â Â 109Â Role of IodineÂ 93Â JUN-2005Â 110Â Iodine Deficiency GoitreÂ 94Â Â 111Â CretinismÂ 94Â MAY-2002Â 112Â NEWBORN INFANTSÂ Â Â 113Â LBWÂ Â Â 114Â VLBWÂ Â Â 115Â ELBWÂ Â Â 116Â Secondary ApneaÂ 96Â Â 117Â Neonatal ResuscitationÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; ApgarÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; TABCÂ 96Â Â 118Â Apgar ScoreÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Heart RateÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; RespirationÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; ToneÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; ReflexÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; ColorÂ 97Â 107Â MAR-2003Â 119Â TABC of ResuscitationÂ 98Â MAR-2003Â 120Â Five CleansÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; clean handsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; clean delivery surfaceÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; clean cord cutÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; clean cord tieÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; clean cord stumpÂ 103Â Â 121Â OmphalitisÂ 105Â Â 122Â Physiological JaundiceÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; &amp;gt; 5mg/dlÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; subsides within 7-10 daysÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; seen in 60% of newbornÂ 105Â 147Â JUL-2007Â 123Â Ponderal IndexÂ 109Â Â 124Â CraniotabesÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; skull feels like a ping pong ballÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; delayed ossification &amp;amp; resorptionÂ 112Â Â 125Â CephalhematomaÂ 112Â AUG-2002Â JUL-2008Â 126Â Developmental Dysplasia of HipÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Barlow's TestÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Ortolani's TestÂ 114Â Â 127Â Warm ChainÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; TEN stepsÂ 116Â Â 128Â Advantages of Breast FeedingÂ 122Â JUL-2008Â SEP-2000Â 129Â Reflexes in Breast FeedingÂ 124Â Â 130Â Draw &amp;amp; Label : Oxytocin ReflexÂ 124Â JUL-2007Â 131Â Nipple ConfusionÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; seen in bottle fed infantsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; finds it difficult and confusingÂ 125Â Â 132Â ColostrumÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; milk secreted in the initial 3-4 daysÂ Composition of ColostrumÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; antibodiesÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Vit ADEKÂ 125Â JUL-2007Â FEB-2002Â 133Â Problems of Pre-Term BabiesÂ 129Â Â 134Â Problems of LBW BabiesÂ 129Â Â 135Â Neonatal SepsisÂ 136Â Â 136Â Respiratory Distress SyndromeÂ 143Â Â 137Â Meconium Aspiration SyndromeÂ 144Â 100Â Â 138Â A 15 days old baby is brought with yellowish discolouration of eyes and skin.Â Is it physiological or pathological?Â What are the probable causes?Â What investigations will you order?Â What history will you specifically ask for?Â Â JUN-2006Â 139Â Prolonged Physiological JaundiceÂ 147Â Â 140Â Breast Milk JaundiceÂ 147Â Â 141Â Clinical Estimation of JaundiceÂ 147Â Â 142Â Causes of Jaundice in the new bornÂ 148Â JUL-2008Â 143Â PhototherapyÂ 149Â AUG-2002Â MAY-2002Â 144Â BFHIÂ Â JUN-2005Â 145Â Significance of Moro ReflexÂ Â MAR-2003Â FEB-2008Â 146Â X-Ray findings in Congenital Diaphragmatic HerniaÂ 153Â Â 147Â IMMUNITY AND IMMUNISATIONÂ Â Â 148Â Vaccine FailureÂ 164Â Â 149Â Live VaccinesÂ 165Â Â 150Â Vaccine StorageÂ 166Â Â 151Â Cold ChainÂ Â JUN-2005Â 152Â National Immunisation ScheduleÂ Â Â 153Â Vaccine preventable DiseasesÂ Â Â 154Â Ring ImmunisationÂ Â Â 155Â BCG VaccineÂ 166Â Â 156Â Preservation of BCG VaccineÂ Â MAR-2003Â 157Â OPVÂ 167Â MAR-2003Â 158Â IPVÂ 168Â Â 159Â Vaccine Vial MonitorÂ Â DEC-2004Â 160Â Complications of DPT VaccineÂ 168Â FEB-2008Â JUL-2007Â 161Â Contraindications of Pertusis VaccineÂ 169Â Â 162Â Acellular Pertusis VaccineÂ 169Â Â 163Â Measles VaccineÂ 171Â JUL-2008Â 164Â MMR VaccineÂ 171Â SEP-2000Â 165Â Congenital Rubella SyndromeÂ Â JUL-2007Â 166Â Hepatitis B VaccineÂ 171Â Â 167Â Management of Dogbite on FaceÂ 172Â JUL-2007Â 168Â Typhoral VaccineÂ 174Â Â 169Â HIB VaccineÂ 175Â DEC-2005Â 170Â INFECTIONS AND INFESTATIONSÂ Â Â 171Â Normal Body temperature in childrenÂ 36.1 â€“ 37.8Â Â Â 172Â PUOÂ 183Â DEC-2004Â 173Â Causes of PUO in Children Â 183Â Â 174Â MeaslesÂ 185Â Â 175Â Complications of MeaslesÂ 185Â FEB-2008Â AUG-2001Â 176Â Atypical MeaslesÂ -Â Â 177Â Modfiied MeaslesÂ -Â Â 178Â Infectious MononucleosisÂ 187Â Â 179Â Complications of MumpsÂ 188Â Â 180Â PoliomyelitisÂ 188Â Â 181Â What are the causes of Acute Flaccid paralysis in a five year old boy?Â PoliomyelitisÂ Guillen Barre SyndromeÂ Transverse MyelitisÂ Traumatic NeuritisÂ Meningitis / EncephalitisÂ Describe the clinical features of poliomyelitis. Â Enumerate the likely complications. Â Write about the management of poliomyelitis and strategies adopted towards its eradication.Â 190Â SEP-2000Â 182Â Three Causes of AFPÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; PoliomyelitisÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Guillen Barre SyndromeÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Transverse MyelitisÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Traumatic NeuritisÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Meningitis / EncephalitisÂ 190Â Â 183Â Define AFPÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; sudden onset of weakness and floppiness in any part of the body in a child &amp;lt; 15yrÂ ORÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; paralysis in a person of any age in whom polio is suspectedÂ 191Â JUN-2006Â FEB-2002Â 184Â Oral Polio VaccineÂ Â FEB-2001Â 185Â Pulse Polio ImmunisationÂ 190Â AUG-2001Â 186Â AFP SurveillanceÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; notify AFP casesÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; District Immunisation officer (DIO) investigates for 60 daysÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; Two stool samples to be collectedÂ 191Â 555Â JUL-2008Â 187Â Non-Polio AFPÂ 191Â Â 188Â Extrahepatic manifestations of Hepatitis BÂ Â Â 189Â Hepatitis C VirusÂ 194Â FEB-2002Â 190Â Dengue Hemorrhagic FeverÂ 196Â JUN-2005Â 191Â Draw &amp;amp; Label : Human Immunodeficiency VirusÂ -Â DEC-2005Â 192Â Diagnosis of HIV in ChildrenÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; HIV PCR Â &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; HIV CultureÂ 207Â DEC-2004Â 193Â AIDS Prophylaxis in ChildrenÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; CotrimoxazoleÂ Â Â 194Â Prevention of parent to child transmission of HIVÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; MTCTÂ 207Â 208Â FEB-2008Â 195Â Miliary TuberculosisÂ 210Â Â 196Â Primary ComplexÂ 210Â Â 197Â Mantoux TestÂ 216Â JUL-2008Â 198Â Management of TuberculosisÂ 217Â Â 199Â RifampicinÂ Â AUG-2002Â 200Â Advere effects of RifampicinÂ Â Â 201Â Adverse effects of INHÂ Â Â 202Â Complications of DiphtheriaÂ 220Â MAY-2002Â 203Â Clinical features of Enteric Fever Â 222Â AUG-2002Â 204Â Investigations in Enteric FeverÂ Â JUL-2008Â 205Â Complications of Enteric FeverÂ Â Â 206Â Draw &amp;amp; Label : Peripheral Smear showing falciparumÂ Â JUN-2005Â 207Â Treatment of P vivax MalariaÂ 233Â JUL-2008Â 208Â Drug of choice in Cerebral MalariaÂ 233Â Â 209Â Draw &amp;amp; Label : Roundworm OvaÂ Â FEB-2008Â 210Â Draw &amp;amp; Label : Hookworm OvaÂ Â JUL-2008Â 211Â Treatment of Hookworm InfestationÂ 246Â MAR-2003Â 212Â Draw &amp;amp; Label : Whipworm OvumÂ Â JUN-2006Â 213Â Treatment of ScabiesÂ Â Â 214Â DISEASES OF GASTROINTESTINAL SYSTEM AND LIVERÂ Â Â 215Â Inguinal Hernia in a ChildÂ Â Â 216Â Vaccines to be given before SplenectomyÂ Â Â 217Â Two surgical causes for persistant vomiting in a 1yr old childÂ Â Â 218Â Hypertrophic Pyloric Stenosis Â 253Â Â 219Â Common causes of constipation in an infantÂ 255Â JUL-2008Â 220Â Define Acute Watery DiarrhoeaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; passage of watery stoolsÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; starts suddenly and persists for hours / daysÂ 260Â Â 221Â A 9month old infant is brought  with watery diarrhea and vomitting. On examination child is thirsty, irritable and oral mucous membrane dry.Â What is the diagnosis?Â What treatment will you advice?Â What are the criteria for discharge from hospital?Â What instructions will you give to the mother on discharge?Â Â AUG-2002Â 222Â A 1yr old weighing 8kg presents to the hospital with a one day history of vomiting and watery diarrhea, following an URTI. On examinationhe was found to be moderately dehydrated.Â What are the signs of dehydration you are ikely to find in this child?Â What are the important investigations you order and what are the likely results?Â What organisms are likely the causative agents?Â Â MAY-2002Â 223Â Define DysentryÂ 260Â Â 224Â Persistent DiarrhoeaÂ &lt;span style='font-family:Arial'&gt;â–ª&lt;/span&gt; 14 days or longerÂ 260Â Â 225Â RotavirusÂ 261Â Â 226Â Treatment of Acute Bacillary Dysentry in a childÂ Â Â 227Â Key Signs of DehydrationÂ 261Â FEB-2002Â 228Â Causes of Malnutrition in DiarrheaÂ 261Â Â 229Â Oral Rehydration TherapyÂ 263Â Â 230Â Composition of WHO ORSÂ 263Â MAY-2002Â FEB-2008Â 231Â Improved ORSÂ 263Â Â 232Â Management of DiarrheaÂ 264Â Â 233Â Treatment of Severe DehydrationÂ 265Â FEB-2008Â 234Â Indications for Antibiotics in ADDÂ 267Â Â 235Â Four Clinical manoevers to diagnose CholeraÂ 267Â Â 236Â Seizures in DiarrheaÂ 268Â Â 237Â Lactose intoleranceÂ 273Â JUN-2005Â 238Â Milk protein intoleranceÂ 273Â Â 239Â Four causes of Splenomegaly in childrenÂ 279Â JUL-2007Â 240Â Fatty Liver in ChildrenÂ 281Â Â 241Â Neonatal HepatitisÂ 281Â Â 242Â Clinical signs of liver cell failureÂ 286Â JUL-2007Â 243Â Management of Acute Fulminant Liver cell failureÂ 287Â FEB-2008Â 244Â Hepatic EncephalopathyÂ 288Â DEC-2004Â 245Â Portal Hypertension in ChildrenÂ 289Â Â 246Â Causes of Liver CirrhosisÂ Â MAY-2002Â 247Â HEMATOLOGICAL DISORDERSÂ Â Â 248Â A 4yr old girl is brought with purpura and gum bleeding. On examination there  is no lymphadenopath, bone tenderness or hepatosplenomgaly.Â What is the  clinical diagnosis?Â Mention three important 'investigations to confirm diagnosis?Â What are the differential diagnosis?Â What are the drugs used for treatment?Â Â FEB-2002Â 249Â Draw &amp;amp; Label : MyeloblastÂ Â Â 250Â Draw &amp;amp; Label : LymphoblastÂ Â Â 251Â Define Anemia in a 2yr old?Â What is Severe Anemia?Â Â Â 252Â Lab findings of Iron Deficiency AnemiaÂ 300Â JUN-2005Â 253Â Treatment of Iron deficiency AnemiaÂ 301Â FEB-2001Â 254Â Iron requirement in Pediatric age GroupÂ Â Â 255Â Iron rich foodsÂ Â Â 256Â Causes of failure of Iron therapy in a childÂ Â Â 257Â DeferiproneÂ Â Â 258Â Types of Hemolytic AnemiasÂ 303Â JUN-2006Â 259Â Nutritional Anemia â€“ Management and PreventionÂ Â SEP-2000Â 260Â Most common Thalassemia?Â Defect in common secondary immunodeficiencies in children?Â Â Â 261Â Draw &amp;amp; Label : Peripheral Smear in beta thalassemia majorÂ 308Â JUL-2008Â 262Â Investigations in a child with recurrent bleedingÂ 318Â JUL-2007Â 263Â Lab Diagnosis of ITPÂ 320Â AUG-2002Â 264Â Drugs used in ITP with dosageÂ Â Â 265Â Clinical features of ALLÂ Â MAY-2002Â 266Â Bone Marrow AspirationÂ Â MAY-2002Â 267Â Draw &amp;amp; Label : Target CellÂ Â AUG-2002Â 268Â DISEASES OF EAR, NOSE AND THROATÂ Â Â 269Â Management of Acute EpiglottitisÂ Â FEB-2002Â 270Â DISORDERS OF RESPIRATORY SYSTEMÂ Â Â 271Â Draw &amp;amp; Label : Bronchial BreathingÂ Â FEB-2002Â 272Â Draw &amp;amp; Label : Vesicular BreathingÂ Â Â 273Â Respiratory NoisesÂ 346Â Â 274Â Causes of WheezingÂ 347Â Â 275Â Staphylococcal PneumoniaÂ 353Â Â 276Â Clinical Signs of Severe PneumoniaÂ Â FEB-2002Â 277Â Signs of very Severe PneumoniaÂ Â Â 278Â Oxygen therapy in PneumoniaÂ Â Â 279Â Indications of chest X Ray in PneumoniaÂ Â Â 280Â Treatment of Mycoplasma PneumoniaÂ 352Â DEC-2005Â 281Â Define ARIÂ 356Â JUN-2005Â 282Â ARI Control ProgrammeÂ Â Â 283Â Management of a six month olf under ARI control programmeÂ Â SEP-2000Â 284Â A 4 month old baby is brought with a history of cold. cough a nd difficulty in breathin g. OnÂ examination his respiratory rate is 66/min. He has inte'costal and subcostal recession. His chest looks prominent and hyperâ€¢resonant to percussion. Auscultation reveals a scattered rhonchi.Â What is the probable diagnosis?Â What is the organism which causes this condition?Â What are the differential diagnosis?Â What are the Chest X-ray findings in this child?Â How will you manage this child?Â Â JUL-2007Â 285Â 1 year old child is brought with pyoderma, fever and cough. On examination he is cyanosed,Â respiratory rate is 62/minute, grunting and chest retractions are present.Â What is the diagnosis?Â What treatment will you advise?Â What investigations will you order?Â What complication will you expect?Â What is the duration of antibiotic therapy?Â Â MAR-2003Â 286Â BronchiolitisÂ 356Â Â 287Â Two common complications of BronchiolitisÂ Â Â 288Â Triggering Factors of Bronchial Asthma Â 358Â Â 289Â Prophylaxis of Bronchial AsthmaÂ Â Â 290Â Classification of AsthmaÂ IntermittentÂ Mild PersistentÂ Moderate PersistantÂ Sever PersistantÂ 363Â Â 291Â Treatment of Acute Severe AsthmaÂ 366Â JUL-2008Â JUN-2006Â 292Â Treatment of Status AsthmaticusÂ Status asthmaticus is an acute exacerbation of asthma that does not respond to standard treatments of bronchodilators and corticosteroids. Symptoms include chest tightness, rapidly progressive dyspnea (shortness of breath), dry cough, use of accessory muscles, labored breathing and extreme wheezing. It is a life-threatening episode of airway obstruction considered a medical emergency. Complications include cardiac and/or respiratory arrest.Â The lung failure means that oxygen can no longer be provided, carbon dioxide can no longer be eliminated, which leads to acidosis.Â It is characterized histologically by smooth muscle hypertrophy and basement membrane thickening.Â Interventions include initiating and maintaining IV access, bronchodilators as prescribed, telemetry monitoring in the PCU, usually arterial blood gas tests sometimes arterial lines are inserted and preparing for emergency intubation.Â Intravenous treatments such as Aminophylline, Theophylline and Salbutamol are typically given. Many patients eventually respond avoiding more aggressive measures.Â Status Asthmaticus does not respond adequately to nebulised treatment alone therefore the intravenous treatments such as those above sometimes in addition to Intravenous Magnesium Sulphate are also given.Â 366Â MAY-2002Â 293Â SalbutamolÂ Â MAR-2003Â 294Â TachypneaÂ Â Â 295Â Genetic causes of BronchiectasisÂ 368Â Â 296Â DISORDERS OF CARDIOVASCULAR SYSTEMÂ Â Â 297Â Normal BP in a newborn?Â Â Â 298Â Draw &amp;amp; Label : JVPÂ Â Â 299Â Causes of Collapsing PulseÂ Â JUL-2008Â 300Â Draw &amp;amp; Label : Pansystolic MurmerÂ Â FEB-2002Â 301Â Causes of CCFÂ 372Â Â 302Â Treatment of CCFÂ Â DEC-2005Â FEB-2002Â 303Â Classification of Congenital Heart DiseasesÂ 372Â Â 304Â Common Congenital Heart DiseasesÂ Â AUG-2002Â 305Â Features of CCFÂ 375Â Â 306Â Treatment of CCFÂ 376Â JUL-2007Â 307Â Jones CriteriaÂ 380Â AUG-2002Â 308Â Rheumatic fever ProphylaxisÂ 383Â MAY-2002Â 309Â Rheumatic MRÂ Â Â 310Â Treatment of Rheumatic CarditisÂ Â DEC-2004Â 311Â What is the Serum therapeutic level of Aspirin in RF?Â Â Â 312Â Draw &amp;amp; Label : Mitral Regurgitation MurmerÂ 384Â DEC-2005Â 313Â Carey Coomb MurmerÂ Â Â 314Â Infective Endocarditis â€“ C/FÂ 391Â Â 315Â Prophylaxis in Infective EndocarditisÂ 393Â JUN-2006Â 316Â Fetal CirculationÂ 394Â Â 317Â NADAS CriteriaÂ 399Â Â 318Â ASD â€“ TypesÂ 401Â Â 319Â Complications of ASDÂ Â MAR-2003Â 320Â Draw &amp;amp; Label : Development of Interatrial SeptumÂ Â MAY-2002Â 321Â Draw &amp;amp; Label : ASD MurmerÂ 402Â DEC-2004Â 322Â VSD â€“ TypesÂ 403Â Â 323Â Draw &amp;amp; Label : VSD MurmerÂ 404Â JUN-2005Â 324Â VSD â€“ Small v/s LargeÂ 403Â Â 325Â Complications of VSDÂ 403Â Â 326Â Draw &amp;amp; Label : PDA MurmerÂ 405Â JUN-2006Â 327Â Diagnostic features of PDAÂ 405Â FEB-2002Â 328Â Components of TOFÂ 408Â AUG-2002Â 329Â Complications of TOFÂ 408Â FEB-2001Â 330Â Management of TOFÂ 408Â Â 331Â Chest X Ray in TOFÂ 408Â Â 332Â Fallots PhysioogyÂ 412Â Â 333Â Cyanotic SpellsÂ Â FEB-2008Â 334Â Treatment of Hyper Cyanotic SpellsÂ 415Â JUN-2005Â MAR-2003Â 335Â Causes of Hypertension In childrenÂ 431Â Â 336Â Draw &amp;amp; Label : Murmer of ARÂ Â MAR-2003Â 337Â Hills SignÂ in aortic insufficiency, greater systolic blood pressure in the legs than in the arms; normal arterial systolic pressure in the leg is 10â€“20 mm of Hg above that in the arm, whereas in aortic insufficiency the difference may be 60â€“100 mm of Hg. Syn: Hill phenomenon.Â Â MAR-2003Â 338Â DISORDERS OF KIDNEY AND URINARY TRACTÂ Â Â 339Â Draw and Label : NephronÂ 440Â MAY-2002Â 340Â Heat and Acetic Acid TestÂ 443Â Â 341Â Significant BacteruriaÂ 443Â Â 342Â Asymptomatic BacteruriaÂ 443Â Â 343Â Causes of HematuriaÂ 445Â Â 344Â IgA NephropathyÂ 446Â Â 345Â ProteinurisÂ Define ProteinuriaÂ 447Â FEB-2002Â 346Â Define Massive ProteinuriaÂ 447Â Â 347Â Complications of AGNÂ 447Â Â 348Â Draw &amp;amp; Label : PS in Hemolytic Uremic SyndromeÂ Â Â 349Â Draw &amp;amp; Label : Urinary findings in Acute GlomerulonephritisÂ Â FEB-2008Â 350Â Treatment of Acute GlomerulonephritisÂ Â JUN-2006Â 351Â Diagnostic criteria of Nephritic SyndromeÂ Â AUG-2002Â 352Â Management of Nephrotic SyndromeÂ 450Â Â 353Â Complications of Nephrotic SyndromeÂ 450Â Â 354Â UTI in ChildrenÂ Â JUN-2006Â 355Â Management of UTIÂ 456Â Â 356Â Vesicourethral ReflexÂ 457Â Â 357Â Posterior Urethral ValvesÂ Â MAY-2002Â 358Â ENDOCRINE AND METABOLIC DISORDERSÂ Â Â 359Â Clinical features of Congenital HypothyroidismÂ 481Â FEB-2008Â 360Â Common causes of Acquired HypothyroidismÂ Â Â 361Â Drug therapy in HyperthyroidismÂ Â MAR-2003Â 362Â PanhypopituitarismÂ Â Â 363Â CENTRAL NERVOUS SYSTEMÂ Â Â 364Â Management of Status Epilepticus ina 2yr old childÂ Â Â 365Â Causes of Convulsions in ChildrenÂ 523Â DEC-2004Â FEB-2008Â 366Â Febrile ConvulsionsÂ 528Â JUL-2008Â SEP-2000Â 367Â A 6 month old baby is brought with history of fever of 2 days duration, refused to feed, extreme irritability and convulsions.Â What is the probable diagnosis?Â Name one important clinical sign you will elicit for diagnosis?Â How will you investigate?Â Name two complications?Â How will you prevent this condition?Â Â JUL-2008Â 368Â Petit Mal SeizuresÂ 530Â MAY-2002Â 369Â Treatment of Neonatal SeizuresÂ 531Â DEC-2004Â 370Â Infantile Myoclonic SeizuresÂ 531Â JUL-2007Â 371Â Organisms causing Pyogenic MeningitisÂ 536Â Â 372Â Complications of Pyogenic MeningitisÂ 536Â Â 373Â Management of Bacterial Meningitis in a 1yr oldÂ 536Â Â 374Â Organisms causing Acute Bacterial Meningitis in a 18 month old babyÂ Â FEB-2008Â 375Â CSF findings in Normal childÂ Â SEP-2000Â 376Â CSF findings in Pyogenic MeningitisÂ 539Â SEP-2000Â 377Â CSF findings in TB MeningitisÂ Â SEP-2000Â 378Â CSF findings in Viral MeningitisÂ Â Â 379Â Clinical features of TB MeningitisÂ 539Â Â 380Â CSF findings in TB MeningitisÂ 540Â MAR-2003Â 381Â Bilirubin EncephalopathyÂ 542Â JUN-2006Â 382Â Reye's SyndromeÂ 543Â Â 383Â Hydrocephalous - TypesÂ Â Â 384Â Guillen Barre SyndromeÂ 554Â Â 385Â Define Acute Flaccid ParalysisÂ 555Â Â 386Â Causes of Acute Flaccid ParalysisÂ 555Â Â 387Â DD of AFPÂ 556Â DEC-2004Â 388Â Define Cerebral PalsyÂ Â Â 389Â Cerebral Palsy â€“ TypesÂ 559Â Â 390Â Neurocutaneous MarkersÂ 564Â Â 391Â AutismÂ Â Â 392Â MyelodysplasiaÂ Â Â 393Â Typical v/s Atypical seizuresÂ Â Â 394Â NEUROMUSCULAR DISORDERSÂ Â Â 395Â Duchenne Muscular DystrophyÂ 566Â Â 396Â DD of Floppy InfantÂ 573Â JUN-2005Â 397Â CHILDHOOD MALIGNANCIESÂ Â Â 398Â Draw &amp;amp; Label : PS in Acute Lymphoblastic LeukemiaÂ 580Â JUL-2007Â 399Â Classification of ALLÂ 580Â DEC-2005Â 400Â RHEUMATOLOGICAL DISORDERSÂ Â Â 401Â Juvenile Idiopathic ArthritisÂ 599Â Â 402Â A 5 year old child is brought with joint pain, abdominal pain, high coloured urine. She has sore throat 10 days back. OlE skin rash present in the lower limbs.Â What is the probable diagnosis?Â What investigations will you order?Â What treatment will you give?Â What are the differential diagnosis?Â Â DEC-2005Â 403Â GENETIC DISORDERSÂ Â Â 404Â Kawasaki DiseaseÂ 609Â Â 405Â Behcet's DiseaseÂ Â Â 406Â Clinical features of Down's SyndromeÂ 613Â DEC-2005Â 407Â Two chromosomal pattern seen in Down's SyndromeÂ Â Â 408Â Kleinfelter's SyndormeÂ 615Â Â 409Â Chromosomal anomaly in Turner SyndromeÂ 616Â AUG-2002Â 410Â Features of Autosomal Dominant InheritanceÂ 617Â MAY-2002Â 411Â Marfans SyndromeÂ Â Â 412Â CraniosynostosisÂ Â Â 413Â INBORN ERRORS OF METABOLISMÂ Â Â 414Â PhenylketonuriasÂ 628Â Â 415Â Gauchers DiseaseÂ 638Â Â 416Â Wilsons DiseaseÂ 640Â Â 417Â Alpha 1 Antitrypsin DeficiencyÂ 640Â Â 418Â EYE DISORDERSÂ Â Â 419Â SKIN DISORDERSÂ Â Â 420Â Causes of Purpura in ChildrenÂ Â JUN-2005Â 421Â Treatment of ScabiesÂ 665Â DEC-2005Â 422Â POISONINGS, INJURIES AND ACCIDENTSÂ Â Â 423Â Keroscene PoisoningÂ Â JUL-2008Â 424Â PEDIATRIC CRITICAL CAREÂ Â Â 425Â COMMON MEDICAL PROCEDURESÂ Â Â 426Â Contraindications for Lumbar PunctureÂ 717Â 520Â JUL-2007Â 427Â RATIONAL DRUG THERAPYÂ Â Â 428Â INTEGRATED MANAGEMENT OF NEONATAL AND CHILDHOOD ILLNESSESÂ Â Â 429Â Define Infant Mortality RateÂ 753Â FEB-2008Â 430Â RIGHTS OF CHILDRENÂ Â Â 431Â UNALLOCATED QUESTIONSÂ Â Â 432Â Age Independent Anthropometric MeasurementÂ Â JUN-2005Â 433Â Draw &amp;amp; Label : LE CellÂ Â DEC-2004Â 434Â Treatment of Methicillin Resistant Staphylococcal InfectionÂ Â DEC-2004Â  Â Â &lt;/p&gt;&lt;/span&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/4164540472824980814-3188455601850433532?l=mesmedicalcollege.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://mesmedicalcollege.blogspot.com/feeds/3188455601850433532/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=4164540472824980814&amp;postID=3188455601850433532' title='2 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4164540472824980814/posts/default/3188455601850433532'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4164540472824980814/posts/default/3188455601850433532'/><link rel='alternate' type='text/html' href='http://mesmedicalcollege.blogspot.com/2010/03/final-mbbs-questions.html' title='FINAL MBBS QUESTIONS'/><author><name>Hafeesh Fazulu</name><uri>http://www.blogger.com/profile/17139976392365489719</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='22' height='32' src='http://2.bp.blogspot.com/_NnNOcS4DuOU/SxakX6Ie8VI/AAAAAAAAHpw/VmFBc5kW3pk/S220/me+face.jpg'/></author><thr:total>2</thr:total></entry><entry><id>tag:blogger.com,1999:blog-4164540472824980814.post-4337258127845778922</id><published>2010-03-18T00:03:00.001-07:00</published><updated>2010-03-18T00:03:07.333-07:00</updated><title type='text'>Index to Davidson Principles and Practice of Medicine - 5</title><content type='html'>&lt;span xmlns=''&gt;&lt;p&gt;&lt;span style='font-size:12pt'&gt;&lt;span style='color:#5c5863; font-family:Times New Roman'&gt;404,Â &lt;/span&gt;&lt;span style='color:#6e6a76; font-family:Times New Roman'&gt;406,407,408,414Â &lt;/span&gt;&lt;span style='color:#5c5863; font-family:Times New Roman'&gt;presenting problemsÂ men 406-408Â women 409-410Â prevention 410-411Â those &lt;/span&gt;&lt;span style='color:#6e6a76; font-family:Times New Roman'&gt;at &lt;/span&gt;&lt;span style='color:#5c5863; font-family:Times New Roman'&gt;particular risk 405Â &lt;/span&gt;&lt;span style='color:#6e6a76; font-family:Times New Roman'&gt;viral &lt;/span&gt;&lt;span style='color:#5c5863; font-family:Times New Roman'&gt;415-418Â Sezary &lt;/span&gt;&lt;span style='color:#6e6a76; font-family:Times New Roman'&gt;syndrome &lt;/span&gt;&lt;span style='color:#5c5863; font-family:Times New Roman'&gt;1269Â SH &lt;/span&gt;&lt;span style='color:#6e6a76; font-family:Times New Roman'&gt;(self-harm) &lt;em&gt;see &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#5c5863; font-family:Times New Roman'&gt;Self-harmÂ SH &lt;/span&gt;&lt;span style='color:#6e6a76; font-family:Times New Roman'&gt;(standard &lt;/span&gt;&lt;span style='color:#5c5863; font-family:Times New Roman'&gt;heparin) 1062, 1063,Â 1064Â Shagreen patches 1308Â ShampooÂ antifungal 1278Â ketoconazole &lt;/span&gt;&lt;span style='color:#6e6a76; font-family:Times New Roman'&gt;386, &lt;/span&gt;&lt;span style='color:#5c5863; font-family:Times New Roman'&gt;1287Â &lt;/span&gt;&lt;span style='color:#6e6a76; font-family:Times New Roman'&gt;Sheehan's syndrome &lt;/span&gt;&lt;span style='color:#5c5863; font-family:Times New Roman'&gt;798Â Shellfish toxin&lt;/span&gt;&lt;span style='color:#94949a; font-family:Times New Roman'&gt;, &lt;/span&gt;&lt;span style='color:#5c5863; font-family:Times New Roman'&gt;paralytic &lt;/span&gt;&lt;span style='color:#6e6a76; font-family:Times New Roman'&gt;331Â &lt;/span&gt;&lt;span style='color:#5c5863; font-family:Times New Roman'&gt;Sheltered &lt;/span&gt;&lt;span style='color:#6e6a76; font-family:Times New Roman'&gt;accommodation 244Â &lt;em&gt;Shigella &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#5c5863; font-family:Times New Roman'&gt;dysentery/Shigellosis &lt;/span&gt;&lt;span style='color:#6e6a76; font-family:Times New Roman'&gt;294,Â 295,330-331Â &lt;/span&gt;&lt;span style='color:#5c5863; font-family:Times New Roman'&gt;reactive arthritis and 1108Â Shingles 305-306, 1230Â immunocompromised patientsÂ 1042Â &lt;/span&gt;&lt;span style='color:#6e6a76; font-family:Times New Roman'&gt;Shivering &lt;/span&gt;&lt;span style='color:#5c5863; font-family:Times New Roman'&gt;136, &lt;/span&gt;&lt;span style='color:#6e6a76; font-family:Times New Roman'&gt;285Â &lt;/span&gt;&lt;span style='color:#5c5863; font-family:Times New Roman'&gt;Shock 177, 182,186--187Â &lt;/span&gt;&lt;span style='color:#6e6a76; font-family:Times New Roman'&gt;acute &lt;/span&gt;&lt;span style='color:#5c5863; font-family:Times New Roman'&gt;renal failure 482-483Â anaphylactic 187Â &lt;/span&gt;&lt;span style='color:#6e6a76; font-family:Times New Roman'&gt;cardiogenic &lt;/span&gt;&lt;span style='color:#5c5863; font-family:Times New Roman'&gt;187, 540-542Â dengue &lt;/span&gt;&lt;span style='color:#6e6a76; font-family:Times New Roman'&gt;shock syndrome 309Â early &lt;/span&gt;&lt;span style='color:#5c5863; font-family:Times New Roman'&gt;186Â hypovolaernic 187, 197Â management 191-J &lt;/span&gt;&lt;span style='color:#6e6a76; font-family:Times New Roman'&gt;92Â &lt;/span&gt;&lt;span style='color:#676573'&gt;&lt;span style='font-family:Times New Roman'&gt;Shock &lt;em&gt;(COllI &lt;/em&gt;&lt;/span&gt;&lt;span style='font-family:Arial'&gt;&lt;em&gt;'d)Â &lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;infection 136Â late 186Â malaria &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;345Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;managel,nent 191 &lt;/span&gt;&lt;span style='color:#868690; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;192Â neurogenic 187Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;obstructive &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;187Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;septic &lt;em&gt;see &lt;/em&gt;Septic shockÂ &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;toxic &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;shock syndrome 314-315Â 'Shock' &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;liver 198, &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;983Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;Short bowel &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;syndrome &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;898-899Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;Short stature 764Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;Turner's &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;syndrome 769&lt;/span&gt;&lt;span style='color:#868690; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;771Â ShoulderÂ frozen (capsulitis) &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1079&lt;/span&gt;&lt;span style='color:#868690; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1080Â pain 1079-1080Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;stroke &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;patients 1207Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;Shrinking &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;lungs &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;723Â ShuntsÂ &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;peritoneo-venous &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;(LeVeen) 949Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;portasystemic &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;949, 950, 958, 960,Â 961, 962, 983Â Shunts, cardiacÂ congenital &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;heart disease &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;634, 636,Â 638,639,640Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;left-to-right &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;634, 636, 638, 639Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;reversal &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;638, 639Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;right-to-Ieft &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;634, 640, 668Â Shy-Drager syndrome &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1221Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;S1 &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;units 1318Â SIADH &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;(syndrome of &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;inappropriateÂ &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;secretion of ADH) 430, 431,Â 793Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;bronchial &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;carcinoma 707Â Sibutrarnine &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;115Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;Sick euthyroidism 751, 753Â Sick sinus syndrome &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;569Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;Sickle-cell anaemia 1012,Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1035&lt;/span&gt;&lt;span style='color:#43364a; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1037Â Sickle-cell diseaseÂ &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;inheritance 52Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;nephropathy 506Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;Sickle-cell trait 1035, 1036Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;Sickle &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;chest syndrome &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1036, 1037Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;Siderosis 720Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;Sieverts &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;(Sv) 99Â Sigmoidoscopy 255, 860Â abdominal &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;pain &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;876Â colorectal cancer 927, 928-929Â familial adenomatous polyposisÂ 925Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;inflammatory &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;bowel diseaseÂ 915-916Â SildenafiI477,729, &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1216Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;Silicosis 720, &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;721Â Simplified &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;Acute &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;Physiology &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;ScoreÂ (SAPS) 200Â &lt;em&gt;Simulium &lt;/em&gt;spp&lt;/span&gt;&lt;span style='color:#43364a; font-family:Times New Roman'&gt;.&lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;, onchocerciasis 365,Â 366Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;SIMV &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;(synchronised &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;intermittentÂ mandatory &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;ventilation) &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;193,Â 194, 196Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;SimvastatinÂ effect of &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;hepatic impairment &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;27Â stroke &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;prevention 1210Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;Sinemet &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1220Â Single-nucleotide polymorphismsÂ &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;(SNPs; snips) 44, &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;59Â Single photon &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;emissionÂ &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;tomography &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;(SPECT) &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1156,Â 1157Â Sinoatrial disease 569Â Sinoatrial &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;(SA) &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;node &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;522, 523, 524,Â 526,527Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;depolarisation 526Â Sinus, definition 1259Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;Sinus &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;bradycardia &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;561Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;myocardial infarction &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;597Â Sinus &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;rhythms &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;526, 560, 561, &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;565Â Sinus tachycardia 561Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;Sipple's syndrome 803Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;Sirolimus 587Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;STRS (systemic inflammatoryÂ &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;response &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;syndrome) &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;185,Â 186, 187, 198, 199Â pancreatitis &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;905Â Sister &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;Joseph's nodule &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;893, 909Â Sitosterolaemia &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;448Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;Sjogren's syndrome 82, 1075,Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1137-1138Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;secondary &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1103Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;Skeletal &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;muscle &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;1069, &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1071Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;SkinÂ anatomy and &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;physiologyÂ 1260-1262Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;assessment, gastrointestinalÂ &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;disease &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;850Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;biopsy 1264, 1275, 1313-1314Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;changes &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;in &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;older &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;people 1263Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;common &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;infecting &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;organisms &lt;/span&gt;&lt;span style='color:#545261'&gt;&lt;span style='font-family:Times New Roman'&gt;133Â &lt;/span&gt;&lt;span style='font-family:Arial'&gt;. &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#676573'&gt;&lt;span style='font-family:Arial'&gt;.Â &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;exarrunattonÂ &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;diabetes &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;806Â endocrine &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;disease &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;740Â febrile &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;injecting &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;drug &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;user &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;291 &lt;/span&gt;&lt;span style='color:#868690; font-family:Times New Roman'&gt;,Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;292Â gastrointestinal &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;disease &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;850Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;renal/urinary &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;tract &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;disease 456Â functions 1262Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;infestations &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1297-1298Â rheumatic fever &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;617Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;in &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;systemic &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;disease 1307-131 IÂ tumoursÂ malignant &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;&lt;em&gt;see &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;Skin &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;cancerÂ older &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;people 1307Â Skin &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;cancer &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1302-1307Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;changing &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;mole &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;and &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1264-1266Â human papilloma &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;virus &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;and 1296Â immunosuppression &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;and &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1304,Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;1305Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;incidence &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;and &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;risk &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;factorsÂ &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1302-1303Â pre-malignant tumoursÂ 1303&lt;/span&gt;&lt;span style='color:#868690; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1304Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;&lt;em&gt;see also names of 5pecijicÂ tumoursÂ &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;Skin diseases/disorders 1258-1315Â clinical &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;examination 1258&lt;/span&gt;&lt;span style='color:#868690; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1259Â colour &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;abnormalities &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1279-1281Â iliagnosi &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;s/i &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;nvesti &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;gati onsÂ &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1263-1264Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;genetic 52Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;HIV-related &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;378, 384-385Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;in/from tropics &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;298&lt;/span&gt;&lt;span style='color:#868690; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;299Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;infections &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;&lt;em&gt;see &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;Skin &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;infectionsÂ &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;inflammatory, &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;older &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;people 1293Â leishmaniasis, post-kala-azarÂ &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;351-352Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;leprosy &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;334, 336, 337Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;medical treatments 1311-1313Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;older people &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1260Â presenting problems 1264-1283Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;prevalence/age &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;distribution 1260Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;systemic &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;lupus &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;erythematosusÂ &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1133Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;systemic sclerosis 1135Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;terminology 1259Â tumours &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;1301 &lt;/span&gt;&lt;span style='color:#868690; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1307Â benign 1301-1302Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;&lt;em&gt;see also &lt;/em&gt;Skin cancer; &lt;em&gt;specificÂ &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;&lt;em&gt;tumoursÂ &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;Skin grafts, '\Iitiligo &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1280Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;Skin &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;infections 1293&lt;/span&gt;&lt;span style='color:#868690; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1297Â bacterial &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;312&lt;/span&gt;&lt;span style='color:#868690; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;317Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;diabetes &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;818Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;fungal 132, 1297Â deep &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;372-375Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;injecting drug users &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;313-314Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;investigations 1263&lt;/span&gt;&lt;span style='color:#868690; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1264Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;tropics 298-299Â viral 303-306Â Skin snip &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1274, 1294Â Skin testsÂ &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;asthma 675Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;prick tests 85Â respiratory disease &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;655Â tuberculosis 696, 699, 700Â Slapped cheek syndrome 30 &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;I, &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;302Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;SLE &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;&lt;em&gt;see &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;Systemic lupusÂ &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;erythematosusÂ &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;Sleep apnoealhypopnoea &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;syndromeÂ &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;666-667Â Sleep disorders 1176-1178Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;Sleep disturbance, &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;fibromyalgiaÂ 1119,1120Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;Sleep &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;paralysis &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;667Â Sleepiness 666Â Epworth scale 666Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;persistent, &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;differential &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;diagnosisÂ &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;667Â &lt;em&gt;see also &lt;/em&gt;SomnolenceÂ Sleeping sickness (AfricanÂ trypanosomiasis) 343,Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;354-355Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;Small &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;intestineÂ bacterial &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;overgrowth &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;896-898,Â 1028Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;older &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;people &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;898Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;biopsy, &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;coeliac &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;disease &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;894Â chronic &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;pseudo-obstruction 900Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;common &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;infecting &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;organisms 133Â Crohn's &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;disease &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;915, &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1028Â diseases/disorders 894-904Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;vitamin &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;B1&lt;/span&gt;&lt;span style='color:#868690; font-family:Times New Roman'&gt;2 &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;deficiency 1028Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;functional anatomy 853&lt;/span&gt;&lt;span style='color:#868690; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;856Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;immunoproliferative disease &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;904Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;infections 902-903Â ischaemia 921-923Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;obstruction 874Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;protective function &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;856Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;resection 898-899Â transit, tests &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;863Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;transplantation &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;899,923Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;tumours 903-904Â ulceration 901Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;Small-vessel vasculitis 515Â Smallpox &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;141, &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;306, 342Â Smith-Lemli-Opitz syndrome 53Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;Smith-Magenis &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;syndrome &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;53Â Smoke, toxicity &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;216Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;SmokingÂ &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;atherosclerotic vascular &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;d&lt;/span&gt;&lt;span style='color:#9b99a7; font-family:Arial'&gt;, &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;iseaseÂ &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;579Â chronic obstructive &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;pulmonaryÂ &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;disease and 678-679Â effects on &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;health 97-98Â Graves' disease &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;and 754, 756Â and &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;idiopathic pulmonary &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;fibrosisÂ 717Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;lung &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;cancer &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;and &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;705Â and obesity &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;111Â passive &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;705Â peptic &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;ulcers &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;and 886-887Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;rheumatoid arthritis and 1101Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;stopping &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;98-99Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;chronic obstructive &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;pulmonaryÂ disease &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;681, 682Â Crohn's &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;disease &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;919Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;myocardial infarctionÂ management 599Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;older &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;people &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;684Â Snake &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;bites 221-223Â Snoring &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;666Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;SNPs &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;(single-nucleotideÂ polymorphisms) &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;44, &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;59Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;Social factors, psychiatric disordersÂ &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;229Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;Sodium 421Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;daily &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;requirements &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;425Â depletion &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;424 426Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;dietary &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;intake, diabetics &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;831Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;disorders &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;of &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;balance &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;424 427Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;in drugs &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;949Â excess/retention &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;426-428Â drugs &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;and 949Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;renal retention &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;479, &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;480Â intake, &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;chronic &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;renal failure 489Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;reabsorption 422-423Â reference valuesÂ &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;urine 1321Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;venous blood 1318Â renal handling 422-424Â renal &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;retention &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;479&lt;/span&gt;&lt;span style='color:#868690; font-family:Times New Roman'&gt;, &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;480Â restriction, ascites 948Â transport regulation 424Â &lt;em&gt;see also &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;Hypernatraemia;Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;HyponatraemiaÂ Sodium&lt;/span&gt;&lt;span style='color:#868690; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;potassium pump &lt;em&gt;see &lt;/em&gt;Na&lt;/span&gt;&lt;span style='color:#868690; font-family:Times New Roman'&gt;,Â &lt;/span&gt;&lt;span style='color:#676573'&gt;&lt;span style='font-family:Arial'&gt;K &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;-acti vated ATPaseÂ Sodium aurothiomalate &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#868690; font-family:Times New Roman'&gt;(&lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;gold&lt;/span&gt;&lt;span style='color:#868690; font-family:Times New Roman'&gt;) &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;1093Â Sodium bicarbonateÂ acute renal failure 484, 485Â cardiotoxic drug poisoning 210Â chronic renal failure 489Â diabetic ketoacidosis 822Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;hyperkalaemia &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;436Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;lactic &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;acidosis 823Â salicylate poisoning 209Â stone disease 472Â Sodium chlorideÂ acute renal failure 485Â chronic &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;renal &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;failure 489Â hypertonic 430Â isotonic 439Â Sodi &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;urn &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;cromoglicate 86Â allergic &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;rhinitis &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;730Â eosinophilic gastroenteritis 901Â food allergy 902Â Sodium dichloroacetate 823Â Sodium &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;iopodate &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;749Â Sodium &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;nitroprussideÂ hypertension &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;614Â phaeochromocytoma 788Â Sodium &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;phosphate &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;442Â Sodium stibogluconate 350Â Sodium &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;thiosulphate &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;208Â Sodium valproate 238, 242Â epilepsy 1170, &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1172, 1173, &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;1175,Â 1176Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;hepatotoxici ty &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;973Â migraine &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;prevention &lt;/span&gt;&lt;span style='color:#676573'&gt;&lt;span style='font-family:Times New Roman'&gt;1163Â myoclonus &lt;/span&gt;&lt;span style='font-family:Arial'&gt;I &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;183Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;Soft &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;tissue &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;infectionsÂ bacterial 312-317Â clostridial 316Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;necrotising &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;315-317Â Soft tissue &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;release 1096Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;Solitary pulmonary &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;lesion &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;(SPN&lt;/span&gt;&lt;span style='color:#868690; font-family:Times New Roman'&gt;)Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;663-664Â Solitary &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;rectal &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;ulcer syndrome &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;933Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;Solvent &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;inhalation &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;246Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;Somatic &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;disorders, &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;medicallyÂ unexplained &lt;/span&gt;&lt;em&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;see &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;underÂ &lt;/span&gt;&lt;/em&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;Somatic symptomsÂ Somatic symptomsÂ anxiety 240Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;medically unexplained &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;236-237&lt;/span&gt;&lt;span style='color:#868690; font-family:Times New Roman'&gt;,Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;249-251Â Somatic syndromes, functional 236Â Somatisation ilisorder 236, 237,Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;249,251Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;Somatoform &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;disorders &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;236,Â &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;249-250Â prevalence &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;228Â Somatostatin 8] 0, 853, 859Â Somatostatin analogues, acromegalyÂ 802Â Somatostatin &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;receptor &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;scan (SRS)Â 864Â Somatostatinomas 791Â SomnolenceÂ daytime &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;1177, 1178Â idiopathic hypersomnolence &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;667Â Sorbitol 902Â Sota]ol &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;573, 574Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;South American &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;botfly &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;299Â Space of &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;Disse &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;938, 954Â Sparfloxacin &lt;/span&gt;&lt;span style='color:#545261; font-family:Times New Roman'&gt;151Â &lt;/span&gt;&lt;span style='color:#676573; font-family:Times New Roman'&gt;Sparganosis 372Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;Spastic paraplegia. hereditary 52&lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;.Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1245Â Spasticity 1179Â multiple &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;sclerosis &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1216Â SPECT &lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;(&lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;single &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;photon &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;emissionÂ &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;tomography) 1156, 1157Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;Spectinomycin &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;154,414Â Spectrin 1031, 1032Â Spectrophotometry &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;420Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;Spectroscopy, mass &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;420Â Speech/Speech &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;disordersÂ 1190-1191Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;assessment, &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;psychiatric interviewÂ &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;230Â Speech &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;therapy, Parkinson's diseaseÂ 1221Â Spermatogenesis &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;762Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;Spherocytes 1004, 10 I &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;0Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;Spherocytosis, hereditaryÂ 1031-1032Â Sphincter &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;of &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;Oddi dysfunctionÂ &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;996-997Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;Sphincterotomy &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;862Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;pancreatic &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;997Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;SphinctersÂ bladder I 199Â rectal I 199&lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1200Â Sphygmomanometry 609Â Spider bites 223-224Â Spider telangiectasia &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;936. 955Â Spina &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;bifida 1245Â Spinal &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;cord &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1151, 1152Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;compression &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1243-1245Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;canccr &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;patients &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;260Â cervical &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1241Â lumbar 1242Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;degeneration, vitamin &lt;/span&gt;&lt;span style='color:#5c5967'&gt;&lt;span style='font-family:MS PGothic'&gt;BI~&lt;/span&gt;&lt;span style='font-family:Arial'&gt;Â &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;deficiency &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;and &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;125Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;disorders &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1241-1246Â HIV-related &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;394Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;lesions I 179-1 180. 1183-1185Â bladder dysfunction I 199Â tumours 1243, 1244 1245Â Spinal muscular &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;atrophies &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1224Â inheritance 52Â Spinal root Ie ions &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;&lt;em&gt;seeÂ &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;RadiculopathyÂ Spinal &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;stenosis &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1085Â SpineÂ bamboo I 108Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;cervicalÂ &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;imaging I 156. 1158Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;subluxation &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1104Â disorders 1241 &lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1246Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;epidural abscess &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1232Â imaging 1241, 1242, 1243,Â 1244 1245, 1246Â lumbarÂ imaging 1156-1157Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;&lt;em&gt;see also &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;Lumbar &lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;.&lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;.&lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;.Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;tuberculosis 698, 699Â Spinobulbar mu &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;cular atrophy 46Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;Spinocerebellar ataxia 46. 1222Â Spiramycin &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;358Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;Spirometry &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;656, 657, 680Â asthma 673Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;Spironolactone &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;769Â ascites 949Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;heart &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;failure 548Â site of action 549Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;mineralocorticoid &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;cxcess 786Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;Splanchnic &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;vasodilatation 948Â Splanchnicectomy, &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;thorascopicÂ &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;908Â Spleen 68Â clinical examination 937Â examination &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1001Â myeloproliferative disordersÂ 1054-1055Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;sickle-cell &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;disease 1036Â SplenectomyÂ &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;autoimmunc &lt;/span&gt;&lt;span style='color:#5c5967'&gt;&lt;span style='font-family:MS PGothic'&gt;hacmoly~is &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;1034Â &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;chronic &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;lymphocytic leukacmiaÂ 1046Â hereditary &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;spherocytosis &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1032Â idiopathic thrombocytopenicÂ &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;purpura &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1056-1057Â myeloproliferative disorders 1055Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;patient &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;management 1032Â Splenomegaly 1015Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;cause&lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;s &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1015. 1016Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;chronic &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;myeloid leukaemia 1045Â hyperreactive malarial &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;(tropicalÂ splcnomegaly syndrome)Â 296Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;in/from tropics &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;296Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;portal hypertension &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;957Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;primary biliary &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;cirrhosis 978Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;Splints, musculoskeletal diseaseÂ 1089Â SPN &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;(solitary &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;pulmonary lesion)Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;663-664Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;Spondarthritis, &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;seronegative &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1068&lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;,Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1072, 1076, &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;1077, &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1078.Â 1082,1l06-1110Â radiology 1072Â Spondylitis 1106-1108Â inflammatory 1079Â pain 1083&lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1084Â psoriatic I 109-1110Â reactive arthritis I 109Â Spondylolisthesis 1085Â Spondylolysis 1085Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;Spondylosis &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1084Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;cervical &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1241-1242Â lumbosacral 1242-1243Â Spondylotic myelopathy, &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;cervicalÂ &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1241&lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1242Â Spondylotic radiculopathy&lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;, &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;cervicalÂ &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1241Â Sponges&lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;, &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;venomous 225Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;Spongiosis 1283Â Spontaneous bacterial peritonitisÂ &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;(S8P) &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;147,950Â Sporotrichosis 372-373Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;Sporozoitcs, &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;malaria &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;343Â SputumÂ &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;bronchiectasis &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;685Â cytology 710Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;respiratory disease &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;648Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;investigations 655Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;Squamous ccll carcinomaÂ oesophagus &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;883, &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;884Â skin &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1303, l305Â SRS &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;(somatostatin &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;receptor &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;scan)Â 864Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;SSPE &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;(subacute sclerosingÂ &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;panencephalitis) &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;300, &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1189,Â 1230-1231Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;SSRls (serotonin selective (specific)Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;re&lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;-&lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;uptake inhibitors) &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;238&lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;,Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;241Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;toxicity &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;210Â SSSS (staphylococcal scalded skinÂ syndrome) &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1274,1294-1295Â Stamping &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;gait &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1181Â Stannosis &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;720Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;Stanozolol I 126, 1277Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;Staphylococcal &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;infectionsÂ bone &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;and joint &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;I I 18Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;cndocarditis 629. 630Â antimicrobial &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;treatment &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;632Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;food poi;,oning &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;325-326Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;pneumonia &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;692Â scalded skin syndrome &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1274,Â 1294-1295Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;skin 312-314, &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1293, 1294Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;soft &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;tissuc &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;312&lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;314Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;toxic &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;shock syndrome &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;314Â urinary tract 470Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;vulvovaginal 409Â &lt;em&gt;Swphvlococcus aI/reusÂ &lt;/em&gt;al1hriti, &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1118 &lt;/span&gt;&lt;span style='color:#b4afbc; font-family:Arial'&gt;I &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;cystic &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;fibrosis &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;686Â &lt;/span&gt;&lt;span style='color:#b4afbc; font-family:Arial'&gt;â€¢Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;eczema &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1269, 1285Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;endocarditis &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;629. 630, 632Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;injecting &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;drug user &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;293Â food &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;poisoning &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;294, 325-326Â glycopeptide intermediate 313Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;HIV/ArDS &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;385Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;immunocompromised patientsÂ &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;695Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;infections &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;caused &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;by &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;312Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;meningitis 1226Â meticillin-resistant 190,313.693,Â 1295Â pncumonia &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;689, &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;690&lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;, &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;694Â hospital-acquired 693Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;skin and soft &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;tissue infectionsÂ &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;312,313&lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;, &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;314,1294Â vancomycin-resistant 313Â &lt;em&gt;Staphylococcus epidenllis 315Â &lt;/em&gt;endocarditis 629Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;urinary tract infection 467Â &lt;/span&gt;&lt;em&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;Staphylococcus &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;lugdel1sis&lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;,Â &lt;/span&gt;&lt;/em&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;endocarditis &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;629&lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;630Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;Starch, hydrolysis 854&lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;855Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;Starches, dietary 109Â resistant I 10Â Starling's Law of the Heart 191,Â 525,543Â Starvation 117&lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1 18Â StatinsÂ acute limb ischaemia &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;604Â atherosclerotic &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;disease preventionÂ &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;581Â chronic &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;renal &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;failure 489Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;diabetic dyslipidaemia &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;837Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;hepatotoxicity 973Â hyperlipidaemia 449, 450, &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;451Â older &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;people 451Â hypertension 615Â microalbuminuria in diabetesÂ &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;842Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;myocardial infarction preventionÂ &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;599Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;prescription &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;26Â stroke, secondary &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;preventionÂ 1209,1210Â StatisticsÂ normal range 6-7Â ri &lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;s&lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;k &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;9Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;Status &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;epilepticus &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1173Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;Stavudine (d4T) &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;394, &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;397, 398Â Steatohepatitis, &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;non-alcoholic &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;971,Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;972Â SteatorrhoeaÂ &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;cystic &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;fibrosis 909Â malabsorption &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;871Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;pancreatitis &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;907. 908Â small &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;bowel disorders &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;897, 898,Â 899Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;Steatosis, hepatic 971 &lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;973Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;Stellate &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;cells 938, &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;954Â hepatic fibrosis 955Â Stem &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;cell &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;factor &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;(SCF) &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1003Â Stem-cell plasticity 1003Â Stem cells 43 44Â haematopoietic 1002&lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1003Â making &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;of &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;insulin 846Â therapeutic use &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;38, &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;60. 61Â transplantation &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;73, &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1043, 1044Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;acute &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;leukaemia 1041Â myeloma 1053Â non-Hodgkin's lymphomaÂ 1051Â &lt;/span&gt;&lt;em&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;Stellotmpholllollas &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;maltopllilia &lt;/span&gt;&lt;/em&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;&lt;em&gt;686Â &lt;/em&gt;Stents/StentingÂ &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;bronchial &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;carcinoma 71 &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;IÂ &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;coronary &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;artery 533, 586-687Â pancreatic &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;cancer &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;909Â rectal &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;cancer 928Â stent &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;insertion &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;862Â Stercobilin 944&lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;, &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;946. &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1005Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;Stercobilinogen 944. 946Â Sternal angle &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;180Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;SteroidsÂ anabolic 973, &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1126Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;&lt;em&gt;see also &lt;/em&gt;CorticosteroidsÂ Stevens&lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;Johnson &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;syndromeÂ &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1308&lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1309Â Stimulant misuse &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;246Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;management &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;247Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;StingsÂ insect &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;87, &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;88Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;scorpion &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;224-225Â STls &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;&lt;em&gt;see &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;Sexually transmittedÂ infectionsÂ Stockings, &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;compression &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1064Â StomachÂ diseases 884-894Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;emptying 863. 864Â defective 878, 891Â erosions 867Â functional anatomy 852&lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;853Â outlet obstruction 889&lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;890Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;tumours/carcinoma &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;867,Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;891-894Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;after gastric &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;resection &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;889Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;u \eers 885-891Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;complications &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;889-890Â management &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;887-889Â surgery 868Â watemelon &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1135Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;&lt;em&gt;see also &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;Gastric ...Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;StonesÂ &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;bile duct &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;992. &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;994-995Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;endoscopy 862Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;pancreatitis &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;906Â gallbladder &lt;em&gt;see &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;GallstonesÂ renal &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;898Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;uric &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;acid &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1112, 1113&lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1114Â urinary tract 466, 471-473, &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;510Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;Stool &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;cultures &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;862Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;Stratum corneum &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1261Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;Strawberry &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;tongue &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;314, 315Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;Streptococcal infections 314-317Â bone and &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;joint &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;II 18Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;chemoprophylaxis &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;147Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;eczema &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1269Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;endocarditis 630, 632Â glomerulonephritis &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;503Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;rheumatic &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;fever &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;616, 617Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;treatment &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;617-618Â skin &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;1293, 1295Â urinary tract 467Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;vulvovaginal &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;409Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;StrcptococciÂ alpha-haemolytic 315Â anaerobic 315Â group &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;A &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;316, 616, 617Â group &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Arial'&gt;B &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;315Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;meningitis 1226Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;viridans, &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;bacteraemiaÂ &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;&lt;em&gt;Streptococcus bovis &lt;/em&gt;endocarditisÂ 629,630,632Â &lt;em&gt;Streptococcus &lt;/em&gt;&lt;/span&gt;&lt;em&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;milleri &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;629Â Streptococclls &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;mitis &lt;/span&gt;&lt;/em&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;315, 629Â &lt;em&gt;Streptococcus &lt;/em&gt;&lt;/span&gt;&lt;em&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;IIIl1talls &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;315Â Streptococcus &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;pllelllllolliaeÂ &lt;/span&gt;&lt;/em&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;(pneumococcus)Â antigen 655Â endocarditis &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;629Â immunisation &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;72, &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;138, &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;683Â &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;meningitis 1225. 1226. 1227Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;pneumonia 689, 690. 691, 694Â &lt;em&gt;Strepto&lt;/em&gt;&lt;/span&gt;&lt;em&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;c&lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;oc&lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;c&lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;Lis pyogelles &lt;/span&gt;&lt;/em&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;315, 316Â endocarditis 629Â pneumonia 694Â &lt;em&gt;Streptococcus saliva &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;&lt;em&gt;riLlS &lt;/em&gt;315Â &lt;/span&gt;&lt;em&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;Streptococ&lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;c&lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;us sallguis &lt;/span&gt;&lt;/em&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;134,315,628Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;&lt;em&gt;Streptococclls viridalls &lt;/em&gt;endocarditisÂ 630. &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;632Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;Streptogramins &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;144, 154Â &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;Streptokinasc, &lt;/span&gt;&lt;span style='color:#5c5967; font-family:Times New Roman'&gt;myocardialÂ infarction &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;595Â StreptomycinÂ adversc effect&lt;/span&gt;&lt;span style='color:#8a8792; font-family:Times New Roman'&gt;s &lt;/span&gt;&lt;span style='color:#716e7b; font-family:Times New Roman'&gt;702Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;Streptomycin &lt;/span&gt;&lt;em&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;(collt &lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;'&lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;d&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;)Â &lt;/span&gt;&lt;/em&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;brucellosis &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;319Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;infective &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;endocarditis 632Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;mycetoma &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;373Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;plague &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;323Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;tuberculosis &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;70 &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;IÂ HIV &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;/ &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;AIDS patients &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;391Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;tularaemia &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;325Â StressÂ acute &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;reaction &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;239Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;adjustment disorder &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;239Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;atherosclerotic &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;vascular &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;diseaseÂ &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;and 580Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;diabetes and &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;812, 817, 818Â oxidative &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;163Â post-traumatic &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;stress &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;disorderÂ 239 &lt;/span&gt;&lt;span style='color:#ad9da6; font-family:Times New Roman'&gt;â€¢Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;psychiatric disorder&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;s &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;and &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;229Â Stress (exercise) ECG 528&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;529Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;Stress incontinence &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;474, &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;475Â Stress testing 582-583Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;echocardiography 583Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;Stretch reflex 1178, 1179Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;Stria, &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;definition 1259Â Strictures, endoscopic techniquesÂ for management &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;862Â StridorÂ &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;bronchial &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;carcinoma 706&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;707Â connective &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;tissue disorders &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;722Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;laryngeal paralysis &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;730Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;tracheal &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;obstruction 731Â Stroke &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1200-1212Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;acute &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1200-120 IÂ &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;complications &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1207Â investigation &lt;em&gt;1205&lt;/em&gt;&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;&lt;em&gt;- &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;&lt;em&gt;1207Â &lt;/em&gt;management 1207&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1210Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;clinical &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;classification 1200-120 IÂ clinical assessment 1201Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;completed &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;&lt;em&gt;1201Â &lt;/em&gt;haemorrhagic 1210-1211Â treatment 1208&lt;/span&gt;&lt;span style='color:#91919b; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1209Â hypertension &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;610Â &lt;/span&gt;&lt;span style='color:#565362'&gt;&lt;span style='font-family:Times New Roman'&gt;investigations &lt;/span&gt;&lt;span style='font-family:Arial'&gt;I &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;&lt;em&gt;157Â &lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;ischaemic &lt;/span&gt;&lt;em&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1201 &lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1203&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;, &lt;/span&gt;&lt;/em&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;&lt;em&gt;1206Â &lt;/em&gt;management 1207&lt;/span&gt;&lt;span style='color:#91919b; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1208Â migraine and 1162Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;older people &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1206Â pathology 1201Â progressing &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;(in evolution)Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1200-1201Â risk in atrial fibrillation &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;564Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;risk factors 1202Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;secondary &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;prevention 1209-1210Â Stroke &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;volume &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;192, &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;525Â Stroke &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;work, &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;ventricular &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;192Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;&lt;em&gt;StrOllgyloides &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;hyperinfestationÂ &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;syndrome 361, 362Â &lt;em&gt;Strollgyloides stercoralis 361Â &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;Strongyloidiasis &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;297, &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;361-362Â Strontium, &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;osteoporosis &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1125, 1126Â Struvite &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;stones 471Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;Subacromial bursitis 1079Â Subacute &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;cutaneous &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;lupusÂ &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;erythematosus (SCLE)Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1133Â Subacute &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;sclerosing &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;panencephalitisÂ &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;(SSPE) 300, &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1189,Â 1230-1231Â Subarachnoid haemorrhage 1I61 &lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;,Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1203, 1210-1211Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;cerebrospinal &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;fluid in &lt;em&gt;1160Â &lt;/em&gt;Subclavian &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;steal 603Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;Subdural empyema 1164,Â 1231-1232Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;Subdural &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;haematomas 1211-1212Â Substance misuse &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;235&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;236,Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;246-247Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;Substance &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;P &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;857, 858, &lt;/span&gt;&lt;span style='color:#565362'&gt;&lt;span style='font-family:Arial'&gt;I &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;150Â Sucralfate 197&lt;/span&gt;&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;198, &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;889Â Sudden &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;death 581Â athletes &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;642Â cardiac causes 555Â epilepsy and &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;I 173Â hypertrophic &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;cardiomyopathyÂ 642,643Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;Sugar intolerances &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;902Â Sugar &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;tests &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;863Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;Sugars, dietary 109Â recom mended intake I I IÂ Suicide &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;234Â attempted 234Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;poisoning &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;205Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;depression and &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;232, 242Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;risk/risk factors &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;206, 232Â schizophrenia &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;and &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;244Â SulfadiazineÂ &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;rheumatic fever &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;618Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;toxoplasmosis &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;358Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;HIV-related &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;393Â Sulfadoxine 346Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;SulfasalazineÂ &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;ankylosing spondylitis &lt;/span&gt;&lt;span style='color:#565362'&gt;&lt;span style='font-family:Arial'&gt;I &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;108Â haemolysis from 1034Â inflammatory bowel disease &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;917Â psoriatic arthritis &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1110Â pyoderma &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;gangrenosum &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1309Â rheumatic disease &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;1093Â &lt;/span&gt;&lt;span style='color:#565362'&gt;&lt;span style='font-family:Times New Roman'&gt;rheumatoid arthritis &lt;/span&gt;&lt;span style='font-family:Arial'&gt;I &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;105Â &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;side&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;-&lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;effects &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1093Â SulfinpyrazoneÂ &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;gout &lt;/span&gt;&lt;span style='color:#565362'&gt;&lt;span style='font-family:Arial'&gt;I &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;115Â platelet inhibition 1056Â Sulindac &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;925Â Sulphonamides &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;144, &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;153Â contraindications 22Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;Sulphonylureas 832-833Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;effect of &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;hepatic &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;impairment 27Â effect of &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;renal insufficiency &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;27Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;hypoglycaemia &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;and 790, 791,Â 823, 824Â overdose 21 &lt;/span&gt;&lt;span style='color:#565362; font-family:Arial'&gt;IÂ &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;Sulpiride 243&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;, &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1222Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;Sumatriptan &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1163Â SUNCT 1163Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;SunlightÂ sensitivity &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;to 1271 &lt;/span&gt;&lt;span style='color:#91919b; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1273Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;skin cancer and &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1303, &lt;em&gt;1305Â &lt;/em&gt;Sunscreens 1272, 1273Â pigmentation diseases 1280Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;porphyria 453Â role &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;in &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;skin cancer 1303Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;Superior &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;vena cava 522, 523Â obstruction 712Â cancer &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;patients &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;261Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;Superior &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;vena cava syndrome&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;,Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;bronchial &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;carcinoma 707,Â 710Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;Superwarfarins &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;220Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;Supranuclear palsy, progressiveÂ &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;1189,1222Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;Supraventricular tachycardiaÂ 564-565Â Suramin &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;355Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;Surfactant &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;651, 652Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;SurgeryÂ bariatric 116&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;, &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;&lt;em&gt;117Â &lt;/em&gt;bone metastases I 143Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;cardiac &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;risk &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;60 &lt;/span&gt;&lt;span style='color:#565362; font-family:Arial'&gt;IÂ &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;cerebral &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;tumours 1237Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;cholecystitis 994Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;dermatological 1313&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;/314Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;skin cancer &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1304&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;, &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;1305&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;, &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1306,Â 1314Â diabetes &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;and 827&lt;/span&gt;&lt;span style='color:#91919b; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;828Â endocrine &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;diseaseÂ &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;Cushing's syndrome/diseaseÂ 782Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;hyperparathyroidism &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;776Â gastrointestinalÂ &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;achalasia &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;882Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;acute abdomen &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;874-875Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;anaemia and 1025&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;, &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1028Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;colorectal cancer 927&lt;/span&gt;&lt;span style='color:#91919b; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;928Â gastric cancer 893Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;inflammatory bowel diseaseÂ &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;919,920Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;peptic ulcer 888&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;889Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;upper acute haemorrhage &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;868Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;haemophiliacs &lt;em&gt;1060Â &lt;/em&gt;musculoskeletal disordersÂ 1095&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;/096Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;osteoarthritis &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1100&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;, &lt;/span&gt;&lt;span style='color:#565362'&gt;&lt;span style='font-family:Arial'&gt;I &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;101Â rheumatoid arthritis 1105Â &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;obesity &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;116, &lt;em&gt;117Â &lt;/em&gt;pancreatitic disease &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;908, 909, 910Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;Parkinson's disease &lt;em&gt;122/Â &lt;/em&gt;pituitary tumours &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;799, 800, 802Â &lt;/span&gt;&lt;span style='color:#565362'&gt;&lt;span style='font-family:Times New Roman'&gt;prostatic disease 5 I &lt;/span&gt;&lt;span style='font-family:Arial'&gt;I&lt;/span&gt;&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Arial'&gt;, &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;512Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;respiratory diseaseÂ bronchial &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;carcinoma 709&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;710Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;bronchiectasis 685Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;chronic obstructive &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;pulmonaryÂ disease &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;681, 682-683Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;tuberculosis &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;70 &lt;/span&gt;&lt;span style='color:#565362; font-family:Arial'&gt;IÂ &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;solid &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;tumours &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;269&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;, &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;270-271Â spinal &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;disorders 1242, &lt;em&gt;1245, 1246Â &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;stone &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;disease &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;472, 473Â &lt;/span&gt;&lt;span style='color:#565362'&gt;&lt;span style='font-family:Times New Roman'&gt;trigeminal neuralgia &lt;/span&gt;&lt;span style='font-family:Arial'&gt;I &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;164Â urinary tract tumours &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;513&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;, &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;514Â Surviving Sepsis &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;Campaign 200Â Swabs, &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;bacterial/viral 1264, 1286Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;Swallowing 852, &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1192Â difficulty in &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;&lt;em&gt;see &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;DysphagiaÂ &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;Swan &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;neck defonnity &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;of &lt;/span&gt;&lt;span style='color:#565362'&gt;&lt;span style='font-family:Times New Roman'&gt;fingersÂ I 102, &lt;/span&gt;&lt;span style='font-family:Arial'&gt;I &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;103Â &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;Sweat glands &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1262&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;1263Â Sweating &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;102, 136Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;excessive 285Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;diabetic neuropathy &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;845Â Sweeteners, &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;diabetic diet &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;831Â Sydcnham&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;'&lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;s chorea (St &lt;/span&gt;&lt;span style='color:#565362'&gt;&lt;span style='font-family:Times New Roman'&gt;Vitus dance)Â &lt;/span&gt;&lt;span style='font-family:Arial'&gt;617Â &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;Sylvan &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;fissure lesions 1191Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;Sympathetic &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;nervous &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;system &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1153Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;sodium &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;transport regulation &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;424Â Synacthen &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;test &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;(ACTH stimulationÂ &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;test) &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;783-784, 785Â Synchronised &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;intermittentÂ mandatory ventilationÂ &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;(SIMV) &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;193, 194, 196Â Syncope I 165, 1167Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;aortic stenosis &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;624Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;cardiac &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;551-554Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;congenital &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;heart disease 634Â di rferential diagnosis &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;551 &lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;554Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;gastrointestinal &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;haemorrhageÂ &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;866Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;heat 102Â investigations &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;553Â older &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;people 166Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;vasovagal 552, &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;553&lt;/span&gt;&lt;span style='color:#91919b; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;554Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;Syndesmophytes &lt;/span&gt;&lt;span style='color:#565362'&gt;&lt;span style='font-family:Times New Roman'&gt;1072, 1106, 1107,Â 1108, &lt;/span&gt;&lt;span style='font-family:Arial'&gt;I &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;109, III &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;0Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;Syndrome &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;of &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;inappropriateÂ &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;secretion of &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;ADH &lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;(&lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;SIADH)Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;430, 431, 793Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;bronchial &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;carcinoma &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;707Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;Syndrome &lt;/span&gt;&lt;span style='color:#565362; font-family:Arial'&gt;X &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;&lt;em&gt;see &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;Insulin resistanceÂ &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;syndromeÂ Synovectomy &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1095&lt;/span&gt;&lt;span style='color:#91919b; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1096Â medical &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;(radiation) &lt;/span&gt;&lt;span style='color:#565362'&gt;&lt;span style='font-family:Times New Roman'&gt;1095Â rheumatoid arthritis &lt;/span&gt;&lt;span style='font-family:Arial'&gt;I &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;105Â Synovial fluid 1071Â &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;acute &lt;/span&gt;&lt;span style='color:#565362'&gt;&lt;span style='font-family:Times New Roman'&gt;pseudogout &lt;/span&gt;&lt;span style='font-family:Arial'&gt;I I &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;16Â &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;analysis &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1071 &lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1072Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;gout &lt;/span&gt;&lt;span style='color:#565362'&gt;&lt;span style='font-family:Arial'&gt;I I &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;14Â &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;septic &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;arthritis 1118Â Synovial joints 1070-1071Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;osteoarthritis &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1096-1100Â Synovial membrane 1071Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;Synoviocytes &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1071Â Synovitis 1077Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;acute (pseudogout) &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1076, 1077,Â 1099&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;, &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1I15-1Jl6Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;crystal &lt;/span&gt;&lt;span style='color:#565362'&gt;&lt;span style='font-family:Times New Roman'&gt;1076, 1077Â rheumatoid arthritis &lt;/span&gt;&lt;span style='font-family:Arial'&gt;I &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;101 &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#91919b; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1102Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;seronegative &lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;s&lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;pondarthritis 1106Â signs and symptoms &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1067Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;Synovium &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1069Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;osteoarthritis &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1098Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;Syphilis 406, 408&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;, &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;411-413Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;acquired 41 &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;&lt;em&gt;1-412Â &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;cardiovascular &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;412&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;, &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;413Â classification 411Â congenital 412, &lt;/span&gt;&lt;span style='color:#565362'&gt;&lt;span style='font-family:Times New Roman'&gt;413Â dementia &lt;/span&gt;&lt;span style='font-family:Arial'&gt;I &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;189Â &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;endemic (non-venereal) &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;413Â HIV/AIDS &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;385,386Â investigations &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;412-413Â management &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;413Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;neurosyphilis 1233-1234Â in pregnancy 412, 413Â quaternary &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;412Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;treatment &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;386Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;Syringomyelia 1245Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;Systemic &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;inflammatory responseÂ &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;syndrome &lt;em&gt;see &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;SIRSÂ &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;Systemic &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;lupus &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;erythematosusÂ (SLE) &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1132-1134Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;autoantibodies 81-82, &lt;/span&gt;&lt;span style='color:#565362'&gt;&lt;span style='font-family:Times New Roman'&gt;1075Â management &lt;/span&gt;&lt;span style='font-family:Arial'&gt;I &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;134Â renal involvement 515Â respiratory &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;complications 665,Â 722,723Â sibling &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;risk &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;58Â Systemic sclerosis (scleroderma&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;)Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;82, &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1078, 1134-1136Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;diffuse 82Â oesophagi &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;tis &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;882Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;renal involvement &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;498-499Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;respiratory &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;complications 722Â small &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;bowel disease &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;897Â &lt;/span&gt;&lt;span style='color:#566683; font-family:Times New Roman'&gt;TÂ &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;T&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;3 &lt;/span&gt;&lt;em&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;s&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;e&lt;/span&gt;&lt;/em&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;&lt;em&gt;e &lt;/em&gt;TriiodothyronineÂ &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;T4 &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;&lt;em&gt;see &lt;/em&gt;ThyroxineÂ T20 (enruvirtide) 397, 399Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;T lymphocytes &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;(T cells) 68, 69, &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;70,Â 1004, 1007Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;asthma 672Â cytotoxic (CD8+) 70, 383Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;deficiencies &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;71, &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;72-73Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;gastrointestinal &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;tract &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;856Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;helper &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;(CD4+) 70Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;HIV infection/AIDS &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;383Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;inflammatory bowel di &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;911Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;leukaemias &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;48, &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1046Â Tachyarrhythmias &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;560Â atrial &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;561-564, 569Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;ventricular &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;560, 566-569Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;Tachycardia 560Â antidromic 565Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;atrial &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;562Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;AV nodal re-entry 564-565Â Wolff&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;Parkinson&lt;/span&gt;&lt;span style='color:#857f8d; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;WhiteÂ &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;syndrome &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;565-566Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;orthrodromic &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;565Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;sinus &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;561Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;supraventricular &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;564-565Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;ventricular &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;567-568Â TacrolimusÂ &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;eczema &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1287Â liver transplant patient; &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;990Â &lt;/span&gt;&lt;span style='color:#565362'&gt;&lt;span style='font-family:Times New Roman'&gt;myositis &lt;/span&gt;&lt;span style='font-family:Arial'&gt;I &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;137Â nephrotoxicity &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;517Â &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;renal &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;transplantation patients 495Â systemic &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;lupus &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;erythematosusÂ &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1134Â Tactoids 1036Â &lt;/span&gt;&lt;em&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;Taenia echinococclII &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;371-372Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;Taenia saginaw &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;370Â &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;ulenia so/ill'" &lt;/span&gt;&lt;/em&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;&lt;em&gt;370-371Â &lt;/em&gt;Takayasu'\ &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;arteritis 497, &lt;/span&gt;&lt;span style='color:#565362; font-family:Times New Roman'&gt;1140Â Tamoxifen &lt;/span&gt;&lt;span style='color:#6a6776; font-family:Times New Roman'&gt;169Â familial adenornatous polyposisÂ 925Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Tamoxifen &lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;&lt;em&gt;(cont'd)Â &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;hepatotoxicity 973Â TamponadeÂ balloon, variceal bleeding 960Â cardiac/pericardial 526, 540, 542,Â 598,645Â &lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;ca&lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;ncer patient&lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;s &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;261Â Tangier disease 448Â Tanui disease 443Â Tapeworms &lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;(cestodes) 360, &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;370-372Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Tar preparations, psoriasis 1291Â Target cells &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;10 &lt;/span&gt;&lt;span style='color:#656371'&gt;&lt;span style='font-family:Arial'&gt;IOÂ &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;Tarsal coalition 1082Â Tarsal tunnel &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;syndrome &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;1104Â Taxanes 266, 269Â Tay&lt;/span&gt;&lt;span style='color:#96909c; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Sachs disease 40, 56, 444Â Tazobactam, neutropenic &lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;sepsis 293Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;TBG &lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;(thyrox&lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;ine-binding &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;globulin)Â 744Â TBNA (trans &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;bronchial &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;needleÂ aspiration) 655Â 3TC &lt;em&gt;see &lt;/em&gt;LamivudineÂ TCAs &lt;em&gt;see &lt;/em&gt;Tricyclic antidepressantsÂ Teardrop poikilocytes &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1055Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Teichopsia &lt;/span&gt;&lt;span style='color:#52505e'&gt;&lt;span style='font-family:Arial'&gt;I &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;195Â &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Teicoplanin &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;152Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;TelangiectasiaÂ definition &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1259Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;hereditary &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;haemorrhagicÂ 1055-1056Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;spider, liver disease 936, 955Â Teletherapy 263Â Telithromycin &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;150Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Temperature, peripheraVskin,Â circulation monitoring 182Â Temperature, body 99-100Â heat illness 102, 103Â hypothermia 100, 101Â thermoregulation 136-138Â Temporal artery biopsy, pyrexia &lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;ofÂ &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;unknown &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;origin 288Â Temporal &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;lobes &lt;/span&gt;&lt;span style='color:#656371; font-family:Arial'&gt;I &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;151Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;functions &lt;/span&gt;&lt;span style='color:#52505e'&gt;&lt;span style='font-family:Arial'&gt;I &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;151, 1152, &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#656371'&gt;&lt;span style='font-family:Times New Roman'&gt;1190Â effects of damage &lt;/span&gt;&lt;span style='font-family:Arial'&gt;I &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;152, 1190,Â &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1191Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Tendon reflexes, root values 1147Â TendonitisÂ hip &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1081Â &lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;shou&lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;lder 1079&lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;, &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;1080Â Tendons 1071Â repair &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1096Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;transfer 1096Â xanthomas 520Â Tenecteplase &lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;(TNK) &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;595, 597Â Tennis elbow 1080Â Tenofovir 389, 397, 398, 399Â hepatitis B 966Â Tenosynovectomy &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1095Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Tenosynovitis &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1078, &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;1080Â flexor (trigger finger) 807, 1080Â psoriatic anhritis 1109Â TENS &lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;(tra&lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;nscutaneou&lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;s &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;electricalÂ &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;nerve &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;stimulation)Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;pain management &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;278Â post-herpetic &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;neuralgia &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;306Â Tensilon test &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1253Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Teratomas 771Â chemotherapy 262Â Terazosin 512Â Terbinafine 154, 156, 373Â chromomycosis 373Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;ringworm 1297Â tinea &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;capitis 1278Â Terbutaline 677Â Teriparatide &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1125&lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;, &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;1126Â Terlipressin 949, 960Â Terminal &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;illness &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;&lt;em&gt;see &lt;/em&gt;Palliative careÂ &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;Terodiline &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;512Â Terrorism &lt;em&gt;see &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;Bioterrori&lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;smÂ &lt;/span&gt;&lt;span style='color:#52505e; font-family:Arial'&gt;&lt;em&gt;1, &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Testicular ablation 267Â Testicular &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;tumours 771Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;chemotherapy 262Â Testis 762Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;unde&lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;scended &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;765Â Testosterone 762, 763Â deficiency, osteoporosis &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1122Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;reference values in venous bloodÂ 1319Â Testosterone therapy 765, 767, 769Â osteoporosis I &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;125Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Tests &lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;&lt;em&gt;see &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;InvestigationsÂ Tetanus 141,1232-1233Â chemoprophylaxis 147Â prevention/immunisation 137,Â 138, 139, 1233Â wound 316Â Tetany &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;775Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Tetrabenazine &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1222Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Telracosactide test &lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;(ACTHÂ &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;stimulation test) 783&lt;/span&gt;&lt;span style='color:#96909c; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;784,Â 785Â Tetracycline(s) &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;144&lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;,1&lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;53Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;adverse reactions &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;153Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;arthritis, reactive &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1109Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;cholera 330Â contraindications 22Â older &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;people &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;28Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;renal &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;insufficiency 27, 28Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;drug &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;interactions 23, 31Â &lt;/span&gt;&lt;em&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;H&lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;e&lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;li&lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;cobacter &lt;/span&gt;&lt;/em&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;&lt;em&gt;pylori &lt;/em&gt;eradicationÂ 887Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;hepatotoxicity &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;973Â plague 323Â prescription 26Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;relap&lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;si&lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;ng &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;fever 320, 321Â rickellsial fevers 340Â &lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;s&lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;mall &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;bowel bacterial overgrowthÂ 897Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;timing &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;of administration 25Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;trachoma &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;341Â tropical sprue 896Â Whipple's disease &lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;898Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Tetralogy of Fallot 634, &lt;/span&gt;&lt;span style='color:#52505e'&gt;&lt;span style='font-family:MS PGothic'&gt;639~0&lt;/span&gt;&lt;span style='font-family:Arial'&gt;Â &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;acyanotic 640Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;incidence &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;634Â Tetraparesis 1179-1 &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1&lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;80Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Tetraploidy 47Â TF &lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;(t&lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;issue &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;factor) 1008Â TFPI &lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;(t&lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;i&lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;ss&lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;ue &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;factor pathwayÂ inhibitor) 1008Â Tg &lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;(&lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;thyroglobulin) &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;&lt;em&gt;see &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;ThyroglobinÂ &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;TG &lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;(&lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;triglyceride) &lt;/span&gt;&lt;span style='color:#656371'&gt;&lt;span style='font-family:Times New Roman'&gt;&lt;em&gt;see &lt;/em&gt;TriglycerideÂ &lt;/span&gt;&lt;span style='font-family:MS PGothic'&gt;TGF-~ &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;49Â Thalamotomy, stereotactic &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1221Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Thalamus &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;I 151Â lesions &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;1184, &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1185Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Thalassaemias &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1005, &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;1023, &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1035&lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;,Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1036,1038Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;inheritance 52Â Thalidomide 22Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;Beh"et&lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;'s &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;syndrome 1142Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;leprosy reactions &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;338Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;myeloma &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;1053Â Thallium poisoning 331Â TbeophyllineÂ asthma 676Â chronic obstructive pulmonaryÂ disease 681, 682Â effect of hepatic impairment 27Â formulations 24Â plasma c(Â¥1centrations 34Â poisoning 212Â Therapeutic &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;Intervention &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;ScoringÂ System &lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;(T&lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;ISS&lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;) &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;201Â Therapeutic privilege IIÂ Thermodilution, cardiac outputÂ measurement 181Â Thermoregulation &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;100, 136&lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;138Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;older people 100Â Thermotherapy, benign prostaticÂ &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;hyperplasia &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;51 IÂ Thiacetazone 391Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;Thiamin &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;(vitamin B,) &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;121 &lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;,Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;123-124Â &lt;/span&gt;&lt;span style='color:#b3a8af; font-family:Arial'&gt;â€¢Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;deficiency 121, &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;123&lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;124&lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;, &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;245,Â 246,1189,1196,1218Â dietary sources &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;121, 123Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;therapy &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1188,1218Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Thiamin pyrophosphate &lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;(TPP) &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;123Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Thiazides 427, 428Â diabetes &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;insipidUS &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;797Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;heart &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;failure 548Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;hypenen&lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;sion &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;613, 614, 615Â oedema 481Â stone disease/hypercalciuria 472Â Thiazolidinediones 832, &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;833&lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;, &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;846Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;non-alcoholic &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;fatty liver diseaseÂ 973Â polycystic ovarian syndrome 770Â Thienobenzodiazepine 238, 243Â Thioacetazone 702Â Thiopurines, inflammatory &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;bowelÂ &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;disease 917, 918, 919Â Thioxanthenes 238, 243Â Thirst 428Â diabetes &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;insipidus &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;431, 797Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;Thom&lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;sen's &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;disease &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1256Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Thoracic &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;duct &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;obstruction, &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;pleuralÂ &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;effusion 665Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;Thoracic &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;"J'phoscoliosis &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;736-737Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Thoracic outlet syndrome 125 &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;IÂ Thorax, &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;examination, &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;respiratoryÂ &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;disease 648, 649Â Thought, &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;passivity &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;of 242Â Thought content, assessment 230Â Threadworm &lt;/span&gt;&lt;em&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;(E&lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;nt&lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;e&lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;robiusÂ &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;vermicularis) &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;362-363Â &lt;/span&gt;&lt;/em&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Threonine &lt;/span&gt;&lt;span style='color:#52505e'&gt;&lt;span style='font-family:Arial'&gt;I &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;10Â ThroatÂ &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;common &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;infecting &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;organisms 133Â &lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;so&lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;re &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;689Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;role &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;of antibiotics &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;137Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Thrombasthenia &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1056Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Thrombin &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1008Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Thromboangiitis obliterans 603Â Thrombocythemia, &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;primary 1054,Â 1055Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Thrombocytopenia &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1011,1017,Â 1056Â heparin-induced &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;(HIT) &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1063Â hepatobi I iary disease &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;940Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;HJV infection/AIDS &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;395Â older people &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1061Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;rheumatic disease 1075Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;Thrombocytopenic purpuraÂ &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;idiopathic &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1056-1057Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;thrombotic &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;498, &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;1057Â Thrombocytosis &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1017Â hepatobiliary &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;disease 941Â ThromboembolismÂ atrial fibrillation 564Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;hean &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;failure 546Â older &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;people &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;728Â pulmonary 660, 661, &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;724-728Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;&lt;em&gt;for detailed entry seeÂ &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;Pulmonary &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;embolism!Â thromboembolismÂ venous &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1061-1064Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;management &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1062&lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1064Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;prevention 1064Â Thromboendarterectomy 729Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;Thrombolysis, &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;small &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;bowelÂ ischaemia &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;922Â Thrombolytic &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;therapyÂ myocardial infarction 595-596Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;pulmonary embolism 728Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;relative &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;contra &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;indications &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;596Â &lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;s&lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;troke &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;1207, &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1208Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Thrombophilia, investigationÂ 1011-1012Â Thrombophlebitis &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;migrans &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;909Â Thrombopoietin (Tpo) &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1003&lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;, &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;1004Â ThrombosisÂ acute &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;limb &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;ischaemia 604Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;investigation 1011-10 12Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;older &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;people 1061Â &lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;venous &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;1012, &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1018, 1061&lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1064Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;cerebral 1211Â hepatic 982Â management 1062-1064Â ponal982Â predisposing factors &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1061Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;prevention 1064Â Thrombotic microangiography &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;498Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Thrombotic thrombocytopenicÂ purpura &lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;(TIP) &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;498&lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;, &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;1057Â ThromboxanesÂ allergy 84Â thromboxane A &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1007Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Thrush 373Â oral &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;877Â Thumb&lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;, &lt;/span&gt;&lt;span style='color:#656371'&gt;&lt;span style='font-family:Arial'&gt;Z &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;deformity &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1102Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Thumb-base osteoarthritis &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1098&lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;,Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;1100Â Thymectomy, myasthenia gravisÂ &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1253Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Thymine 38Â Thymus 68Â transplantation 73Â Thyroglobulin (Tg) 745Â Thyroglobulin antibodies 749Â Thyroid disease 744Â autoimmune 751, 754-757Â classification 744Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;clinical &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;features 748Â congenital 762Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;inve&lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;stiga&lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;tions &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;744 745Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;iodine-induced &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;758Â malignant 744, 753-754,Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;760-762Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;pruritus in 1268Â Thyroid function &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;test &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;745, 746, 753Â asymptomatic abnormal &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;resultsÂ &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;752-753Â hypothyroidism 750Â pregnancy 756Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;thyrotoxicosis &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;747Â and &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;thyroxine therapy &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;751-752Â transient &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;thyroiditis &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;758Â Thyroid glandÂ enlargement 753-754Â &lt;em&gt;see also &lt;/em&gt;GoitreÂ examination 741Â functional anatomy andÂ physiology 744 745Â in old age 762Â Thyroid &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;hormones &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;744-745, 746,Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;762Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;dyshormonogenesis 762Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;hypothyroidism &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;managementÂ 75(}-752Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;in pregnancy &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;756Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;reference &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;values in venous bloodÂ 1319Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;replacementÂ hypopituitarism &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;796Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;neonates &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;762Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;resistance &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;744, 746, &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;762Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Thyroid &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;nodule, &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;solitary &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;753--754Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Thyroid &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;peroxidase &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;antibodies 749,Â 750,751Â Thyroid-stimulating &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;hormone &lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;(TSH;Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;thyrotrophin) 743, 744 745Â deficiency 793Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;hypopituitarism &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;795Â Graves' disease 755Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;levels &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;of 744,745Â &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;hypothyroidism &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;750Â thyrotoxicosis 747Â reference values in venous bloodÂ &lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;1319Â &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;Thyroid-stimulating hormone&lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;receptorÂ &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;antibodies (TRAb)Â 749, 754, 755Â maternal, pregnancy 756Â Thyroid-stimulatingÂ immunoglobulins 754, 755Â Thyroid &lt;/span&gt;&lt;span style='color:#7a7886; font-family:Times New Roman'&gt;s&lt;/span&gt;&lt;span style='color:#52505e; font-family:Times New Roman'&gt;torm &lt;/span&gt;&lt;span style='color:#656371; font-family:Times New Roman'&gt;749-750Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;ThyroidectomyÂ hypoparathyroidism and 774Â partiaVsubtotalÂ &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;goitre 759, &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;760Â Graves' disease &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;755, 774Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;pregnancy &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;756Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;thyroid &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;cancer 760Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;ThyroiditisÂ Hashimoto's 744, 757Â post-partum 758Â Reidel's 761Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;subacute (de &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Quervain's) &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;744,Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;757-758Â transient 746,747,757&lt;/span&gt;&lt;span style='color:#8c8e92; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;758Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Thyrotoxic &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;crisis &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;749-750Â Thyrotoxicosis 746-750Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;amiodarone and 758-759Â atrial &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;fibrillation &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;749Â causes 746Â clinical &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;features &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;746-747, 748Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;differential diagnosis &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;747Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;factitious &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;747, 749Â goitre &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;759Â Graves' disease 746-747,Â 754-756, &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;756Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;management 754-756Â investigations &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;745, &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;747&lt;/span&gt;&lt;span style='color:#8c8e92; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;748, 749Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;iodine-associated 755, &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;758&lt;/span&gt;&lt;span style='color:#8c8e92; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;759Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;low-uptake &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;747Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;management &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;749-750Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;musculoskeletal manifestationsÂ 1143Â neonatal &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;756Â older &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;people &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;762Â pregnancy 750, 756Â subclinical 746, 749, 752, 760Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Tr &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;746Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;toxic &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;adenoma 760Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Thyrotrophin &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;&lt;em&gt;see &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Thyroid&lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;stimulatingÂ &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;hormoneÂ Thyrotrophin-releasing honnoneÂ &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;(TRH) &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;743, &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;745Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Thyroxine &lt;/span&gt;&lt;span style='color:#6e6c77'&gt;&lt;span style='font-family:Arial'&gt;&lt;em&gt;(T4) &lt;/em&gt;&lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;743, &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;744, &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;745Â Graves' &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;disease &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;755Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;hypothyroidism managementÂ &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;750-752, 796Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Hashimoto's thyroiditis &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;757Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;ischaemic heart diseaseÂ patients &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;752Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;pregnancy &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;752Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;levels &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;of 744, 745Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;hypothyroidism &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;750Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;thyrotoxicosis 747Â poisoning 212Â reference &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;values &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;in &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;venous &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;bloodÂ 1319Â thyroid &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;cancer &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;treatment &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;760-761Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;u &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;e &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;in &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;older &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;people 762Â Thyroxine-binding &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;globulin (TBG)Â 744Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Tiabendazole &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;298Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Tiagabine 1172, I 175Â TIAs &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;(transient &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;ischaemic attacks)Â 1200, 1201,1202, 1210Â TlBC &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;(total &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;iron binding &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;capacity)Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;1026, 1030Â Tibial &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;compartment syndrome,Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;anterior 1082Â Ti bolone 1126Â Ticarcillin 147,148Â Tick-borne diseasesÂ babesiosis &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;348Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Lyme disease &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;319-320Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;relapsing fever &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;321Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;rickettsiaVtyphus &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;338-340Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;tularaemia &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;325Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;viral haemorrhagic feversÂ &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;310-311Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Tics 1183Â Tietze's syndrome 536Â Tigecycline 153Â Tilt testing, head-up 553Â Tiludronate 1033, 1130Â Tinea &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;capitis &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;1278Â Tinea &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;corporis &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;1297Â rash 1269Â Tinea cruris 1297Â Tinea incognito 1297Â Tinea pedis 1297Â Tingling I 183Â Tinidazole 153-154,358,359,360Â Tipranavir &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;397, &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;399Â TlPSS &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;(transjugular &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;intrahepaticÂ portasystemic &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;shunts) 949,Â 960,961,962,983Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;TlSS &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;(Therapeutic &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;InterventionÂ Scoring System) &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;20 &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;IÂ Tissue factor &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;(TF) &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;1008Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;Tissue &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;factor pathway inhibitorÂ &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;(TFPl) &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;1008Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;Tissue &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;plasminogen activator &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;(tPA)Â 595, &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;1008-1009Â recombinant, &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;stroke &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;1207, 1208Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;Tissue &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;transglutaminase &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;&lt;em&gt;(TTG) 894,Â &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;895Â Titubation I 181Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;Tizanidine &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;1216Â TLC &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;(total &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;lung &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;capacity) &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;656, &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;657Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;TLco &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;(gas &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;transfer factor for carbonÂ monoxide) 656, 657Â TMC-114399Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;TMC-125399Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;T F &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;&lt;em&gt;see &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Thmour necrosis factorÂ TNK &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;(tenecteplase) &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;595, 597Â TNM classification &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;of &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;tumours &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;259Â Tobramycin &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;151, 686Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;0.-&lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Tocopherol 123Â Todd's palsy 1169Â Toe nails, ingrowing 1283Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;Toes, cock-up &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;deformities 1102Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;Togaviruses 299Â Tolbutamide 832Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Tolterodine 1199, 1200Â Tongue, &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;strawberry 314, 315Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;TonsillitisÂ &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;acute 687Â streptococcal &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;284Â Tonsils &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;69Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Tophi, &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;gout &lt;/span&gt;&lt;span style='color:#5b5863'&gt;&lt;span style='font-family:Times New Roman'&gt;1073, 1113, &lt;/span&gt;&lt;span style='font-family:Arial'&gt;I &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;I 14Â Topiramate I 172, 1175Â Topoisomerase antagonists &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;266Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Torres bodies &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;309Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Torsades de pointes 568-569Â Torticollis, &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;spasmodic &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;1182Â Total body water &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;421Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Total iron binding capacity &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;(TlBC)Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;1026, 1030Â Total lung &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;capacity (TLC) 656, 657Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Total parenteral nutrition &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;(TPN)Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;197Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;short &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;bowel &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;syndrome &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;899Â Toxaemia, pregnancy &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;988Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Toxic megacolon 913Â Toxic &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;shock syndrome (TSS)Â staphylococca1314Â streptococcal 314-315Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;ToxinsÂ &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;chemical 331Â elimination 207, 208Â food &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;poisoning 331Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;fungal 505, &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;517Â marine &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;sources 225Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;plant &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;331, &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;505, 517Â renal &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;effects &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;517Â interstitial nephritis 505Â routes &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;of exposure 207Â substance of &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;low toxicity &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;208Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Toxocariasis &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;297Â &lt;/span&gt;&lt;em&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Toxoplasma &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;gondii 356Â &lt;/span&gt;&lt;/em&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;mV-related &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;392Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;life &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;cycle 357Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;ToxoplasmosisÂ acquired 356-358Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;cerebral, &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;HIV-related &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;392, &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;393Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;congenital 358Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;HIV-related, prevention 401Â pregnancy &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;357, 358Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;tPA &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;&lt;em&gt;see &lt;/em&gt;Tissue plasminogenÂ activatorÂ &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;TPN &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;(total &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;parenteral nutrition)Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;197, 899Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Tpo &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;(thrombopoietin) &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;1003, 1004Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;TPP (thiamin &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;pyrophosphate) 123Â TRAb &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;(TSH-receptor &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;antibodies)Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;749, 754, &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;755Â maternal, pregnancy &lt;/span&gt;&lt;span style='color:#6e6c77'&gt;&lt;span style='font-family:MS PGothic'&gt;7~6&lt;/span&gt;&lt;span style='font-family:Arial'&gt;Â &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Trace &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;elements, &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;absorption &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;856Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Trachea, &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;obstruction 731Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Trachcal intubation &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;&lt;em&gt;seeÂ &lt;/em&gt;Endotracheal &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;intubationÂ Tracheitis 688Â Tracheo-oesophageal fistulaÂ &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;731 &lt;/span&gt;&lt;span style='color:#8c8e92; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;732Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Tracheostomy 196, 731Â Trachoma 341Â Tramadol 1092Â Tranexamic acid 1060Â Transaminases &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;&lt;em&gt;seeÂ &lt;/em&gt;AminotransferasesÂ &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Transbronchial needle &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;aspirationÂ (TBNA) 655Â &lt;/span&gt;&lt;span style='color:#5b5863'&gt;&lt;span style='font-family:Times New Roman'&gt;Transcobalamin &lt;/span&gt;&lt;span style='font-family:Arial'&gt;IT &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;1028Â Transcription, DNA &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;38-39Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Transcription factors &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;39-40Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;transcription &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;factor-2 815Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Transcutaneous nerve &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;stimulationÂ &lt;em&gt;see &lt;/em&gt;TENSÂ &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Transfer &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;coefficient &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;for &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;carbonÂ &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;monoxide &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;(K&lt;/span&gt;&lt;span style='color:#8c8e92; font-family:Times New Roman'&gt;e&lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;o) 656, 657Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Transference &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;239Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Transferrin 1026, 1030, 1322Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;older people 1030Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Transforming &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;growth factorÂ (TGF)-P &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;49Â Transient ischaemic &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;attacks (TIAs)Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;1200,1201,1202,1210Â Transjugular intrahepaticÂ portasystemic &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;shuntsÂ (TIPSS) 949, 960, &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;961, &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;962,Â 983Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Translocations, &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;chromosomesÂ &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;47-48Â Robertsonian 48Â Transmissible &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;spongiformÂ encephalopathies (TSEs)Â 341, &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;1234Â TransplantationÂ bone marrow &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;&lt;em&gt;see &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Bone marrowÂ transplantationÂ &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;graft &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;rejection 89-90Â heart &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;91, &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;550-551, &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;642Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;heart-lung &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;91, 550, 639, &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;670,Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;729,909, &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;1136Â islet &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;cells 845Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;kidney &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;&lt;em&gt;see &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;J&amp;lt;jdneys,Â transplantationÂ liver &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;&lt;em&gt;see &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Liver, transplantationÂ living donors &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;91, 990Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;lung 670, &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;683, 718Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;organ donation &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;200Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;pancreas &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;91, 843, 846Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;pre-transplant investigations &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;90Â small &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;bowel &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;899, 923Â statistics 89Â stem cell &lt;em&gt;see &lt;/em&gt;Stem cells,Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;transplantationÂ thymus 73Â Transrectal ultrasound &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;scan (TRUS)Â of &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;prostate 510Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;Transurethral &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;resection &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;of &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;prostateÂ &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;(TURP) 511Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Tranylcypromine &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;241Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;TRAPS &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;(TNF-associated &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;periodicÂ &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;syndrome) &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;79Â Trastuzumab &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;268, 269Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Trauma, &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;psychiatric &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;disorders &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;229Â &lt;/span&gt;&lt;span style='color:#354352; font-family:Arial'&gt;IN D E XÂ &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;TravellersÂ &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;eosinophilia 296-297Â fever &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;in &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;286, 288-290Â immunisations 139Â skin &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;disorders &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;298&lt;/span&gt;&lt;span style='color:#8c8e92; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;299Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;splenomegaly 296Â Traveller's &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;diarrhoca &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;328Â Treadmill &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;testing 528&lt;/span&gt;&lt;span style='color:#8c8e92; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;529, &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;582Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Trematodes &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;&lt;em&gt;see &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;FlukesÂ &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;Tremor &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;1181-1182Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;action &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;1181-1182Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;essential &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;1182Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;flapping (asterixis) 937, 950,Â 952, &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;1182Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;. intention &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;I 179, 1182Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;Parkinson's &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;disease 1181,1218,Â 1219, 1220, 1221Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;peduncular/rubraVHolmes &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;1182Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;physiological &lt;/span&gt;&lt;span style='color:#5b5863'&gt;&lt;span style='font-family:Arial'&gt;I &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;182Â rest 1181Â Trench &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;fever 340Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Trenchfoot 102Â &lt;em&gt;Treponema &lt;/em&gt;&lt;/span&gt;&lt;em&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;carateum 317Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Treponema &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;pallidum &lt;/span&gt;&lt;/em&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;410, 412Â &lt;/span&gt;&lt;em&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;Treponema pertenue &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;317Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;Treponema vincentii &lt;/span&gt;&lt;/em&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;&lt;em&gt;298Â &lt;/em&gt;Treponemal &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;(specific) &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;antibodyÂ tests &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;412-413Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;TreponematosesÂ &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;endemic 3 &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;17, &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;413Â &lt;em&gt;see also &lt;/em&gt;SyphilisÂ &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Tretinoin&lt;/span&gt;&lt;span style='color:#8c8e92; font-family:Times New Roman'&gt;, &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;acne 1300Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;TRH (thyrotrophin-releasingÂ &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;hormone) 743, 745Â Triamcinolone 1095, 1279,1300Â Triamterene 427Â &lt;/span&gt;&lt;em&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;Triatoma &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;injestans &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;355&lt;/span&gt;&lt;span style='color:#8c8e92; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;356Â &lt;/span&gt;&lt;/em&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Tricalcium &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;phosphate 1116Â Tricarboxylic acid (Krebs) cycleÂ 123Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Trichiasis &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;341Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Trichinosis &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;(trichinellosi) &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;366-367Â Trichloroacetic &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;acid &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;1297Â &lt;em&gt;Trichomonas &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;&lt;em&gt;vaginalis &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#5b5863'&gt;&lt;span style='font-family:Arial'&gt;&lt;em&gt;406Â &lt;/em&gt;&lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;Trichomoniasis &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;343Â genital &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;409Â &lt;em&gt;Trichophyton mentagrophytes 1297Â Trichophyton rubrum 1297Â Trichophyton &lt;/em&gt;&lt;/span&gt;&lt;em&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;to/lsurans &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;1278Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;Trichophyto/l verrucosum &lt;/span&gt;&lt;/em&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;&lt;em&gt;1278,Â &lt;/em&gt;1297Â &lt;/span&gt;&lt;em&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;Trichuris &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;trichiura &lt;/span&gt;&lt;/em&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;(whipworm) &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;363Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;Triclabendazole 370Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Tricuspid regurgitation 628Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;Tricuspid stenosis &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;628Â Tricuspid &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;valve 522, &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;523Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;atresia 640Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;repairlreplacement 628, 643Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;Tricyclic antidepressants (TCAs)Â 238,241Â irritable &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;bowel &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;syndrome 922Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;migraine prevention 1163Â neuropathic pain &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;278Â poisoning 210Â sphincter of Oddi &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;dysfunctionÂ &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;997Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Trientine dihydrochloride, Wilson'sÂ disease &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;976Â Trifluoperazine 243Â Trigeminal (5th cranial) &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;nerve, testsÂ 1147Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;Trigeminal &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;neuralgia 1164, 1248Â Trigger &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;finger (flexor tenosynovitis)Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;1080Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;diabetes 807Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Triglycerides &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;443 444,445,854Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;measurement &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;446Â reference values, venous &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;bloodÂ &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;1320Â &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;Trihexyphenidyl 1221Â Triiodothyronine &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;(T) &lt;/span&gt;&lt;span style='color:#5b5863; font-family:Times New Roman'&gt;743, 744, 745Â &lt;/span&gt;&lt;span style='color:#6e6c77; font-family:Times New Roman'&gt;Graves' disease 755 &lt;/span&gt;&lt;span style='color:#8c8e92; font-family:Times New Roman'&gt;'Â &lt;/span&gt;&lt;span style='color:#58535d'&gt;&lt;strong&gt;&lt;span style='font-family:Times New Roman'&gt;I l"f LI &lt;/span&gt;&lt;span style='font-family:Arial'&gt;L. &lt;/span&gt;&lt;/strong&gt;&lt;span style='font-family:Times New Roman'&gt;&lt;strong&gt;&lt;em&gt;1\Â &lt;/em&gt;&lt;/strong&gt;Triiodothyronine &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#69656f; font-family:Times New Roman'&gt;(T3) &lt;em&gt;(cont'd)Â &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#58535d; font-family:Times New Roman'&gt;levels &lt;/span&gt;&lt;span style='color:#69656f; font-family:Times New Roman'&gt;of 744, 745Â &lt;/span&gt;&lt;span style='color:#58535d; font-family:Times New Roman'&gt;hypothyroidism &lt;/span&gt;&lt;span style='color:#69656f; font-family:Times New Roman'&gt;750Â &lt;/span&gt;&lt;span style='color:#58535d; font-family:Times New Roman'&gt;thyrotoxicosis &lt;/span&gt;&lt;span style='color:#69656f; font-family:Times New Roman'&gt;747Â &lt;/span&gt;&lt;span style='color:#58535d; font-family:Times New Roman'&gt;myxoedema &lt;/span&gt;&lt;span style='color:#69656f; font-family:Times New Roman'&gt;coma &lt;/span&gt;&lt;span style='color:#58535d; font-family:Times New Roman'&gt;managementÂ &lt;/span&gt;&lt;span style='color:#69656f; font-family:Times New Roman'&gt;752Â reference values &lt;/span&gt;&lt;span style='color:#58535d; font-family:Times New Roman'&gt;in &lt;/span&gt;&lt;span style='color:#69656f; font-family:Times New Roman'&gt;venous &lt;/span&gt;&lt;span style='color:#58535d; font-family:Times New Roman'&gt;bloodÂ &lt;/span&gt;&lt;span style='color:#69656f; font-family:Times New Roman'&gt;1319Â reverse (rT3) 745Â &lt;/span&gt;&lt;span style='color:#58535d; font-family:Times New Roman'&gt;Trimethoprim 152, 153, &lt;/span&gt;&lt;span style='color:#69656f; font-family:Times New Roman'&gt;469Â &lt;/span&gt;&lt;span style='color:#58535d; font-family:Times New Roman'&gt;Trimethoprirnlsulfamethoxazole &lt;/span&gt;&lt;span style='color:#69656f; font-family:Times New Roman'&gt;&lt;em&gt;seeÂ &lt;/em&gt;Co-trimoxazoleÂ &lt;/span&gt;&lt;span style='color:#58535d; font-family:Times New Roman'&gt;Triolein &lt;/span&gt;&lt;span style='color:#69656f; font-family:Times New Roman'&gt;test 863Â &lt;/span&gt;&lt;span style='color:#58535d; font-family:Times New Roman'&gt;Triploidy &lt;/span&gt;&lt;span style='color:#69656f; font-family:Times New Roman'&gt;47Â &lt;/span&gt;&lt;span style='color:#58535d; font-family:Times New Roman'&gt;Tripotassium dicitratobismuthateÂ &lt;/span&gt;&lt;span style='color:#69656f; font-family:Times New Roman'&gt;889Â &lt;/span&gt;&lt;span style='color:#58535d; font-family:Times New Roman'&gt;Triptans 1163Â Trismus &lt;/span&gt;&lt;span style='color:#69656f; font-family:Times New Roman'&gt;1232Â &lt;/span&gt;&lt;span style='color:#58535d; font-family:Times New Roman'&gt;Trisomy 13 &lt;/span&gt;&lt;span style='color:#69656f; font-family:Times New Roman'&gt;(patau's syndrome) 47Â &lt;/span&gt;&lt;span style='color:#58535d; font-family:Times New Roman'&gt;Trisomy 18 &lt;/span&gt;&lt;span style='color:#69656f; font-family:Times New Roman'&gt;(Edwards' syndrome)Â 47Â Trisomy 21 (Down's syndrome)Â genetics 47, &lt;/span&gt;&lt;span style='color:#58535d; font-family:Times New Roman'&gt;48, 53Â &lt;/span&gt;&lt;span style='color:#69656f'&gt;&lt;span style='font-family:Times New Roman'&gt;screening 47, 57Â Trisomy &lt;/span&gt;&lt;span style='font-family:Arial'&gt;X &lt;/span&gt;&lt;span style='font-family:Times New Roman'&gt;47Â &lt;/span&gt;&lt;/span&gt;&lt;span style='color:#58535d; font-family:Times New Roman'&gt;Trochanteric bursitis 1080, 1081Â &lt;/span&gt;&lt;span style='color:#69656f; font-family:Times New Roman'&gt;Trochlear (4th cranial) &lt;/span&gt;&lt;span style='color:#58535d; font-family:Times New Roman'&gt;nerve 1195Â palsy &lt;/span&gt;&lt;span style='color:#69656f; font-family:Arial'&gt;I &lt;/span&gt;&lt;span style='color:#58535d; font-family:Times New Roman'&gt;195Â tests 1147Â &lt;/span&gt;&lt;span style='color:#69656f; font-family:Times New Roman'&gt;Troglitazone 833Â Troisier's sign 893Â &lt;em&gt;Tropheryma whippelli 898Â &lt;/em&gt;Tropical diseasesÂ fever and 288-290Â &lt;/span&gt;&lt;span style='color:#58535d; font-family:Times New Roman'&gt;patterns &lt;/span&gt;&lt;span style='color:#69656f; font-family:Times New Roman'&gt;in tropical countriesÂ 130--132Â skin 298&lt;/span&gt;&lt;span style='color:#7a6ea7; font-family:Times New Roman'&gt;- &lt;/span&gt;&lt;span style='color:#69656f; font-family:Times New Roman'&gt;299Â splenomegaly 296Â &lt;em&gt;see also names oj specificÂ diseasesÂ &lt;/em&gt;&lt;/span&gt;&lt;span style='color:#58535d; font-family:Times New Roman'&gt;Tropical &lt;/span&gt;&lt;span style='color:#69656f; font-family:Times New Roman'&gt;sprue 296, &lt;/span&gt;&lt;span style='color:#58535d; font-family:Times New Roman'&gt;896Â Tropical ulcer 298--299Â Tropomyosin 525Â &lt;/span&gt;&lt;span style='color:#69656f; font-family:Times New Roman'&gt;Troponins &lt;/span&gt;&lt;span style='color:#58535d; font-family:Times New Roman'&gt;525Â
